UCB   [ADDRESS_317778] Number: 2012 -001770 -29 
IND Number (tablet): [ZIP_CODE]  
IND Number (oral solution): [ADDRESS_317779]  
Raleigh, NC [ZIP_CODE]  
UNITED S TATES  
Protocol/Amendment number  Date  Type of amendment  
Final Protocol  [ADDRESS_317780] 2012  Not applicable  
Protocol Amendment 1  27 Jan 2015  Substantial  
Protocol Amendment 2  09 Jun 2016  Substantial  
Protocol Amendment 3  29 Nov 2017  Substantial  
Protocol Amendment 4 13 Dec 2019  Substantial  
Protocol Amendment 5  28 Aug 2020  Non-substantial  
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full or in part – be passed 
on, reproduced, published, or otherwise used without the expre ss permission of 
UCB . 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317781]  
Raleigh, NC [ZIP_CODE]  
UNITED STATES  
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Phone:   
Email:   
 
Clinical Project Manager  
Name:   
[CONTACT_2761]:  Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Phone:   
Email:   
 
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  [ADDRESS_317782]  
Raleigh, NC [ZIP_CODE]  
UNITED STATES  
Phone:   
Email:   
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317783] Research Organization  
Name:  [CONTACT_67645] (PRA), Inc.  
Address:  [ADDRESS_317784]  
Raleigh, NC [ZIP_CODE]  
UNITED STATES  
Phone:  +[PHONE_443]  
Fax: +[PHONE_444]  
 
Interactive Response Technology  
Name:  [CONTACT_261557]:  Lady Bay House, Meadow Grove  
Nottingham, NG23HF  
[LOCATION_006]  
Phone:  [PHONE_5429] 7333  
Fax: +44 [PHONE_5426]  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 4 of 274 SERIOUS ADVERSE EVEN T REPORTING  
 
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World:  [PHONE_1064]  
[LOCATION_003]:  +[PHONE_299]  
 or +[PHONE_300]  
Email  Global: [EMAIL_311]  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317785] OF ABBREVIATION S ................................ ................................ ................................ .. 10 
1 SUMMARY  ................................ ................................ ................................ .....................  12 
2 INTRODUCTION  ................................ ................................ ................................ ...........  13 
3 STUDY OBJECTIVE( S) ................................ ................................ ................................ . [ADDRESS_317786]  ................................ ................................ ...........  20 
5.1.2  Planned number of subjects and site(s)  ................................ ........................  [ADDRESS_317787] AWAL OF SUBJECTS  ................................ ...................  37 
6.1 Inclusion criteria  ................................ ................................ ................................ .... 37 
6.2 Exclusion criteria  ................................ ................................ ................................ ... 37 
6.3 Withdrawal criteria  ................................ ................................ ................................  38 
6.3.1  Potential drug -induced liver injury IMP discontinuation criteria  ................  39 
7 STUDY TREATMENT(S)  ................................ ................................ ..............................  [ADDRESS_317788](s)  ................................ ..............  40 
7.2 Treatment(s) to be administered  ................................ ................................ ............  [ADDRESS_317789] compliance  ................................ ......................  44 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 6 of 274 7.8 Concomitant medication(s)/treatment(s)  ................................ ...............................  44 
7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  ..................  44 
7.8.2  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  .................  45 
7.9 Blinding ................................ ................................ ................................ ..................  45 
7.10  Randomization and numbering of subjects  ................................ ............................  45 
8 STUDY PROCEDURES BY [CONTACT_16990]  ................................ ................................ ...............  45 
8.1 Treatment Period  ................................ ................................ ................................ .... 45 
8.1.1  Visit 1 (Week 0)  ................................ ................................ ...........................  45 
8.1.2  Visits 2 to 8 (Weeks 2 to 46, Year 1, excluding Visit 6 and Visit 7)  ..........  47 
8.1.3  Visits 9 and 11 (Weeks 62 and 94, Year 2, excluding Visit 10)  ..................  47 
8.1.4  Visits 12, 13, 14, 15, 16, 17 and X (Weeks 118, 142, 166, 190, 214, 238, 
and X, Years 3 to 5 + Extended Period)  ................................ ......................  48 
[IP_ADDRESS]  Subjects <18 years  ................................ ................................ .............  48 
[IP_ADDRESS]  Subjects ≥[ADDRESS_317790]  ................................ ............................  54 
8.5 Unscheduled Visit  ................................ ................................ ................................ .. 54 
9 ASSESSMENT OF EFFICA CY ................................ ................................ ......................  55 
9.1 Seizure variables  ................................ ................................ ................................ .... 55 
9.1.1  PGTCS  ................................ ................................ ................................ .........  55 
9.1.2  Absence and myoclonic seizures  ................................ ................................ . 56 
9.2 Health outcome variables  ................................ ................................ .......................  56 
9.2.1 Patient Weighted Quality of Life in Epi[INVESTIGATOR_261379] -Form 31 
(QOLIE -31-P) ................................ ................................ ..............................  [ADDRESS_317791] due to epi[INVESTIGATOR_002]  ..............................  57 
9.2.6  Number of days with help from a caregiver due to epi[INVESTIGATOR_002]  .......................  57 
10 ASSESSMENT OF SAFETY  ................................ ................................ ..........................  57 
10.1  Adverse events  ................................ ................................ ................................ ....... 57 
10.1.1  Definitions  ................................ ................................ ................................ ... 57 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 7 of 274 [IP_ADDRESS]  Adverse event  ................................ ................................ .....................  57 
[IP_ADDRESS]  Serious adverse events  ................................ ................................ ....... 58 
[IP_ADDRESS]  Adverse events of special interest  ................................ ......................  59 
10.1.2  Procedures for reporting and recording adverse events  ...............................  60 
[IP_ADDRESS]  Description of adve rse events  ................................ ............................  60 
[IP_ADDRESS]  Rule for repetition of an adverse event  ................................ ..............  61 
[IP_ADDRESS]  Additional procedures for reporting serious adverse events  ..............  [ADDRESS_317792]  ................................ ...........  63 
10.1.7  Safety signal detection  ................................ ................................ .................  63 
10.2  New seizure types, increase in days with and worsening of days with absence 
or myoclonic seizures  ................................ ................................ ............................  63 
10.3  Laboratory measurements  ................................ ................................ ......................  64 
10.3.1  Evaluation of PDILI  ................................ ................................ .....................  64 
[IP_ADDRESS]  Consultation with Medical Monitor and local hepatologist  ...............  68 
[IP_ADDRESS]  Immediate action: determination of IMP discontinuation  .................  68 
[IP_ADDRESS]  Testing: identification/exclusion of alternative etiology  ...................  69 
[IP_ADDRESS]  Follow -Up evaluation  ................................ ................................ ........  70 
10.3.2  Pregnancy testing  ................................ ................................ .........................  71 
10.4  Other safety measurements  ................................ ................................ ....................  71 
10.4.1  Vital signs, body weight and height  ................................ .............................  71 
10.4.2  12-lead ECG  ................................ ................................ ................................  71 
[IP_ADDRESS]  Overall ECG interpretation  ................................ ................................  71 
10.4.3  Assessment of suicidality  ................................ ................................ .............  71 
10.4.4  Physical examination  ................................ ................................ ...................  72 
[IP_ADDRESS]  Complete physical examination  ................................ .........................  72 
[IP_ADDRESS]  Brief physical examination  ................................ ................................  72 
10.4.5  Neurological examination  ................................ ................................ ............  72 
[IP_ADDRESS]  Complete neurological examination  ................................ ..................  73 
[IP_ADDRESS]  Brief neurological examination  ................................ ..........................  [ADDRESS_317793] Enrollment log/Subject Identification Code list  .............................  [ADDRESS_317794] health data  ................................ ................................ . 81 
13.5  Protocol amendments  ................................ ................................ .............................  82 
14 FINANCE, INSURANCE, AND PUBLICATION  ................................ .........................  82 
15 REFERENCES  ................................ ................................ ................................ ................  83 
16 APPENDICES  ................................ ................................ ................................ .................  84 
16.1  Appendix 1: International Classification of Epi[INVESTIGATOR_207161] (1981)  .................  84 
16.2  Appendix 2: Patient Weighted Quality Of Life in Epi[INVESTIGATOR_002]: QOLIE -31-P 
(Version 2.0, US – English)  ................................ ................................ ...................  85 
16.3  Appendix 3: EuroQol -5 Dimension (EQ -5D-3L) Quality of Life Assessment  ..... 95 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 9 of 274 16.4  Appendix 4: Protocol Amendment 1  ................................ ................................ ..... 98 
16.5  Appendix 5: Protocol Amendment 2  ................................ ................................ ... 168 
16.6  Appendix 6: Protocol Amendment 3  ................................ ................................ ... 207 
16.7  Appendix 7: Protocol Amendment 4  ................................ ................................ ... 233 
16.8  Appendix 8: Protocol Amendment 5  ................................ ................................ ... 267 
16.9  Appendix 9: Contraception Table  ................................ ................................ ........  [ADDRESS_317795] OF TABLES  
Table  5‒1:  Schedule of study assessments for Years 1 and 2 for EP0012 (Treatment 
Period, ET Visit, Termination Visit, and Unscheduled Visit)  ..............................  23 
Table  5‒2:  Schedule of study assessments for Years 3 through 5 for EP0012 
(Treatment Period, ET Visit, Ter mination Visit, and Unscheduled Visit 
for subjects <18  years at enrollment) ................................ ................................ .... 28 
Table  5‒3:  Schedule of study assessments for Years 3 t hrough 5 for EP0012 
(Treatment Period, ET Visit, Termination Visit, and Unscheduled Visit 
for subjects ≥18  years at enrollment)  ................................ ................................ .... 32 
Table 5-4:Schedule of study assessments (Taper Period and Safety Follow -Up 
Period)  ................................ ................................ ................................ ...................  35 
Table  7‒1:  Minimum and maximum LCM dose during the Treatment Period  ......................  41 
Table  7‒2:  Lacosamide dosing for subjects requiring taper  ................................ ...................  42 
Table  10‒1:  Anticipated serious adverse events for the epi[INVESTIGATOR_67513]  ..................  59 
Table  10‒2:  Laboratory tests  ................................ ................................ ............................  64 
Table  10‒3:  Required investigations and follow up for PDILI  ................................ ....... 66 
Table  10‒4:  PDILI laboratory measurements  ................................ ................................ .. 69 
Table  10‒5:  PDILI information to be collected  ................................ ...............................  70 
Table  5-4:Schedule of study assessments (Taper Period and Safety Follow -Up 
Period)  ................................ ................................ ................................ .................  270 
Table  5-4:Schedule of study assessments (Taper Period and Safety Follow -Up 
Period)  ................................ ................................ ................................ .................  [ADDRESS_317796] OF ABBREVIATION S 
AE adverse event  
AED  antiepi[INVESTIGATOR_32551](s)  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
AV atrioventricular  
bid twice daily  
BMI  body mass index  
BP blood pressure  
BRIEF® Behavior Rating Inventory of Executive Function® 
BRIEF -P® Behavior Rating Inventory of Executive Function -Preschool 
Version® 
CBCL  Child Behavior Checklist  
CDMS  clinical data management system  
CPM  Clinical Project Manager  
CRO  contract research  organization  
C-SSRS  Columbia -Suicide Severity Rating Scale  
ECG  electrocardiogram  
eCRF  electronic Case Report form  
EDC  electronic data capture  
EI-AED  enzyme -inducing antiepi[INVESTIGATOR_261380]-5D-3L 3-level EuroQol -[ADDRESS_317797]  
MAO -A monoamine oxidase A  
MAP  managed access program  
PDILI  potential drug-induced liver injury  
PedsQL™  Pediatric Quality of Life Inventory  
PGTCS  primary generalized tonic -clonic seizure(s)  
PK pharmacokinetic  
PS Patient Safety  
QOLIE -31-P Patient Weighted Quality of Life in Epi[INVESTIGATOR_261379] -Form [ADDRESS_317798]  upper limit of normal  
VAS  visual analogue scale  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 12 of 274 1 SUMMARY  
This Phase 3, multicenter, open -label extension study is designed to assess the long -term 
safety and efficacy of oral lacosamide (LCM, VIMPAT®; SPM 927; previously referred to as 
harkoseride; (R) -2-acetamido -N-benzyl -3-methoxypropi[INVESTIGATOR_67515], ADD  2340 37) as an 
adjunctive therapy for uncontrolled primary generalized tonic -clonic seizures (PGTCS) in 
subjects ≥4  years of age with idiopathic generalized epi[INVESTIGATOR_002] (IGE). This study will enroll 
subjects who have completed the LCM SP0982 study. In addition, su bjects who completed 
the SP0982 Prospective Baseline Period and met all entry criteria except the minimum 
PGTCS criteria required for randomization into SP0982 may choose to enter EP0012 
(eligible Baseline failures and completers are defined in Section 5.1). It is estimated that up to 
[ADDRESS_317799] met its 
protocol -defined stoppi[INVESTIGATOR_261381]0012 or taper off 
study medication. Subjects who completed SP0982 will start at Visit 1 on a dose of 
LCM  10mg/kg/day for pediatric subject s weighing <30kg, LCM 8mg/kg/day for pediatric 
subjects weighing ≥30kg to <50kg, and LCM 400mg/day (200mg  twice daily [bid]) for adult 
subjects (≥18 years of age) or pediatric subjects weighing ≥50kg. Subjects who are eligible 
Baseline failures from SP0982  will start at Visit 1 on a dose of  LCM 2mg/kg/day for 
pediatric subjects weighing <50kg, and LCM 100mg/day (50mg bid) for adult subjects (≥18 
years of age) or pediatric subjects weighing ≥50kg.  
Baseline failures are required to complete Week [ADDRESS_317800] should hold the dose for a longer duration. 
There is no limit to the number of back titration steps or dose holds allowed and all are at the 
Investigator’s discretion; however, subjects must achieve the minimum LCM target dose of 
4mg/kg/day (oral solution) or 200mg/day (tablets) within [ADDRESS_317801] this minimum dose of 4mg/kg/day (oral solution) or 200mg/day (tablets), then 
the subject must enter the Taper Period and be withdrawn from the study.  
During EP0012, investigat ors will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased 
in steps of no more than 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects must 
remain on t he dose for ≥[ADDRESS_317802] of a Treatment Period, an up to 4 -week Taper Period, and a 30 -day 
Safety Follow -Up Period. During the Treatment Period, Visit 2 will occur 2  weeks after Visit 
1, and Visit 3 will  occur 4  weeks later (Week 6). Clinical visits will then occur every [ADDRESS_317803] udy. From 
Year 2 (Visit 11) to 3 onwards, pediatric subjects weighing <50kg will return to the clinic for 
an additional Dispensation Visit 12 weeks after each 24 -weekly visit, for the dispensation of 
LCM solution; LCM usage will be reviewed and empty LCM b ottles will be returned.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317804] ’s country for the treatment of PGTCS 
in subjects with IGE, or until UCB has determined that the clinical development program for 
the indication will be formally discontinued, or until UCB decides to close the study.  
At the completion of the study, investi gators should discuss treatment options with the 
subject and/or their parent(s)/legal representative(s) to best manage the subject’s epi[INVESTIGATOR_002]. 
Taper of LCM may not be required for some subjects who complete the study depending on 
the treatment option selec ted by [CONTACT_207259]/or their 
parent(s)/legal representative(s).  
The primary study objective is to assess the safety and tolerability of LCM as an adjunctive 
therapy for uncontrolled PGTCS in subjects with IGE durin g long -term exposure. Secondary 
objectives are to assess the efficacy of adjunctive LCM therapy during long -term exposure 
for the treatment of uncontrolled PGTCS in subjects with IGE, and to allow subjects who 
have completed SP0982 and eligible Baseline fa ilures from SP0982 to receive LCM.  
The primary safety variables are a dverse events (AEs), s ubject withdrawals due to AEs, 
incidence of new seizure types, and increase in absence seizure days per 28 days or 
myoclonic seizure days per 28 days during the Trea tment Period. Secondary safety variables 
are percentage of treatment -emergent marked abnormalities in hematology and chemistry 
parameters; percentage of treatment -emergent marked abnormalities in 12 -lead 
electrocardiograms (ECGs); and percentage of treatme nt-emergent marked abnormalities in 
vital sign measurements (ie,  blood pressure [BP] and pulse rate).  Other safety variables 
include changes in hematology, chemistry, and urinalysis parameters, changes in 12 -lead 
ECGs, and changes in in vital sign measurem ents (ie, BP and pulse rate), including height 
and weight and physical (including neurological) examination findings.  In addition, for 
pediatric subjects <18 years of age, safety will be evaluated using behavioral assessments 
(Achenbach Child Behavior Che cklist [CBCL]), and cognitive function assessments 
(Behavior Rating Inventory of Executive Function®/Behavior Rating Inventory of Executive 
Function -Preschool Version® [BRIEF®/BRIEF -P®]). The seizure efficacy variables are 
evaluations of seizure frequency,  based on information included in subject diaries. The health 
outcome variables, including the Patient Weighted Quality of Life in Epi[INVESTIGATOR_261379] -
Form 31 (QOLIE -31-P), the Pediatric Quality of Life Inventory™ (PedsQL™), the 3 -level 
EuroQol -5 Dimension Quality of Life Assessment (EQ -5D-3L), healthcare resource use, the 
number of working or school days lost by [CONTACT_261478][INVESTIGATOR_002], and the number of days 
with help from a caregiver due to epi[INVESTIGATOR_261382] [ADDRESS_317805] 70 million people worldwide (Ngugi et al, 2011). Epi[INVESTIGATOR_261383] a wide range of epi[INVESTIGATOR_261384], structural/metabolic, or 
unknown origin.  
Generalized seizures are those in which the first clinical changes indicate initial involvement 
of both brain hemispheres. Consciousness typi[INVESTIGATOR_261385].
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 14 of 274 the initial man ifestation. Motor manifestations are typi[INVESTIGATOR_261386]. Generalized seizures 
typi[INVESTIGATOR_261387] (genetic) or symptomatic generalized epi[INVESTIGATOR_207163]. Idiopathic generalized epi[INVESTIGATOR_24571] a category of disorders defined by [CONTACT_261479][INVESTIGATOR_002] 
(ILAE) classification of epi[INVESTIGATOR_122245] (ILAE, 1989). Clinical experience has shown 
that IGEs represent a heterogeneous condition in which many factors i nteract (such as age at 
onset, external factors, role of medications, and sleep) (Jallon and Latour, 2005). Idiopathic 
generalized epi[INVESTIGATOR_261388] a genetic etiology and onset almost always occurs 
during childhood or adolescence, although th ere are exceptions; some patients develop these 
kinds of epi[INVESTIGATOR_261389], rarely, even later.  
Treatment of PGTCS in IGE is complex because the patient population is heterogeneous, as 
PGTCS can occur as an isolated seizure type  or in association with other generalized seizure 
types.  
Although some forms of epi[INVESTIGATOR_261390], most patients with 
epi[INVESTIGATOR_207165] (Perucca, 1996). In the past decade, 
several new options for the medical treatment of epi[INVESTIGATOR_207166], including 
novel antiepi[INVESTIGATOR_006] (AEDs) and vagus nerve stimulation. The newer AEDs differ from 
older agents in several important ways, including mechanism of action, spectrum of activity, 
and pharmacokinetic (PK) characteristics (Herman and Pedley, 1998).  
Between 15% and 40% of patients with generalized epi[INVESTIGATOR_261391] (Bartolomei et al, 1997; 
Verrotti  et al, 2007); some of these AEDs can induce serious, life threatening AEs 
(eg, aplastic anemia, rash, hepatic failure). Generalized tonic -clonic seizures may respond to 
drugs that aggravate typi[INVESTIGATOR_261392]/or myoclonic jerks (Genton, 2000; Verrotti e t al, 
2007). Two IGE seizure types, typi[INVESTIGATOR_261393], are particularly 
prone to aggravation by [CONTACT_261480] (carbamazepi[INVESTIGATOR_050], vigabatrin, tiagabine, phenytoin, 
phenobarbital, and lamotrigine).  
Lacosamide belongs to a novel class of fu nctionalized amino acids that were specifically 
synthesized as anticonvulsive drug candidates. It has minimal protein binding and effect on 
cytochrome P450 enzyme system function (reducing the risk of drug -drug interactions), high 
oral bioavailability, and  a half -life of approximately 13 hours (in adults), which allows a bid 
dose regimen. It also displays dose -proportional PK following administration over a range of 
doses up to 800mg in adults.  
Lacosamide has been approved in the European Union (oral tablet s, oral solution [syrup], and 
solution for intravenous [iv] infusion) as monotherapy or adjunctive therapy in the treatment 
of partial -onset seizures with or without secondary generalization in patients 4 years of age 
and older. Lacosamide has also been ap proved in the US (oral tablets, oral solution [syrup], 
and solution for iv infusion) as monotherapy or adjunctive therapy in the treatment of partial -
onset seizures in patients 17  years of age and older.  The safety and efficacy of LCM has also 
been evalua ted in Phase 2/[ADDRESS_317806] that the exposure -response in pediatric and 
adult subjects treated with LCM will be similar. Lacosamide has been evaluated in 
3 completed pediatric studies; 2 studies in subjects aged 1 month to 17 years, and in subjects 
with epi[INVESTIGATOR_002] ≥4 years to <[ADDRESS_317807] udy.  
In addition, LCM is being evaluated in the following ongoing pediatric efficacy and safety 
studies:  
• SP0967 (ages ≥1 month to <4 years) as adjunctive therapy in partial -onset seizures  
• EP0034, Open -label extension study to SP0967 and SP0969  
• SP0966 (ages ≥1 month to <18 years) as adjunctive therapy, exploratory study in subjects 
with epi[INVESTIGATOR_261394], as well as the PK, efficacy, and safety 
profiles, can be obtained  from the current version of the LCM Investigator’s Brochure.  
Considering the significant unmet medical need for new treatment options for patients with 
IGE and PGTCS, the efficacy and tolerability profiles for LCM were evaluated in a series of 
animal mode ls followed by a Phase [ADDRESS_317808] discharges in the WAG/R and 
Genetic Absence Epi[INVESTIGATOR_261395].  
SP0961, the Phase 2, multicenter, open -label pi[INVESTIGATOR_261396] (400mg/day) for uncontrolled PGTCS in subjects aged 16 to 65  years with 
IGE, is complete. The results of this pi[INVESTIGATOR_261397], with a small reduction in absence seizure frequency. A minority of 
subjects (~10%) in SP0961 showed an increase in absence seizures (reported as treatment -
emergent adverse events [TEAEs]) that, in this uncontr olled study, cannot be distinguished 
between the drug versus the natural course of the disease. The AE profile was similar to what 
has been observed with adjunctive LCM for the treatment of subjects with partial -onset 
seizures, with the exception of seizur e-related AEs.  
SP0982 is a Phase 3, double -blind, randomized, placebo -controlled, parallel -group, 
multicenter study designed to evaluate the efficacy and safety of LCM for uncontrolled 
PGTCS in subjects ≥4 years of age with IGE.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 16 of 274 The current study (EP0012) will assess the long -term safety, tolerability, and efficacy of 
LCM and will enroll subjects who have completed SP0982 as well as eligible Baseline 
failures from SP0982. At the completion of the study, investigators should discuss treatment 
options with th e subject and/or legal representative to best manage the subject's epi[INVESTIGATOR_002].  
3 STUDY OBJECTIVE(S)  
3.1 Primary objective  
The primary objective is to assess the safety and tolerability of LCM as an adjunctive therapy 
for uncontrolled PGTCS in subjects with IGE dur ing long -term exposure.  
3.2 Secondary objectives  
The secondary objectives are:  
• To assess the efficacy of adjunctive LCM therapy during long -term exposure for the 
treatment of subjects with IGE experiencing uncontrolled PGTCS  
• To allow subjects who have complete d SP0982 and eligible Baseline failures from 
SP0982 to receive LCM  
4 STUDY VARIABLES  
4.1 Safety variables  
4.1.1  Primary safety variables  
The primary safety variables are:  
• The incidence of TEAEs over the duration of the Treatment Period.  
• Subject withdrawals due to TEAE s 
• Incidence of new appearance of absence and/or myoclonic seizures during the Treatment 
Period  
• An increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days with absence 
seizures per 28 days compared to the Prospective Baseline  
• An increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days with 
myoclonic seizures per 28 days compared to the Prospective Baseline  
• At least 50% worsening in days with absence seizures  
• At least 50% worsening in days with myoclonic seizures  
4.1.2  Secondary safety variables  
Secondary safety variables are:  
• Percentage of treatment -emergent marked abnormalities in hematology and chemistry 
parameters  
• Percentage of treatment -emergent marked abnormalities in 12 -lead ECGs  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 17 of 274 • Percentage of treatment -emergent marked abnormalities in vita l sign measurements (ie, 
BP and pulse rate)  
4.1.3  Other safety variables  
• Changes in hematology, chemistry, and urinalysis parameters  
• Changes in 12 -lead ECGs  
• Changes in vital sign measurements (ie, BP and pulse rate), including weight and height 
and physical (including neurological) examination findings  
• Achenbach CBCL1½ -5 or CBCL/6 -18 (for pediatric subjects only)  
• Cognitive function assessment BRIEF/BRIEF -P (for pediatric subjects only)  
4.2 Efficacy variables  
4.2.1  Primary efficacy variable  
No primary efficacy variables  are defined for this study.  
4.2.2  Secondary efficacy variable  
The secondary efficacy variable is:  
• Percent change in PGTCS frequency per 28  days from Combined Baseline, where 
Combined Baseline is defined as the combined 12 -week Historical Baseline and 4 -week 
Prospective Baseline periods immediately prior to randomization in the parent study 
(SP0982)  
4.2.3  Other efficacy variables  
The other efficacy variables are:  
• Change in days with myoclonic seizures per 28 days relative to the Prospective Baseline  
• Percent change in d ays with myoclonic seizures per 28  days relative to the Prospective 
Baseline  
• Change in days with absence seizures per 28 days relative to the Prospective Baseline  
• Percent change in days with absence seizures per 28  days relative to the Prospective 
Baseline  
• At least a 50% reduction in PGTCS frequency compared to the Combined Baseline  
• At least a 50% reduction in myoclonic seizure days compared to the Prospective Baseline  
• At least a 50% reduction in absence seizure days compared to the Prospective Baseline  
• Seizure-free status (yes/no) for PGTCS  
• Seizure -free status (yes/no) for all generalized seizure types  
• Change from Baseline in QOLIE -31-P subscale (Seizure Worry, Daily Activities/Social 
Functioning, Energy/Fatigue, Emotional Well -being, Mental Activity/Cognit ive 
Functioning, Overall Quality of Life, and Medication Effects) and total scores in subjects 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 18 of 274 ≥18 years of age or change from Baseline in the PedsQL subscale (Physical Functioning, 
Emotional Functioning, Social Functioning, and School Functioning) and tot al scores in 
subjects <[ADDRESS_317809] 2 years of treatment  
• Change from Baseline in the EQ -5D-3L visual analogue scale (VAS) score and change in 
utility as converted from the 5 dimensions (for subjects ≥12 years of age) for the first two 
years of treatment  
• Healthcare resource use: medical procedures, hospi[INVESTIGATOR_602], and healthcare provider 
visits  for the first 2 years of treatment.  
• Number of working or school days lost by [CONTACT_261481][INVESTIGATOR_261398].  
• Number of days with help from a caregiver due to epi[INVESTIGATOR_261399]  
5 STUDY DESIGN  
5.1 Study description  
This is a multicenter, open -label extension study to assess the long -term safety, tolerability 
and change in seizure frequency associated  with long -term adjunctive oral LCM for 
uncontrolled PGTCS in subjects ≥[ADDRESS_317810] completed the 
LCM SP0982 study (or have left t he primary study at the time of the 125th event, whichever 
came first) as well as eligible Baseline failures from SP0982. Then, some subjects who 
tapered in SP0982 after the 125th event may enter EP0012 for the Safety Follow -Up only 
(ICF to be signed befor ehand). Up to 250  subjects from 150 to 180 study sites are planned to 
be enrolled in EP0012.  
For the purposes of this study, Baseline failures, randomized subjects who meet SP0982 exit 
criteria, study completers from SP0982 who are eligible for inclusion i n EP0012, SP0982 
Safety Follow -Up subjects, and Other are defined as:  
SP0982 Baseline failures  
• Subjects who complete the Prospective Baseline Period of SP0982 and meet all entry 
criteria except the minimum PGTCS criteria required for randomization (Baselin e 
failures)  
Randomized subjects meeting SP0982 exit criteria  
• Subjects who completed the first 6 weeks of the Treatment Period (after randomization) 
of SP0982 and experienced ≥[ADDRESS_317811] 6 weeks of the Treatment Period of 
SP0982  
SP0982 completers  
• Subjects who experience <2 PGTCS within the 24 -week Treatment Period of SP0982  
• Subjects who were ongoing in SP0982 when the 125th event occurred  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 19 of 274 SP0982 Safety Follow -Up subjects  
• Subjects tapered in SP0982 after the 125th event occurs will enter EP0012 for the Safety 
Follow -Up Visit only  
Other  
• Subjects that enrolled in EP0012 that did not fall into the above categories  
Randomized subjects meeting SP0982 exit criteria and subjects who compl eted SP0982 will 
start at Visit 1 on a dose of  LCM  10mg/kg/day for pediatric subjects weighing <30kg, LCM 
8mg/kg/day for pediatric subjects weighing ≥30kg to <50kg, and LCM 400mg/day (200mg 
bid) for adult subjects (≥18 years of age) or pediatric subjects w eighing ≥50kg. Subjects who 
are eligible Baseline failures from SP0982 will start at Visit 1 on a dose of  LCM 2mg/kg/day 
for pediatric subjects weighing <50kg, and LCM  100mg/day (50mg bid) for adult subjects 
(≥18 years of age) or pediatric subjects weighin g ≥50kg. In addition, once [ADDRESS_317812] 
had a second PGTCS in SP0982 (ie, the 125th event has occurred), that study will have met its 
protocol -defined end. All subjects ongoing in SP0982 will transition into EP0012 for further 
long-term treatment or f or a Safety Follow -Up. 
Baseline failures are required to complete Week [ADDRESS_317813] s hould hold the dose for a longer duration. 
There is no limit to the number of back titration steps or dose holds allowed and all are at the 
investigator’s discretion; however, subjects must achieve the minimum LCM target dose of 
4mg/kg/day (oral solution) or 200mg/day (tablets) within [ADDRESS_317814] this minimum dose of 4mg/kg/day (oral solution) or 200mg/day (tablets), then 
the subject mus t enter the Taper Period and be withdrawn from the study.  
During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased 
in steps of no mor e than 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects must 
remain on the dose for ≥7 days before a subsequent dose escalation.  
The LCM dose may be increased or decreased at the investigator’s discretion after the subject 
receives the first do se of LCM in the study (see Table  7‒1). Baseline failures must complete 
Week 1 of dosing before LCM may be increased or decreased. The maximum dose for  
pediatric subjects weighing <50kg is 12mg/kg/day (oral solution). The maximum dose for 
pediatric subjects weighing ≥50kg is 600mg/day (tablets) and for adult subjects is 800mg/day 
(tablets).  
A clinic visit (scheduled or unscheduled) is required if:  
• The dose is increased for the first time to any dose above 10mg/kg/day for pediatric 
subjects weighing <[ADDRESS_317815] be conducted to ensure that the dose is well tolerated.  
• The dose is increased for the first time to any dose above LCM 400mg/day for all adult 
subjects or pediatric subjects weighing ≥50kg. One week after the first time the dose is 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317816] of a Treatment Period, an up to 4 -week Taper 
Period, and a 30 -day Safety Follow -Up Period. Visit 1 of EP0012 is the same as the Final 
Clinic Visit of SP0982 for completers and subjects wh o meet the SP0982 exit criteria. 
Eligible Baseline failures from SP0982 who choose to enter this study will undergo a 
complete Visit 1. Visit 2 will occur 2 weeks after Visit 1 and Visit  3 will occur 4  weeks later 
(Week 6). Clinic visits will then occur ev ery [ADDRESS_317817] year, and every 16 weeks in 
the second year. For subjects who continue in the study after Year 2, visits will occur every 
24 weeks thereafter until the end of the study. From Year 2 (Visit 11) to 3 onwards, pediatric 
subjects weig hing <50kg will return to the clinic for an additional Dispensation Visit 12 
weeks after each 24 -weekly visit, for the dispensation of LCM solution; LCM usage will be 
reviewed and empty LCM bottles will be returned.  
A telephone contact [CONTACT_18378] 8  weeks if no clinic visit is scheduled. Telephone 
contacts will be used to obtain information regarding concomitant medication use, and assess 
withdrawal criteria and AEs, as well as to ensure subjects are compliant with LCM 
administration and diary complet ion.  
Subjects and/or their caregiver will be dispensed a seizure diary to record all types of 
seizures, concomitant AEDs, and other pertinent health status information. Subjects must 
bring their diary to each visit. Baseline seizure frequency and type wil l be verified by a 
reliably documented seizure history collected (eg, in a seizure diary during SP0982).  
New concomitant AEDs may be introduced to optimize treatment, if the concomitant 
medication has been approved by [CONTACT_261482]’s country. New AEDs should be added only when the subject has not optimally 
or adequately responded to a maximum tolerated dose of LCM. Concomitant AEDs may be 
carefully tapered and discontinued to achieve LCM monoth erapy, if clinically appropriate. 
The Medical Monitor must be consulted prior to initiation of concomitant AED withdrawal.  
At the completion of the study, investigators should discuss treatment options with the 
subject and/or their parent(s)/legal represen tative(s) to best manage the subject’s epi[INVESTIGATOR_002]. 
Taper of LCM (Taper Visit and SFU) may not be required for some subjects who leave the 
study depending on the treatment option selected by [CONTACT_261483]/or their paren t(s)/legal representative(s).  
5.1.[ADDRESS_317818] 2 years.  Once 2 years of participation 
are reached, adult subjects will continue to participate until 1 of the 2 following conditions 
are met.  
• LCM is approved for use for the treatment of PGTCS in subjects with IGE in the 
subject’s country for or until the latest approval is granted either by [CONTACT_16096], FDA, or 
PMDA.  
• For pediatric subjects, treatment will continue until 1 of the following 2 conditions  are 
met: 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 21 of 274 − up to 5 years of participation or  
− until the  approval of the extension of indication to cover the target age group is 
granted  
Adult and pediatric subjects are completers if they continue in the study for the maximum 
duration in their respective region.  
The following study periods are defined:  
• A Treatment Period lasting for at least 5 years (238 weeks) for the population less than 
18 years old at enrollment and will be shorter for adults leaving the study when the 
PGTCS indication approvals are being obtained during the course of the study.  
• An up to 4 -week Taper Period and a 30 -day Safety Follow -Up Period.  
− Subjects continuing LCM treatment with commercially available LCM will transition 
to a dose determined by [CONTACT_261484] 
(Taper Visit and SFU).  
− Subje cts tapering off LCM will do so over a period of up to 4 weeks (see taper 
schedule, Table 7‒2). 
− An End of Taper Visit (latest 3 days after the final do se) will occur after the final 
LCM dose for subjects who taper off LCM. Following the End of Taper Visit, there 
will be a [ADDRESS_317819] visit/telephone contact [CONTACT_261485].  
Subjects who entered EP0012 as <18 year s and become adults (≥18 years) during the study, 
will remain in the study for at least 5 years (238 weeks).  
5.1.2  Planned number of subjects and site(s)  
Up to 250  subjects across 150 to 180 international sites are planned to be enrolled in this 
study.  
5.1.3  Anticip ated regions and countries  
This study is planned to be conducted in the US, Europe, Asia, and Australia with possible 
extension to other countries and regions.  
5.2 Schedule of study assessments  
The schedule of study assessments for treatment Years 1 to 2 (Trea tment Period, ET Visit, 
Termination Visit, and Unscheduled Visit) is provided in Table  5‒1. An additional schedule 
of study assessments for treatment Ye ars 3 to 5 (Treatment Period, Early Termination [ET] 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 22 of 274 Visit, Termination Visit, and Unscheduled Visit) is provided in Table  5‒2 for subjects 
<18 years an d Table  5‒3 for subjects ≥18 years. The schedule of study assessments for the 
Taper Period and Safety Follow -Up Visit (including subjects who tapered i n SP0982 after the 
125th event consented to enter EP0012 for the Safety Follow -up only) is provided in Table  5-
4. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study  Protocol  Lacosamide  EP0012  
   
Confidential  Page 23 of 274 Table  5‒1: Schedule of study assessments for Years 1 and 2 for EP0012 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit)  
  Treatment Perioda  Unscheduledb 
Duration  Open -label: at least 2 years   NA 
Year of study  Year 1  Year 2    
Visitc V1 V2 V3 V4 V5 V6**  V7**  V8 Telephone 
Contactd V9 V10**  V11 ET 
Visite Termination 
Visitf Unscheduled 
Visit  
Week  0 2 6 14 22 30 38 46  62 78 94   NA 
Informed Consent/Assent  X               
Inclusion/Exclusion criteria  X               
Subject ID card dispensing  X               
Concomitant medications and 
AED(s)  X* X X X X   X X X  X X X X 
Medical history/Epi[INVESTIGATOR_261400]  X               
Physical exam (complete)g X*       X    X X X  
Physical exam (brief)h  X X X X     X     X 
Neurological exam (complete)i X*       X    X X X  
Neurological exam (brief)j  X X X X     X     X 
12-lead ECGk X* X  X    X  X  X X X  
Vital signs (BP and pulse)  
including orthostatic 
assessmentsl X* X X X X   X  X  X X X X 
Body weight and heightm X*   X    X  X  X X X  
Tanner Stagen X       X    X X X  
Laboratory testso X* X   X   X  X  X X X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study  Protocol  Lacosamide  EP0012  
   
Confidential  Page 24 of 274 Table  5‒1: Schedule of study assessments for Years 1 and 2 for EP0012 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit)  
  Treatment Perioda  Unscheduledb 
Duration  Open -label: at least 2 years   NA 
Year of study  Year 1  Year 2    
Visitc V1 V2 V3 V4 V5 V6**  V7**  V8 Telephone 
Contactd V9 V10**  V11 ET 
Visite Termination 
Visitf Unscheduled 
Visit  
Week  0 2 6 14 22 30 38 46  62 78 94   NA 
Endocrinologyp X*            X X  
Pregnancy testq X X X X X   X  X  X X X  
Call IRT X X X X X   X  X  X X X X 
C-SSRSr X X X X X   X  X  X X X X 
Dispense subject diary  X X X X X   X  X  X X X  
Subject diary return/review   X X X X   X  X  X X X X 
Dispense LCM  X X X X X   X  X  X X X  
LCM review/return   X X X X   X  X  X X X  
Withdrawal criteria  X* X X X X   X X X  X X X X 
AE reporting  X* X X X X   X X X  X X X X 
EQ-5D-3L X    X   X  X  X X X  
QOLIE -31-P/PedsQLs X    X   X  X  X X X  
Achenbach CBCLt X    X   X  X  X X X  
BRIEF -P/BRIEFu X    X   X  X  X X X  
Healthcare resource use  X* X X X X   X  X  X X X  
Work/school days lost  due to 
epi[INVESTIGATOR_002]  X* X X X X   X  X  X X X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study  Protocol  Lacosamide  EP0012  
   
Confidential  Page 25 of 274 Table  5‒1: Schedule of study assessments for Years 1 and 2 for EP0012 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit)  
  Treatment Perioda  Unscheduledb 
Duration  Open -label: at least 2 years   NA 
Year of study  Year 1  Year 2    
Visitc V1 V2 V3 V4 V5 V6**  V7**  V8 Telephone 
Contactd V9 V10**  V11 ET 
Visite Termination 
Visitf Unscheduled 
Visit  
Week  0 2 6 14 22 30 38 46  62 78 94   NA 
Days with help from a caregiver  
due to epi[INVESTIGATOR_002]  X* X X X X   X  X  X X X  
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; BP=blood pressure; BRIEF=Behavior Rating Inventory of Executive Function; BRIEF -P=Behavior Rating 
Inventory of Executive Function -Preschool Version; CBCL=Child Behavior Checklist; C -SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; EQ -5D-3L=3 -level EuroQol -5 Dimension Quality of Life Assessment; ET=early termin ation; exam=examination; ID=identification; 
IRT=interactive response technology; LCM=lacosamide; NA=not applicable; PedsQL=Pediatric Quality of Life Inventory; QOLIE -31-P=Patient Weighted 
Quality of Life in Epi[INVESTIGATOR_261379] -Form 31; V=Visit  
Note: For sub jects who have completed SP0982, assessments marked (*) should have already been completed during the last visit of the previ ous protocol and do 
not need to be repeated at Visit 1; for eligible Baseline failures from SP0982, a full Visit 1 is required incl uding all scheduled tasks and procedures.  
Note: Visit 6, Visit 7 and Visit 10 (**) assessments will not be performed according to Protocol Amendment 3.  
a The duration of the Treatment Period will continue for at least [ADDRESS_317820] age group and is defined in Secti on 5.1.1 .  
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of the investigat or. In addition to the 
required assessments listed above, depending on the type of visit (clinic or telephone), further assessments  can be completed as needed and may include 
ECG, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to an AE.  
c A window of ±[ADDRESS_317821] every 8 weeks if no clinic 
visit is scheduled.  
d Telephone contacts are required every 8 weeks including Week 30 and Week 38 during the study, except during weeks in which a clinic visit is planned (eg, 
Week 62). Therefore, telephone conta cts in Year [ADDRESS_317822] be completed for all subjects who prematurely discontinue from the study. This will be followed by [CONTACT_261486] , an End of Taper Visit, and 
a Safety Follow -Up Period; see  Table  5-4. For subjects who continue on commercial LCM, the early Termination Visit is the last visit in the study.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317823] be comple ted for all subjects who complete the study. This can be combined with Visit 17 if appropriate (see Table  5‒2). For 
subjects who will not continue on L CM, this visit will be followed by [CONTACT_261486], an End of Taper Visit, and a Safety Follow -Up Period; see Table  5-4. For 
subjects who continue on LCM, the T ermination Visit is the last visit in the study.  
g The complete physical examination will include cardiac and respi[INVESTIGATOR_261401]. 
h The brief physical examination will include review of the following body syste ms: cardiovascular, pulmonary, abdominal (hepato -gastrointestinal), and 
dermatologic.  
i The complete neurological examination will include selected assessment of mental status, sensory systems, motor functions, cr anial nerves, reflexes, and 
coordination/cer ebellar function.  
j The brief neurological examination will include selected assessment of general neurological status, reflexes, muscle strength , and coordination/cerebellar 
function.  
k The ECG recordings should be performed at the same time of day (when poss ible) and prior to blood sample collection and vital sign assessments. Care 
should be taken to assure proper lead placement and quality ECG recordings. If possible, subjects should rest in a supi[INVESTIGATOR_261402] 5 minutes prior to 
each recording and sh ould be motionless during the recording. In pediatric subjects (<18 years of age) a 12 -lead ECG (2 interpretable recordings) 
approximately [ADDRESS_317824] be performed.  
l Blood pressure measurements should be taken with the proper placement and p roper sized cuff to obtain accurate measurements.  
m Height will be recorded at Visits 1 and 9, and at the ET and Termination Visit.  
n The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who enter puberty during the course of t he study.  
o Urinalysis will be required for all subjects.  
p If the patient was treated in SP0982, endocrinology should be done if age was <18 years at SP0982 Visit 1. If the patient was  a Baseline failure in SP0982, 
endocrinology should be done if age is <18 years at EP0012 Visit 1.  
q Pregnancy tests will be performed for female subjects of childbearing potential only. Serum pregnancy tests will be conducted  at the following visits: Visit 1 
(W0), ET, and Termination Visit. All other pregnancy tests will be urine  dipstick. Baseline failures from SP0982 may have an additional urine pregnancy 
test at V1 of EP0012, at the investigator’s discretion.  
r The C -SSRS will be completed for all subjects ≥6 years of age (see Section 10.4.3 ).  
s The QOLIE -31-P will be performed for subjects who are ≥18 years of age  and the PedsQL will be performed for subjects <[ADDRESS_317825]’s ag e should be completed, with the following exception: if a subject ages up to the next form of the PedsQL within 1 year 
after the Baseline assessment of the primary study, the form that was used at the Baseline assessment should be completed for  1 year afte r the Baseline 
assessment, and subsequently the form consistent with his/her age at the time of assessment should be completed. For each version of the PedsQL subjects 
must have at least 1 year of data before transitioning to the next age range (see Sectio n 9.2.1 ).  
t The Achenbach CBCL: CBCL/1½ -5 for children 18 months to 5 years and 11 months of age and CBCL/6 -18 for children ≥6 years to <18 years of a ge; to be 
completed by [CONTACT_7071](s)/legal representative(s) (estimated completion time 45 minutes). The version of the Achenbach CBCL appropriate to each 
subject’s age should be administered with the following exception: for subjects who completed the CBC L/1½ -5 at the Baseline assessment of the previous 
study and turn 6 years of age within 1 year after the Baseline assessment of the primary study, the CBCL/1½ -5 should be completed for 1 year after the 
Baseline assessment of the primary study, and subsequen tly the CBCL/[ADDRESS_317826] 1 year  of data before transitioning to 
the next ag e range. The Achenbach CBCL should be completed by [CONTACT_261487]/legal representative, if possible (see Section 10.4.6 ).  
u The BRIEF -P should be us ed for subjects who are <5 years of age at Visit 1, and the BRIEF should be used for subjects who are ≥[ADDRESS_317827] 1 year of data before transitioning to  the next age range (see 
Section  10.4.7 ). 
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study  Protocol  Lacosamide  EP0012  
   
Confidential  Page 28 of 274 Table  5‒2: Schedule o f study assessments for Years 3 through 5 for EP0012 (Treatment 
Period, ET Visit, Termination Visit, and Unscheduled Visit for subjects <18  years 
at enrollment)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately  5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5 + Extended Period     
Visitc TCd V12 V13 V14 V15 V16 V17 Vxf ET Visitg Term  Visith LCM Solution 
Dispensation 
Visiti Unscheduled 
Visit  
Week   118 142 166 190 214 238 X    NA 
Concomitant medications and 
AED(s)  X X X X X X X X X X  X 
Physical exam (complete)j   X  X  X X (odd 
visits only)  X X   
Neurological exam (brief)k  X  X  X X X (even 
visit only)  X X   
12-lead ECGl   X  X  X X (odd 
visits only)  X X   
Vital signs (BP and pulse)  
including orthostatic 
assessmentsm  X X X X X X X X X  X 
Body weight and heightn  X X X X X X X (even 
visits only)  X X   
Tanner Stageo   X  X  X X (odd 
visits only)  X X   
Laboratory tests   X  X  X Xp Xp X X   
Endocrinologyq         X X   
Pregnancy testr  X X X X X X X X X   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study  Protocol  Lacosamide  EP0012  
   
Confidential  Page 29 of 274 Table  5‒2: Schedule o f study assessments for Years 3 through 5 for EP0012 (Treatment 
Period, ET Visit, Termination Visit, and Unscheduled Visit for subjects <18  years 
at enrollment)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately  5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5 + Extended Period     
Visitc TCd V12 V13 V14 V15 V16 V17 Vxf ET Visitg Term  Visith LCM Solution 
Dispensation 
Visiti Unscheduled 
Visit  
Week   [ADDRESS_317828] diary return/review   X X X X X X X X X  X 
Dispense LCM   X X X X X X X X X X  
LCM review/return   X X X X X X X X X X  
Withdrawal criteria  X X X X X X X X X X  X 
AE reporting  X X X X X X X X X X  X 
Achenbach CBCLt   X  X  X X (odd 
visits only)  X X   
BRIEFu   X  X  X X (odd 
visits only)  X X   
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; BP=blood pressure; BRIEF=Behavior Rating Inventory of Executive Function; BRIEF -P=Behavior Rating 
Inventory of Executive Function -Preschool Version; CBCL=Child Behavior Checklist; C -SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; ET=early termination; exa m=examination; IRT=interactive response technology; LCM=lacosamide; NA=not applicable; 
Term=Termination; V=Visit; Vx=Visit X  
Note: Subjects who turn [ADDRESS_317829] age group and is defined in Section 5.1.1 . 
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of th e investigator. In addition to the 
required assessments listed above, depending on the type of visit (clinic or telephone), further assessments can be completed as needed and may include 
physical or neurological examination, ECG, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to a psychiatric AE.  
c A window of ±[ADDRESS_317830] every 8 weeks if no clinic  
visit is scheduled.  
d Telephone contacts are required every 8 weeks during the study. Telephone contacts are not required during wee ks in which a clinic visit is planned 
(eg, Week 118). Therefore, telephone contacts are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 158, 
Week 174, Week 182; Year [ADDRESS_317831] and/or legal representative t o best manage the subject's 
epi[INVESTIGATOR_002].  
f Subjects may require additional routine visits (Visit X) if the study is still ongoing at Week [ADDRESS_317832] . Vx visits are to be performed 
every 24 weeks. Additional routine visits should be scheduled and performed in accordance w ith footnote ‘b’ to avoid visit window deviations. Assessments 
must be performed in accordance with Table  5‒3. 
g An ET Visit must be completed for all su bjects who prematurely discontinue from the study. This will be followed by [CONTACT_261486], an End of Taper Visit, and 
a Safety Follow -Up Period; see Table  5-4. For subjects who continue on commercial LCM, the early Termination Visit is the last visit in the study.  
h A Termination Visit must be completed for all subjects who complete the study. This can be performed in alignment of the date  of the last scheduled  visit if 
appropriate. For subjects who will not continue on LCM, this visit will be followed by [CONTACT_261486], an End of Taper Visit, and a Safety Follow -Up Period; 
see Table  5-4. For subjects who continue on LCM, the Termination Visit is the last visit in the study.  
i Dispensation Visit will occur 12 weeks after each 24 -weekly visit from Year 2 (Visit 11) to Year 3 onwards and will be for the purpose of dispen sing LCM 
solution for pediatric subjects <50kg.  
j The complete physical examination will include cardiac and respi[INVESTIGATOR_261401]. 
k The brief neurological examination will include selected assessment of general neurological status, reflexes, muscle strength, and coordination/cerebellar 
function.  
l The ECG recordings should be performed at the same time of day (when possible) and prior to blood sample collection and vital  sign assessments. Care 
should be taken to as sure proper lead placement and quality ECG recordings. If possible, subjects should rest in a supi[INVESTIGATOR_207187] 5 minu tes prior to 
each recording and should be motionless during the recording. In pediatric subjects (<18 years of age) a 12 -lead ECG ( 2 interpretable recordings) 
approximately [ADDRESS_317833] be performed.  
m Blood pressure measurements should be taken with the proper placement and proper sized cuff to obtain accurate measurements.  
n Height will be recorded at Visits 12, 14, 16, V isit X (even visits), and at the ET and Termination Visit.  
o The Tanner Stage will be performed only for subjects who are pubescent at Visit [ADDRESS_317834] schedule d visit/Termination Visit. If the last scheduled visit is not the Termination Visit, laboratory 
tests are not required.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study  Protocol  Lacosamide  EP0012  
   
Confidential  Page 31 of 274 q If the patient was treated in SP0982, endocrinology should be done if age was <18 years at SP0982 Visit 1. If the patient was  a Baseline  failure in SP0982, 
endocrinology should be done if age is <18 years at EP0012 Visit 1.  
r Pregnancy tests will be performed for female subjects of childbearing potential only. Serum pregnancy tests will be conducted  at the following visits: Visit 1 
(W0), ET,  and Termination Visit. All other pregnancy tests will be urine dipstick. Baseline failures from SP0982 may have an additional  urine pregnancy 
test at V1 of EP0012, at the investigator’s discretion.  
s The C -SSRS will be completed for all subjects ≥6 years of  age (see Section 10.4.3 ).  
t The Achenbach CBCL: CBCL/6 -18 for children ≥6 years to <18 years of age; to be completed by [CONTACT_7071](s)/legal representative(s) (estimated completion 
time 45 minutes). For each version of the CBCL, subjects must have at least 1 year of data before transi tioning to the next age range. The Achenbach CBCL 
should be completed by [CONTACT_261487]/legal representative, if possible (see Section 10.4.6 ).  
u The BRIEF should be used for subjects who are ≥[ADDRESS_317835] 
1 year of data before transitioning to the next age range (see Section  10.4.7 ). 
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study  Protocol  Lacosamide  EP0012  
   
Confidential  Page 32 of 274 Table  5‒3: Schedule of study assessments for Years 3 through 5 for EP0012 
(Treatment Period , ET Visit, Termination Visit, and Unscheduled Visit for 
subjects ≥18  years at enrollment)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of 
study  Year 3  Year 4  Year 5 +Extended  Period     
Visitc TCd V12 V13 V14 V15 V16 V17 Vxe ET Visitf Term  Visitg LCM Solution 
Dispensation 
Visit  Unscheduled 
Visit  
Week   118 142 166 190 214 238 X    NA 
Concomitant 
medications 
and AED(s)  X X X X X X X X X X  X 
Laboratory 
testsh  X  X  X Xi Xi X X   
Pregnancy 
testj  X X X X X X X X X   
Dispense 
subject diary   X X X X X X X X X   
Subject diary 
return/review   X X X X X X X X X  X 
Call IRT  X X X X X X Xe X X  X 
Dispense 
LCM   X X X X X X X X X X  
LCM 
review/return   X X X X X X X X X X  
Withdrawal 
criteria  X X X X X X X X X X  X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study  Protocol  Lacosamide  EP0012  
   
Confidential  Page 33 of 274  
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ET=early termination; IRT=interactive 
response technology; LCM=lacosamide; NA=not applicable; Term=Termination; V=Visit; Vx=Visit X  
a The duration of the Treatment Period will vary by [CONTACT_261488] 5.1.1 . 
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of th e investigator. In addition to the 
required assessments listed above, depending on the type of visit (clinic  or telephone), further assessments can be completed as needed and may include 
physical or neurological examination, ECG, vital signs, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to a psychiatric 
AE. 
c A window of ±[ADDRESS_317836] every 8 w eeks if no clinic 
visit is scheduled.  
d Telephone contacts are required every 8 weeks during the study. Telephone contacts are not re quired during weeks in which a clinic visit is planned (eg, 
Week 118). Therefore, telephone contacts are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 158, Week 
174, Week 182; Year [ADDRESS_317837] and/or legal 
representative to best manage the subject's epi[INVESTIGATOR_002].  
f An ET Visit must be completed for all subjects who prematurely discontinue from the study. For subjects who will not continue  on LCM, this visit will be 
followed by [CONTACT_261486], an End of  Taper Visit, and a Safety Follow -Up Period; see Table  5-4. For subjects who continue on commercial LCM, the early 
Termination Visit is the last visit in  the study. Investigators should discuss treatment options with the subject and/or legal representative to best manage the 
subject's epi[INVESTIGATOR_002].  
g A Termination Visit must be completed for all subjects who complete the Treatment Period (Week 238 or extended t reatment period). This can be performed 
in alignment of the date of the last scheduled visit if applicable. For subjects who will not continue on commercial LCM, thi s visit will be followed by [CONTACT_261489], an End of Taper Visit, and a Safety Follow -Up Period ; see Table  5-4. For subjects who continue on LCM, the Termination Visit is the last visit in the 
study. A Termination Visit is to be done if the subject is leaving the study prior to Week 238 following the approval of the PGTCS indication in their 
respective region/coun try as follows: for US subjects, when the US approval is obtained; for EU subjects, if the EU approval is obtained; and for a ll other 
adults at the approval of the PGTCS indication in Japan (last targeted approval). When subjects leave the study, investiga tors should discuss treatment 
options with the subject and/or legal representative to best manage the subject's epi[INVESTIGATOR_002].  
h Laboratory tests include chemistry, hematology and, urinalysis.  
i Laboratory tests are applicable for the combined last scheduled visit /Termination Visit. If the last scheduled visit is not the Termination Visit, laboratory 
tests are not required.  
j Pregnancy tests will be performed for female subjects of childbearing potential only. Serum pregnancy tests will be conducted  at the following visits: Visit 1 
(W0), ET, and Termination Visit. All other pregnancy tests will be urine dipstick. Baseline failures from SP0982 may have an additional urine pregnancy 
test at V1 of EP0012, at the investigator’s discretion.  AE reporting  X X X X X X X X X X  X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study  Protocol  Lacosamide  EP0012  
   
Confidential  Page 34 of 274  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 35 of 274 Table  5-4:Schedule of study assessments (Taper Period and Safety Follow -
Up Period)  
 
Assessment  
 Taper Perioda 
(up to 4 weeks)  Safety Follow -Up Periodb 
End of Taper Visit 
(maximum [ADDRESS_317838] dose)c 
 Safety Follow -Up 
Visit  Safety Follow -Up 
TC 
2 weeks (±2 days) 
after last dose of 
study drug  30 days ( -1/+3 
days) after last 
dose of study drug  
Concomitant medications and AED(s)  X X X 
Physical exam (complete)  X X  
Neurological exam (brief)  X X  
12-lead ECGd X Xe  
Vital signs (BP and pulse) including 
orthostatic assessments  X X  
Body weight  X X  
Laboratory tests:     
 Chemistry/hematology  X Xe  
 Endocrinology   Xe  
 Urine pregnancy testf X X  
Contact [CONTACT_12067]  X   
Subject diary return/reviewg X   
LCM review/return  X   
Withdrawal criteria  X   
AE reporting  X X X 
C-SSRSh X X  
Healthcare resource usei X X  
Work/school days lost  due to epi[INVESTIGATOR_261403] X X  
Days with help from a caregiver  due to 
epi[INVESTIGATOR_261403] X X  
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; BP=blood pressure; C -SSRS=Columbia -Suicide Severity Rating 
Scale; ECG=electrocardiogram; IRT=interactive response technology; LCM=lacosamide; TC=telephone contact  
[CONTACT_41936]: The schedule of study assessments for the Taper Period and Safety Follow -Up Visit includes some of the 
subjects who tapered in SP0982 after the 125th event who consented to enter EP0012 for the Safety Follow -Up 
only.  
a Subjects who will not continue on LCM must complete an End of Taper Visit and a Safety Follow -Up 
Period; see Table  5-4. For subjects who continue on commercial LCM, the (Early) Termination Visit is the 
last visit in the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 36 of 274 b There will be a 30 -day ( -1/+3 days) Safety Follow -Up Period for subjects who complete the End of Taper 
Visit. The Safety Follow -Up Period consists of a clinic visit 2  weeks after the End of Taper Visit followed 2 
weeks later by a TC Visit.  
c An End of Taper Visit will be scheduled at the end of the Taper Period (up to 4 weeks) depending on dose 
level achieved; see Table 7‒2. Of note, for subjects who enter the Taper Period at ≤2mg/kg/day (oral 
solution) or 100mg/day (tablets), the End of Taper Visit will take place at the ET or Termination Visit.  
d The ECG recordings shou ld be performed at the same time of day (when possible) and prior to blood 
sample collection and vital sign assessments. Care should be taken to assure proper lead placement and 
quality ECG recordings. If possible, subjects should rest in a supi[INVESTIGATOR_261404] 5 minutes prior to each 
recording and should be motionless during the recording. In pediatric subjects (<18 years of age) a 12 -lead 
ECG (2 interpretable recordings) approximately [ADDRESS_317839] be performed.  
e The assessment will only be required for subjects with an abnormal value (clinical chemistry, hematology, 
or endocrinology) or reading (ECG) at the previous clinic visit.  
f Pregnancy tests will be performed for female subjects of childbearing potential only. A urine pregnancy test 
will be performed.  
g The last subject diary will be returned at the End of Taper Visit.  
h The C -SSRS will be completed for all subjects ≥6 years of age (see Section  10.4.3 ). 
i Healthcare resource use, work/schools days lost due to epi[INVESTIGATOR_002], and days with help from a caregiver due to 
epi[INVESTIGATOR_261405] ≤2 years. These assessments are not 
applicable for patie nts tapering down or performing the SFU -visits during Years 3, 4 or 5).  
5.3 Rationale for study design and selection of dose  
Clinical experience has shown that up to 30% of patients with PGTCS who are treated with 
currently available AEDs have inadequate seizu re control or poor drug tolerability. Thus, 
there is a significant unmet medical need for new treatment options in this patient population.  
The efficacy, safety, and tolerability of LCM as an adjunctive therapy  have been 
demonstrated in the partial -onset seizure population. The approach for further LCM 
development is to evaluate the use of adjunctive LCM for the treatment of uncontrolled 
PGTCS in patients with IGE.  
The goal of the Phase 3 LCM PGTCS program is to provide clinical evidence of the efficacy 
and safety of LCM as an adjunctive therapy  for uncontrolled PGTCS in subjects with IGE as 
the basis for approval of this indication . SP0982 is a double -blind, randomized, placebo -
controlled, parallel -group, multicenter study designed to evaluate the efficac y and safety of 
LCM for uncontrolled PGTCS in subjects ≥[ADDRESS_317840] completed SP0982 and eligible Baseline 
failures from SP0982.  
For adult subjects (≥18 years of age), the LCM 400mg/day maintenance dose was well 
tolerated and demonstrated efficacy in 3 primary efficacy studies as adjunctive therapy in 
subjects with partial -onset seizures. In SP0961 (the Phase 2 pi[INVESTIGATOR_799]) and SP09 62 (the 
open -label extension study) in subjects with uncontrolled PGTCS with IGE, the 400mg/day 
dose was also well tolerated. Generally, the doses of AEDs used for the treatment of partial -
onset seizures are similar to those used to treat generalized seizu res. Thus, the 300mg/day to 
400mg/day target dose range is considered the optimal maintenance dose for the population 
with uncontrolled PGTCS with IGE. The maximum dose of LCM  800mg/day is the highest 
dose that has been used in previous clinical studies. D ose selection in EP0012 is based on the 
primary study (SP0982). During EP0012, investigators will be allowed to increase or 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317841]. 
Lacosamide doses may be increased up to a maximum of LCM  12mg/kg/day (oral solution) 
for pediatric subjects weighing <50kg. The maximum dose for pediatric subjects (<18 years 
of age) ≥50kg is 600mg/day (tablets) and for adult subjects is 800mg/day (tablets).  
[ADDRESS_317842] be met:  
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved 
written Informed Consent/Assent form for the open -label extension stud y (EP0012) must 
be signed and dated by [CONTACT_261490](s) or legal representative. The 
Informed Consent form or a specific Assent form, where required, will be signed and 
dated by [CONTACT_122256].  
2. Subject must have completed or be an eligible Baseline failure from the parent study 
(SP0982), as defined in Section 5.1. Note: Other subjects screened for SP0982 may be 
considered for roll -over to EP00 [ADDRESS_317843]/legally acceptable representative considered as relia ble and capable of adhering to 
the protocol (eg, able to understand and complete diaries and questionnaires), visit 
schedule, and medication intake according to the judgment of the investigator.  
6.2 Exclusion criteria  
Subjects are not permitted to enroll in the study if any of the following criteria is met:  
1. Subject is receiving any investigational drugs or using any experimental devices in 
addition to LCM.  
2. Subject meets the withdrawal criteria for SP0982 or is experiencing an ongoing serious 
adverse event (SA E). 
3. Subject has an active suicidal ideation as indicated by a positive response (“Yes”) to 
either Question 4 or Question 5 of the “Since Last Visit” version of the Columbia -Suicide 
Severity Rating Scale (C -SSRS). The subject should be referred immediately to a Mental 
Healthcare Professional.  
4. Subject has ≥2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), 
or >ULN total bilirubin (≥1.5xULN total bilirubin if kno wn Gilbert’s syndrome). If 
subject has elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate 
bilirubin to identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).  
For all subjects who entered EP0012 directly with a  Baseline result >ULN for ALT, AST, 
ALP, or total bilirubin, a Baseline diagnosis and/or the cause of any clinically meaningful 
elevation must be understood and recorded in the eCRF.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317844], or ALP up to 25% above the exclusion limit  may be 
repeated once for confirmation.  
If the investigator has any doubts concerning the subject’s eligibility, he/she should consult 
the UCB Study Physician or representative for clarification.  
6.[ADDRESS_317845] be withdrawn from the study if any of the following events occur:  
1. Tapered subjects from SP0982 who enter EP0012 after the 125th event will be withdrawn 
at the enrollment visit and enter directly into the Safety Follow -Up Period without a nd ET 
Visit being performed in EP0012.  
2. The subject develops second or third degree atrioventricular  (AV) block.  
3. The subject becomes pregnant, as evidenced by a positive pregnancy test.  
4. The sponsor or a regulatory agency requests withdrawal of the subject.  
5. The subject is unwilling or unable to continue, or the legal representative is unwilling or 
unable to allow the subject to continue in the study.  
6. In the case of liver function test (LFT) results of transaminases (ALT and/or aspartate 
AST) ≥3x ULN to <5xUL N and total bilirubin ≥2xULN or transaminases (AST and/or 
ALT) ≥5xULN, LCM must be immediately discontinued, and the subject withdrawn from 
the study. The LFTs will be repeated as soon as possible, and in no case more than 
[ADDRESS_317846] ≥[ADDRESS_317847] visit as indicated by a 
positive response “Yes” to either Question  4 or Question  5 of the “Since Last Visit” 
version of the C -SSRS. The subject should be referred immediately to a Mental 
Healt hcare Professional and must be withdrawn from the study . 
8. Subject is unable to tolerate at least the minimum LCM target dose of 4mg/kg/day (oral 
solution) or 200mg/day (tablets).  
Subjects may be withdrawn from the study if any of the following events occur:  
• The subject requires a medication that is not permitted (see Section 7.8). 
• The subject is unable to manage the completion of the diary, demonstrates a questionable 
diary, or is noncompliant with the study procedures or medications in the opi[INVESTIGATOR_261406] r. 
• An epi[INVESTIGATOR_261407], a prolongation of seizure duration, a worsening of 
seizure frequency, or emergence of a new seizure type considered by [CONTACT_261491].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 39 of 274 • Subject develops a clinically relevant change in medical c ondition (or ECG or laboratory 
parameter) as determined by [CONTACT_093], and the investigator feels it is in the interest 
of the subject to withdraw.  
• Discontinuation criteria for potential drug -induced liver injury (PDILI) are described in 
Section 6.3.[ADDRESS_317848] igator should make an effort (at least [ADDRESS_317849]), and document his/her effort (date and 
summary of the phone call and copy of the written message in the source documents), to 
complete the final evaluation. All resul ts of these evaluations and observations, together with 
a narrative description of the reason(s) for removing the subject, must be recorded in the 
source documents. The electronic Case Report form (eCRF) must document the primary 
reason for withdrawal.  
After the decision to withdraw the subject, the investigator will provide the subject with 
information about available alternative treatments.  
6.3.[ADDRESS_317850] 
(IMP) must be immediately and permanently discontinued. In addition, all concomitant 
medications and herbal supplements that are not medically necessary should also be 
discontinued.  
The PDILI criteria below require imme diate and permanent discontinuation of IMP:  
− ALT or AST ≥5xULN  
− ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).  
If a nondrug -related cause for the symptoms can be confirmed, these subjects may  resume 
IMP administration after discussion with the responsible UCB physician, but only when the 
requirements for rechallenge with IMP as provided in Section [IP_ADDRESS].1  are followed.  
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator.  
• Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%) , with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).  
Evaluation of PDILI must be initiated as described in Section 10.3.[ADDRESS_317851] be discontinued immediately. See 
Section 6.3 for when and how to discontinue subjects from the IMP. See Section 8.2 for the 
procedures to be performed at the time of discontinuation.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 40 of 274 Investigators should attempt to obtain information on subjects in the case of IMP 
discontinuation to complete the final evaluation. Subjects with PDILI should not be 
withdrawn from the stu dy until investigation and monitoring are complete. All results of 
these evaluations and observations, as well as the reason(s) for IMP discontinuation and 
subject withdrawal (if applicable), must be recorded in the source documents. The CRF must 
document the primary reason for IMP discontinuation.  
7 STUDY TREATMENT(S)  
7.[ADDRESS_317852](s)  
Investigational medicinal product (IMP) will be provided as LCM oral solution (LCM 
10mg/mL) and LCM tablets (LCM 50mg and LCM 100mg).  
The ora l solution formulation contains 10mg/mL of drug substance and is colorless to pale 
yellow in appearance.  
The tablet formulation will be supplied in doses of 50mg and 100mg. The 50mg tablets are 
light pi[INVESTIGATOR_8745], oval, film -coated tablets debossed with “SP” on 1 side and “50” on the other. The 
100mg tablets are dark yellow, oval, film -coated tablets debossed with “SP” on 1 side and 
“100” on the other.  
7.2 Treatment(s) to be administered  
Lacosamide will be orally administered bid (at approximately 12 -hour intervals in the 
morning and in the evening) in 2 equally divided doses (oral solution for pediatric subjects 
weighing <50kg or tablets for adult subjects [≥18 years of age] and pediatric  subjects 
[<18  years of age] weighing ≥50kg); during the study, subjects who initially started on oral 
solution may transfer to tablets at the investigator’s discretion.  
Tablets must not be broken . In rare cases where uneven dosing (e.g., 350mg/day, 
450mg /day, 550mg/day, etc) is medically needed, although the interactive response 
technology (IRT) will not dispense the exact dose, please contact [CONTACT_261492]. If subjects are taking an odd number of tablets per day, (eg, 7 tablets 
totaling 350mg), they should take the lower dose in the morning (eg, 150mg [3 tablets]) and 
the higher dose in the evening (eg, 200mg [4 tablets]).  
During the study, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction for each subject, within the dose range described 
in Table  7‒1.  
7.2.1  Treatment Period  
At Visit 1, subjects who completed  SP0982 will start on a dose of  LCM  10mg/kg/day for 
pediatric subjects weighing <30kg, LCM 8mg/kg/day for pediatric subjects weighing ≥30kg 
to <50kg, and LCM 400mg/day (200mg bid) for adult subjects (≥18 years of age) or pediatric 
subjects weighing ≥50kg. Subjects who are eligible Baseline failures from SP0982 will start 
at Visit 1 on a dose of  LCM 2mg/kg/day for pediatric subjects weighing <50kg, and 
LCM  100mg/day (50mg bid) for adult subjects (≥18 years of age) or pediatric subjects 
weighing ≥50kg.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317853] should hold the dose for a lo nger duration. 
There is no limit to the number of back titration steps or dose holds allowed and all are at the 
Investigator’s discretion; however, subjects must achieve the minimum LCM target dose of 
4mg/kg/day (oral solution) or 200mg/day (tablets).  
Subjects who tapered in SP0982 after the 125th event will enroll at Visit [ADDRESS_317854] this minimum dose of 4mg/kg/day (oral solution) or 200mg/day (tablets), then 
the subject must enter the Taper Period and be withdrawn from the study.  
During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolera bility and seizure reduction. Lacosamide doses may be increased or decreased 
in steps of no more than 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects must 
remain on the dose for ≥7 days before a subsequent dose escalation.  
Table  7‒1 provides the minimum and maximum LCM dose during the Treatment Period.  
Table  7‒1: Minimum and maximum LCM dose during the Treatment Period  
Formulation  Minimum LCM dose  Maximum LCM dose  
Oral solution (pediatric subjects <50 kg)  4mg/kg/day  12mg/kg/day  
Tablets (pediatric subjects ≥50kg)  200mg/day  600mg/day  
Tablets (adult subjects)  200mg/day  800mg/day  
LCM=lacosamide  
The LCM dose may be adjusted at the investigator’s discretion after the subject receives the 
first dose of LCM in the study. Baseline failures must complete Week 1 of dosing  before 
LCM may be increased or decreased. The maximum dose for pediatric subjects weighing 
<50kg is 12mg/kg/day (oral solution). The maximum dose for pediatric subjects weighing 
≥50kg is 600mg/day (tablets) and for adult subjects is 800mg/day (tablets).  
A clinic visit (scheduled or unscheduled) is required if:  
• The dose is increased for the first time to any dose above 10mg/kg/day for pediatric 
subjects weighing <50kg. One week after the first time the dose is increased, an 
unscheduled telephone contact m ust be conducted to ensure that the dose is well tolerated.  
• The dose is increased for the first time to any dose above LCM 400mg/day for all adult 
subjects or pediatric subjects weighing ≥50kg. One week after the first time the dose is 
increased, an unsche duled telephone contact [CONTACT_261493].  
Subjects withdrawing from the study must complete the ET Visit and (if they do not proceed 
with commercially available LCM)  an up to 4 -week taper followed by [CONTACT_261494] 
(see taper schedule, Table 7‒2). Following the End of Taper Visit, there will be a [ADDRESS_317855] and/or their parent(s)/legal representative(s) to best manage the subject’s 
epi[INVESTIGATOR_002]. Taper of LCM may not be required for some subjects who complete the study 
depending on the treatment option selected by [CONTACT_261495]/or parent(s)/legal representative(s).  
Subjects completing the Treatment Period and not continuing with commercially available 
LCM must complete the Termination Visit and also undergo taper, followed by [CONTACT_261496] (see taper schedule, Table 7‒2), and a 30-day Safety Follow -Up Period.  
The following table summarizes the recommended LCM dose taper:  
Table 7‒2: Lacosamide dosing for subjects requiring taper  
Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  Week 4  
11 or 12mg/kg/day  9mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
9 or 10mg/kg/day  8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
7 or 8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  NA 
5 or 6mg/kg/day  4mg/kg/day  2mg/kg/day  NA NA 
4mg/kg/day  2mg/kg/day  NA NA NA 
800mg/day  600mg/day  400mg/day  200mg/day  100mg/day  
700mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
600mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
500mg/day  400mg/day  300mg/day  200mg/day  100mg/day  
400mg/day  300mg/day  200mg/day  100mg/day  NA 
300mg/day  200mg/day  100mg/day  NA NA 
200mg/day  100mg/day  NA NA NA 
ET=early termination; LCM=lacosamide; NA=not applicable  
Note: The oral solution is dosed as mg/kg/day and tablets are dosed as mg/day.  
aSubjects will begin taper on ET/Termination Visit.  
7.3 Packaging  
Lacosamide (tablets and oral solution) is manufactured, packaged, and labeled according to 
Good Manufacturing Practice guidelines and applicable laws or regulations. The IMP is 
suitably packaged in such a way as to protect the IMP from deterioration during transport and 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 43 of 274 storage. Oral solution will be packaged in amber polyethylene terephthalate bottles. Tablets 
will be supplied in high -density polyethylene bottles with child proof polypropylene screw 
caps.  
7.4 Labeling  
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and Good Manufacturing 
Practice and will include any locally required statements. If necessary, labels will be 
translated into the local language.  
7.5 Handling and storage requirements  
The investigator (or designee) is responsible for the safe and proper storage of IMP at the 
site. Investigational medicinal product stored by [CONTACT_207278] a secured 
area with limited access according to t he storage conditions mentioned on the label.  
Appropriate storage conditions must be ensured by [CONTACT_261497] (eg, room, 
refrigeration unit) or by [CONTACT_37142] a temperature log (showing actual and minimum/ 
maximum temperatures reached over the time interval) in accordance with local requirements 
on a regular basis.  
In case an out -of-range temperature is noted, it must be immediately reported as per the 
instructions contained in the IMP Handing Manual.  
The investigator (or designee) will instruct the subject to store the IMP following the 
instructions on the label.  
7.[ADDRESS_317856], damaged (due to breakage or wastage), not used, partially used, 
disposed of at the study site, or returned to the sponsor’s designee must also be recorded on 
the appropriate forms. All supplies and pharmacy documentation must be made available 
throughout the study for UCB (or designee) to review.  
The investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.  
The investigator may assign some of the investigator’s duties for drug accountability at the 
study site to an appropriate pharmacist/designee.  
The investigator must ensure that the IMP is used only in accordance with the protocol.  
Periodically, and/or after completion of the c linical phase of the study, all used (including 
empty containers)/partially used, unused, damaged, and/or expi[INVESTIGATOR_261408], regulations, and UCB Standard 
Operating Procedures (SOPs) or returned to UCB (or designee). Investigational medicinal 
product intended for the study cannot be used for any other purpose than that described in this 
protocol.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317857]’s presence in order to obtain 
explanations regarding discrepancies in compliance with the dosing regimen. Drug 
accountability must be recorded on the Drug  Accountability Form.  
If a subject is found to be persistently noncompliant (defined as less than 75% or more than 
125% compliant with the dosage schedule), the sponsor, in conjunction with the investigator, 
will make a decision as to whether the subject should be withdrawn from the study.  
Timely completion of the subject diary is essential for evaluation of safety and efficacy. 
Subject diary completion, including AED usage, will be evaluated at each clinic visit and 
telephone contact. Sites are encouraged  to call subjects to inquire about their diary 
completion. Investigators should advise subjects and/or caregivers about the importance of 
reporting non -PGTCS.  
7.8 Concomitant medication(s)/treatment(s)  
All concomitant medication and treatment must be recorded  in the appropriate study 
documents (eg, eCRF and source document).  
7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  
Female subjects not surgically sterile or 2 years postmenopausal should practice 1 highly 
effective method of contraception (ac cording to ICH guidance, defined as those that result in 
a failure rate of <1% per year when used consistently and correctly), unless sexually 
abstinent, for the duration of the study. Recommended contraception methods for subjects on 
enzyme -inducing antie pi[INVESTIGATOR_006] (EI -AEDs) or not on EI -AEDs are detailed in 
Section  16.7. Subjects on EI -AEDs who do not use one of the highly effective contraception  
methods recommended for this group may practice 2 combined methods of contraception (ie, 
combined hormonal contraception plus barrier method with spermicidal agent).  
The initiation of felbamate treatment while participating in EP0012 is prohibited.  
The us e of neuroleptics except for clozapi[INVESTIGATOR_140730]. The use of barbiturates and narcotic 
analgesics is also allowed. Stable use of benzodiazepi[INVESTIGATOR_261409], 
but intermittent use is only allowed as rescue medication for epi[INVESTIGATOR_261410] (maximum 
1 dose per week).  
During the Treatment Period, new concomitant AEDs may be introduced, if the concomitant 
medication has been approved by [CONTACT_261498]’s country. For example, a new AED may be added when the subject has not 
optimally or adequately responded (lack of efficacy or tolerance) to LCM. Concomitant 
AEDs may be carefully tapered and discontinued to achieve LCM monotherapy, if clinically 
appropriate. The Medical Monitor mu st be consulted prior to initiation of concomitant AED 
withdrawal.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 45 of 274 7.8.2  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  
The following medications/therapi[INVESTIGATOR_207178]:  
• Clozapi[INVESTIGATOR_050]  
• MAO -A inhibitors  
• Vigabatrin  
Ther apy that becomes necessary (in the investigator’s opi[INVESTIGATOR_1649]) during the course of the study 
must not be refused to a subject, even if described above as a therapy that is expressly not 
permitted. In cases where this occurs but withdrawal criteria have not be en met, the 
advisability of the subject’s continuation in the study must be discussed between the Medical 
Monitor and the investigator.  
7.9 Blinding  
This is an open -label study; there will be no blinding.  
7.[ADDRESS_317858] or legal representative will be asked to read  and sign 
an Informed Consent form that has been approved by [CONTACT_2717]/IEC and that complies with 
regulatory requirements. The subject or legal representative will be given adequate time to 
consider any information concerning the study, given to them by [CONTACT_941] i nvestigator or designee. 
As part of the informed consent procedure, the subject or legal representative will be given 
the opportunity to ask the investigator any questions regarding potential risks and benefits of 
participation in the study. Additionally, if applicable (according to the subject’s age and local 
requirements), the subject will sign an IRB/IEC Assent form.  
All visits occur at the end of the respective week in the study and a window of ±[ADDRESS_317859] every 8 weeks if no clinic visit is scheduled.  
A detailed schedule of study assessments for treatment Years 1 to 2 is provided in Table  5‒1, 
for treatment Years 3 to 5 in Table  5‒2, Table  5‒3 and for the Taper Period and Safety 
Follow -Up Period in Table  5-4.  
8.1 Treatment Period  
8.1.1  Visit 1 (Week 0)  
The following tasks and procedures are to be performed at this visit (for subjects who have 
completed SP0982, assessments mark ed [*] should have already been completed during the 
last visit of the previous protocol and do not need to be repeated at Visit 1; for eligible 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 46 of 274 Baseline failures from SP0982, a full Visit 1 is required including all scheduled tasks and 
procedures). Tapere d subjects from SP0982 will enter EP0012 for the Safety Follow -Up only 
and will be withdrawn at Visit [ADDRESS_317860] been performed. Details of 
the Safety Follow -Up are provided in Section  8.4.2  and Section 8.4.3 . 
• Written Informed Consent/Assent  
• Inclusion/exclusion criteria  
• Subje ct identification card dispensed  
• Concomitant medications and AEDs*  
• Medical history/epi[INVESTIGATOR_261411]  
• Physical examination (complete)*  
• Neurological examination (complete)*  
• ECG (12 -lead) assessment*  
• Vital signs ( pulse rate, BP) including orthostatic assessments*  
• Body weight and height*  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical  laboratory assessments (includes hematology, 
chemistry, endocrinology for subjects <[ADDRESS_317861] [for women of childbearing potential]).* Baseline failures from SP0982 
may have an additional urine preg nancy test at V1 of EP0012, at the investigator’s 
discretion.  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Dispense LCM  
• Assess withdrawal criteria*  
• AE reporting*  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects  <18 years of age)  
• Achenbach CBCL for subjects <18 years of age  
• BRIEF for subjects <18 years of age  
• Healthcare resource use*  
• Work/school days lost due to epi[INVESTIGATOR_002]*  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 47 of 274 • Days with help from a caregiver  due to epi[INVESTIGATOR_002]*  
8.1.2  Visits 2 to 8 (Weeks 2 to 46, Year 1, excluding Visit 6 and Visit 7)  
The following tasks and procedures are to be performed at these visits:  
• Concomitant medications and AEDs  
• Physical examination (brief, Visit 2, 3, 4, and 5; complete, Visit 8)  
• Neurological examination (brief, Visit 2, 3, 4, an d 5; complete, Visit 8)  
• ECG (12 -lead) assessment (Visit 2, 4, and 8 only)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight (Visit 4, and 8 only)  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or w ho 
enter puberty during the course of the study) (Visit 8 only)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and urinalysis) [Visit 2, 5, and 8 only] , and a ur ine pregnancy test [for women 
of childbearing potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (Visit 5 and 8) (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age) 
(Visit 5 and 8 only)  
• Achenbach CBCL for subjects <18 years of age  (Visit 5 and 8 only)  
• BRIEF for subjects <18 years of age  (Visit 5 and 8 only)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver due to epi[INVESTIGATOR_59661] 
8.1.3  Visits 9 and 11 (Weeks 62 and 94, Year 2, excluding Visit 10)  
The following tasks and procedures are to be performed at these visits:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 48 of 274 • Concomitant medications and AEDs   
• Physical exami nation (brief, Visit 9; complete, Visit 11)  
• Neurological examination (brief, Visit 9; complete, Visit 11)  
• ECG (12 -lead) assessment (Visit 9 and 11)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight and height (height at Visit 9 onl y) 
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 11 only)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assess ments (includes hematology, 
chemistry, urinalysis, and a urine pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (Visit 9 and 11) (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age) 
(Visit 9  and 11  only)  
• Achenbach CBCL for subjects <18 years of age  (Visit 9 and 11 only)  
• BRIEF for subjects <18 years of age (Visit 9 and 11 only)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_002]  
8.1.4  Visits 12, 13, 14, 15, 16, 17 and X (Weeks 118, 142, 166, 190, 214, 
238, and X, Years 3 to 5 + Extended Period)  
[IP_ADDRESS]  Subjects  <18 years  
The following tasks and procedures are to be performed at these visits (Visit X [Vx] visits are 
to be performed every 24 weeks):  
• Concomitant medications and AEDs  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 49 of 274 • Physical examination (complete, Visit 13, 15, 17, and odd numbered visits thereafte r) 
• Neurological examination (brief, Visit 12, 14, 16, 17, and even numbered visits 
thereafter)  
• ECG (12 -lead) assessment (Visit 13, 15, 17, and odd numbered visits thereafter)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight and he ight (height at Visit 12, 14, 16, and even numbered visits thereafter)  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 13, 15, 17, and odd numbered visits 
thereaft er) 
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and urinalysis) (laboratory tests are applicable for combined Visit 
17/Termination Visit. If Visit 17 is not the Termination Visit, laboratory tests are not 
required. Laboratory tests are not performed at Visit 13 and 15 according to Protocol 
Amendment 3.  
• Urine pregnancy test (for women of childbearing potential)  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary r eturn/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• Achenbach CBCL for subjects ≥6 years to <18 years of age (Visit 13, 15, 17, and odd 
numbered visits thereafter)  
• BRIEF for subjects ≥5 to <18 years of age (Visit 13, 15, 17,  and odd numbered visits 
thereafter)  
[IP_ADDRESS]  Subjects ≥18 years  
The following tasks and procedures are to be performed at these visits, additional routine 
visits (Visit X) can be done after Visit 17 (Vx visits are to be performed every 24 weeks) with 
assessments d escribed in Table  5‒3. 
• Concomitant medications and AEDs  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, an d urinalysis) (laboratory tests are applicable for combined Visit 
17/Termination Visit. If Visit 17 is not the Termination Visit, laboratory tests are not 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 50 of 274 required. Laboratory tests are not performed at Visit 13 and 15 according to Protocol 
Amendment 3.  
• Urine pregnancy test (for women of childbearing potential)  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
8.1.[ADDRESS_317862]  
Telephone contacts are required at Week 30 and  Week 38 and every 8 weeks during Year 2 
to Year 5, except during weeks in which a clinic visit is planned (eg, Week 62). Therefore, 
telephone contacts in Year 2 are scheduled for Week 54, Week 70, Week 78, and Week 86. 
Telephone contacts in Years 3 to 5  are scheduled for: Year 3 - Week 102, Week 110, Week 
126, Week 134; Year 4 - Week  150, Week 158, Week 174, Week 182; Year [ADDRESS_317863] the following assessments will be performed:  
• Concomitant medications and AEDs  
• Assess withdrawal criteria  
• AE reporting  
The investigator will also ensure subjects are compliant with LC M administration and diary 
completion during the telephone contact.  
8.1.6  LCM Solution Dispensation Visit  
From Year 3 onwards, pediatric subjects weighing <50kg will return to the clinic for an 
additional Dispensation Visit 12 weeks after each 24 -weekly visit, f or the dispensation of 
LCM solution; LCM usage will be reviewed, and empty LCM bottles will be returned.  
8.2 Early Termination Visit  
Subjects withdrawing from the study will complete the ET Visit, and LCM will be tapered 
over a period of up to 4 weeks if not continuing with commercially available LCM (see taper 
schedule, Table 7‒2). 
The following tasks and procedures are to be performed at this visit:  
• Concomitant medications and AEDs  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 51 of 274 • Physical examination (complete), excluding subjects ≥[ADDRESS_317864] 2 years  
• Neurological exa mination (brief), excluding subjects ≥[ADDRESS_317865] 2 years  
• ECG (12 -lead) assessment, excluding subjects ≥[ADDRESS_317866] 2 years  
• Vital signs ( pulse rate, BP) including orthostatic assessments, excluding subjects ≥[ADDRESS_317867] 2 years  
• Body weight and height, excluding subjects ≥[ADDRESS_317868] 2 years  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study), excluding subjects ≥[ADDRESS_317869] 2 
years  
• C-SSRS assessment (for subjects ≥6  years of age), excluding subjects ≥[ADDRESS_317870] 2 years  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology for subjects <[ADDRESS_317871] [for women of childbearing potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• Achenbach CBCL for subjects <18 years of age  
• BRIEF for subjects <[ADDRESS_317872] 2 years (see Section 4.2.3 ): 
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help  from a caregiver  due to epi[INVESTIGATOR_002]  
8.3 Termination Visit  
A Termination Visit will be completed by [CONTACT_261499] 1 of the following conditions:   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317873] chooses not to continue treatment with LCM.   
Subjects not continuing treatment with LCM will complete the Termination Visit, and LCM 
will be tapered over a period of up to 4  weeks (see taper schedule, Table 7‒2). Subjects who 
continue treatment with commercial LCM must also complete the Termination Visit.  
Taper of LCM is not required for subjects who leave the Termination Visit and transitio n to 
commercial LCM. Subjects transitioning to commercial LCM will do so immediately and 
will continue at a dose determined by [CONTACT_093].  In this instance, the Termination Visit 
will serve as the subject's last visit in the study.   
The following t asks and procedures are to be performed at this visit:  
• Concomitant medications and AEDs  
• Physical examination (complete),  excluding subjects ≥[ADDRESS_317874] 2 years  
• Neurological examination (complete) Note: Complete neurological exam to be perform ed 
for subjects terminating the study during Years 1 -2, for all subjects and brief exam for 
subjects <18 years terminating during Years 3 -5. Neurological exam is excluded for 
subjects ≥[ADDRESS_317875] 2 years.  
• ECG (12 -lead) assessment, excluding s ubjects ≥[ADDRESS_317876] 2 years  
• Vital signs ( pulse rate, BP) including orthostatic assessments excluding subjects 
≥[ADDRESS_317877] 2 years  
• Body weight and height, excluding subjects ≥[ADDRESS_317878] 2 years  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study),  excluding subjects ≥[ADDRESS_317879] 2 
years  
• C-SSRS assessment (for subjects ≥6  years of age), excluding subjects ≥[ADDRESS_317880] 2 years  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology for subjects <[ADDRESS_317881] [for women of childbearing potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary for subjects undergoing taper  
• Subject diary return/review  
• Dispense LCM for subjects undergoing taper  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 53 of 274 • Achenbach CBCL for subjects <18 years of age  
• BRIEF for subjects <[ADDRESS_317882] 2 years (see Section 4.2.3 ): 
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_002]  
8.4 Taper and Safety Follow -Up Period  
8.4.1  End of Taper Visit  
An End of Taper Visit will occur after the final LCM dose for subjects who taper off LCM. 
The following tasks and procedures are to be performed at this visit:  
• Concomitant medications and AEDs  
• Physical examination  (complete)  
• Neurological examination (brief)  
• ECG (12 -lead) assessment  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (i ncludes hematology, 
chemistry, and a urine pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_12067]  
• Subject diary return/review  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
The following assessments are only applicable at the End of Taper Visit for subjects 
terminating/early terminating the study during the first 2 years (see Section 4.2.3 ): 
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_261412].
UCB   [ADDRESS_317883] dose of study 
drug for a Safety Follow -Up Visit (including s ubjects tapered in SP0982 a fter the 125th event 
occurs who enter EP0012 only for a Safety Follow -Up Visit) . During the Safety Follow -Up 
Visit, the following assessments will be performed:  
• Concomitant medications and AEDs  
• Physical examination (complete)  
• Neurological examination (brie f)  
• ECG (12 -lead) assessment (only required for subjects with an abnormal reading at the 
previous clinic visit)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology, [only required for subjects with an abnormal value at the 
previous clinic visit], and a urine pregnancy test [for women of childbearing potential])  
• AE reporting  
The following assessments are only applicable at the Safety Follow -Up Visit for subjects 
terminating/early terminating the study during the first 2 years (see Section 4.2.3 ): 
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_002]  
8.4.[ADDRESS_317884]  
Thirty days ( -1/+3 days) after the last dose of study drug the subject will receive a Sa fety 
Follow -Up telephone contact. During the Safety Follow -Up telephone contact, the following 
assessments will be performed:  
• Concomitant medications and AEDs  
• AE reporting  
8.5 Unscheduled Visit  
Unscheduled Visits may be performed at any time after Visit 1, at the discretion of the 
investigator. A clinic visit (scheduled or unscheduled) is required the first time the dose is 
increased above the dose of 10mg/kg/day (oral solution) for pediatric sub jects weighing 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 55 of 274 <50kg or 400mg/day (tablets) for adult and pediatric subjects ≥50kg. One week after the first 
time the dose is increased above the dose of 10mg/kg/day or 400mg/day, an unscheduled 
telephone contact [CONTACT_261500] i s well tolerated. Similarly, a 
clinic visit (scheduled or unscheduled) is required for pediatric subjects weighing <[ADDRESS_317885] time the dose is increased to 11mg/kg/day, or 12mg/kg/day, and all adult subjects or 
pediatric subjects weighing ≥50kg the f irst time the dose is increased to LCM  500mg/day, 
LCM  600mg/day, LCM  700mg/day, and LCM  800mg/day. One week after the first time the 
dose is increased to 11mg/kg/day, or 12mg/kg/day for pediatric subjects <50kg, and 
LCM  500mg/day, LCM 600mg/day, LCM  700mg/ day, or LCM  800mg/day for all adult 
subjects or pediatric subjects weighing ≥50kg, an unscheduled telephone contact [CONTACT_261501].  
During an Unscheduled Visit the following assessments are required:  
• Concomitant  medications and AEDs   
• Physical examination (brief) during the first 2 years, excluding subjects ≥[ADDRESS_317886] 2 years  
• Neurological examination (brief) during the first 2 years, excluding subjects ≥[ADDRESS_317887] 2 years  
• Vital signs ( pulse rate, BP) including orthostatic assessments, excluding subjects ≥[ADDRESS_317888] 2 years  
• Contact [CONTACT_12067]  
• Subject diary return/review  
• Assess withdrawal criteria  
• AE reporting  
If Unscheduled Visit is due to a psychiatric AE, then the C -SSRS is requ ired. 
In addition to the required assessments listed above, further assessments can be completed as 
needed and may include ECG, laboratory tests, etc.  
[ADDRESS_317889] be consistent with the 
seizure information (including specific type of seizure) reported in the seizure diary.  
9.1.1  PGTCS  
The following information will be recorded as applicable:  
• Seizure type  
• Number of PGTCS  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317890] diary, the following information will be recorded:  
• Seizure type  
• Number of seizures to be recorded although for the purpose of data analysis, only the 
number of days with seizure will be analyzed.  
Investigators should advise subjects and/or caregivers about the importance of reporting 
absence and myoclonic seizures.  
9.[ADDRESS_317891] 2 years of treatment.  
9.2.1  Patient Weighted Quality of Life in Epi[INVESTIGATOR_261379] -Form 31 
(QOLIE -31-P) 
The QOLIE -31-P Version 2 (see Section 16.2) will be used to evaluate the health -related 
quality of life (HRQoL) of study subjects ≥18 years of age (Cramer and Van Hammée, 2003).  
The QOLIE -31-P is an adaptation of the orig inal QOLIE -31 instrument (Cramer et al, 1998) 
that includes 30 items grouped into 7 multi -item subscales (Seizure Worry [5 items], Overall 
Quality of Life [2 items], Emotional Well -being [5 items], Energy/Fatigue [4 items], 
Cognitive Functioning [6 items],  Medication Effects [3 items], and Daily Activities/Social 
Functioning [5 items]) and 1 health status item.  
In addition to the 31 items, the QOLIE -31-P contains 7 items assessing the degree of 
“distress” associated with the topic of each subscale (ie, dist ress items) and 1 item asking 
about the relative importance of each subscale topic (ie, prioritization item).  
9.2.2  Pediatric Quality of Life Inventory  
The PedsQL is a validated instrument that consists of generic core scales suitable for use with 
pediatric popu lations, including those with acute or chronic health conditions (Varni et al, 
2001).  
The PedsQL Measurement Model consists of forms for pediatric subjects ≥2  years to 
≤4 years, ≥5  years to ≤7  years, ≥8  years to ≤12  years, and ≥13  years to ≤18  years of ag e. 
Self-report is measured for pediatric subjects ≥5  years to <18  years of age, and parent proxy 
report of child HRQoL is measured for pediatric subjects ≤[ADDRESS_317892]’s age should be completed, with the following  exception: if a 
subject ages up to the next form of the PedsQL within 1 year after the Baseline assessment of 
the primary study, the form that was used at the Baseline assessment should be completed for 
1 year after the Baseline assessment, and subsequent ly the form consistent with his/her age at 
the time of assessment should be completed.  
For each version of the PedsQL, subjects must have at least 1  year of data before 
transitioning to the next age range.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 57 of 274 The multidimensional PedsQL generic core scales en compass the essential core domains for 
pediatric HRQoL measurement: Physical Functioning, Emotional Functioning, Social 
Functioning, and School Functioning. The PedsQL assessment is retrospective to the prior 
4 weeks, and individual items are scored using a 5-point Likert scale (never, almost never, 
sometimes, often, or always). A total health summary score ranging between 0 and 100 is 
calculated from the sum of the raw scores, with higher scores indicating higher HRQoL.  
9.2.3  EuroQol -5D-3L Quality of Life Assess ment  
The EQ -5D-3L (EuroQol Group, 2011) (see Section 16.3) is a self -administered 
questionnaire designed to measure health status in subjects ≥12 years of age. The EQ -5D-3L 
defines health in terms of 5  dimensions (mobility, self -care, usual activities, pain/discomfort, 
and anxiety/depression). Each dimension is divided into 3 levels:  
• No problem=1  
• Some or moderate problems=2  
• Extreme problems=3  
The EQ -5D-3L also captures a self -rating of health status on a 20cm vertical VAS, anchored 
at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) at the 
bottom.  
9.2.[ADDRESS_317893] 2 years of treatment.  
10 ASSESSMENT OF SAFETY  
10.1 Adverse events  
10.1.1  Definitions  
[IP_ADDRESS]  Adverse event  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship 
with this treatment. An AE can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 58 of 274 In order to ensure complete safety data collection, all AEs occurring during the study 
(ie, after the signing of the Informed Consent/Assent form), including any pretreatment and 
posttreatment periods required by [CONTACT_760], must be reported in t he eCRF even if no 
investigational product was taken but specific study procedures were conducted. This 
includes all AEs not present prior to the initial visit and all AEs that recurred or worsened 
after the initial visit.  
Signs or symptoms of the conditio n/disease for which the investigational product is being 
studied should be recorded as AEs only if their nature changes considerably or their 
frequency or intensity increases in a clinically significant manner as compared to the clinical 
profile known to t he investigator from the subject’s history or the Baseline Period.   
Should an AE involving a seizure be reported, it must be consistent with the seizure 
information (including specific type of seizure) reported in the seizure diary.  
[IP_ADDRESS]  Serious adverse events  
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:  
• Death  
• Life-threatening  
(Life -threatening does not include a reaction that might have caused death ha d it occurred 
in a more severe form.)  
• Significant or persistent disability/incapacity  
• Congenital anomaly/birth defect (including that occurring in a fetus)  
• Important medical event that, based upon appropriate medical judgment, may jeopardize 
the patient or  subject and may require medical or surgical intervention to prevent 1 of the 
other outcomes listed in the definition of serious  
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section [IP_ADDRESS] ], allergic bronchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias that do not result in inpatient hospi[INVESTIGATOR_059], or the 
development  of drug dependency or drug abuse.)  
• Initial inpatient hospi[INVESTIGATOR_318]  
(A patient admitted to a hospi[INVESTIGATOR_307], even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospi[INVESTIGATOR_059]. An emergen cy room visit that results in 
admission to the hospi[INVESTIGATOR_261413]. However, emergency room visits that do not result in admission to the hospi[INVESTIGATOR_261414], instead, should be evaluated for 1 of the other 
criteria in the definition of serious [eg, life -threatening adverse experience, important 
medical event].  
Hospi[INVESTIGATOR_58913] [eg, preplanned 
surgery or elective su rgery for a pre -existing condition that has not worsened or 
manifested in an unusual or uncharacteristic manner] do not qualify for reporting. For 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317894] has a condition recorded on his/her medical history and later has a 
preplanned surgery for this condition, it is not appropriate to record the surgery or 
hospi[INVESTIGATOR_18256], since there is no AE upon which to assess the serious criteria. 
Please note that, if the pre -existing condition has worsened or manifested in an unusual or 
unchar acteristic manner, this would then qualify as an AE and, if necessary, the 
seriousness of the event would need to be determined.)  
If commercial LCM is given during hospi[INVESTIGATOR_059], this needs to be recorded on the CRF.  
[IP_ADDRESS].[ADDRESS_317895] does not change the investigator’s obligation to report all SAEs (including 
Anticipated SAEs ) as detailed in Section 10.1.2 . 
Table  10‒1: Anticipated serio us adverse events for the epi[INVESTIGATOR_261415], Familial and Genetic Disorders  Teratogenicity  
General disorders and Administration Site Conditions  Sudden unexplained death in epi[INVESTIGATOR_261416], Puerperium and Perinatal Disorders  Abortion spontaneous  
Psychiatric Disorders  Psychotic behavior  
 Abnormal behavior  
 Anxiety  
 Sleep disorder  
Reproductive System and Breast Disorders  Menstrual  disorder  
 Impotence  
[IP_ADDRESS]  Adverse events of special interest  
An AE of special interest is any AE that a regulatory authority has mandated be reported on 
an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to 
the administration of a UCB product/compound.  
The following are AEs of special interest:  
• The following arrhythmias: atrial fibrillation/flutter, ventricular tachycardia or fibrillation, 
AV block (second degree, Type I and II, and third degree), and marked bradycardia 
(<45  beats/min)  
• Syncope or loss of consciousness (other than seizure related)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 60 of 274 • Serious suspected multiorgan hypersensitivity reactions.  
Serious suspected multiorgan hypersensitivity cases may be identified and reported to the 
sponsor by [CONTACT_261502]:  
An AE or laboratory value (as defined in the following text) suggestive of internal organ 
involvement (including but not limited to hepatitis, nephritis, pneumoniti s, carditis, 
colitis, encephalitis, pancreatitis, myositis, arthritis, or hematologic system involvement) 
combined with at least 1 of the following: fever, rash, lymphadenopathy, or eosinophilia.  
Treatment -emergent abnormal laboratory value criteria sugges tive of internal organ 
involvement or eosinophilia:  
◦ Eosinophils % ≥10%  
◦ Eosinophils absolute ≥0.5G/L  
◦ Neutrophils absolute <1.5G/L  
◦ Platelets ≤100G/L  
◦ ALT ≥2xULN  
◦ AST ≥2xULN  
• Emergence of non -pre-existing or worsening of any existing epi[INVESTIGATOR_261417]  
• Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the 
biochemical abnormality, must ALWAYS be reported to UCB as an AE of special 
interest (ie, without waiting for any additional etiologic investigations to have been 
concluded). Follow -Up information should then be reported if an alternative etiology is 
identified during investigation and monitoring of the subject.  
10.1.[ADDRESS_317896] AEs. For example:  
“Did you notice anything unusual about your health (since your last visit)?”  
In additio n, the investigator should review any self -assessment procedures (eg, diary cards) 
employed in the study.  
[IP_ADDRESS]  Description of adverse events  
When recording an AE, the investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own 
words on his/her own records (eg, diary card) and the corresponding medical terminology 
should be clarified in the source documentation.  
Details for completion of the AE eCRF (including judgment of relationship to study drug) are 
described in the eCRF Completion Guidelines.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 61 of 274 [IP_ADDRESS]  Rule for repetition of an adverse event  
An increase in the intensity of an AE should lead  to the repetition of the AE being reported 
with:  
• The outcome date of the first AE that is not related to the natural course of the disease 
being the same as the start date of the repeated AE, and the outcome of “worsening”  
The AE verbatim term being the s ame for the first and repeated AE, so that the repeated 
AE can be easily identified as the worsening of the first one  
[IP_ADDRESS]  Additional procedures for reporting serious adverse events  
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information 
by [CONTACT_779] (see contact [CONTACT_261503]). The investigator must forward to UCB (or its 
representative) a duly completed “Investigator SAE Report F orm for Development Drug” 
(SAE report form) provided by [CONTACT_18338], even if the data are incomplete, or if it is obvious that 
more data will be needed in order to draw any conclusions. Information recorded on this form 
will be entered into the global safety datab ase. 
An Investigator SAE Report Form will be provided to the investigator. The Investigator SAE 
Report Form must be completed in English.  
It is important for the investigator, when completing the SAE report form, to include the 
assessment as to a causal r elationship between the SAE and the IMP administration. This 
insight from the investigator is very important for UCB to consider in assessing the safety of 
the IMP and in determining whether the SAE requires reporting to the regulatory authorities 
in an ex pedited manner.  
Additional information (eg, autopsy or laboratory reports) received by [CONTACT_261504] [ADDRESS_317897] and report to UCB (or its representative) 
any SAEs (even if the investigator is certain that they are in no way associate d with the IMP), 
up to [ADDRESS_317898] be reported to UCB 
regardless of the time between the event and the end of the study.  
Upon receipt of the SAE report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on  the Investigator’s 
Brochure.  
10.1.[ADDRESS_317899]; further details 
regarding follow up of PDILI events are provided in Section [IP_ADDRESS] . 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317900], follow up should be provided 
until resolution/stable level of sequelae is achieved, or until the investigator no longer deems 
that it is clinically significant, or until the subject is lost to follow up. If no follow up is 
provided, the investigator must provide a justification. The follow up will usually be 
continued for  [ADDRESS_317901] has discontinued his/her IMP.  
Information on SAEs obtained after clinical database lock will be captured through the 
Patient Safety (PS) database without limitation of time.  
10.1.[ADDRESS_317902] immediately notify UCB’s PS department by [CONTACT_261505] (for contact [CONTACT_261506]). The subject should be 
withdrawn from the study as soon as pregnancy is known (by [CONTACT_18390]), and 
the following should be completed:  
• The subject should return for an ET visit.  
• The subject should immediately stop the intake of the IMP or be down -titrated as 
instructed at the ET visit.  
• A Safety Follow -Up Visit should be scheduled [ADDRESS_317903] of information currently known about potential risks 
and about available treatment alternatives.  
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to 
the investigator. The progression of the pregnancy and the eventual birth (if applicable) must 
be followed up using the Pregnancy Report and Outcome form in which the investigator has 
to report on the health of the mother and of the child. Ever y reasonable attempt should be 
made to follow the health of the child for [ADDRESS_317904]  to follow up and/or refuses to give information, 
written documentation of attempts to contact [CONTACT_261507]. UCB’s PS department is the primary contact [CONTACT_261508], eventual birth, and follow up.  
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, 
UCB will ask the investigator or designee to contact [CONTACT_261509]/IEC and should be available in the investigator site file. In case of questions about the 
consent process, the investigator may contact [CONTACT_58973]/contract research organization (CR O) 
contract monitor for the study. The investigator will complete the Pregnancy Report and 
Outcome form and send it to UCB’s PS department (for contact [CONTACT_261506]) only after th e partner has 
agreed that additional information can be captured and has provided the signed Partner 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 63 of 274 Pregnancy Consent form. UCB’s PS department is also the primary contact [CONTACT_261510], eventua l birth, and follow up.  
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective 
or spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly used), ectopic pregna ncy, fetal demise, or any congenital 
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report Form.  
10.1.[ADDRESS_317905] should be considered as an SAE; such cases must be reported immediately, 
recorded in the AE module of the CRF, and followed as any other SAE. Any organism, virus, 
or infectious particle  (eg, prion protein transmitting transmissible spongiform 
encephalopathy), pathogenic or nonpathogenic, is considered an infectious agent.  
10.1.[ADDRESS_317906]  
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs 
if there are associated clinical signs and symptoms or if t he act of taking the excess medicine 
itself is an AE or SAE (eg,  suicide attempt).  
10.1.[ADDRESS_317907] as early as possible any 
safety concern(s) related to the IMP so that investiga tors, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.  
The Study Physician or medically qualified designee/equivalent will conduct an ongoing 
review of SAEs and perform ongoing SAE reco nciliations in collaboration with the PS 
representative.  
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg,  AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the 
course of the study.  
10.2 New seizure types, increase in days with and worsening of 
days with absence or myoclonic seizures  
Incidence of new seizure types, increase in absence seizure days or myoclonic seizure days 
per 28 days during the Treatment Period, and 50% worsening in days with absence seizures 
or myoclonic seizures per [ADDRESS_317908] diari es (see Section 9.1). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020 13 
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 64 of 274 10.3 Laboratory measurements  
Blood and urine specimens for routine assay of hematology, clinical chemistry, and urinalysis 
parameter s will be collected according to the schedule of study assessments in Table  5‒1, 
Table  5‒2, Table  5‒3 and Table  5-4. A central laboratory will perform the routine analysis of 
blood and urine  specimens. Pregnancy testing will also be performed (see Section  10.3.2 ). 
The procedures for handling and shippi[INVESTIGATOR_261418].  
The laboratory tests to be performed are presented in Table  10‒2. 
Table  10‒2: Laboratory tests  
Hematology  Clinical chemistry  Endocrinology  Urinalysis  
Hematocrit  
Hemoglobin  
Platelet count  
RBC count  
WBC count  
Differential count  Calcium  
Phosphorus  
Serum electrolytes 
(sodium, potassium, 
chloride, bicarbonate)  
Creatinine  
BUN  
AST  
ALT  
Total bilirubin  
Alkaline phosphatase  
GGT  
Glucose  
Albumin  
Total serum protein  
Uric acid  TSH  
T3 (total and serum -free)  
T4 (total and serum -free)  pH 
Ketones  
Glucose  
Albumin  
Specific gravity  
Microscopic exam for 
blood cells or 
casts/hpf  
 
Urine pregnancy test  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; GGT=gamma 
glutamyl transferase; hpf=high power field; RBC=red blood cell; T3=triiodothyronine; T4=thyroxine; 
TSH=thyroid stimulating hormone;  WBC=white blood cell  
10.3.[ADDRESS_317909] be reported as an AE and reported to the study site and sponsor within 24 hours 
of learning of their occurrence. Any PDILI event that meets the cr iterion for potential Hy’s 
Law must be reported as an AE of special interest (see Section [IP_ADDRESS] ), and, if applicable, 
also reported as an SAE (se e Section [IP_ADDRESS] ).  
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table  10‒3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section [IP_ADDRESS] ). The local 
hepatologist is the expert usually consulted by [CONTACT_58979]. This would usual ly be a hepatologist but may be a 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317910]. Additional investigation and monitoring may be required and adapted 
based on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section [IP_ADDRESS] ). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.  
All initial tests resulting in a bnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.  
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whe never possible. Medical care decisions are to be made initially using 
the most rapi[INVESTIGATOR_58916] a conservative approach must be taken if the results 
from the 2 laboratory tests are significantly different. Data from the local and central 
labor atory are to be recorded on the applicable CRF pages.  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose redu ction for medically necessary concomitant medication and consider 
changing any medically required concomitant medication known to be hepatotoxic to a 
suitable alternative.  
When IMP is stopped due to PDILI (as described in Section 6.3.1 ), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explain s the hepatic findings, and the requirements 
provided in Section [IP_ADDRESS].[ADDRESS_317911] not occur.  
The table below summarizes the approach to investigate PDILI.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 66 of 274 Table  10‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULNb NA Hepatology consult.c 
Medical Monitor 
must be notified 
within 24  hours 
(eg, by [CONTACT_67600]) and subject 
discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation.  Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP ( see 
Section  [IP_ADDRESS] ); 
recommended to 
occur at the site 
with HCP.  Monitoring of liver chemistry 
values at least twice per week 
until values normaliz e, 
stabilize, or return to within 
Baseline values.d 
 ≥8xULN  NA NA 
≥3xULN  NA Yes 
≥3xULN 
(and ≥2x 
Baseline) 
and 
<5xULN  <2xULN  No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.  Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  [IP_ADDRESS] ). Not required unless 
otherwise 
medically indicated 
(at discretion of 
investigator).  
≥5xULN 
(and ≥2x 
Baseline)  <2xULN  No Discussion with 
Medical Monitor 
required.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48  hours at 
the site with HCP 
(see 
Section  [IP_ADDRESS] ). Monitoring of liver chemistry 
values at least twice per week 
until values normalize, 
stabilize, or return to within 
Baseline values.d 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 67 of 274 ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible;  AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug -induced liver injury; ULN=upper limit of normal  
a Hepa titis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms incl ude eosinophilia (>5%), 
rash, and fever (without clear alternative cause).  
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi cal Monitor.  
.c Details provided in Section  [IP_ADDRESS] . The local hepatologist is the expert usually consulted by [CONTACT_261511] e. This would usually be a hepatologist, but may be a gastroenterologist.  
d Unless an alternative monitoring schedule is agreed by [CONTACT_58982]. Determination of  stabilization is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.  
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 68 of 274  
[IP_ADDRESS]  Consultation with Medical Monitor and local hepatologist  
Potential drug -induced liver injury events require n otification of the Medical Monitor within 
24 hours (eg, by [CONTACT_58980]), and the subject must be discussed with the Medical 
Monitor as soon as possible. If required, the subject must also be discussed with the local 
hepatologist. The local hepatologis t is the expert usually consulted by [CONTACT_261512]. This would usually be a 
hepatologist, but may be a gastroenterologist. If determined necessary, this discussion should 
be followed by a full hepatology assessment (see Section  [IP_ADDRESS] ) and SAE report (if 
applicable).  
[IP_ADDRESS]  Immediate action: determination of IMP discontinuation  
All PDILI e vents require immediate action, testing, and monitoring. The immediate action is 
dependent on the laboratory values and symptoms of hepatitis or hypersensitivity and ranges 
from continuation of IMP (followed by [CONTACT_58984]) to immediate and per manent 
discontinuation (see Section  6.3.1  and Table  10‒3 for details).  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose 
reduction for medically necessary concomitant m edication and consider changing any 
medically required concomitant medication known to be hepatotoxic to a suitable alternative.  
[IP_ADDRESS].1  IMP restart/rechallenge (if applicable)  
Rechallenge with a substance potentially causing drug -induced liver injury is dangerous , may 
be fatal, and must not occur.  
Subjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as described in Section 6.3.1  and Table  10‒3), but for whom an alternative diagnosis 
is confirmed, can rarely restart IMP. Rechallenge with IMP can occur only if ALL of the 
following requirements are met:  
• The results of additional testing and monitoring described in Section [IP_ADDRESS]  and 
Section  [IP_ADDRESS]  confirm a nondrug -related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative di agnosis fully 
explains the hepatic findings).  
• No alternative treatment options are available to the subject.  
• The subject has shown clear therapeutic benefit from the IMP.  
• Subject’s ALT or AST elevations do not exceed ≥3xULN.  
• Subject’s total bilirubin is < 1.5xULN.  
• Subject has no signs or symptoms of hypersensitivity.  
• The rechallenge is approved by [CONTACT_261513] a hepatologist. The 
hepatologist must be external to UCB. It is recommended that the hepatologist be a local 
hepatology expert or the hepatologist treating the subject.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317912] agrees to the investigator -recommended monitoring plan.  
[IP_ADDRESS]  Testing: identification/exclusion of alternative etiology  
The measurements and additional information required for the assessment of PDILI events 
when  there is a reasonable possibility  that they may have been caused by [CONTACT_261514]  10‒4 (laboratory measurements) and Table  10‒5 (additional information). Results of 
the laboratory measurements and information collected are to be submitted to the sponsor on 
the corresponding CRF. If th e medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be completed and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for  more rapid 
results, a concurrent sample must also be sent to the central laboratory.  
The following measurements are to be assessed:  
Table  10‒4: PDILI laboratory measureme nts 
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Differential count, hematocrit, hemoglobin, platelet count, RBC and WBC  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Albumin, AST, ALT, ALP, GGT, serum CPK, and LDH to evaluate possible 
muscle injury causing transaminase elevation  
Additional  Prothrombin time/INRa 
Serum pregnancy test  
PK sample  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 70 of 274 ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine 
phosphokinase; GGT=gamma glutamyl transferase; HBcAb -IgM=hepatitis B core antibody -IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RBC=red blood 
cell count; RNA=ribonucleic acid; ULN=upper limit of normal; WBC=white blood cell count  
a Measured only for subjects with ALT >8xULN, elevations in total  bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
The following additional information is to be collected:  
Table  10‒5: PDILI information to be collected  
New or updated information  
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
• History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)  
• Adverse reactions to drugs  
• Allergies  
• Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
• Recent travel  
• Progression of malignancy involving the liver (Note: Metastatic disea se to the liver, by [CONTACT_5071], 
should not be used as an explanation for significant AST and/or ALT elevations.)  
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or ten derness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)  
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function  
Alcohol and illicit drug use  
Results of liver imaging or liver biopsy, if done  
Results of any specialist or hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury  
[IP_ADDRESS]  Follow -Up evaluation  
Potential drug -induced liver injury events require follow -up monitoring as described in 
Table  10‒3. 
Monitoring should continue until liver chemistry val ues normalize, stabilize, or return to 
Baseline. Determination of stabilization is at the discretion of the investigator in consultation 
with the hepatologist (as applicable) and UCB responsible physician, as needed.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 71 of 274 10.3.2  Pregnancy testing  
Females of childbeari ng potential (who have not been surgically sterilized or who are not at 
least 2 years postmenopausal) will have serum and urine dipstick pregnancy testing 
performed according to the schedule of study assessments in Table  5‒1, Table  5‒2, Table  5‒3 
and Table  5-4.  
10.4 Other safety measurements  
10.4.1  Vital signs, body weight and height  
Noninvasive BP (systolic and diastolic) and pulse rate will be measured at clinic visits in a 
supi[INVESTIGATOR_96839] [ADDRESS_317913], according to the schedule of study assessments 
in Table  5‒1, Table  5‒2, Table  5‒3 and Table  5-4. Assessment of orthostatic changes will be 
as follows: after the [ADDRESS_317914] stands up, as feasible. Blood pressure measurements should be taken with the 
proper placement and proper sized cuff to obtain a ccurate measurements.  
Body weight will be determined without shoes and wearing light clothing and height will be 
measured without shoes. Body weight and height will be measured using equipment that is 
age appropriate and assessed according to the schedule of study assessments in Table  5‒1, 
Table  5‒2, Table  5‒[ADDRESS_317915] 12 -lead ECGs will be performed according to the sch edule of study assessments in 
Table  5‒1, Table  5‒2, Table  5‒3 and Table  5-4.  
The ECG recordin gs should be performed at the same time of day (when possible) and prior 
to blood sample collection and vital sign assessments. Care should be taken to assure proper 
lead placement and quality ECG recordings. If possible, subjects should rest in a supi[INVESTIGATOR_261419] 5 minutes prior to each recording and should be motionless during the 
recording. In pediatric subjects (<18 years of age), a 12 -lead ECG (2  interpretable recordings) 
approximately [ADDRESS_317916] be performed.  
[IP_ADDRESS]  Overall ECG inter pretation  
Electrocardiograms will be reviewed locally by [CONTACT_093], subinvestigator, or qualified 
designated reader. If the reading identifies a second - or third -degree AV block or another 
abnormal ECG finding that is assessed by [CONTACT_261515], then the 
ECG should be repeated on the same day. If the clinically significant abnormality is 
confirmed by [CONTACT_67605], then the subject must be withdrawn from the study (see 
Section 6.3). The investigator may consult with a cardiologist to confirm the presence of a 
clinically significant ECG abnormality. It remains the responsibility of the investigator to 
decide whether an ECG finding is of clinical significance on the basis of the complete clinical 
pi[INVESTIGATOR_67546]’s participation in the study.  
10.4.3  Assessment of suicidality  
Suicidality will be assessed by [CONTACT_207276] C -SSRS (Columbia 
University Medical Center, 2008). This scale will be used for screening as well as to assess 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 72 of 274 suicidal ideation and behavior that may occur during the study. The C -SSRS will be 
completed according to the schedule of study assessments in Table  5‒1, Table  5‒2, Table  5‒3 
and Table  5-4.  
The C -SSRS will be completed for subjects who are ≥6  years of age. The “Since Last Visit” 
version of the C -SSRS should be used. If a subject becomes 6  years of age during the study, 
the "Already Enrolled" version of the C -SSRS should be used once, followed by [CONTACT_941] “Since 
Last Visit” version at subsequent visits.  
The C -SSRS is not validated for subjects <[ADDRESS_317917]’s parent(s)/legal representative(s)/caregiver(s) (in accordance with 
local regulation) should also be advised accordingly and ef fort should be made at clinic visits 
to specifically assess potential depression.  
10.4.4  Physical examination  
Physical examinations will be performed by a medically qualified clinician licensed to 
perform the examination, according to the schedule of study assess ments in Table  5‒1, 
Table  5‒2, Table  5‒3 and Table  5-4. Clinically significant physical examina tion findings are 
to be reported as AEs.  
[IP_ADDRESS]  Complete physical examination  
The complete physical examination will include cardiac and respi[INVESTIGATOR_261420].  
[IP_ADDRESS]  Brief physical examination  
The brief physical examinati on will include review of the following body systems:  
• Cardiovascular  
• Pulmonary  
• Abdominal (hepato -gastrointestinal)  
• Dermatologic  
10.4.[ADDRESS_317918] of neurological examinations, according to the schedule 
of study assessments in Table  5‒1, Table  5‒2, Table  5‒[ADDRESS_317919] during the study. 
The investigator or subinvestigator is responsible for confirming the diagnosis of IG E with 
PGTCS.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 73 of 274 [IP_ADDRESS]  Complete neurological examination  
The complete neurological examination will include selected assessment of mental status, 
sensory systems, motor functions, cranial nerves, reflexes, and coordination/cerebellar 
function.  
[IP_ADDRESS]  Brief neurological ex amination  
The brief neurological examination will include selected assessments of: general neurological 
status, reflexes, muscle strength and coordination/cerebellar function.  
10.4.6  Achenbach CBCL  
The Achenbach CBCL is a widely used validated questionnaire to ev aluate a child’s 
competencies and behavioral/emotional problems.  
The Achenbach CBCL consists of the CBCL/1½ -5 for children <5  years and 11  months of 
age, and the CBCL/6 -18 for children ≥6  years to <18  years of age. These are to be completed 
by [CONTACT_7071]( s)/legal representative(s). The completion of the Achenbach CBCL will require 
approximately [ADDRESS_317920]’s 
age should be administered with the following exception: for subjects who completed the 
CBCL/1½ -5 at the Baseline assessment of the previous study and turn 6 years of age within 
1 year after the Baseline assessment of the primary study, the CBCL/1½ -5 should be 
completed for 1 year after the Baseline assessment of the primary study, and subseq uently the 
CBCL/[ADDRESS_317921] 6  months will be scored on the 
following scale:  
• 0=not true (as far as known)  
• 1=somewhat or sometimes true  
• 2=very true or often true  
Eight syndrome scores will be calculated from these  questionnaires, which will in turn be 
summarized by 2  composite scores. Additionally, for each score on the questionnaire, 
syndrome, and total level, categorizations based on a normative sample will be used to 
evaluate normal, borderline, or clinically re levant behavior.  
In addition, the Achenbach CBCL/6 to 18 includes ratings related to performance in school, 
activities in leisure time, and special interests.  
10.4.7  BRIEF  
The BRIEF -P and the BRIEF are validated tools that will be used for the evaluation of 
subjects ≥2 years to <5 years of age and ≥[ADDRESS_317922]’s age should be completed, with the following ex ception: 
For subjects who completed the BRIEF -P at the Baseline assessment of the previous study 
and turn 5 years of age within 1 year after the Baseline assessment of the primary study, the 
BRIEF -P should be completed for 1 year after the Baseline assessm ent of the primary study, 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 74 of 274 and subsequently the BRIEF should be completed. The BRIEF -P and BRIEF will be 
administered according to the tabular schedules of study procedures (Section 5.2). The 
BRIEF -P and BRIEF will be used only in countries where a translated scale is available. For 
each developmentally appropriate version of the BRIEF subjects must have at least 1 year of 
data before transitioning to the next age range.  
The BRIEF -P and BRIEF include rating forms used by [CONTACT_67607]’ executive 
functioning. Executive functions broadly encompass a set of cognitive skills that are 
responsible for the planning, initiation, sequencing, and mon itoring of complex goal -directed 
behavior.  
The BRIEF -P rating form consists of items that measure various aspects of executive 
functioning: Inhibit, Shift, Emotional Control, Working Memory, and Plan/Organize. The 
clinical scales form [ADDRESS_317923] indexes (Inh ibitory Self -Control, Flexibility, and Emergent 
Metacognition) and 1  composite score (Global Executive Composite).  
The BRIEF rating form contains items in nonoverlappi[INVESTIGATOR_207235]. These theoretically 
and statistically derived scales form 2 broader I ndexes: Behavioral Regulation (3 scales) and 
Metacognition (5 scales), as well as a Global Executive Composite score.  
Both the BRIEF -P and the BRIEF include validity scales to measure negativity and 
inconsistency of responses.  
10.4.8  Tanner stage  
The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study , according to the schedule of study assessments 
in Table  5‒1 and Table  5‒2. The investigator or qualified designee will evaluate the subject’s 
sexual development using the 3 -item s cale, according to the tabular schedules of study 
procedures (Section 5.2). The investigator should use clinical judgment in deciding which 
subjects are selected for the evaluation of Tanner Stage (ie, those subjects who are pubescent 
at Visit 1 or who will enter puberty  during the course  of the study).  
11 STUDY MANAGEMENT AND  ADMINISTRATION  
11.1 Adherence to protocol  
The investigator should not deviate from t he protocol. In medical emergencies, the 
investigator may use his/her medical judgment and may remove a study participant from 
immediate hazard before notifying UCB (or its representative) and the IRB/IEC in writing 
regarding the type of emergency and the course of action taken.  
11.2 Monitoring  
UCB (or designee) will monitor the study to meet the sponsor’s monitoring SOPs, ICH -GCP 
guideline, and applicable regulatory requirements, and to ensure that study initiation, 
conduct, and closure are adequate. Monitoring  of the study may be delegated by [CONTACT_18410] a 
CRO or a contract monitor.  
The investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The investigator(s)/institution(s) will permit direct access to source 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 75 of 274 data/documents for study -related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).  
The investigator will allow UCB (or designee) to periodically revi ew all eCRFs and 
corresponding source documents (eg, hospi[INVESTIGATOR_261421]). Monitoring visits will provide UCB (or designee) with the opportunity to 
evaluate the progress of the study, verify the accuracy and completen ess of eCRFs, ensure 
that all protocol requirements, applicable authorities’ regulations, and investigator’s 
obligations are being fulfilled, and resolve any inconsistencies in the study records.  
11.2.[ADDRESS_317924] be accu rate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typi[INVESTIGATOR_007], printing, 
optical disc). They should not be obscured by [CONTACT_18411] 
(such as remo vable self -stick notes). Printouts of eCRF screens are not considered acceptable 
source documents.  
Source documents are original records in which raw data are first recorded. These may 
include hospi[INVESTIGATOR_307]/clinic/general practitioner records, charts, diaries,  x-rays, laboratory results, 
printouts, pharmacy records, care records, ECG or other printouts, completed scales, or 
quality of life questionnaires, for example. Source documents should be kept in a secure, 
limited access area.  
Source documents that are co mputer generated and stored electronically must be printed for 
review by [CONTACT_2037] (eg, ECG reports). Once printed, these copi[INVESTIGATOR_261422] a permanent part of the subject’s source documents. 
The investigato r will facilitate the process for enabling the monitor to compare the content of 
the printout and the data stored in the computer to ensure all data are consistent.  
11.2.[ADDRESS_317925] to being accurate, complete, and 
verifiable from source documents (eg, subject files, recordings from automated instruments, 
tracings [ECG], x -ray films, laboratory notes). All data reported on the eCRF should be 
supported by [CONTACT_18412], unless otherwise specified in Section 11.2.[ADDRESS_317926] be accompanied by a reason for the 
change.  
Corrections made after the investigator’s review and approval (by [CONTACT_3553] a 
password/electronic signature) will be reapproved by [CONTACT_093].  
The investigator should maintain a list of personnel authorized to enter data into the eCRF.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 76 of 274 Detailed instructions will be provided in the eCRF completion guidelines.  
11.3.2  Database entry and reconciliation  
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleani ng 
checks will be used in addition to manual review to check for discrepancies and to ensure 
consistency of the data. This study will be performed using electronic data capture (EDC); 
the data are entered into the eCRFs once and are subsequently verified.  
An electronic audit trail system will be maintained within the CDMS to track all data changes 
in the database once the data have been saved initially into the system or electronically 
loaded. Regular backups of the electronic data will be performed.  
11.3.3  Subjec t Enrollment log/Subject Identification Code list  
The subject’s enrollment will be recorded in the Subject Enrollment Log.  
The investigator will keep a Subject Identification Code list. This list remains with the 
investigator and is used for unambiguous id entification of each subject.  
The subject’s consent/assent and enrollment in the study must be recorded in the subject’s 
medical record. These data should identify the study and document the dates of the subject’s 
participation.  
11.[ADDRESS_317927] to quality or quantity.  
If the study is prematurely terminated or suspended, UCB (or its representative) will inform 
the investigators/institutions and the regulatory authority(ies) of the termi nation or suspension 
and the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by [CONTACT_261516]/institution, as specified by [CONTACT_12926](s). In addition, arrangements will be made for the return of 
all unused IMP and other material in accordance with UCB procedures for the study.  
11.5 Archiving and data retention  
The i nvestigator will maintain adequate records for the study, including eCRFs, medical 
records, laboratory results, Informed Consent/Assent documents, drug dispensing and 
disposition records, safety reports, information regarding participants who discontinued,  and 
other pertinent data.  
All essential documents are to be retained by [CONTACT_12415] [ADDRESS_317928]. These 
documents should be retained for a longer period, however, if required by [CONTACT_261517].
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 77 of 274 regulatory requirement(s) or by [CONTACT_18415] (CPMP/ICH/135/95, 2002 
[Section  4.9.5]). The investigator will contact [CONTACT_261518]. The 
investigator will also notify UCB should he/she relocate or move the study -related files to a 
location other than that specified in the sponsor’s trial master file (TMF).  
11.[ADDRESS_317929] been protected, that enrolled subjects (ie, signing consen t/assent 
and undergoing study procedures) are appropriate for the study, and that all data relevant for 
the evaluation of the IMP have been processed and reported in compliance with the planned 
arrangements, the protocol, investigational site, and IRB/IEC SOPs, ICH -GCP, and 
applicable regulatory requirements.  
The investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the investigator will 
immediately inform UC B (or designee).  
11.7 Good Clinical Practice  
Noncompliance with the protocol, ICH -GCP, or local regulatory requirements by [CONTACT_1275], institution, institution staff, or designees of the sponsor will lead to prompt 
action by [CONTACT_18418]. Cont inued noncompliance may result in the termination 
of the site’s involvement in the study.  
12 STATISTICS  
A description of statistical methods follows and will be described in more detail in the 
Statistical Analysis Plan (SAP).  
12.1 Definition of analysis sets  
12.1.1  Enrol led Set  
The Enrolled Set (ES) will consist of all subjects who have a signed Informed Consent/
Assent form.  
12.1.2  Safety Set  
The Safety Set (SS) consists of all enrolled subjects who received at least [ADDRESS_317930] deviation (SD), median, 
minimum, and maximum.  
12.3 Planned safety and other analyses  
12.3.1  Safety analyses  
The incidence of all TEAEs, treatment emergent SAEs and TEAEs  leading to premature 
discontinuation from study drug will also be summarized descriptively. Additional 
summaries will be provided by [CONTACT_174802]. All tables 
of TEAEs will include Medical Dictionary for Regulatory Activities primary System Org an 
Class and Preferred Term. Further details on the analysis of each variable will be given in the 
SAP.  
Incidence of new seizure types, increase in days with absence seizure or myoclonic seizures 
per 28 days during the Treatment Period, and 50% worsening in days with absence seizures 
or myoclonic seizures per [ADDRESS_317931] a 50% reduction in PGT CS frequency per 28 days compared to the 
combined Baseline Period, and freedom from PGTCS during the study will also be presented 
descriptively.  
Days with myoclonic or absence seizures are more clinically relevant endpoints; therefore, 
change in and percen t change in days with myoclonic and/or absence seizures will be 
summarized. The percentage of subjects with 50% reduction in days with absence and/or 
myoclonic seizures per [ADDRESS_317932]’s Informed Consent/Assent must be obtained and documented in accordance with 
local regulations, ICH -GCP requirements, and the ethical principles that have their origin in 
the pr inciples of the Declaration of Helsinki.  
Prior to obtaining Informed Consent/Assent, information should be given in a language and at 
a level of complexity understandable to the subject in both oral and written form by [CONTACT_1275] (or designee). Each subject will have the opportunity to discuss the study and its 
alternatives with the investigator.  
Prior to participation in the study, the Informed Consent/Assent form should be signed and 
personally dated by [CONTACT_423], or his/her legal representative, and by [CONTACT_261519]/Assent discussion (investigator or designee). The subject or 
his/her legal representative must receive a copy of the signed and dated Informed 
Consent/Assent form. As part of the consent/assent process, each subject must consent/assent 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317933] access to his/her medical records for study -related moni toring, auditing, IRB/IEC 
review, and regulatory inspection.  
If the Informed Consent/Assent form is amended during the study, the investigator (or the 
sponsor, if applicable) must follow all applicable regulatory requirements pertaining to the 
approval of the amended Informed Consent/Assent form by [CONTACT_1201]/IEC and use of the 
amended form.  
All studies conducted at centers in the US must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.  
The subject may withdraw his/h er consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the Informed Consent/Assent 
form. An eCRF must not be started, nor may any study specific procedure be performed for a 
given subject , without having obtained his/her written consent/assent to participate in the 
study.  
13.[ADDRESS_317934] identification cards  
Upon signing the Informed Consent/Assent form (as applicable), the subject or legal 
representative will be provided with a subject identifica tion card in the language of the 
subject. The investigator will fill in the subject identifying information and medical 
emergency contact [CONTACT_3031]. The investigator will instruct the subject to keep the card 
with him/her at all times.  
13.3 Institutional Revi ew Boards and Independent Ethics 
Committees  
The study will be conducted under the auspi[INVESTIGATOR_18279]/IEC, as defined in local 
regulations, ICH -GCP, and in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki.  
The inv estigator/UCB will ensure that an appropriately constituted IRB/IEC that complies 
with the requirements of the current ICH -GCP version or applicable country -specific 
regulations will be responsible for the initial and continuing review and approval of the 
clinical study. Prior to initiation of the study, the investigator/UCB will forward copi[INVESTIGATOR_261423], Informed Consent/Assent form, Investigator’s Brochure, investigator’s curriculum 
vitae (if applicable), advertisement (if applicable), and all other  subject -related documents to 
be used for the study to the IRB/IEC for its review and approval.  
Before initiating a study, the investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.  
The investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol 
deviations, to eliminate immediate hazards to subjects.  
The investigator will not make any changes in the stud y or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. 
For minor changes to a previously approved protocol during the period covered by [CONTACT_259010].
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 81 of 274 original approval, it may be possible for the investigator to obtain an expedited review by [CONTACT_5040]/IEC as allowed.  
As part of the IRB/IEC requirements for continuing review of approved studies, the 
investigator will be responsible for submitting periodic progress reports to the IRB/IEC 
(based on IRB/ IEC requirements), at intervals appropriate to the degree of subject risk 
involved, but no less than once per year. The investigator should provide a final report to the 
IRB/IEC following study completion.  
UCB (or its representative) will communicate safet y information to the appropriate regulatory 
authorities and all active investigators in accordance with applicable regulatory requirements. 
The appropriate IRB/IEC will also be informed by [CONTACT_8893], as 
specified by [CONTACT_261520]. Where 
applicable, investigators are to provide the sponsor (or its representative) with evidence of 
such IRB/IEC notification.  
13.[ADDRESS_317935] privacy  
UCB staff (or designee) will affirm and uphold the subject’s conf identiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by [CONTACT_261521]0982 study.  
The investigator agrees that representatives of UCB, its designee, representatives of the 
relevant IRB/IEC, or representatives of regulatory authorities will be allowed to review that 
portion of the subject’s primary medical records that directly concerns this study (including, 
but not limited to, laboratory test result reports, ECG reports, adm ission/discharge summaries 
for hospi[INVESTIGATOR_1684] a subject’s study participation, and autopsy reports 
for deaths occurring during the study).  
13.4.[ADDRESS_317936] udy is allowed for the purpose of 
scientific research to evaluate the efficacy and the safety of the tested drug, in accordance 
with legal requirements from:  
• the laws governing the conduct of clinical studies (ie, the provisions of the French Public 
Health  Code and the EU clinical trial regulation 536/[ADDRESS_317937] and analyze such data before they are submitted to health authorities)  
• the EU regulation 1235/[ADDRESS_317938] be approved by [CONTACT_18338], the IRB/IEC, and the regulatory authorities (if required), prior to 
being implemented.  
14 FINANCE, INSURANCE, AND PUBLICATION  
Insurance coverage will be handled according to local requirements.  
Finance, insurance, and publication r ights are addressed in the investigator and/or CRO 
agreements, as applicable.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 83 of 274 15 REFERENCES  
Bartolomei F, Roger J, Bureau M, Genton P, Dravet C, Viallat D, et al. Prognostic factors for 
childhood and juvenile absence epi[INVESTIGATOR_31629]. Eur Neurol. 1997;37:169 -75. 
Columbia University Medical Center. Columbia -Suicide Severity Rating Scale (2008). 
http://www.cssrs.columbia.edu/. Accessed on 10 Apr 2012.  
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.  
Cramer JA, Perrine K, Devinsky O, Brya nt-Comstock L, Meador K, Hermann B. 
Development and cross -cultural translation of a 31 -item quality of life in epi[INVESTIGATOR_261424]. 
Epi[INVESTIGATOR_8330]. 1998;39:81 -8. 
Cramer JA, Van Hammée G, N132 Study Group. Maintenance of improvement in health 
related quality of l ife during long -term treatment with levetiracetam. Epi[INVESTIGATOR_41744]. 
2003;4:118 -23. 
EuroQol Group. EQ -5D. Basic information on how to use the EQ -5D-3L instrument. 
EQ-5D-3L User guide. Version 4.0. Apr 2011.  
Food and Drug Administration. Guidance for Industry . Drug -induced liver injury: 
premarketing clinical evaluation. US Dept of Health and Human Services, Center for Drug 
Evaluation and Research, Center for Biologics Evaluation and Research, 07/2009.  
Genton P. When antiepi[INVESTIGATOR_261425]. Brai n Dev. 2000;22:[ADDRESS_317939], Pedley TA. New options for the treatment of epi[INVESTIGATOR_002]. JAMA. 1998;280:693 -4. 
ILAE, 1989; Commission on classification and terminology of the International League 
Against Epi[INVESTIGATOR_002]. Proposal for revised classification of epi[INVESTIGATOR_67553]. 
Epi[INVESTIGATOR_8330]. 1989;30:389 -99. 
Jallon P, Latour P. Epi[INVESTIGATOR_261426]. Epi[INVESTIGATOR_8330]. 
2005;46(Suppl  9):S10 –4.  
Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of 
epi[INVESTIGATOR_002]: a systematic review and meta -analysis. Neurology. 2011;77(10):1005 -12. doi: 
10.1212/WNL.0b013e31822cfc90.  
Perucca E. Established antiepi[INVESTIGATOR_006]. Baillieres Clin Neurol. 1996;5:693 -722. 
Verrotti A, Greco R, Giannuzzi R, Chiarelli F, Latini G.  Old and new antiepi[INVESTIGATOR_261427]. Curr Clin Pharmacol. 2007;2:249 -59. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 84 of 274 16 APPENDICES  
16.1 Appendix 1: International Classification of Epi[INVESTIGATOR_207161] 
(1981)  
Adapted from the International Classification of E pi[INVESTIGATOR_207161] (1981)  
Clinical Seizure Types  
I. Partial seizures (focal, local)  
A. Simple partial seizures (consciousness not impaired)  
1. With motor signs  
2.  With somatosensory or special sensory symptoms (simple hallucinations, eg, 
tingling, light fl ashes, buzzing)  
3.  With autonomic symptoms or signs (including epi[INVESTIGATOR_207201], pallor, 
sweating, flushing, pi[INVESTIGATOR_2657], and pupi[INVESTIGATOR_207202])  
4.  With psychic symptoms (disturbance of higher cerebral function). These 
symptoms rarely occur witho ut impairment of consciousness and are much more 
commonly experienced as complex partial seizures.  
B. Complex partial seizures (with impairment of consciousness: may sometimes begin 
with simple symptomatology)  
C. Partial seizures evolving to secondarily generalized seizures (this may be 
generalized tonic -clonic, tonic, or clonic)  
II. Generalized seizures (convulsive or non -convulsive)  
A. Absence seizures  
B. Myoclonic seizures - Myoclonic jerks (single or multiple)  
C. Clonic seizures  
D. Tonic seizures  
E. Tonic-clonic seizures  
F. Atonic seizures - (Astatic)  
III. Unclassified epi[INVESTIGATOR_261428]. This inclu des some neonatal 
seizures, eg, rhythmic eye movements, chewing, and swimming movements.  
Status epi[INVESTIGATOR_261429].  
Commission on Classification and Terminology of the International Leag ue Against Epi[INVESTIGATOR_002]. Proposal for 
revised clinical and electroencephalographic classification of epi[INVESTIGATOR_122174]. Epi[INVESTIGATOR_8330]. 1981;22:489 -501. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 85 of 274 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 86 of 274 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 87 of 274 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 88 of 274  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 89 of 274  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 90 of 274  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 91 of 274 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 92 of 274  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 93 of 274 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 94 of 274 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 95 of 274 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 96 of 274 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 97 of 274  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 98 of 274 16.4 Appendix 4: Protocol Amendment 1  
Rationale for the amendment  
The primary purpose of this substantial amendment follows the amendment made to the 
SP0982 protocol, which is to identify significant changes to the study design and the 
inclusion of pediatric subjects (≥4 to 12 years of age).  
Modifications and changes  
Global changes  
The following changes were made throughout the protocol:  
• Duration of this study (EP0012) has been clarified as at least 2 years.  
• Lacosamide plasma concentration analysis has been removed as it provides limited ability 
to interpret compliance and to  perform an accurate PK modeling.  
• Clarification on subjects being able to participate in a substudy at some sites, without 
being withdrawn from EP0012.  
• For pediatric subjects <50kg, a Dispensation Visit has been added 12 weeks after each 
24-weekly visit fr om Year 3 onwards, in order to dispense LCM solution.  
• The use of concomitant medications and treatments has been clarified.  
• Behavior Rating Inventory of Executive Function Preschool Version® (BRIEF -P®) has 
been added.  
• Socio -professional data assessment has  been removed in this study.  
• Permitted and prohibited concomitant treatments have been clarified to be consistent with 
SP0982.  
• In order to optimize study operations, ECGs will be evaluated locally and not centrally.  
• Other changes made in this amendment ar e to provide clarification or are administrative 
in nature.  
Specific changes  
Change #1  
Title page:  
IND Number: [ZIP_CODE]  
Has been changed to:  
IND Number (tablet): [ZIP_CODE]  
IND Number (oral solution): [ZIP_CODE]  
The information below was revised to include Protocol Amendment 1 and the type of 
protocol amendment:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 99 of 274  
Protocol/Amendment number  Date  Type of amendment  
Final Protocol  [ADDRESS_317940] 2012  Not applicable  
 
Has been  changed  to: 
 
Protocol/Amendment number  Date  Type of amendment  
Final Protocol  [ADDRESS_317941] 2012  Not applicable  
Protocol Amendment 1  27 Jan 2015  Substantial  
Change #2  
The sponsor declaration page was deleted, as sponsor signatures are now captured 
electronically.  
Change #[ADDRESS_317942] Manager  
Name:   
[CONTACT_2761]:  [ADDRESS_317943]  
Raleigh, NC [ZIP_CODE]  
UNITED STATES  
Phone:   
Fax:  
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  [ADDRESS_317944]  
Raleigh, NC [ZIP_CODE]  
UNITED STATES  
Phone:   
Fax:  
Has been changed to:  
Clinical Project Manager  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 100 of 274 GERMANY  
Phone:   
Fax:  
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  [ADDRESS_317945]  
Raleigh, NC [ZIP_CODE]  
UNITED STATES  
Phone:   
Fax:  
Change #4  
SERIOUS ADVERSE EVENT REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World (except Japan):  [PHONE_1064]  
[LOCATION_003]:  +[PHONE_299]  
Canada:  +[PHONE_1063]  
Japan:  [PHONE_4455]  
Email  Global (except Japan): [EMAIL_311]  
Japan:  [EMAIL_4057]  
Has been changed to:  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World (except Japan):  [PHONE_1064]  
[LOCATION_003]:  +[PHONE_5427]  
 or +[PHONE_299]  
 or +[PHONE_300]  
Canada:  +[PHONE_1063]  
Email  Global (except Japan): DSICT. -@ucb.com  
Change #[ADDRESS_317946] OF ABBREVIATIONS  
The following abbreviation has been added:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 101 of 274 VAS  visual analogue scale  
Change #6  
Section 1  SUMMARY  
Paragraphs 1 through 8  
This is a Phase 3, multicenter, open -label extension study designed to assess the long -term 
safety and efficacy of oral lacosamide (LCM, VIMPAT®; SPM 927; previously referred to as 
harkoseride; (R) -2-acetamido -N-benzyl -3-methoxypropi[INVESTIGATOR_67515], AD 234037) as an 
adjunctive therapy for uncontrolled primary generalized tonic -clonic (PGTC) seizures in 
subjects with idiopathic generalized epi[INVESTIGATOR_002] (IGE). This study will enroll subjects who have 
completed the LCM SP0982 study. In addition, subjects who completed the SP0982 
Prospective Baseline Period and met all entry criteria except the minimum PGTC seizure 
criteria required for randomization into SP0982 m ay choose to enter EP0012 (eligible 
Baseline failures and completers are defined in Section  5.1). It is estimated that 
approximately 200 subjects across approximately 150  sites will be enrolled in EP0012. 
Subjects who completed SP0982 will start at Visit 1  on a dose of LCM 400mg/day (200mg 
twice daily [bid]); subjects who are eligible Baseline failures from SP0982 will start at Visit 1 
on a dose of LCM 100mg/day (50mg bid). Investigators will be allowed to increase or 
decrease the dose of LCM to optimize to lerability and seizure reduction in a range from 
LCM  100mg/day to 800mg/day.  
EP0012 will last up to approximately 6 years and consists of a Treatment Period and an End 
of Study Period lasting up to 5 weeks. During the Treatment Period, Visit 2 will occur 
2 weeks after Visit 1, and Visit 3 will occur 4 weeks later (Week 6). Visits will then occur 
every [ADDRESS_317947]’s country 
for the treatment of PGTC seizures in subjec ts with IGE, or until UCB has determined that 
the clinical development program for the indication will be formally discontinued, or until the 
sponsor decides to close the study.  
Upon study completion, subjects must either transition to commercial LCM or ta per off study 
drug. Subjects continuing treatment with commercial LCM will transition at their current 
dose. Subjects tapering off LCM will do so at a recommended decrease rate of 
LCM  200mg/day per week, unless the investigator feels that safety concerns r equire a more 
rapid withdrawal of LCM.  
Have been changed to:  
This Phase 3, multicenter, open -label extension study is designed to assess the long -term 
safety and efficacy of oral lacosamide (LCM, VIMPAT®; SPM 927; previously referred to as 
harkoseride; (R)  2 acetamido -N-benzyl -3-methoxypropi[INVESTIGATOR_67515], ADD 234037) as an 
adjunctive therapy for uncontrolled primary generalized tonic -clonic (PGTC) seizures in 
subjects ≥4  years of age with idiopathic generalized epi[INVESTIGATOR_002] (IGE). This study will enroll 
subjects who have completed the LCM SP0982 study. In addition, subjects who completed 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 102 of 274 the SP0982 Prospective Baseline Period and met all entry criteria except the minimum PGTC 
seizure criteria required for randomization into SP0982 may choose to enter EP0012 (eligible 
Baseline failures and completers are defined in Section 5.1). It is estimated that 
approximately 200 subjects across approximately 150 sites will be enrolled in EP0012.  
Subjects who completed SP0982 will start at Visit 1 on a dose of LCM 10mg/kg/day for 
pediatric subjects weighing <30kg, LCM 8mg/kg/day for pediatric subjects weighing ≥30kg 
to <50kg, and LCM 400mg/day (200mg twice daily [bid]) for adult subjects (≥18 years of 
age) or pediatric subjects weighing ≥50kg. Subjects who are eligible Baseline failu res from 
SP0982 will start at Visit 1 on a dose of LCM 2mg/kg/day for pediatric subjects weighing 
<50kg, and LCM 100mg/day (50mg bid) for adult subjects (≥18 years of age) or pediatric 
subjects weighing ≥50kg.  
Baseline failures are required to complete Wee k [ADDRESS_317948] should hold the dose for a longer duration. 
There is no limit to the n umber of back titration steps or dose holds allowed and all are at the 
Investigator’s discretion; however, subjects must achieve the minimum LCM target dose of 
4mg/kg/day (oral solution) or 200mg/day (tablets) within [ADDRESS_317949] this minimum dose of 4mg/kg/day (oral solution) or 200mg/day (tablets), then 
the subject must enter the Taper Period and be withdrawn from the study.  
During EP00 12, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased 
in steps of no more than 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects wh o 
have dose adjustments must remain on the dose for ≥3 days (in order to reach steady state) 
before a subsequent dose adjustment.  
EP0012 will last at least 2 years and consists of a Treatment Period, an up to 4 week Taper 
Period, and a 30 -day Safety Follow -Up Period. During the Treatment Period, Visit 2 will 
occur 2 weeks after Visit 1, and Visit 3 will occur 4 weeks later (Week 6). Clinical visits will 
then occur every [ADDRESS_317950] year, and every 16 weeks in the second year. For 
subjects who cont inue in the study after Year 2, visits will occur and every 24 weeks 
thereafter until the end of the study. From Year 3 onwards, pediatric subjects weighing <50kg 
will return to the clinic for an additional Dispensation Visit 12 weeks after each 24 -weekly 
visit, for the dispensation of LCM solution; LCM usage will be reviewed and empty LCM 
bottles will be returned.  
A telephone contact [CONTACT_18378] [ADDRESS_317951]’s country for the 
treatment of PGTC seizures in subjects wit h IGE, or until UCB has determined that the 
clinical development program for the indication will be formally discontinued, or until UCB 
decides to close the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317952] and/or their parent(s)/legal representative(s) to best manage the subject’s epi[INVESTIGATOR_002]. 
Taper of LCM may not be required for some subjects who complete the study depending on 
the treatment option selected by [CONTACT_261522]/or their 
parent(s)/legal representative(s).  
Paragraph 10, third sentence:  
In addition, for pediatric subjects <18 years of age, safety will be evaluated using behavioral 
assessments (Achenbach Child Behavior Checklist [CBCL]), and cognitive functi on 
assessments (Behavior Rating Inventory of Executive Function® [BRIEF®]).  
Has been changed to:  
In addition, for pediatric subjects <18 years of age, safety will be evaluated using behavioral 
assessments (Achenbach Child Behavior Checklist [CBCL]), and cognitive function 
assessments (Behavior Rating Inventory of Executive Function®/Behavior Rating Inventory 
of Executive Function -Preschool Version® [BRIEF®/BRIEF -P®]).  
Change #[ADDRESS_317953] pre valent neurological disorder in the world. More than 
40 million people suffer from epi[INVESTIGATOR_002] –about 1% of the world’s population (Dichek, 1999). 
The most common seizure type in patients with epi[INVESTIGATOR_261430] (57%), followed 
by [CONTACT_261523] -clonic seizur es (23%), absence seizures (6%), and myoclonic seizures (3%); the 
latter 3  seizure types comprise the majority of generalized seizures (convulsive and 
nonconvulsive) (Hauser et al, 1993).  
Generalized seizures are those in which the first clinical changes indicate initial involvement 
of both brain hemispheres. Consciousness may be impaired and this impairment may be the 
initial manifestation. Motor manifestations are typi[INVESTIGATOR_261386]. Generalized epi[INVESTIGATOR_261431]/idiopathic  and secondary/symptomatic epi[INVESTIGATOR_31629]. Idiopathic 
generalized epi[INVESTIGATOR_24571] a category of disorders defined by [CONTACT_261524][INVESTIGATOR_002] 
(ILAE) classification of epi[INVESTIGATOR_261432] s (ILAE, 1989). Clinical experience has shown 
that IGEs represent a heterogeneous condition in which many factors interact (such as age at 
onset, external factors, role of medications, and sleep) (Jallon and Latour, 2005). Idiopathic 
generalized epi[INVESTIGATOR_261433] a genetic etiology and onset almost always occurs 
during childhood or adolescence, although there are exceptions; some patients develop these 
kinds of epi[INVESTIGATOR_261389], rarely, even later.  
Treatment of PGTC  seizures is complex because the patient population with PGTC seizures 
is heterogeneous, as PGTC seizures can occur as an isolated seizure type or in association 
with other generalized seizure types.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317954] been changed to:  
Epi[INVESTIGATOR_261434]. More than 
40 million people suffer from epi[INVESTIGATOR_002] –about 1% of the world’s population (Dichek, 1999). 
Epi[INVESTIGATOR_261435] a wide range of epi[INVESTIGATOR_261436], structural/met abolic, or unknown origin.  
Generalized seizures are those in which the first clinical changes indicate initial involvement 
of both brain hemispheres. Consciousness typi[INVESTIGATOR_261437]. Motor manifesta tions are typi[INVESTIGATOR_261386]. Generalized seizures 
typi[INVESTIGATOR_261387] (genetic) or symptomatic generalized epi[INVESTIGATOR_207163]. Idiopathic generalized epi[INVESTIGATOR_24571] a category of disorders defined by [CONTACT_261525][INVESTIGATOR_002] 
(ILAE) classification of epi[INVESTIGATOR_122245] (ILAE, 1989). Clinical experience has shown 
that IGEs represent a heterogeneous condition in which many factors interact (such as age at 
onset, external factors, role of medications, and sleep) (Jallon and Latour, 2005). Idiopathic 
generalized epi[INVESTIGATOR_261388] a genetic etiology and onset almost always occurs 
during childhood or adolescence, although there are exceptions; some pa tients develop these 
kinds of epi[INVESTIGATOR_261389], rarely, even later.  
Treatment of PGTC seizures in IGE is complex because the patient population is 
heterogeneous, as PGTC seizures can occur as an isolated seizure type or in asso ciation with 
other generalized seizure types.  
Paragraph 5, first sentence  
Between 15% and 40% of patients with generalized epi[INVESTIGATOR_261391] (phenobarbital, valproa te, 
ethosuximide, lamotrigine, topi[INVESTIGATOR_052], and levetiracetam) (Bartolomei et al, 1997; Verrotti et 
al, 2007);  
Has been changed to:  
Between 15% and 40% of patients with generalized epi[INVESTIGATOR_261438] (Bartolomei et al, 1997; 
Verrotti et al, 2007);  
Paragraph 6   
The following paragraph was deleted:  
Of patients with IGE experiencing PGTC seizures, clinical experience has shown that up to 
30% of patients who are treated wi th currently available AEDs have insufficient seizure 
control or unacceptable drug tolerability. Thus, there is a significant unmet medical need for 
new treatment options in this patient population.  
Paragraph 8  
The following paragraph was added:  
Preliminar y safety and PK data suggest that exposure -response in pediatric and adult subjects 
treated with LCM will be similar. Lacosamide is evaluated in pediatric subjects 1 month to 17 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 105 of 274 years of age in 2 completed studies and 1 ongoing study: SP847 (open -label, Ph ase 2, PK, 
tolerability, and safety study), SP1047 (PK study with a 1 day Evaluation Period), and SP848 
(open -label long -term safety study).  
Paragraph 9  
Considering the significant unmet medical need for new treatment options for patients with 
PGTC seizure s, the efficacy and tolerability profiles for LCM were evaluated in a series of 
animal models followed by a Phase 2 pi[INVESTIGATOR_261439].  
Has been changed to:  
Considering the significant unmet medical need for new treatme nt options for patients with 
IGE and PGTC seizures, the efficacy and tolerability profiles for LCM were evaluated in a 
series of animal models followed by a Phase 2 pi[INVESTIGATOR_261440].  
Paragraphs 11, 12, and 13  
SP0961, the Phase 2, multicenter, open -label pi[INVESTIGATOR_261396] (400mg/day) for uncontrolled PGTC seizures in adult subjects aged 16 to 
65 years with IGE, is clinically complete. The results of this pi[INVESTIGATOR_261441], with a small reduction in absence seizure 
frequency. A minority of subjects (~10%) in SP0961 showed an increase in absence seizures 
(reported as treatment -emergent adverse events [TEAEs]) that, in th is uncontrolled study, 
cannot be distinguished between the drug versus the natural course of the disease. The AE 
profile was similar to what has been observed with adjunctive LCM for the treatment of 
subjects with partial -onset seizures, with the exception  of seizure -related AEs.  
SP0982 is a Phase 3, double -blind, randomized, placebo -controlled, parallel -group, 
multicenter study designed to evaluate the efficacy and safety of LCM for uncontrolled 
PGTC seizures in subjects ≥12 years of age with IGE.  
The curr ent study (EP0012) will assess the long -term safety, tolerability, and efficacy of 
LCM and will enroll subjects who have completed SP0982 as well as eligible Baseline 
failures from SP0982. EP0012 will also allow subjects to receive LCM until it is approved  for 
use in the subject’s country for the treatment of PGTC seizures in IGE.  
Have been changed to:  
SP0961, the Phase 2, multicenter, open -label pi[INVESTIGATOR_261396] (400mg/day) for uncontrolled PGTC seizures in subjec ts aged 16 to 65 years 
with IGE, is complete. The results of this pi[INVESTIGATOR_261442], with a small reduction in absence seizure frequency. A 
minority of subjects (~10%) in SP0961 showed an increase in ab sence seizures (reported as 
treatment -emergent adverse events [TEAEs]) that, in this uncontrolled study, cannot be 
distinguished between the drug versus the natural course of the disease. The AE profile was 
similar to what has been observed with adjunctive  LCM for the treatment of subjects with 
partial -onset seizures, with the exception of seizure -related AEs.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 106 of 274 SP0982 is a Phase 3, double -blind, randomized, placebo -controlled, parallel -group, 
multicenter study designed to evaluate the efficacy and safety of LCM for uncontrolled 
PGTC seizures in subjects ≥4 years of age with IGE.  
The current study (EP0012) will assess the long -term safety, tolerability, and efficacy of 
LCM and will enroll subjects who have completed SP0982 as well as eligible Baseline 
failures  from SP0982. At the completion of the study, investigators should discuss treatment 
options with the subject and/or legal representative to best manage the subject's epi[INVESTIGATOR_002].  
Change #8  
Section 4.1.2   Secondary safety variables  
Secondary safety variables are: 
• Changes in hematology, chemistry, and urinalysis parameters  
• Changes in 12 -lead ECGs  
• Changes in vital sign measurements (ie, BP and pulse rate), including body weight and 
physical (including neurological) examination findings  
• Achenbach CBCL  
• Cognitive f unction assessment BRIEF  
Has been changed to:  
Secondary safety variables are:  
• Changes in hematology, chemistry, and urinalysis parameters  
• Changes in 12 -lead ECGs  
• Changes in vital sign measurements (ie, BP and pulse rate), including body weight and 
physical  (including neurological) examination findings  
Change #9  
The following section has been added:  
Section 4.1.3  Other safety variables  
• Achenbach CBCL1½ -5 or CBCL/6 -18 
• Cognitive function assessment BRIEF/BRIEF -P 
Change #10  
Section 4.2  Efficacy variables  
Effica cy variables are:  
• Percent change in PGTC seizure frequency per 28 days from Baseline, where Baseline is 
defined as the 12 -week Historical Baseline and 4 -week Prospective Baseline periods 
immediately prior to randomization in the parent study (SP0982)  
• Percent change in days with myoclonic seizures per 28 days from Baseline  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 107 of 274 • Percent change in days with absence seizures per 28 days from Baseline  
• Percentage of subjects with at least a 50% reduction in PGTC seizure frequency 
compared to Baseline  
• Percentage o f subjects with at least a 50% reduction in myoclonic seizure days compared 
to Baseline  
• Percentage of subjects with at least a 50% reduction in absence seizure days compared to 
Baseline  
• Seizure -free status (yes/no) for PGTC seizures  
• Seizure -free status (yes/no) for myoclonic seizures  
• Seizure -free status (yes/no) for absence seizures  
• Seizure -free status (yes/no) for all generalized seizure types  
• Change from Baseline in QOLIE -31-P subscale (Seizure Worry, Daily Activities/Social 
Functioning, Energy/Fatigue , Emotional Well -being, Mental Activity/Cognitive 
Functioning, Overall Quality of Life, and Medication Effects) and total scores in subjects 
≥18 years of age or change from Baseline in the PedsQL subscale (Physical Functioning, 
Emotional Functioning, Socia l Functioning, and School Functioning) and total scores in 
subjects <18  years of age  
• EuroQol dimension (EQ -5D-3L) items  
• Healthcare resource use: medical procedures, hospi[INVESTIGATOR_602], and healthcare provider 
visits  
• Number of working or school days lost by s ubject  
• Number of days with help from a caregiver  
Has been changed to:  
Section 4.2.1  Primary efficacy variable  
No primary efficacy variables are defined for this study.  
Section 4.2.2  Secondary efficacy variable  
The second efficacy variable is:  
• Percent chang e in PGTC seizure frequency per 28 days from Baseline, where Baseline is 
defined as the 12 -week Historical Baseline and 4 -week Prospective Baseline periods 
immediately prior to randomization in the parent study (SP0982)  
Section 4.2.3  Other efficacy variabl es 
The other efficacy variables are:  
• Percent change in days with myoclonic seizures per 28 days from Baseline  
• Percent change in days with absence seizures per 28 days from Baseline  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 108 of 274 • Percentage of subjects with at least a 50% reduction in PGTC seizure freque ncy 
compared to Baseline  
• Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared 
to Baseline  
• Percentage of subjects with at least a 50% reduction in absence seizure days compared to 
Baseline  
• Seizure -free status (yes/no) for PGTC seizures  
• Seizure -free status (yes/no) for myoclonic seizures  
• Seizure -free status (yes/no) for absence seizures  
• Seizure -free status (yes/no) for all generalized seizure types  
• Change from Baseline in QOLIE -31-P subscale (Seizure Worry, Daily Activities/ Social 
Functioning, Energy/Fatigue, Emotional Well -being, Mental Activity/Cognitive 
Functioning, Overall Quality of Life, and Medication Effects) and total scores in subjects 
≥18 years of age or change from Baseline in the PedsQL subscale (Physical Functio ning, 
Emotional Functioning, Social Functioning, and School Functioning) and total scores in 
subjects <18 years of age  
• Change from Baseline in the EQ -5D-3L visual analogue scale (VAS) score and change in 
utility as converted from the 5 dimensions (for subj ects ≥12 years of age)  
• Healthcare resource use: medical procedures, hospi[INVESTIGATOR_602], and healthcare provider 
visits  
• Number of working or school days lost by [CONTACT_1130]  
• Number of days with help from a caregiver  
Change #11  
The following section has been deleted  
Section 4.3  Pharmacokinetic variables  
The plasma concentrations of LCM will be assessed.  
Change #[ADDRESS_317955] completed 
the LCM SP0982 study as well as eligible Baseline failures from SP0982. Approximately 
200 subjects from approximately 150 study sites will be enrolled in EP0012. For the purposes 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 109 of 274 of this study Baseline failures and study completers from SP0982 who are eligible for 
inclusion are defined as:  
Has been changed to:  
This is a multicenter, open -label extension study to assess the long -term safety and change in 
seizure frequency associated with long -term adjunctive oral LCM for uncontrolled PGTC 
seizures in subjects ≥[ADDRESS_317956] completed the LCM 
SP0982 study as well as eligible Baseline failures from SP0982. Approximately 200 subjects 
from approximately 150 study sites are planned to be enrolled in EP0012.  
For the purposes of t his study, Baseline failures, randomized subjects who meet SP0982 exit 
criteria, and study completers from SP0982 who are eligible for inclusion in EP0012 are 
defined as:  
Paragraph 2, bulleted items  
• Subjects who complete the Prospective Baseline Period of  SP0982 and meet all entry 
criteria except the minimum PGTC seizure criteria required for randomization (Baseline 
failures)  
• Subjects who complete the end of the first 5 weeks of the Treatment Period (after 
randomization) of SP0982 and have experienced at l east 2 PGTC seizures during that 
time or  
• Subjects who experience a second PGTC seizure after the first 5 weeks of the Treatment 
Period of SP0982 or  
• Subjects who do not have [ADDRESS_317957] been changed to : 
SP0982 Baseline failures  
• Subjects who complete the Prospective Baseline Period of SP0982 and meet all entry 
criteria except the minimum PGTC seizure criteria required for randomization (Baseline 
failures)  
Randomized subjects meeting SP0982 exit criteria  
• Subjects who completed the first 6 weeks of the Treatment Period (after randomization) 
of SP0982 and experienced ≥2 PGTC seizures during that time or  
• Subjects who experience a second PGTC seizure after the first 6 weeks of the Treatment 
Period of SP0982  
SP0982 completers  
• Subjects who experience <2 PGTC seizures within the 24 -week Treatment Period of 
SP0982  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 110 of 274 Paragraph 3  
Subjects who completed SP0982 will start at Visit 1 on a dose of LCM 400mg/day (200mg 
bid); subjects who are eligible Baseline failures fr om SP0982 will start at Visit 1 on a dose of 
LCM 100mg/day (50mg bid). During EP0012, investigators will be allowed to increase or 
decrease the dose of LCM to optimize tolerability and seizure reduction for each subject. The 
LCM dose may be adjusted after the subject receives the first dose of LCM in the study. 
Lacosamide doses may be increased up to a maximum of LCM 800mg/day or decreased to a 
minimum of LCM 100mg/day at the discretion of the investigator. A clinic visit (scheduled 
or unscheduled) is requi red the first time the dose is increased to LCM 500mg/day, 
LCM  600mg/day, LCM 700mg/day, and LCM 800mg/day. One week after the first time the 
dose is increased to LCM 700mg/day or LCM 800mg/day, an unscheduled telephone contact 
[CONTACT_261526].  
Has been changed to:  
Subjects who completed SP0982 will start at Visit 1 on a dose of LCM 10mg/kg/day for 
pediatric subjects weighing <30kg, LCM 8mg/kg/day for pediatric subjects weighing ≥30kg 
to <50kg, and LCM 400mg/day (200mg bid) for adult subjects (≥18 years of age) or pe diatric 
subjects weighing ≥50kg. Subjects who are eligible Baseline failures from SP0982 will start 
at Visit 1 on a dose of LCM 2mg/kg/day for pediatric subjects weighing <50kg, and 
LCM  100mg/day (50mg bid) for adult subjects (≥18 years of age) or pediatri c subjects 
weighing ≥50kg.  
Baseline failures are required to complete Week [ADDRESS_317958] should hold the dose for a longer duration. 
There is no limit to the number of back titration steps or dose holds allowed and all are at the 
Investigator’s discretion; however, subjects must achieve the minimum LCM target dose of 
4mg/kg/day (oral solut ion) or 200mg/day (tablets) within [ADDRESS_317959] this minimum dose of 4mg/kg/day (oral solution) or 200mg/day (tablets), then 
the subjec t must enter the Taper Period and be withdrawn from the study.  
During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased 
in steps of n o more than 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects who 
have dose adjustments must remain on the dose for ≥3 days (in order to reach steady state) 
before a subsequent dose adjustment.  
To optimize tolerability and seizure reduction, the LCM dose may be increased or decreased 
at the investigator’s discretion after the subject receives the first dose of LCM in the study 
(see Table 7‒1). Baseline failures must complete Week 1 of dosing before LCM may be 
increased or decreased. The maximum do se for pediatric subjects weighing <50kg is 
12mg/kg/day (oral solution). The maximum dose for pediatric subjects weighing ≥50kg is 
600mg/day (tablets) and for adult subjects is 800mg/day (tablets).  
A clinic visit (scheduled or unscheduled) is required if:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Pr otocol  Lacosamide  EP0012  
   
Confidential  Page 111 of 274 • The dose is increased for the first time to any dose above 10mg/kg/day for pediatric 
subjects weighing <[ADDRESS_317960] be conducted to ensure that the dose is well tolerate d. 
• The dose is increased for the first time to any dose above LCM 400mg/day for all adult 
subjects or pediatric subjects weighing ≥50kg. One week after the first time the dose is 
increased, an unscheduled telephone contact [CONTACT_261493].  
Paragraph [ADDRESS_317961] up to approximately 6 years and consists of a Treatment Period and an End 
of Study Period lasting up to 5 weeks. Visit 1 of EP0012 is the same as the Final Clinic Visit 
of SP0982 for completers. Elig ible Baseline failures who choose to enter EP0012 will 
undergo a complete Visit 1 in EP0012. Visit 2 will occur 2 weeks after Visit 1, and Visit 3 
will occur 4 weeks later (Week 6). Clinical visits will then occur every [ADDRESS_317962]’s country for the treatment of PGTC seizures in subjects with IGE, or until UCB has 
determined that the clinical development program for the indication will be formally 
discontinued, or until the sponsor decides to close the study.  
Has been changed to:  
EP0012 will last at least 2 years and consists of a Treatmen t Period, an up to 4 -week Taper 
Period, and a 30 -day Safety Follow -Up Period. Visit 1 of EP0012 is the same as the Final 
Clinic Visit of SP0982 for completers and subjects who meet the SP0982 exit criteria. 
Eligible Baseline failures from SP0982 who choose  to enter this study will undergo a 
complete Visit 1. Visit 2 will occur 2 weeks after Visit 1, and Visit 3 will occur 4 weeks later 
(Week 6). Clinic visits will then occur every [ADDRESS_317963] year, and every 16 weeks in 
the second year. For subjec ts who continue in the study after Year 2, visits will occur and 
every 24 weeks thereafter until the end of the study. From Year 3 onwards, pediatric subjects 
weighing <50kg will return to the clinic for an additional Dispensation Visit 12 weeks after 
each 24-weekly visit, for the dispensation of LCM solution; LCM usage will be reviewed and 
empty LCM bottles will be returned.  
A telephone contact [CONTACT_18378] [ADDRESS_317964]’s country for the treatment of PGTC seizures in subjects with IGE, or 
until UCB has  determined that the clinical development program for the indication will be 
formally discontinued, or until UCB decides to close the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317965] all types of seizures, concomitant  AEDs, 
and other pertinent health status information.  
Has been changed to:  
Subjects and/or their caregiver will be dispensed a seizure diary to record all types of 
seizures, concomitant AEDs, and other pertinent health status information.  
Paragraphs [ADDRESS_317966]’s country. New 
AEDs should be added only when the subject has not optimally or adequately responded to a 
maximum tolerated dose of LCM. Concomitant AEDs may be carefully tapered and 
discontinued to achieve LCM monotherapy, if clinically appropriate. The Medical Monitor 
must be consulted prior to initiation of concomitant AED withdrawal.  
Upon study comple tion, subjects must either transition to commercially available LCM or 
taper off study drug. Subjects continuing treatment with commercially available LCM will 
transition at their current dose.  
Taper of LCM may not be required for some subjects who complet e the study depending on 
the treatment option selected by [CONTACT_207259]/or 
parent/legal guardian. Subjects tapering off LCM will do so at a recommended decrease rate 
of LCM 200mg/day per week, unless the investigator  feels that safety concerns require a 
more rapid withdrawal of LCM. A slower taper (eg, LCM 100mg/day per week) is permitted, 
if medically necessary. The Medical Monitor should be contact[CONTACT_35114] a more rapid withdrawal 
is required. A Final Clinic Visit will occur [ADDRESS_317967] been changed to:  
New concomitant AEDs may be introduced to optimize treatment, if the concomitant 
medication has been approved by [CONTACT_261527] t indication 
in the subject’s country. New AEDs should be added only when the subject has not optimally 
or adequately responded to a maximum tolerated dose of LCM. Concomitant AEDs may be 
carefully tapered and discontinued to achieve LCM monotherapy, if cl inically appropriate. 
The Medical Monitor must be consulted prior to initiation of concomitant AED withdrawal.  
At the completion of the study, investigators should discuss treatment options with the 
subject and/or their parent(s)/legal representative(s) to  best manage the subject’s epi[INVESTIGATOR_002]. 
Taper of LCM may not be required for some subjects who complete the study depending on 
the treatment option selected by [CONTACT_207259]/or their 
parent(s)/legal representative(s).  
Change #[ADDRESS_317968]’s country for the treatment of PGTC seizures in subjects with IGE, or until UCB 
has det ermined that the clinical development program for the indication will be formally 
discontinued, or until the sponsor decides to close the study. It is anticipated that up to 
approximately [ADDRESS_317969]’s country at the time the 
sponsor closes the study, access to LCM will be provided according to local laws.  
Has been changed to:  
For each subject, the study will last from study entry until LCM is approved for use in the 
subject’s country for the treatment of PGTC seizures in subjects with IGE, or until UCB has 
determined that the clinical development program for the indication will be formally 
discontinued, or until the sponsor d ecides to close the study. It is anticipated that at least [ADDRESS_317970]’s country at the time the sponsor closes the study, 
access  to LCM will be provided according to local laws.  
Paragraph 2  
The following study periods are defined:  
• A Treatment Period lasting up to approximately 6 years.  
• An End of Study Period lasting up to 5 weeks.  
− Subjects continuing LCM treatment with commercial L CM will transition at their 
current dose (received in the Treatment Period).  
− Subjects tapering off LCM will do so over 1 to 3 weeks (see taper schedule, 
Table  7-1). 
− A Final Clinic Visit will occur [ADDRESS_317971] in the study.  
Has been changed to:  
The following study periods are defined:  
• A Treatment Period lasting at least 2 years.  
• An up to 4 -week Taper Period and a 30 -day Safet y Follow -Up Period.  
− Subjects continuing LCM treatment with commercially available LCM will transition 
to a dose determined by [CONTACT_093].  
− Subjects tapering off LCM will do so over a period of up to 4 weeks (see Taper 
Schedule, Table 7 -2).  
− An End of Taper Visit will occur after the final LCM dose for subjects who taper off 
LCM. Following the End of Taper Visit, there will be a [ADDRESS_317972] visit/telephone contact [CONTACT_261485].  
Depending on the local regulations, after 2 years, subjects may continue to receive LCM in a 
named patient program.  
Change #14  
Section 5.1.2  Planned number of subjects and site(s)  
Approximately 200 subjects across approximately 150 international sites will be eligible to 
enroll in this study.  
Has been changed to:  
Approximately 200 subjects across approximately 150 international sites are planned to be 
enrolled in this study.  
Change #15  
Section 5.1.3  Anticipated regions and countries  
This study will be conducted in the US, Canada, Europe, Asia, and  Australia with possible 
extension to other countries and regions.  
Has been changed to:  
This study is planned to be conducted in the US, Canada, Europe, Asia, and Australia with 
possible extension to other countries and regions.  
Change #16  
Section 5.2  Sche dule of study assessments  
Paragraph 1  
The schedule of study assessments for treatment Years 1 to 2 is provided in Table 5‒1. An 
additional schedule of study assessments for treatment Years 3 to 6 is provided in Table 5‒2.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 115 of 274 Table 5‒1:  Schedule of study assessments for Years 1 and 2 for EP0012  
  Treatment Perioda End of Study Period  Unscheduledb 
Duration  Open -label: up to approximately 6  years  Up to 5 weeksc NA 
Year of study  Year 1  Year 2    
Visitd V1 V2 V3 V4 V5 V6 V7 V8 Telephone  
contacte V9 V10 V11 ET 
Visitf Termination 
Visitg Final 
Clinic 
Visith Unscheduled 
Visit  
Week  0 2 6 14 22 30 38 46  62 78 94   2 weeks 
after 
final 
LCM 
dose  NA 
Informed Consent/Assent  X                
Inclusion/Exclusion 
criteria  X                
Subject ID card 
dispensing  X                
Concomitant medications 
and AED(s)  X* X X X X X X X X X X X X X X X 
Medical history/Epi[INVESTIGATOR_261443]  X                
Physical exam 
(complete)i X*         X   X X   
Physical exam (brief)j  X X X X X X X   X X    X 
Neurological exam 
(complete)k X*         X   X X   
Neurological exam 
(brief)l  X X X X X X X   X X    X 
12-lead ECGm X* X X X    X    X X X   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 116 of 274 Table 5‒1:  Schedule of study assessments for Years 1 and 2 for EP0012  
  Treatment Perioda End of Study Period  Unscheduledb 
Duration  Open -label: up to approximately 6  years  Up to 5 weeksc NA 
Year of study  Year 1  Year 2    
Visitd V1 V2 V3 V4 V5 V6 V7 V8 Telephone  
contacte V9 V10 V11 ET 
Visitf Termination 
Visitg Final 
Clinic 
Visith Unscheduled 
Visit  
Week  0 2 6 14 22 30 38 46  62 78 94   2 weeks 
after 
final 
LCM 
dose  NA 
Vital signs (BP and 
pulse)  including 
orthostatic assessmentsn X* X X X X X X X  X X X X X X X 
Body weight and heighto X*   X  X  X  X X X X X X  
Tanner Stagep X    X   X   X X X X   
Laboratory tests  X* X X X  X  X  X X X X X   
Pregnancy testq X* X X X X X X X  X X X X X X  
LCM plasma 
concentrationr  X    X       X X   
Call IVRS/IWRS  X X X X X X X X  X X X X X X X 
C-SSRS  X* X X X X X X X  X X X X X X X 
Dispense subject diary  X X X X X X X X  X X X X X   
Subject diary 
return/review   X X X X X X X  X X X X X X X 
Dispense LCM  X X X X X X X X  X X X X X   
LCM review/return   X X X X X X X  X X X X X   
Withdrawal criteria  X* X X X X X X X X X X X X X  X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 117 of 274 Table 5‒1:  Schedule of study assessments for Years 1 and 2 for EP0012  
  Treatment Perioda End of Study Period  Unscheduledb 
Duration  Open -label: up to approximately 6  years  Up to 5 weeksc NA 
Year of study  Year 1  Year 2    
Visitd V1 V2 V3 V4 V5 V6 V7 V8 Telephone  
contacte V9 V10 V11 ET 
Visitf Termination 
Visitg Final 
Clinic 
Visith Unscheduled 
Visit  
Week  0 2 6 14 22 30 38 46  62 78 94   2 weeks 
after 
final 
LCM 
dose  NA 
AE reporting  X* X X X X X X X X X X X X X X X 
EQ-5D-3L X    X     X   X X   
QOLIE -31-P/PedsQLs X    X   X  X  X X X   
Achenbach CBCLt X    X   X  X  X X X   
BRIEFu X    X   X  X  X X X   
Healthcare resource use  X* X X X X X X X  X X X X X   
Work/school days lost  X* X X X X X X X  X X X X X   
Days with help from a 
caregiver  X* X X X X X X X  X X X X X   
Socio -professional data  X                
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; bid=twice daily; BP=blood pressure; BRIEF=Behavior Rating Inventory of Executive Fu nction; CBCL=Child 
Behavior Checklist; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; EQ -5D-3L=EuroQol -5 Dimension Quality of Life Assessment; 
ET=early termination; exam=examination; ID=identification; IVRS/IWRS =interactive voice/web response system; LCM=lacosamide; NA=not applicable; 
PedsQL=Pediatric Quality of Life Inventory; QOLIE -31-P=Patient Weighted Quality of Life in Epi[INVESTIGATOR_261379] -Form 31; V=Visit; W=Week  
Note: For subjects who have completed SP0982, assessments marked (*) should have already been completed during the last visit  of the previous protocol and  do 
not need to be repeated at Visit 1; for eligible Baseline failures from SP0982, a full Visit 1 is required including all sche duled tasks and procedures.  
a The Treatment Period will continue for up to approximately 6 years or until LCM is otherwise avai lable (eg, commercially), whichever is earlier.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_317973] be performed if the Unscheduled 
Visit is due to an AE.  
c For subjects requiring taper, the LCM dose will be reduced by 200mg/day per week until discontinued, unless the investigator feels that safety concerns 
require a more rapid withdrawal of LCM. A slower taper (eg, LCM 100mg/day per week) is permitted, if medically necessary.  
d A window of ±[ADDRESS_317974] every 8 weeks if no clinic 
visit is scheduled.  
e Telephone contacts are required every 8 weeks during the study, except during weeks in which a clinic visit is planned (eg, W eek 62). Therefore, telephone 
contacts in Year [ADDRESS_317975] be completed for all subjects who complete the study. This can be combined with Visit 19 if appropriate (see Table 5 -2). For 
subjects who will not continue on LCM, this visit will be followed by [CONTACT_261528] a Final Clinic Visit. For subjects who co ntinue on LCM, the 
Termination Visit is the last visit in the study.  
h A Final Clinic Visit must be completed for all subjects who taper off LCM.  
j The complete physical examination will include cardiac and respi[INVESTIGATOR_261444], temperature, and review of all body systems.  
k The br ief physical examination will include review of the following body systems: cardiovascular, pulmonary, abdominal (hepato -gastrointestinal), and 
dermatologic.  
l The complete neurological examination will include selected assessment of mental status, sensory systems, motor functions, cranial nerves, reflexes, and 
coordination/cerebellar function.  
m The brief neurological examination will include selected assessment of mental status, cranial nerves, and coordination/cerebe llar function.  
n The ECG recordings should be performed at approximately the same time of day and prior to blood sample collection. Care should be taken to assure prope r 
lead placement and quality ECG recordings. Subjects should rest in a supi[INVESTIGATOR_207187] 5 minutes prior to each recordi ng and should be motionless 
during the recording.  
o Blood pressure measurements should be taken with the proper placement and proper sized cuff to obtain accurate measurements.  
p Height will be recorded at Visits 1 and 9, and at the ET and Termination Visit.  
q The Tanner Stage will be performed only for subjects who are <18 years of age.  
r Serum pregnancy tests will be conducted at the following visits: Visit 1 (W0), ET, Termination Visit and Final Clinic Visit. All other pregnancy tests will be 
urine dipstick.  
s Blood samples for analysis of LCM plasma concentrations will be collected at any time between 2 successive bid doses.  
t The QOLIE -31-P will be performed for subjects who are ≥18 years of age  and the PedsQL will be performed for subjects <[ADDRESS_317976] 1 year of data before transitioning to the next  age range.  
u The Achenbach CBCL to be used is the CBCL/6 to 18 for children ≥12  years to <18  years of age; to be completed by [CONTACT_7071](s)/legal representative(s) 
(estimated completion time 45  minutes).  
v The BRIEF should be used for subjects ≥12 to <[ADDRESS_317977] 
1 year of data before transition ing to the next age range.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 119 of 274 Table 5‒2:  Schedule of study assessments for Years 3 through 6 for EP0012  
 Treatment Perioda End of Study Period  Unscheduledb 
Duration  Open -label: up to approximately 6 years  Up to 5 weeksc NA 
Year of study  Year 3  Year 4  Year  5 Year 6    
Visitd Telephone  
contacte V12 V13 V14 V15 V16 V17 V18 V19/ 
Termf ET 
Visitg Termination 
Visith Final Clinic 
Visiti Unscheduled 
Visit  
Week   118 142 166 190 214 238 262 286   2 weeks after 
final LCM 
dose  NA 
Concomitant medications and 
AED(s)  X X X X X X X X X X X X X 
Physical exam (complete)j  X  X  X  X X X X   
Physical exam (brief)k   X  X  X      X 
Neurological exam (complete)l  X  X  X  X X X X   
Neurological exam (brief)m   X  X  X      X 
12-lead ECGn   X  X  X  X X X   
Vital signs (BP and pulse)  
including orthostatic 
assessmentso  X X X X X X X X X X X X 
Body weight and heightp  X X X X X X X X X X X  
Tanner Stageq  X X X X X X X X X X   
Laboratory tests   X X X X X X X X X X   
Pregnancy testr  X X X X X X X X X X X  
LCM plasma concentrations          X X   
Call IVRS/IWRS   X X X X X X X X X X X X 
C-SSRS   X X X X X X X X X X X X 
Dispense subject diary   X X X X X X X X X X   
Subject diary return/review   X X X X X X X X X X X X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 120 of 274 Table 5‒2:  Schedule of study assessments for Years 3 through 6 for EP0012  
 Treatment Perioda End of Study Period  Unscheduledb 
Duration  Open -label: up to approximately 6 years  Up to 5 weeksc NA 
Year of study  Year 3  Year 4  Year  5 Year 6    
Visitd Telephone  
contacte V12 V13 V14 V15 V16 V17 V18 V19/ 
Termf ET 
Visitg Termination 
Visith Final Clinic 
Visiti Unscheduled 
Visit  
Week   118 142 166 190 214 238 262 286   2 weeks after 
final LCM 
dose  NA 
Dispense LCM   X X X X X X X X X X   
LCM review/return   X X X X X X X X X X   
Withdrawal criteria  X X X X X X X X X X X  X 
AE reporting  X X X X X X X X X X X X X 
EQ-5D-3L  X  X  X  X X X X   
QOLIE -31-P/PedsQLt  X X X X X X X X X X   
Achenbach CBCLu  X X X X X X X X X X   
BRIEFv  X X X X X X X X X X   
Healthcare resource use   X X X X X X X X X    
Work/school days lost   X X X X X X X X X    
Days with help from a caregiver   X X X X X X X X X    
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; bid=twice daily; BP=blood pressure; BRIEF=Behavior Rating Inventory of Executive Function; CBCL=Child 
Behavior Checklist; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; EQ -5D-3L=EuroQol -5 Dimension Quality of Life Assessment; 
ET=early termination; exam=examination; IVRS/IWRS=interact ive voice/web response system; LCM=lacosamide; NA=not applicable; PedsQL=Pediatric 
Quality of Life Inventory; QOLIE -31-P=Patient Weighted Quality of Life in Epi[INVESTIGATOR_261379] -Form 31; Term=Termination; V=Visit; W=Week  
a The Treatment Period will continue for up to approximately 6 years or until LCM is otherwise available (eg, commercially), whichever is earlier.  
b Unscheduled Visits may be performed at any time after Visit 1, at the discretion of the investigator. In addition to the requ ired assessments li sted above, 
further assessments can be completed as needed and may include ECG, vital signs, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled 
Visit is due to an AE.  
c For subjects requiring taper, the LCM dose will be reduced by 200mg /day per week until discontinued, unless the investigator feels that safety concerns 
require a more rapid withdrawal of LCM. A slower taper (eg, LCM 100mg/day per week) is permitted, if medically necessary.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 121 of 274 d A window of ±[ADDRESS_317978] every 8 weeks if no clinic 
visit is scheduled.  
e Telephone contacts are required every 8 weeks during the study. Telephone contacts are not required during weeks in which a clinic visit is planned (eg, 
Week 118). Therefore, telephone contacts are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 158, 
Week  174, Week 182; Year 5 - Week 198, Week 206, Week 222, Week 230; Year 6 - Week 246,  Week 254, Week 270, Week 278.  
f At the completion of the study, subjects will choose to continue commercially available LCM (depending on launch and country availability) or taper off 
LCM until it has been discontinued.  
g An ET Visit must be completed fo r all subjects who prematurely discontinue from the study. This will be followed by [CONTACT_261528] a Final Clinic Visit.  
h A Termination Visit must be completed for all subjects who complete the study. This can be combined with Visit [ADDRESS_317979] be completed for all subjects who taper off LCM.  
j The complete physical examination will include cardiac and respi[INVESTIGATOR_261444], temperature, and review of all body systems.  
k The brief physical examination will include review of the following body systems: cardiovascu lar, pulmonary, abdominal (hepato -gastrointestinal), and 
dermatologic.  
l The complete neurological examination will include selected assessment of mental status, sensory systems, motor functions, cr anial nerves, reflexes, and 
coordination/cerebellar funct ion. 
m The brief neurological examination will include selected assessment of mental status, cranial nerves, and coordination/cerebe llar function.  
n The ECG recordings should be performed at approximately the same time of day and prior to blood sample coll ection. Care should be taken to assure proper 
lead placement and quality ECG recordings. Subjects should rest in a supi[INVESTIGATOR_207187] 5 minutes prior to each recordi ng and should be motionless 
during the recording.  
o Blood pressure measurements shou ld be taken with the proper placement and proper sized cuff to obtain accurate measurements.  
p Height will be recorded at Visits 12, 14, 16 and 18, and at the ET and Termination Visit.  
q The Tanner Stage will be performed only for subjects who are <18 year s of age.  
r Serum pregnancy tests will be conducted at the following visits: Visit 1 (W0), ET, Termination Visit and Final Clinic Visit. All other pregnancy tests will be 
urine dipstick.  
s Blood samples for analysis of LCM plasma concentrations will be col lected at any time between 2 successive bid doses.  
t The QOLIE -31-P will be performed for subjects who are ≥18 years of age and the PedsQL will be performed for subjects <[ADDRESS_317980] 1 year of data before transitioning to the next age range.  
u The Achenbach CBCL to be used is the CBCL/6 to 18 for children ≥12 years to <18 years of age; to be completed by [CONTACT_7071](s )/legal representative(s) 
(estimated completion t ime 45 minutes).  
v The BRIEF should be used for subjects ≥12 to <[ADDRESS_317981] 
1 year of data before transitioning to the next age range.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 122 of 274  
Has been changed to:  
The schedule of study assessments for treatment Years 1 to 2 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit) is provided in Table 5‒1. An additional schedule of 
study assessments for treatment Years 3 to 5 (Treatment Period, ET Visit, Termination Visit, and 
Unscheduled Visit) is provided in Table 5‒2. The schedule of study assessments for the Taper 
and Safety Fol low-Up is provided in Table 5 -3. 
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 123 of 274  
Table  5‒1: Schedule of study assessments for Years 1 and 2 for EP0012 (Treatment Period, ET Visit, 
Termination Visit and Unscheduled Visit)  
  Treatment Perioda  Unscheduledb 
Duration  Open -label: at least 2 years   NA 
Year of study  Year 1  Year 2    
Visitc V1 V2 V3 V4 V5 V6 V7 V8 Telephone 
Contactd V9 V10 V11 ET 
Visite Termination 
Visitf 
 Unscheduled 
Visit  
Week  0 2 6 14 22 30 38 46  62 78 94   NA 
Informed Consent/Assent  X               
Inclusion/Exclusion criteria  X               
Subject ID card dispensing  X               
Concomitant medications and 
AED(s)  X* X X X X X X X X X X X X X X 
Medical history/Epi[INVESTIGATOR_261400]  X               
Physical exam (complete)g X*       X    X X X  
Physical exam (brief)h  X X X X X X   X X    X 
Neurological exam (complete)i X*       X  X  X X X  
Neurological exam (brief)j  X X X X X X    X    X 
12-lead ECGk X* X  X  X  X  X X X X X  
Vital signs (BP and pulse)  including 
orthostatic assessmentsl X* X X X X X X X  X X X X X X 
Body weight and heightm X*   X  X  X  X X X X X  
Tanner Stagen X       X    X X X  
Laboratory testso X* X   X   X  X X X X X  
Pregnancy testp X* X X X X X X X  X X X X X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 124 of 274 Table  5‒1: Schedule of study assessments for Years 1 and 2 for EP0012 (Treatment Period, ET Visit, 
Termination Visit and Unscheduled Visit)  
  Treatment Perioda  Unscheduledb 
Duration  Open -label: at least 2 years   NA 
Year of study  Year 1  Year 2    
Visitc V1 V2 V3 V4 V5 V6 V7 V8 Telephone 
Contactd V9 V10 V11 ET 
Visite Termination 
Visitf 
 Unscheduled 
Visit  
Week  0 2 6 14 22 30 38 46  62 78 94   NA 
Call IVRS/IWRS  X X X X X X X X  X X X X X X 
C-SSRSq X X X X X X X X  X X X X X X 
Dispense subject diary  X X X X X X X X  X X X X X  
Subject diary return/review   X X X X X X X  X X X X X X 
Dispense LCM  X X X X X X X X  X X X X X  
LCM review/return   X X X X X X X  X X X X X  
Withdrawal criteria  X* X X X X X X X X X X X X X X 
AE reporting  X* X X X X X X X X X X X X X X 
EQ-5D-3L X    X   X  X  X X X  
QOLIE -31-P/PedsQLr X    X   X  X  X X X  
Achenbach CBCLs X    X   X  X  X X X  
BRIEF -P/BRIEFt X    X   X  X  X X X  
Healthcare resource use  X* X X X X X X X  X X X X X  
Work/school days lost  X* X X X X X X X  X X X X X  
Days with help from a caregiver  X* X X X X X X X  X X X X X  
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; bid=twice daily; BP=blood pressure; BRIEF=Behavior Rating Inventory of Executive Function; BRIEF -P=Behavior 
Rating Inventory of Executive Function -Preschool Version; CBCL=Child Behavior Checklist; C -SSRS=Columbia -Suicide Severity Ra ting Scale; 
ECG=electrocardiogram; EQ -5D-3L=3 -level EuroQol -5 Dimension Quality of Life Assessment; ET=early termination; exam=examination; ID=identification; 
IVRS/IWRS=interactive voice/web response system; LCM=lacosamide; NA=not applicable; PedsQL=Pediat ric Quality of Life Inventory; QOLIE -31-P=Patient 
Weighted Quality of Life in Epi[INVESTIGATOR_261379] -Form 31; V=Visit; W=Week  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 125 of 274 Note: For subjects who have completed SP0982, assessments marked (*) should have already been completed during the last visit  of the p revious protocol and do 
not need to be repeated at Visit 1; for eligible Baseline failures from SP0982, a full Visit [ADDRESS_317982] 2 years.  
b Unscheduled Visits  may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of the investigator. In addition to the 
required assessments listed above depending on the type of visit (clinic or telephone), further assessments can be  completed as needed and may include 
ECG, vital signs, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to an AE.  
c A window of ±[ADDRESS_317983] every 8 weeks if no clinic 
visit is scheduled.  
d Telephone contacts are required every 8 weeks during the study, except during weeks in which a clinic visit is planned (eg, W eek 62). Therefore, telephone 
contacts in Year [ADDRESS_317984] be completed for all subjects who prematurely discontinue from the study. This will be followed by [CONTACT_261486] , an End of Taper Visit, and 
a Safety Follow -Up Period; see Table [ADDRESS_317985] be completed for all subjects who complete the study. This can be combined with Visit 17 if appropriate (see Table  5‒2). For 
subjects who will not continue on LCM, this visit will be followed by [CONTACT_261486], an End of Taper Visit, and a Safety Fo llow-Up Period; see Table [ADDRESS_317986] visit in the study.  
g The complete physical examination will include cardiac and respi[INVESTIGATOR_261401]. 
h The brief physical examination will include review of the following body systems: cardiovascular, pulmonary, abdominal (hepato -gastrointestinal), and 
dermatologic.  
i The complete neurological examination will include selected assessment of mental status, sens ory systems, motor functions, cranial nerves, reflexes, and 
coordination/cerebellar function.  
j The brief neurological examination will include selected assessment of general neurological status, reflexes, muscle strength , and coordination/cerebellar 
function.  
k The ECG recordings should be performed at the same time of day (when possible) and prior to blood sample collection and vital  sign assessments. Care 
should be taken to assure proper lead placement and quality ECG recordings. If possible, subjec ts should rest in a supi[INVESTIGATOR_207187] 5 minutes prior to 
each recording and should be motionless during the recording. In pediatric subjects (<18 years of age) a 12 -lead ECG (2 interpretable recordings) 
approximately [ADDRESS_317987] be p erformed.  
l Blood pressure measurements should be taken with the proper placement and proper sized cuff to obtain accurate measurements.  
m Height will be recorded at Visits 1 and 9, and at the ET and Termination Visit.  
n The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who enter puberty during the course of the study.  
o Urinalysis will be required for subjects ≥5 years of age only.  
p Pregnancy tests will be performed for female subjects of childbearing potential only. Ser um pregnancy tests will be conducted at the following visits: Visit 1 
(W0), ET, and Termination Visit. All other pregnancy tests will be urine dipstick.  
q The C -SSRS will be completed for all subjects ≥6 years of age (see Section 10.7.3).  
r The QOLIE -31-P will be performed for subjects who are ≥18 years of age and the PedsQL will be performed for subjects <[ADDRESS_317988]’s age should be completed, with the following exception: if a subject ages up to the next form of the PedsQL within 1 year 
after the Baseline assessment of the primary study, the form that was used at the Baseline assessment should be completed for  1 year after the Baseline 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 126 of 274 assessment, and subsequently the form consistent with his/her age at th e time of assessment should be completed. For each version of the PedsQL subjects 
must have at least 1 year of data before transitioning to the next age range (see Section 9.2.1).  
s The Achenbach CBCL: CBCL/1½ -5 for children 18 months to 5 years and 11 mo nths of age and CBCL/6 -18 for children ≥6 years to <18 years of age; to be 
completed by [CONTACT_7071](s)/legal representative(s) (estimated completion time 45 minutes). The version of the Achenbach CBCL appropriate to each 
subject’s age should be administered  with the following exception: for subjects who completed the CBCL/1½ -5 at the Baseline assessment of the previous 
study and turn 6 years of age within 1 year after the Baseline assessment of the primary study, the CBCL/1½ -5 should be completed for 1 year after the 
Baseline assessment of the primary study, and subsequently the CBCL/[ADDRESS_317989] 1 year of data before transitioning to 
the next age range. The Achenbach CBCL should be completed by [CONTACT_261487]/legal representative, if possible (see Section 10.7.6).  
t The BRIEF -P should be used for subjects who are <5 years of age a t Visit 1, and the BRIEF should be used for subjects who are ≥[ADDRESS_317990] 1 year of data before transitioning to  the next age range (see 
Section  10.7.7).  
 
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 127 of 274  
Table  5‒2: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, 
Termination Visit and Unscheduled Visit)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5     
Visitc TCd V12 V13 V14 V15 V16 V17/ 
Terme ET 
Visitf Term 
Visitg LCM Solution 
Dispensation Visith Unscheduled 
Visit  
Week   118 142 166 190 214 238    NA 
Concomitant medications and AED(s)  X X X X X X X X X  X 
Physical exam (complete)i   X  X  X X    
Physical exam (brief)j  X  X  X   X  X 
Neurological exam (complete)k   X  X  X X    
Neurological exam (brief)l  X  X  X   X  X 
12-lead ECGm  X X X X X X X X   
Vital signs (BP and pulse)  including 
orthostatic assessmentsn  X X X X X X X X  X 
Body weight and heighto  X X X X X X X X   
Tanner Stagep   X  X  X X X   
Laboratory tests   X X X X X X X X   
Pregnancy testq  X X X X X X X X   
Call IVRS/IWRS   X X X X X X X X  X 
C-SSRSr  X X X X X X X X  X 
Dispense subject diary   X X X X X X X X   
Subject diary return/review   X X X X X X X X  X 
Dispense LCM   X X X X X X X X X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 128 of 274 Table  5‒2: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, 
Termination Visit and Unscheduled Visit)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5     
Visitc TCd V12 V13 V14 V15 V16 V17/ 
Terme ET 
Visitf Term 
Visitg LCM Solution 
Dispensation Visith Unscheduled 
Visit  
Week   118 142 166 190 214 238    NA 
LCM review/return   X X X X X X X X X  
Withdrawal criteria  X X X X X X X X X  X 
AE reporting  X X X X X X X X X  X 
EQ-5D-3L  X X X X X X X X   
QOLIE -31-P/PedsQLs  X X X X X X X X   
Achenbach CBCLt  X X X X X X X X   
BRIEFu  X X X X X X X X   
Healthcare resource use   X X X X X X X X   
Work/school days lost   X X X X X X X X   
Days with help from a caregiver   X X X X X X X X   
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; bid=twice daily; BP=blood pressure; BRIEF=Behavior Rating Inventory of Executive Fu nction; BRIEF -P=Behavior 
Rating Inventory of Executive Function -Preschool Version; CBCL=Child Behavior Checklist; C-SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; EQ -5D-3L=3 -level EuroQol -5 Dimension Quality of Life Assessment; ET=early termination; exam=examination; 
IVRS/IWRS=interactive voice/web response system; LCM=lacosamide; NA=not applicabl e; PedsQL=Pediatric Quality of Life Inventory; QOLIE -31-P=Patient 
Weighted Quality of Life in Epi[INVESTIGATOR_261379] -Form 31; Term=Termination; V=Visit; W=Week  
a The Treatment Period will continue for at least 2 years.  
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of the investigator. In addition to the 
required assessments listed above depending on the type of visit (clinic or telephone), further assessments can be completed as needed and may include 
ECG, vital signs, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to an AE.  
c A window of ±[ADDRESS_317991] every 8 weeks if no clinic 
visit is scheduled.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 129 of 274 d Telephone contacts are required every 8 weeks during the study. Telephone contacts are not required during weeks in which a c linic visit is planned (eg, 
Week 118). Therefore, telephone contacts are sch eduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 158, 
Week  174, Week 182; Year [ADDRESS_317992]  and/or legal representative to best manage the subject's 
epi[INVESTIGATOR_002].  
f An ET Visit must be completed for all subjects who prematurely discontinue from the study. This will be followed by [CONTACT_261486] , an End of Taper Visit, and 
a Safety Follow -Up Period; see T able [ADDRESS_317993] be completed for all subjects who complete the study. This can be combined with Visit 17 if appropri ate. For subjects who will not 
continue on LCM, this visit will be followed by [CONTACT_261486], an End of Taper Visit, and a Safety Follow -Up Period; see Table [ADDRESS_317994] visit in the study.  
h Dispensation Visit will occur 12 weeks after each 24 -weekly visit from Year 3 onwards and will be for the purpose of dispensi ng LCM solution for pediatric 
subjects <50kg.  
i The complete physical examination will include cardiac and respi[INVESTIGATOR_261401]. 
j The brief physical examination will include review of the following body systems: cardiovascular, pulmonary, abdominal (hepat o-gastrointestinal), and 
dermatologic.  
k The complete neurological examination will include selected assessment of mental status, sensory systems, motor functions, cranial nerves, reflexes, and 
coordination/cerebellar function.  
l The brief neurological examination will include selected assessment of general neurological status, reflexes, muscle strength , and coordination/cerebellar 
function.  
m The ECG recordings should be performed at the same time of day (when possible) and prior to blood sample collection and vital  sign assessments. Care 
should be taken to assure proper lead placement and quality ECG recordings. If possible, subject s should rest in a supi[INVESTIGATOR_207187] 5 minutes prior to 
each recording and should be motionless during the recording. In pediatric subjects (<18 years of age) a 12 -lead ECG (2 interpretable recordings) 
approximately [ADDRESS_317995] be pe rformed.  
n Blood pressure measurements should be taken with the proper placement and proper sized cuff to obtain accurate measurements.  
o Height will be recorded at Visits 12, 14, and 16, and at the ET and Termination Visit.  
p The Tanner Stage will be perf ormed only for subjects who are pubescent at Visit 1 or who enter puberty during the course of the study.  
q Pregnancy tests will be performed for female subjects of childbearing potential only. Serum pregnancy tests will be conducted  at the following visit s: Visit 1 
(W0), ET, and Termination Visit. All other pregnancy tests will be urine dipstick.  
r The C -SSRS will be completed for all subjects ≥6 years of age (see Section 10.7.3).  
s The QOLIE -31-P will be performed for subjects who are ≥18 years of age an d the PedsQL will be performed for subjects <[ADDRESS_317996] 1 year of data before transitioning to the next age range (see Section 9.2.1).  
t The Achenbach CBCL: CBCL/6 -18 for children ≥6 years t o <18 years of age; to be completed by [CONTACT_7071](s)/legal representative(s) (estimated completion 
time 45 minutes). For each version of the CBCL, subjects must have at least 1 year of data before transitioning to the next a ge range. The Achenbach CBCL 
should be completed by [CONTACT_261487]/legal representative, if possible (see Section 10.7.6).  
u The BRIEF should be used for subjects who are ≥[ADDRESS_317997] 
1 year of d ata before transitioning to the next age range (see Section 10.7.7).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 130 of 274 The following table has been added:  
Table 5‒3:  Schedule of study assessments (Taper Period and Safety Follow -
Up Period) for EP0012  
Assessment  
 Taper Perioda 
(up to 4 weeks)  Safety Follow -Up Periodb 
End of Taper Visitc 
 Safety Follow -Up 
Visit  Safety Follow -Up 
TC 
2 weeks (±2 days) 
after last dose of 
study drug  30 days ( -1/+3 
days) after last 
dose of study drug  
Concomitant medications and AED(s)  X X X 
Physical exam (complete)  X X  
Neurological exam (complete)  X X  
12-lead ECGd X X  
Vital signs (BP and pulse) including 
orthostatic assessments  X X  
Body weight  X X  
Laboratory tests:     
 Chemistry/hematology  X Xe  
 Endocrinology   Xe  
 Urine pregnancy testf X X  
Contact [CONTACT_54537]/IWRS  X   
Subject diary return/reviewg X   
LCM review/return  X   
Withdrawal criteria  X   
AE reporting  X X X 
C-SSRSh X X  
Healthcare resource use  X X  
Work/school days lost  X X  
Days with help from a caregiver  X X  
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; BP=blood pressure; C -SSRS=Columbia Suicide Severity Rating Scale; 
ECG=electrocardiogram; IVRS/IWRS= interactive voice/web response system; LCM=lacosamide; TC=telephone 
contact  
a All subjects who discontinue LCM must complete the End of Taper Visit.  
b There will be a 30 -day ( -1/+3 days) Safety Follow -Up Period for subjects who complete the End of Taper Visit. 
The Sa fety Follow -Up Period consists of a Clinic Visit 2 weeks after the End of Taper Visit followed 2 weeks 
later by a TC Visit.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 131 of 274 c An End of Taper Visit will be scheduled at the end of the Taper Period (up to 4 weeks) depending on dose level 
achieved; see Table  7-2. Of note, for subjects who enter the Taper Period at ≤2mg/kg/day (oral solution) or 
100mg/day (tablets), the End of Taper Visit will take place at the ET or Termination Visit.  
d The ECG recordings should be performed at the same time of day (when poss ible) and prior to blood sample 
collection and vital sign assessments. Care should be taken to assure proper lead placement and quality ECG 
recordings. If possible, subjects should rest in a supi[INVESTIGATOR_207187] 5 minutes prior to each recording and 
should be motionless during the recording. In pediatric subjects (<18 years of age) a 12 -lead ECG (2 
interpretable recordings) approximately [ADDRESS_317998] be performed.  
e The assessment will only be required for subjects with an abnormal value (clinical chemistry, hematology, or 
endocrinology) or reading (ECG) at the previous clinic visit.  
f Pregnancy tests will be performed for female subjects of childbearing potential only. A urine pregnancy test 
will be performed.  
g The last subject diary wil l be returned at the End of Taper Visit.  
h The C -SSRS will be completed for all subjects ≥6 years of age (see Section  10.7.3).  
Change #[ADDRESS_317999] been demonstrated in 
the partial -onset seizure population. The approach for further LCM development is to evaluate 
the use of adjunctive LCM for the treatment of uncontrolled PGTC seizures in patients with IGE. 
The maximum  dose of LCM 800mg/day is the highest dose that has been used in previous 
clinical studies. Preclinical evaluations of LCM in animal models of generalized seizures 
indicate that LCM may be an effective treatment. However, the patient population with PGTC 
seizures is heterogeneous, as PGTC seizures can occur as an isolated seizure type or in 
association with other generalized seizure types (eg, myoclonic seizures, absence seizures). 
Primary generalized tonic -clonic seizures may also occur in such distinct sy ndromes as benign 
myoclonic epi[INVESTIGATOR_261445], juvenile myoclonic epi[INVESTIGATOR_002], epi[INVESTIGATOR_261446], childhood and juvenile absence epi[INVESTIGATOR_002], and reflex -induced PGTC seizures. 
Typi[INVESTIGATOR_897], PGTC seizures present initially in childhood, adol escence, or early adulthood.  
Has been changed to:  
The efficacy, safety, and tolerability of LCM as an adjunctive therapy have been demonstrated in 
the partial onset seizure population. The approach for further LCM development is to evaluate 
the use of adju nctive LCM for the treatment of uncontrolled PGTC seizures in patients with IGE.  
Paragraph 3  
The goal of the Phase 3 LCM PGTC seizure program is to provide clinical evidence of the 
efficacy and safety of LCM as an adjunctive therapy for uncontrolled PGTC s eizures in subjects 
with IGE as the basis for approval of this indication. SP0982 is a double -blind, randomized, 
placebo -controlled, parallel -group, multicenter study designed to evaluate the efficacy and safety 
of LCM for uncontrolled PGTC seizures in sub jects ≥12 years of age with IGE.  
Has been changed to:  
The goal of the Phase 3 LCM PGTC seizure program is to provide clinical evidence of the 
efficacy and safety of LCM as an adjunctive therapy for uncontrolled PGTC seizures in subjects 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 132 of 274 with IGE as the bas is for approval of this indication. SP0982 is a double -blind, randomized, 
placebo -controlled, parallel -group, multicenter study designed to evaluate the efficacy and safety 
of LCM for uncontrolled PGTC seizures in subjects ≥[ADDRESS_318000] completed SP0982 and eligible 
Baseline failures from SP0982.  
Paragraph 4  
The following paragraph has been added:  
For adult subjects (≥18 years of age), the LCM 400mg/day maintenance dose was w ell tolerated 
and demonstrated efficacy in 3 primary efficacy studies as adjunctive therapy in subjects with 
partial -onset seizures. In SP0961 (the Phase 2 pi[INVESTIGATOR_799]) and SP0962 (the open -label extension 
study) in subjects with uncontrolled PGTC seizures  with IGE, the 400mg/day dose was also well 
tolerated. Generally, the doses of AEDs used for the treatment of partial -onset seizures are 
similar to those used to treat generalized seizures. Thus, the 300mg/day to 400mg/day target dose 
range is considered t he optimal maintenance dose for the population with uncontrolled PGTC 
seizures with IGE. The maximum dose of LCM  800mg/day is the highest dose that has been 
used in previous clinical studies. Dose selection in EP0012 is based on the primary study 
(SP0982).  During EP0012, investigators will be allowed to increase or decrease the dose of LCM 
to optimize tolerability and seizure reduction for each subject. Lacosamide doses may be 
increased up to a maximum of LCM  12mg/kg/day (oral solution) for pediatric subjec ts weighing 
<50kg. The maximum dose for pediatric subjects (<18 years of age) ≥50kg is 600mg/day 
(tablets) and for adult subjects is 800mg/day (tablets).  
Change #[ADDRESS_318001] has a lifetime history of s uicide attempt (including an actual attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a 
positive response (“Yes”) to either Question 4 or Question 5 of the Columbia -Suicide 
Severity Rating Scal e (C-SSRS) at screening.  
Has been changed to:  
3. Subject has an active suicidal ideation as indicated by a positive response (“Yes”) to either 
Question 4 or Question 5 of the “Since Last Visit” version of the Columbia -Suicide Severity 
Rating Scale (C -SSRS) . The subject should be referred immediately to a Mental Healthcare 
Professional.  
Change #[ADDRESS_318002]  be withdrawn from the study if any of the following events occur:  
• Subject develops second or third degree  atrioventricular (AV) block.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 133 of 274 • The subject becomes pregnant, as evidenced by a positive pregnancy test.  
• The sponsor or a regulatory agency requests withdrawal of the subject.  
• The subject is unwilling or unable to continue and withdraws consent.  
• A prolongation or worsening of overall seizure duration, frequency, type, or pattern 
considered by [CONTACT_261529].  
• In the case of liver function test (LFT) results of transaminases (alanine aminot ransferase 
[ALT] and/or aspartate aminotransferase [AST]) ≥3x upper limit of normal (ULN) to 
<5xULN and total bilirubin ≥2xULN or transaminases (AST and/or ALT) ≥5xULN, LCM 
must be immediately discontinued and the subject withdrawn from the study. The LFTs  will 
be repeated as soon as possible, and in no case more than 1 week later.  
• Subject has actual suicidal ideation since last visit as indicated by a positive response “Yes” 
to either Question 4 or Question 5 of the “Since Last Visit” version of the C -SSRS . The 
subject should be referred immediately to a Mental Healthcare Professional and must be 
withdrawn from the study.  
Has been changed to:  
Subjects must  be withdrawn from the study if any of the following events occur:  
1. The subject develops second or third  degree atrioventricular (AV) block.  
2. The subject becomes pregnant, as evidenced by a positive pregnancy test.  
3. The sponsor or a regulatory agency requests withdrawal of the subject.  
4. The subject is unwilling or unable to continue, or the legal representative  is unwilling or 
unable to allow the subject to continue in the study.  
5. In the case of liver function test (LFT) results of transaminases (alanine aminotransferase 
[ALT] and/or aspartate aminotransferase [AST]) ≥3x upper limit of normal (ULN) to 
<5xULN and total bilirubin ≥2xULN or transaminases (AST and/or ALT) ≥5xULN, LCM 
must be immediately discontinued and the subject withdrawn from the study. The LFTs will 
be repeated as soon as possible, and in no case more than 1 week later.  
6. Subjects ≥[ADDRESS_318003] visit as indicated by a positive 
response “Yes” to either Question 4 or Question 5 of the “Since Last Visit” version of the C -
SSRS. The subject should be referred immediately to a Mental Healthcare Professional and 
must be withdrawn from the study.  
7. Subject is unable to tolerate at least the minimum LCM target dose of 4mg/kg/day (oral 
solution) or 200mg/day (tablets).  
Paragraph 3, bulleted item 1  
• The subject requires a medication that is not permitted  
Has been changed t o: 
• The subject requires a medication that is not permitted (see Section 7.8).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 134 of 274 Paragraph 3, bulleted item 3  
• The following bulleted item has been added: An epi[INVESTIGATOR_261407], a 
prolongation of seizure duration, a worsening of seizure frequency, o r emergence of a new 
seizure type considered by [CONTACT_261530].  
Change #[ADDRESS_318004](s)  
Oral tablets of LCM 50mg and 100mg will be used in the study and will be supplied in 
high-density polyethylene bottles with child proof polypropylene screw caps.  
Has been changed to:  
Investigational medicinal product (IMP) will be provided as LCM oral solution (LCM  10mg/mL) 
and LCM tablets (LCM 50mg and LCM 100mg).  
The oral solution formulation contains 10mg/mL of drug substance and is colorless to pale 
yellow in appearance.  
The tablet formulation will be supplied in doses of 50mg and 100mg. The 50mg tablets are light 
pi[INVESTIGATOR_8745], oval, film -coated tablets debossed with “SP” on 1 side and “50” on the ot her. The 100mg 
tablets are dark yellow, oval, film -coated tablets debossed with “SP” on 1 side and “100” on the 
other.  
Change #21  
Section 7.2  Treatment(s) to be administered  
Paragraphs 1 and 2  
Lacosamide will be orally administered bid (at approximately 12-hour intervals in the morning 
and in the evening) in [ADDRESS_318005].  
At Visit 1 subjects wh o completed SP0982 will start on a dose of LCM 400mg/day (200mg bid); 
subjects who are eligible Baseline failures from SP0982 will start at Visit 1 on a dose of LCM 
100mg/day (50mg bid). The LCM dose may then be adjusted at the discretion of the investigat or 
within the range of 100 to 800mg/day. The investigator should increase or decrease the dose no 
faster than LCM 100mg/day per week. A clinic visit (scheduled or unscheduled) is required the 
first time the dose is increased to LCM 500mg/day, LCM  600mg/day , LCM 700mg/day, and 
LCM 800mg/day. One week after the first time the dose is increased to LCM 700mg/day or 
LCM 800mg/day, an unscheduled telephone contact [CONTACT_261493].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318006] been changed to:  
Lacosamide will b e orally administered bid (at approximately 12 -hour intervals in the morning 
and in the evening) in 2 equally divided doses (oral solution for pediatric subjects weighing 
<50kg or tablets for adult subjects [≥18 years of age] and pediatric subjects [<18  years of age] 
weighing ≥50kg); during the study, subjects who initially started on oral solution may transfer to 
tablets at the investigator’s discretion.  
During the study, investigators will be allowed to increase or decrease the dose of LCM to 
optimize to lerability and seizure reduction for each subject, within the dose range described in 
Table 7‒1.  
Change #22  
The following section header has been added:  
Section 7.2.1  Treatment Period  
Paragraphs 1 through 11  
Subjects withdrawing from the study will complet e the Early Termination (ET) Visit and LCM 
will be tapered over 1 to 3 weeks (see taper schedule, Table 7‒1). Subjects completing the 
Treatment Period and not continuing with commercially available LCM will complete the 
Termination Visit and LCM will be ta pered over 1 to 3 weeks (see taper schedule, Table 7 -1). 
Lacosamide will be tapered off gradually at a recommended decrease rate of LCM 200mg/day 
per week, unless the investigator feels that safety concerns require a more rapid withdrawal of 
LCM. A slower taper (eg, LCM 100mg/day per week) is permitted, if medically necessary. The 
Medical Monitor should be contact[CONTACT_35114] a more rapid withdrawal is required. A Final Clinic Visit 
will occur 2 weeks after the final LCM dose for subjects who taper off LCM.  
Has be en changed to:  
At Visit 1, subjects who completed SP0982 will start on a dose of LCM 10mg/kg/day for 
pediatric subjects weighing <30kg, LCM 8mg/kg/day for pediatric subjects weighing ≥30kg to 
<50kg, and LCM 400mg/day (200mg bid) for adult subjects (≥18 yea rs of age) or pediatric 
subjects weighing ≥50kg. Subjects who are eligible Baseline failures from SP0982 will start at 
Visit 1 on a dose of LCM 2mg/kg/day for pediatric subjects weighing <50kg, and 
LCM  100mg/day (50mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing 
≥50kg.  
Baseline failures are required to complete Week [ADDRESS_318007] should hold the dose for a longer duration. There is no 
limit to the number of back titration steps or dose holds allowed and all are at the Investigator’s 
discretion; however, subjects must achieve the minimum LCM target dose of 4mg/kg /day (oral 
solution) or 200mg/day (tablets).  
At any time during the course of the study if it becomes apparent that a subject is unable to attain 
at least this minimum dose of 4mg/kg/day (oral solution) or 200mg/day (tablets), then the subject 
must enter the Taper Period and be withdrawn from the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 136 of 274 During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased in 
steps of no more than 2 mg/kg/day (oral solution) or 100mg/day (tablets). Subjects who have 
dose adjustments must remain on the dose for ≥3 days (in order to reach steady state) before a 
subsequent dose adjustment.  
Table 7 -1 provides the minimum and maximum LCM dose during the Tr eatment Period.  
Table 7 -1: Minimum and maximum LCM dose during the Treatment Period  
Formulation  Minimum LCM dose  Maximum LCM dose  
Oral solution (pediatric subjects <50kg)  4mg/kg/day  12mg/kg/day  
Tablets (pediatric subjects ≥50kg)  200mg/day  600mg/day  
Tablets (adult subjects)  200mg/day  800mg/day  
LCM=lacosamide  
The LCM dose may be adjusted at the investigator’s discretion after the subject receives the first 
dose of LCM in the study. Baseline failures must complete Week 1 of dosing before LCM may 
be increased or decreased. The maximum dose for pediatric subjects weighing <50kg is 
12mg/kg/day (oral solution). The maximum dose for pediatric subjects weighing ≥50kg is 
600mg/day (tablets) and for adult subjects is 800mg/day (tablets).  
A clinic visit (scheduled or unscheduled) is required if:  
• The dose is increased for  the first time to any dose above 10mg/kg/day for pediatric subjects 
weighing <50kg. One week after the first time the dose is increased, an unscheduled 
telephone contact [CONTACT_261526].  
• The dose is increased f or the first time to any dose above LCM 400mg/day for all adult 
subjects or pediatric subjects weighing ≥50kg. One week after the first time the dose is 
increased, an unscheduled telephone contact [CONTACT_261493] . 
Subjects withdrawing from the study must complete the Early Termination (ET) Visit and an up 
to 4-week taper followed by [CONTACT_261531] (see taper schedule, Table 7‒2). Following the 
End of Taper Visit, there will be a [ADDRESS_318008] 
and/or their legal representative(s) to best manage the subject’s epi[INVESTIGATOR_002]. Taper of LCM may not 
be required for some subjects who complete the study depending on the treatment option selected 
by [CONTACT_207259]/or their legal representative(s).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318009] complete the Termination Visit and also undergo taper, followed by a n End of Taper Visit 
(see taper schedule, Table 7‒2), and a [ADDRESS_318010] complete the Termination Visit and also undergo taper, followed by  [CONTACT_261531] 
(see taper schedule, Table 7‒2), and a 30-day Safety Follow -Up Period.  
The following table summarizes the recommended LCM dose taper:  
Table 7‒1: Lacosamide dosing for subjects requiring taper  
Table  7‒1: Lacosamide dosing for subject s requiring taper  
Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  
LCM 800mg/day  LCM 600mg/day  LCM 400mg/day  LCM 200mg/day  
LCM 700mg/day  LCM 500mg/day  LCM 300mg/day  LCM 100mg/day  
LCM 600mg/day  LCM 400mg/day  LCM 200mg/day  LCM 0mg/day  
LCM 500mg/day  LCM 300mg/day  LCM 100mg/day  LCM 0mg/day  
LCM 400mg/day  LCM 200mg/day  LCM 0mg/day  - 
LCM 300mg/day  LCM 100mg/day  LCM 0mg/day  - 
LCM 200mg/day  LCM 0mg/day  - - 
LCM 100mg/day  LCM 0mg/day  - - 
ET=early termination; LCM=lacosamide  
a Subjects will begin taper on ET/Termination Visit.  
Has been changed to:  
Table  7‒2: Lacosamide dosing for subjects requiring taper  
Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  Week 4  
11 or 12mg/kg/day  9mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
9 or 10mg/kg/day  8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
7 or 8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  NA 
5 or 6mg/kg/day  4mg/kg/day  2mg/kg/day  NA NA 
3 or 4mg/kg/day  2mg/kg/day  NA NA NA 
750 to 800mg/day  600mg/day  400mg/day  200mg/day  100mg/day  
650 to 700mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
550 to 600mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 138 of 274 Table  7‒2: Lacosamide dosing for subjects requiring taper  
Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  Week 4  
450 to 500mg/day  400mg/day  300mg/day  200mg/day  100mg/day  
350 or 400mg/day  300mg/day  200mg/day  100mg/day  NA 
250 or 300mg/day  200mg/day  100mg/day  NA NA 
150 or 200mg/day  100mg/day  NA NA NA 
ET=early termination; LCM=lacosamide  
Note: The oral solution is dosed as mg/kg/day and tablets are dosed as mg/day.  
a Subjects will begin taper on ET/Termination  Visit.  
Change #[ADDRESS_318011] (IMP) is 
suitably packaged in such a wa y as to protect the IMP from deterioration during transport and 
storage. Lacosamide will be packaged in high -density polyethylene bottles with child proof 
polypropylene screw caps.  
Has been changed to:  
Lacosamide (tablets and oral solution) is manufactured , packaged, and labeled according to 
Good Manufacturing Practice guidelines and applicable laws or regulations. The IMP is suitably 
packaged in such a way as to protect the IMP from deterioration during transport and storage. 
Oral solution will be packaged  in amber polyethylene terephthalate bottles. Tablets will be 
supplied in high density polyethylene bottles with child proof polypropylene screw caps.  
Change #[ADDRESS_318012] be ensured either by [CONTACT_58952] a temperature log in accordance with local requirements on a regular basis (eg, 
once a week), showing minimum and maximum temperatures reached over the time interval.  
In case a n out -of-range temperature is noted, it must be immediately communicated to the 
Clinical Project Manager (CPM) (or designee) before further use of the IMP.  
The CPM (or designee) will transmit the out -of-range temperature (copy of the temperature log 
and du ration of the out -of-range temperature, if available) to the Drug Supply Coordinator. 
Based on discussion with a UCB Quality Assurance representative, the Drug Supply Coordinator 
will then provide the CPM (or designee) with instructions for the site regard ing use of the IMP.  
Have been changed to:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318013] be ensured by [CONTACT_261532] a temperature log (showing minimum and maximum temperatures reached over 
the time interval) in accordance with loca l requirements on a regular basis.  
In case an out -of-range temperature is noted, it must be immediately communicated to the 
Clinical Project Manager (CPM) (or designee) before further use of the IMP and communicated 
to the sponsor’s designee in accordance with the pharmacy manual.  
Change #[ADDRESS_318014] (due to breakage or wastage), not used, disposed of at the study site, or 
returned to the sponsor or designee must also be recorded on  the appropriate forms.  
Has been changed to:  
Details of any IMP lost (due to breakage or wastage), not used, disposed of at the study site, or 
returned to the sponsor’s designee must also be recorded on the appropriate forms.  
Paragraph 5, first sentence  
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers) and unused IMP containers must be reconciled and returned to UCB (or designee), 
preferably in their original package.  
Has been changed to:  
Periodi cally, and/or after completion of the clinical phase of the study, all used (including empty 
containers) and unused IMP containers must be reconciled and returned to UCB’s designee, 
preferably in their original package.  
Change #[ADDRESS_318015] 
diary completion, including AED usage, will be evaluated at each visit. Sites are encouraged to 
call subjects to inquire about their diary completion.  
Has been changed to:  
Timely completion of the subject diary is essential for evaluation of safety and efficacy. Subject 
diary completion, including AED usage, will be evaluated at each clinic visit and telephone 
contac t. Sites are encouraged to call subjects to inquire about their diary completion. 
Investigators should advise subjects and/or caregivers about the importance of reporting non -
PGTC seizures. Subjects should be reminded that diaries must include daily entrie s even if no 
seizures have occurred.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 140 of 274 Change #27  
Section 7.8  Concomitant medication(s)/treatment(s)  
The following paragraphs have been added:  
All concomitant medication and treatment must be recorded in the appropriate study documents 
(eg, eCRF and source d ocument).  
Contraceptive treatment is allowed for female subjects of childbearing potential.  
The use of neuroleptics, monoamine oxidase inhibitors, barbiturates (except for treatment of 
epi[INVESTIGATOR_002]), and narcotic analgesics is prohibited throughout the study. However, in the case of 
narcotics or marijuana, certain limited usage may become necessary (eg, acute medical situation, 
perioperative period for subjects requiring surgery). Upon learning of such situations, the 
investigator should consult the medical mon itor to determine whether the narcotic or marijuana 
use should result in discontinuation of a subject’s further participation in the study.  
The use of vigabatrin and felbamate is also prohibited throughout the study.  
Only stable use of amphetamines and sed ative antihistamines is allowed during the study. Also, 
only stable, low doses of anxiolytics or hypnotics are allowed for nonepi[INVESTIGATOR_261447].  
Stable use of benzodiazepi[INVESTIGATOR_261409], but intermittent use is only 
allowed as rescue  medication for epi[INVESTIGATOR_261447] (maximum 1 dose per week).  
During the Treatment Period, new concomitant AEDs may be introduced, if the concomitant 
medication has been approved by [CONTACT_261533]’s country. For example, a new AED may be added when the subject has not optimally 
or adequately responded (lack of efficacy or tolerance) to LCM. Concomitant AEDs may be 
carefully tapered and discontinued to achieve LCM monotherapy, if clinically app ropriate. The 
Medical Monitor must be consulted prior to initiation of concomitant AED withdrawal.  
Change #28  
The following section has been deleted:  
Section 7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  
The following concomitant medications are restricted during the study:  
• Use of benzodiazepi[INVESTIGATOR_1651]  
− The chronic (daily dose) use of benzodiazepi[INVESTIGATOR_261448] 1 of the AEDs.  
− The stable use of benzodiazepi[INVESTIGATOR_261449] -epi[INVESTIGATOR_261450] 1 of the AEDs.  
− The intermittent use of benzodiazepi[INVESTIGATOR_261451], but limited to [ADDRESS_318016]’s 
country. New AEDs should be added only when the subject has not optimally or adequately 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318017] be consulted prior to initiation of concomitant AED withdrawal.  
Change #29  
Section 8  STUDY PROCEDURES BY [CONTACT_261534] 3  
A detailed schedule of study assessments for treatment Years 1 to 2 is provided in Table 5‒1 and 
for treatment Years 3 to 6 in Table 5‒2.  
Has been changed to:  
A detailed schedule of study assessments for treatment Years 1 to 2 is provided in T able 5‒1, for 
treatment Years 3 to 5 in Table 5‒2, and for the Taper Period and Safety Follow -Up Period in 
Table 5‒3.  
Change #30  
Section 8.1.1  Visit 1 (Week 0)  
The following bulleted item has been deleted  
• Socio -professional data  
Bulleted items number 11, 12, 19, and 20  
• Tanner staging (for subjects <18 years of age)  
• C-SSRS assessment*  
• EQ-5D-3L 
• QOLIE -31-P (subjects ≥18 years of age)/PedsQL (subjects <18 years of age)  
Have been changed to:  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study)  
• C-SSRS assessment (for subjects ≥6 years of age)  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
Change #31  
Section 8.1.2  Visits 2 to 8 (Weeks 2 to 46, Year 1)  
Bulleted items number 1 through 19  
• Concomitant medications and AEDs  
• Physical examination (brief)  
• Neurological examination (brief)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 142 of 274 • ECG (12 -lead) assessment (Visit 2, 3, 4 and 8 only)  
• Vital signs (pulse rate, BP) i ncluding orthostatic assessments  
• Body weight (Visit 4, 6 and 8 only)  
• Tanner staging (for subjects <18 years of age) (Visit 5 and 8 only)  
• C-SSRS assessment  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalys is) [Visit 2, 3, 4, 6 and 8 only], and a urine pregnancy test [for women of 
childbearing potential])  
• LCM plasma concentration (Visit 2 and 6 only)  
• Contact [CONTACT_54537]/IWRS  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess wi thdrawal criteria  
• AE reporting  
• EQ-5D-3L (Visit 5 only)  
• QOLIE -31-P (subjects ≥18 years of age)/PedsQL (subjects <18 years of age) (Visit 5 and 8 
only)  
Have been changed to:  
• Concomitant medications and AEDs  
• Physical examination (brief, Visit 2, 3, 4, 5, 6, and 7; complete, Visit 8)  
• Neurological examination (brief, Visit 2, 3, 4, 5, 6, and 7; complete, Visit 8)  
• ECG (12 -lead) assessment (Visit 2, 4, 6, and 8 only)  
• Vital signs (pulse rate, BP) including orthostatic assessments  
• Body weight (Visit 4, 6, and 8 only)  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 8 only)  
• C-SSRS assessment (for subjects ≥6 years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis) [Visit 2, 5, and 8 only], and a urine pregnancy test [for women of 
childbearing potential])  
• Contact [CONTACT_54537]/IWRS  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 143 of 274 • Dispense subject diary  
• Subject diary ret urn/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (Visit 5 and 8) (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age) (Visit 5 
and 8 only)  
Change #32  
Section 8.1.3  Visits 9 to 11 (Weeks 62 to 94, Year 2)  
Bulleted items 1 through 18  
• Concomitant medications and AEDs  
• Physical examination (complete, Visit 9; brief, Visit 10 and 11)  
• Neurological examination (complete, Visit 9; brief, Visit 10 and 11)  
• ECG (12 -lead) assessment (Visit 11 only)  
• Vital signs (pulse rate, BP) including orthostatic assessments  
• Body weight and height (height at Visit 9 only)  
• Tanner staging (for subjects <18 years of age) (Visit 10 and 11 only)  
• C-SSRS assessment  
• Blood and urine samples fo r clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a urine pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_54537]/IWRS  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (Visit 9 only)  
• QOLIE -31-P (subjects ≥18 years of age)/PedsQL (subjects <18 years of age) (Visit 9 and 11 
only)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318018] been changed to:  
• Concomitant medications and AEDs  
• Physical examination (brief, Visit 9 and 10; co mplete, Visit 11)  
• Neurological examination (brief, Visit 9 and 10; complete, Visit 11)  
• ECG (12 -lead) assessment (Visit 9, 10, and 11)  
• Vital signs (pulse rate, BP) including orthostatic assessments  
• Body weight and height (height at Visit 9 only)  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 11 only)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (inc ludes hematology, 
chemistry, urinalysis, and a urine pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_54537]/IWRS  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (Visit 9 and 11) (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age) (Visit 9 
and 11 only)  
Change #33  
Section 8.1.4  Visits 12 to 19 (Weeks 118 to 286, Years 3 to 6)  
The following tasks and proce dures are to be performed at these visits:  
• Concomitant medications and AEDs  
• Physical examination (complete, Visit 12, 14, 16, 18 and 19; brief, Visit 13, 15, and 17)  
• Neurological examination (complete, Visit 12, 14, 16, 18 and 19; brief, Visit 13, 15, and 17) 
• ECG (12 -lead) assessment (Visit 13, 15, 17, and 19)  
• Vital signs (pulse rate, BP) including orthostatic assessments  
• Body weight and height (height at Visit 12, 14, 16 and 18)  
• Tanner staging (for subjects <18 years of age)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 145 of 274 • C-SSRS assessment  
• Blood and uri ne samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a urine pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_54537]/IWRS  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/retur n 
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (Visit 12, 14, 16, 18 and 19)  
• QOLIE -31-P (subjects ≥18 years of age)/PedsQL (subjects <18 years of age)  
• Achenbach CBCL for subjects <18 years of age  
• BRIEF for subjects <18 years of age  
• Healthcare resource use 
• Work/school days lost  
• Days with help from a caregiver  
Has been changed to:  
Section 8.1.4  Visits 12, 13, 14, 15, 16, and 17 (Weeks 118, 142, 166, 190, 
214, and 238, Years 3 to 5)  
The following tasks and procedures are to be performed at these visits:  
• Concomitant medications and AEDs  
• Physical examination (brief, Visit 12, 14, and 16; complete, Visit 13, 15, and 17)  
• Neurological examination (brief, Visit 12, 14, and 16; complete, Visit 13, 15, and 17)  
• ECG (12 -lead) assessment  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight and height (height at Visit 12, 14, and 16)  
• Tanner staging (for subjects who are pubescent at Visit 1 or who enter puberty during the 
course of the study) (Visit 13, 15, and 17)  
• C-SSRS assessment (for subjects ≥6 years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and a urine pregnancy test [for women of childbearing potential])  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 146 of 274 • Contact [CONTACT_54537]/IWRS  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LC M 
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Achenbach CBCL for subjects ≥6 years to <18 years of age  
• BRIEF for subjec ts ≥5 to <18 years of age  
• Healthcare resource use  
• Work/school days lost  
• Days with help from a caregiver  
Change #[ADDRESS_318019] (Years 2 to 6)  
Has been changed to:  
Section 8.1.[ADDRESS_318020]  
Paragraph 1  
Telephone contacts are required every 8 weeks during Year 2 to Year 6, except during weeks in 
which a clinic visit is planned (eg, Week 62). Therefore, telephone contacts in Year 2 are 
scheduled for Week 54, Week 70, and Week 86. Telephone contacts in Years 3 to 6 are 
scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 
158, Week 174, Week 182; Year 5 - Week 198, Week 206, Week 222, Week 230; Year 6 - Week 
246, Week 254, Week 270, Week 278.  
Has been changed to:  
Telephone contacts are required every 8 weeks during Year 2 to Year 5, except during weeks in 
which a clinic visit is planned (eg, Week 62). Therefore, telephone contacts in Year 2 are 
scheduled for Week 54, Week 70, and Week 86. Telephone contacts in Years 3 to 5 are 
scheduled for: Year  3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 
158, Week 174, Week 182; Year 5 - Week 198, Week 206, Week 222, Week 230.  
Paragraph 2  
The following paragraph has been deleted:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318021] time the dose is increased to LCM 700mg/day or LCM 800mg/day, an 
unscheduled telephone contact [CONTACT_261526].  
Paragraph 3  
The following paragraph has been added:  
The investigator will also ensure subjects are compliant with LCM administration a nd diary 
completion during the telephone contact.  
Change #35  
The following section has been added:  
Section 8.1.6  LCM solution Dispensation Visit  
From Year 3 onwards, pediatric subjects weighing <50kg will return to the clinic for an 
additional Dispensation  Visit 12 weeks after each 24 -weekly visit, for the dispensation of LCM 
solution; LCM usage will be reviewed and empty LCM bottles will be returned.  
Change #36  
The following section header has been deleted:  
Section 8.2  End of Study Period  
Change #37  
Sectio n 8.2.1  Early Termination Visit (Years 1 to 6)  
Has been changed to:  
Section 8.2   Early Termination Visit  
Paragraph 1  
Subjects withdrawing from the study will complete the ET Visit and LCM will be tapered over 1 
to 3 weeks (see taper schedule, Table 7‒1).  
Has been changed to:  
Subjects withdrawing from the study will complete the ET Visit, and LCM will be tapered over a 
period of up to 4 weeks (see taper schedule, Table 7‒2).  
Paragraph 2, bulleted items number 7 through 19  
• Tanner staging (for subjects <18 years of age)  
• C-SSRS assessment  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a serum pregnancy test [for women of childbearing potential])  
• LCM plasma concentration  
• Contact [CONTACT_54537]/IWRS  
• Dispense subject diary  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 148 of 274 • Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L 
• QOLIE -31-P (subjects ≥18 years of age)/PedsQL (subjects <18 years of age)  
Have been changed to:  
• Tanner staging (will be performed only  for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study)  
• C-SSRS assessment (for subjects ≥6 years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a serum pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_54537]/IWRS  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for  subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
Change #38  
Section 8.2.2  Termination Visit (Years 1 to 6)  
Has been changed to:  
Section 8.3  Termination Visit  
Paragraphs 1 and 2  
Subjects completing the Treatment Period and not continuing with commercially available LCM 
will complete the Termination Visit, and LCM will be tapered over 1 to 3 weeks (see taper 
schedule, Table 7‒1).  
Once LCM becomes commercially available and the subject elects to continue treatment, they 
must also complete th e Termination Visit and transition to commercially available LCM. Taper 
of LCM is not required for subjects who complete the study and continue on commercially 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318022] been changed to:  
Subjects completing the Treatment Period and not continuing with commercially available LCM 
will complete the Termination Visit, and LCM will be tapered over a period of up to 4  weeks 
(see taper schedule, Table 7‒2).  
Once LCM is approved for use and the subject elects to continue treatment, they must also 
complete the Termination Visit and transition to commercially available LCM. Taper of LCM is 
not required for  subjects who complete the study and continue on commercially available LCM. 
Subjects transitioning to commercially available LCM will do so immediately and will continue 
at a dose determined by [CONTACT_093].  
Note: this visit can be combined with Visit  17 if appropriate.  
Paragraph 4, bulleted items number 7 through 24  
• Tanner staging (for subjects <18 years of age)  
• C-SSRS assessment  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a serum pregna ncy test [for women of childbearing potential])  
• LCM plasma concentration  
• Contact [CONTACT_54537]/IWRS  
• Dispense subject diary for subjects undergoing taper  
• Subject diary return/review  
• Dispense LCM for subjects undergoing taper  
• LCM review/return  
• Assess withdrawal crit eria 
• AE reporting  
• EQ-5D-3L 
• QOLIE -31-P (subjects ≥18 years of age)/PedsQL (subjects <18 years of age)  
• Achenbach CBCL for subjects <18 years of age  
• BRIEF for subjects <18 years of age  
• Healthcare resource use (Years 1 to 2 only)  
• Work/school days lost (Years 1  to 2 only)  
• Days with help from a caregiver (Years 1 to 2 only)  
Have been changed to:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 150 of 274 • Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a serum pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_54537]/IWRS  
• Dispense subject diary for subjects undergoing taper  
• Subject diary return/review  
• Dispense LCM for subjects undergoing taper  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Ache nbach CBCL for subjects <18 years of age  
• BRIEF for subjects <18 years of age  
• Healthcare resource use  
• Work/school days lost  
• Days with help from a caregiver  
Change #39  
Section 8.2.3  Final Clinic Visit  
A Final Clinic Visit will occur 2 weeks after the final  LCM dose for subjects who taper off 
LCM. The following tasks and procedures are to be performed at this visit:  
• Concomitant medications and AEDs  
• Vital signs (pulse rate, BP) including orthostatic assessments  
• Body weight  
• C-SSRS assessment  
• Blood sample for a  serum pregnancy test (for women of childbearing potential)  
• Contact [CONTACT_54537]/IWRS  
• Subject diary return/review  
• AE reporting  
Has been changed to:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 151 of 274 Section 8.4.1  End of Taper Visit  
An End of Taper Visit will occur after the final LCM dose for subjects who taper of f LCM. The 
following tasks and procedures are to be performed at this visit:  
• Concomitant medications and AEDs  
• Physical examination (complete)  
• Neurological examination (complete)  
• ECG (12 -lead) assessment  
• Vital signs (pulse rate, BP) including orthostatic assessments  
• Body weight  
• C-SSRS assessment (for subjects ≥6 years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and a urine pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_54537]/IWRS  
• Subjec t diary return/review  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• Healthcare resource use  
• Work/school days lost  
• Days with help from a caregiver  
Change #40  
Section 8.3  Unscheduled Visit  
Has been changed to:  
Section 8.5  Unscheduled Visit  
Paragraph 1  
Unscheduled Visits may be performed at any time after Visit 1, at the discretion of the 
investigator. A clinic visit (scheduled or unscheduled) is required the first time the dose is 
increased to LCM 500mg/day, LCM 600mg/day, LCM 700mg/day, and  LCM 800mg/day. One 
week after the first time the dose is increased to LCM 700mg/day or LCM 800mg/day, an 
unscheduled telephone contact [CONTACT_261526].  
Has been changed to:  
Unscheduled Visits may be performed at  any time after Visit 1, at the discretion of the 
investigator. A clinic visit (scheduled or unscheduled) is required the first time the dose is 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 152 of 274 increased above the dose of 10mg/kg/day (oral solution) for pediatric subjects weighing <50kg 
or 400mg/day (tab lets) for adult and pediatric subjects ≥50kg. One week after the first time the 
dose is increased above the dose of 10mg/kg/day or 400mg/day, an unscheduled telephone 
contact [CONTACT_261526]. Similarly, a clinic visit 
(scheduled or unscheduled) is required for pediatric subjects weighing <[ADDRESS_318023] time the 
dose is increased to 11mg/kg/day, or 12mg/kg/day, and all adult subjects or pediatric subjects 
weighing ≥50kg the first time the dose is increased to LCM  500mg/day, LCM 600mg/day, LCM 
700mg/day, and LCM 800mg/day. One week after the first time the dose is increased to 
11mg/kg/day, or 12mg/kg/day for pediatric subjects <50kg, and LCM  500mg/day, LCM 
600mg/day, LCM 700mg/day, or LCM 800mg/day for all adult su bjects or pediatric subjects 
weighing ≥50kg, an unscheduled telephone contact [CONTACT_261493].  
Paragraph 3  
If unscheduled visit is due to an AE, then the C -SSRS is required.  
Has been changed to:  
If Unscheduled Vi sit is due to an AE, then the C -SSRS is required.  
Change #41  
The following header section was added:  
Section 8.4  Taper and Safety Follow -Up Period  
Change #42  
The following section has been added:  
Section 8.4.[ADDRESS_318024] dose of study drug 
for a Safety Follow -Up Visit. During the Safety Follow -Up Visit, the following assessments will 
be performed:  
• Concomitant medications and AEDs  
• Physical examination (complete)  
• Neurological examination (complete)  
• ECG (12 -lead) assessment (only required for subjects with an abnormal reading at the 
previous clinic visit)  
• Vital signs (pulse rate, BP) including orthostatic assessments  
• Body weight  
• C-SSRS assessment (for subjects ≥6 year s of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology, [only required for subjects with an abnormal value at the previous 
clinic visit], and a urine pregnancy test [for women of childbearing po tential])  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 153 of 274 • AE reporting  
• Healthcare resource use  
• Work/school days lost  
• Days with help from a caregiver  
Change #43  
The following section has been added:  
Section 8.4.[ADDRESS_318025]  
Thirty days ( -1/+3 days) after the last dose of study drug the subject will receive a Safety 
Follow -Up telephone contact. During the Safety Follow -Up telephone contact, the following 
assessments will be performed:  
• Concomitant medications and AEDs  
• AE reporting  
Change #44  
Section 9.1  Seizure frequency  
The foll owing paragraph was added:  
Investigators should advise subjects and/or caregivers about the importance of reporting 
non-PGTC seizures. Subjects should be reminded that diaries must include daily entries even if 
no seizures have occurred.  
Change #45  
Section  9.2.1  Patient -Weighted Quality of Life in Epi[INVESTIGATOR_261379] -Form 31 
(QOLIE -31-P) 
Paragraphs 1 and 2  
The QOLIE -31-P Version 2 (see Section 17.2) will be used to evaluate the health -related quality 
of life (HRQoL) of study subjects (Cramer and Van Hammée, 2003).  
The QOLIE -31-P is an adaptation of the original QOLIE -31 instrument (Cramer et al, 1998) that 
includes 30 items grouped into 7 multi -item subscales (Seizure Worry [5 items], Overall Quality 
of Life [2 items], Emotional Well being [5 items], Energy/F atigue [4 items], Cognitive 
Functioning [6 items], Medication Effects [3 items], and Daily Activities/Social Functioning [5 
items]) and [ADDRESS_318026] been changed to:  
The QOLIE -31-P Version 2 (see Section 16.2) will be used to evaluate the hea lth-related quality 
of life (HRQoL) of study subjects ≥18 years of age (Cramer and Van Hammée, 2003).  
The QOLIE -31-P is an adaptation of the original QOLIE -31 instrument (Cramer et al, 1998) that 
includes 30 items grouped into 7 multi -item subscales (Seizu re Worry [5 items], Overall Quality 
of Life [2 items], Emotional Well -being [5 items], Energy/Fatigue [4 items], Cognitive 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 154 of 274 Functioning [6 items], Medication Effects [3 items], and Daily Activities/Social Functioning [5 
items]) and 1 health status item.  
Change #46  
Section 9.2.2  Pediatric Quality of Life Inventory  
Paragraphs 2 through 4  
The PedsQL Measurement Model consists of developmentally appropriate forms for pediatric 
subjects 12 years of age and ≥13 years to <18 years of age. Self -report is measured fo r pediatric 
subjects ≥5 years to <18 years of age, and parent proxy report of child HRQoL is measured for 
pediatric subjects ≥2 years to ≤[ADDRESS_318027] 1 year of data  before transitioning to the next age range.  
The multidimensional 23 -item PedsQL generic core scales encompass the essential core domains 
for pediatric HRQoL measurement: Physical Functioning (8 items), Emotional Functioning (5 
items), Social Functioning ( 5 items), and School Functioning (5 items). The PedsQL assessment 
is retrospective to the prior 4 weeks, and individual items are scored using a 5 -point Likert scale 
(never, almost never, sometimes, often, or always). A total health summary score ranging 
between [ADDRESS_318028] been changed to:  
The PedsQL Measurement Model consists of forms for pediatric subjects ≥2 years to ≤4  years, 
≥5 years to ≤7 year s, ≥8 years to ≤12 years, and ≥13 years to ≤18 years of age. Self -report is 
measured for pediatric subjects ≥5 years to <18 years of age, and parent proxy report of child 
HRQoL is measured for pediatric subjects ≤[ADDRESS_318029]’s age should be completed, with the following exception: if a subject ages up to the next 
form of the PedsQL within 1 year after the Baseline assessment of the primary study, the form 
that was used at the Baseline assessment should be complete d for 1 year after the Baseline 
assessment, and subsequently the form consistent with his/her age at the time of assessment 
should be completed.  
For each version of the PedsQL subjects, must have at least 1  year of data before transitioning to 
the next age  range.  
The multidimensional PedsQL generic core scales encompass the essential core domains for 
pediatric HRQoL measurement: Physical Functioning, Emotional Functioning, Social 
Functioning, and School Functioning. The PedsQL assessment is retrospective to  the prior 
4 weeks, and individual items are scored using a 5 point Likert scale (never, almost never, 
sometimes, often, or always). A total health summary score ranging between 0 and 100 is 
calculated from the sum of the raw scores, with higher scores ind icating higher HRQoL.  
Change #[ADDRESS_318030] sentence  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 155 of 274 The EQ -5D-3L (EuroQol Group, 2011) (see Section 17.3) is a self -administered questionnaire 
designed to measure health status.  
Has been changed to:  
The EQ -5D-3L (EuroQol Group, 2011) (see Section 16.3) is a self -administered questionnaire 
designed to measure health status in subjects ≥12 years of age.  
Paragraph 2  
The EQ -5D-3L also captures a self -rating of health status on a 20cm vertical visual analog scale, 
anchored at 100 (best imaginable health state) at the top and 0 (worst imaginable health state) at 
the bottom.  
Has been changed to:  
The EQ -5D-3L also captures a self -rating of health status on a 20cm vertical VAS, anchored at 
100 (best  imaginable health state) at the top and 0 (worst imaginable health state) at the bottom.  
Change #[ADDRESS_318031] will be recorded.  
Has been changed to:  
The number of working or school days lost by [CONTACT_41614], as applicable.  
Change #49  
Section 9.2.6  Number of days with help from a caregiver  
The number of days with help from a caregiver will be recorded.  
Has been changed to:  
The number of days  with help from a caregiver will be recorded, as applicable.  
Change #[ADDRESS_318032] level of education, current professional status, housing 
status, a nd regular assistance will be collected according to the schedule of study assessments in 
Table 5‒1.  
Change #51  
The following section has been deleted:  
Section 10  ASSESSMENT OF PHARMACOKINETIC VARIABLE(S)  
Blood samples for analysis of LCM plasma concentrat ions will be collected at any time between 
2 successive bid doses, according to the schedule of study assessments in Table  5-1and Table 5‒
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318033] be 
recorded. Actual dosin g and sampling times will be recorded in the eCRF to the minute.  
Each blood sample drawn for LCM plasma concentration determination will be centrifuged and 
split into 2 duplicate samples prior to freezing. The samples will be stored at -20°C until shipped 
to a central laboratory. The central laboratory will store the plasma samples at -70°C until 
analysis.  
Blood draws for these assessments will coincide with the blood collection times for assessment 
of the hematology and clinical chemistry parameters. Time and date of each blood draw will be 
documented on the eCRF.  
Instructions on blood sample collection, processing, storage, and labeling/shippi[INVESTIGATOR_261452].  
 
Change #[ADDRESS_318034]  
Has been changed to:  
Section 10.[ADDRESS_318035]  
Paragraph 2, bulleted item number 3  
• Serious suspected multiorgan hypersensitivity reactions; serious suspected multiorgan 
hypersensitivity cases may be identified and reported to  the sponsor by [CONTACT_261535]:  
− An AE or laboratory value (as defined in the following text) suggestive of internal organ 
involvement (including but not limited to hepatitis , nephritis, pneumonitis, carditis, 
colitis, encephalitis, pancreatitis, myositis, arthritis, or hematologic system involvement) 
combined with at least 1 of the following: fever, rash, lymphadenopathy, or eosinophilia  
Treatment -emergent abnormal laboratory  value criteria suggestive of internal organ 
involvement or eosinophilia:  
◦ Eosinophils % ≥10%  
◦ Eosinophils absolute ≥0.5G/L  
◦ Neutrophils absolute <1.5G/L  
◦ Platelets ≤100G/L  
◦ ALT ≥2xULN  
◦ AST ≥2xULN  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 157 of 274 Has been changed to:  
• Serious suspected multiorgan hypersensitivity reactions.  
Serious suspected multiorgan hypersensitivity cases may be identified and reported to the 
sponsor by [CONTACT_261536] : 
An AE or laboratory value (as defined in the following text) suggestive of internal organ 
involvement (including but not limited to hepatitis, nephritis, pneumonitis, carditis, colitis, 
encephalitis, pancreatitis, myositis, arthritis, or hematologic syst em involvement) combined 
with at least 1 of the following: fever, rash, lymphadenopathy, or eosinophilia.  
Treatment -emergent abnormal laboratory value criteria suggestive of internal organ involvement 
or eosinophilia:  
◦ Eosinophils % ≥10%  
◦ Eosinophils absolut e ≥0.5G/L  
◦ Neutrophils absolute <1.5G/L  
◦ Platelets ≤100G/L  
◦ ALT ≥2xULN  
◦ AST ≥2xULN  
Bulleted item number 4 has been added  
• Emergence of non -pre-existing or worsening of any existing epi[INVESTIGATOR_261453] #53  
Section 11.6  Laboratory measurements  
Has been  changed to:  
Section 10.[ADDRESS_318036] sentence  
Blood and urine specimens for routine assay of hematology, clinical chemistry, and urinalysis 
parameters will be collected according to the schedule of study assessments in Table  5‒1 and 
Table 5‒2.  
Has been changed to:  
Blood and urine specimens for routine assay of hematology, clinical chemistry, and urinalysis 
parameters will be collected according to the schedule of study assessments in Table 5‒1, Table 
5‒2, and Table 5 -3. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 158 of 274 Table  11-2: Laboratory tests  
Table  11‒2: Laboratory tests  
Hematology  Clinical chemistry  Urinalysis  
Hematocrit  
Hemoglobin  
Platelet count  
RBC count  
WBC count  
Differential count  Calcium  
Phosphorus  
Serum electrolytes (sodium, 
potassium, chloride, 
bicarbonate)  
Creatinine  
BUN  
AST  
ALT  
Total bilirubin  
Alkaline phosphatase  
GGT  
Glucose  
Albumin  
Total serum protein  
Uric acid  pH 
Ketones  
Glucose  
Albumin  
Specific gravity  
Microscopic exam for blood 
cells or casts/hpf  
 
Urine pregnancy test  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen;  
GGT=gamma glutamyl transferase; hpf=high power field; RBC=red blood cell; WBC=white blood cell  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 159 of 274 Has been changed to:  
Table 10 -2: Laboratory tests  
Hematology  Clinical chemistry  Endocrinology  Urinalysis  
Hematocrit  
Hemoglobin  
Platelet count  
RBC count  
WBC count  
Differential count  Calcium  
Phosphorus  
Serum electrolytes 
(sodium, potassium, 
chloride, bicarbonate)  
Creatinine  
BUN  
AST  
ALT  
Total bilirubin  
Alkaline phosphatase  
GGT  
Glucose  
Albumin  
Total serum protein  
Uric acid  TSH  
T3 (total and serum -free)  
T4 (total and serum -free)  pH 
Ketones  
Glucose  
Albumin  
Specific gravity  
Microscopic exam for 
blood cells or casts/hpf  
 
Urine pregnancy test  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; GGT=gamma 
glutamyl transferase; hpf=high power field; RBC=red blood cell; T3=triiodothyronine; T4=thyroxine; 
TSH=thyroid stimulating hormone; WBC=white blood cell  
Change #54  
Section 11.6.1  Liver function tests  
Has been changed to:  
Section 10.6.1  Liver function tests  
Paragraph 4  
In all cases of transaminases (AST, ALT, or both) ≥3xULN, testing for hepatitis A, B, and C will 
be done.  
Has been changed to:  
In all cases of transaminases (AST, ALT, or both) ≥3xULN, te sting for hepatitis A, B, and C will 
be performed. In all cases of transaminases (AST, ALT, or both) ≥8xULN or a potential case of 
drug-induced liver injury (ie, Hy’s law), testing for hepatitis E immunoglobulin M antibodies 
will be performed.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 160 of 274 Change #55  
Section 11.6.2  Pregnancy testing  
Females of childbearing potential (who have not been surgically sterilized or who are not at least 
2-years postmenopausal) will have serum and urine dipstick pregnancy testing performed 
according to the schedule of study ass essments in Table 5‒1 and Table 5‒2.  
Has been changed to:  
Section 10.6.2  Pregnancy testing  
Females of childbearing potential (who have not been surgically sterilized or who are not at least 
2 years postmenopausal) will have serum and urine dipstick pregnan cy testing performed 
according to the schedule of study assessments in Table 5‒1, Table 5‒2, and Table  5-3. 
Change #56  
Section 11.7.1  Vital signs and body weight  
Noninvasive BP (systolic and diastolic) and pulse rate will be measured at clinic visits in a 
supi[INVESTIGATOR_96839] [ADDRESS_318037], according to the schedule of study assessments in 
Table 5‒1 and Table 5‒2. Assessment of orthostatic changes will be as follows: after the 
3-minute measurement in a supi[INVESTIGATOR_2547], the subject is asked to stand and BP and pulse rate 
are taken 1 minute and 3 minutes after standing up as feasible. Blood pressure measurements 
should be taken with the proper placement and proper sized cuff to obtain accurate 
measurements.  
Body weight will be determined without shoes and wearing light clothing and height will be 
measured without shoes. Body weight and height will be measured using equipment that is age 
appropriate and assessed according to the schedule of study assessments in Table 5‒1 and Table 
5‒2. 
Has been cha nged to:  
Section 10.7.1  Vital signs, body weight and height  
Noninvasive BP (systolic and diastolic) and pulse rate will be measured at clinic visits in a 
supi[INVESTIGATOR_96839] [ADDRESS_318038], according to the schedule of study assessments in 
Table 5‒1, Table 5‒2, and Table 5 -3. Assessment of orthostatic changes will be as follows: after 
the [ADDRESS_318039] stands up, 
as feasible. Blood pressure measurements should be taken with the proper placement and proper 
sized cuff to obtain accurate measurements.  
Body weight will be determined without shoes and wearing light clothing and height will be  
measured without shoes. Body weight and height will be measured using equipment that is age 
appropriate and assessed according to the schedule of study assessments in Table 5‒1, Table 5‒2, 
and Table 5 -3. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 161 of 274 Change #[ADDRESS_318040] 12-lead ECGs will be performed according to the schedule of study assessments in 
Table 5‒1 and Table 5‒2. The [ADDRESS_318041] 5 
minutes prior to each recording and should be motionless during the recording.  
Section [IP_ADDRESS] Overall ECG interpretation  
Electrocardiograms will be initially reviewed locally by [CONTACT_093], subinvestigator, or 
qualified designated reader and also transmitted to and evaluated by a central ECG laboratory. If 
the reading identifies a second - or third -degree AV block or another abnormal ECG finding that 
is assessed by [CONTACT_11150], then the ECG should be repeated on 
the same day. If the clinically significant abnormality is confirmed by [CONTACT_67605], then the 
subject must be withdrawn from the study (see Section 6.3 ). The investigator may consult with 
the cardiologist at the central ECG laboratory to confirm the presence of a clinically significant 
ECG abnormality. It remains the responsibility of the investigator to decide whether an ECG 
finding is of clinical signi ficance on the basis of the complete clinical pi[INVESTIGATOR_261454]’s participation in the study.  
Has been changed to:  
Section 10.7.[ADDRESS_318042] 12 -lead ECGs will be performed according to the schedule of study a ssessments in 
Table 5‒1, Table 5‒2, and Table 5 -3.  
The ECG recordings should be performed at the same time of day (when possible) and prior to 
blood sample collection and vital sign assessments. Care should be taken to assure proper lead 
placement and qua lity ECG recordings. If possible, subjects should rest in a supi[INVESTIGATOR_261455] 5 minutes prior to each recording and should be motionless during the recording. In 
pediatric subjects (<18 years of age), a 12 -lead ECG (2 interpretable recordings) appro ximately 
[ADDRESS_318043] be performed.  
Section [IP_ADDRESS] Overall ECG interpretation  
Electrocardiograms will be reviewed locally by [CONTACT_093], subinvestigator, or qualified 
designated reader. If the reading identifies a second - or third -degree AV block or another 
abnormal ECG finding that is assessed by [CONTACT_11150], then the 
ECG should be repeated on the same day. If the clinically significant abnormality is confirmed 
by [CONTACT_67605], then the subject mus t be withdrawn from the study (see Section 6.3). The 
investigator may consult with a cardiologist to confirm the presence of a clinically significant 
ECG abnormality. It remains the responsibility of the investigator to decide whether an ECG 
finding is of clinical significance on the basis of the complete clinical pi[INVESTIGATOR_261454]’s participation in the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 162 of 274 Change #58  
Section 11.7.3  Assessment of suicidality  
Suicidality will be assessed by [CONTACT_261537] C -SSRS (Columbia University 
Medical Center, 2008). This scale will be used for screening as well as to assess suicidal ideation 
and behavior that may occur during the study. The C -SSRS will be completed according to the 
schedule of study assessment s in Table 5‒1 and Table 5‒2.  
Has been changed to:  
Section 10.7.3  Assessment of suicidality  
Suicidality will be assessed by [CONTACT_207276] C -SSRS (Columbia University 
Medical Center, 2008). This scale will be used for screening as well as to assess suicidal ideation 
and behavior that may occur during the study. The C -SSRS will be completed according to the 
schedule of study assessments in Table 5‒1, Table 5‒2, and Table  5-3. 
The C -SSRS will be completed for subjects who are ≥6 years of a ge. The “Since Last Visit” 
version of the C -SSRS should be used. If a subject becomes 6 years of age during the study, the 
"Already Enrolled" version of the C -SSRS should be used once, followed by [CONTACT_941] “Since Last 
Visit” version at subsequent visits.  
The C -SSRS is not validated for subjects <[ADDRESS_318044]’s 
parent(s)/legal representative(s)/caregiver(s) (in accordance with local regulation) should also be 
advised accordingly and effort should be made at clinic visits to specifically assess potential 
depression.  
Change #59  
Section 11.7.4  Physical examination  
Physical examinations will be performed by a medically qualified clinician licensed to perform 
the examination, according to the schedule of study assessments in Table 5‒1 and Table 5‒2. 
Clinically significant  physical examination findings are to be reported as AEs.  
Has been changed to:  
Section 10.7.4  Physical examination  
Physical examinations will be performed by a medically qualified clinician licensed to perform 
the examination, according to the schedule of study assessments in Table 5‒1, Table  5‒2, and 
Table 5 -3. Clinically significant physical examination findings are to be reported as AEs.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 163 of 274 Change #60  
Section [IP_ADDRESS]  Complete physical examination  
The complete physical examination will include cardiac and r espi[INVESTIGATOR_67545], temperature, and review of all body systems.  
Has been changed to:  
Section [IP_ADDRESS]  Complete physical examination  
The complete physical examination will include cardiac and respi[INVESTIGATOR_261456].  
Change #[ADDRESS_318045] of neurological examinations, according to the schedule of  
study assessments in Table 5‒1 and Table 5‒2. If possible, the same clinician should conduct all 
neurological examinations for the same subject during the study. The investigator or 
subinvestigator is responsible for confirming the diagnosis of IGE with P GTC seizures.  
Has been changed to:  
Section 10.7.[ADDRESS_318046] of neurological examinations, according to the schedule of 
study assessments in Table 5‒1, Table 5‒2, and Table [ADDRESS_318047] during the study. The investigator or 
subinvestigator is responsible for confirming the diagnosis of I GE with PGTC seizures.  
Change #62  
Section [IP_ADDRESS] Brief neurological examination  
The brief neurological examination will include selected assessment of mental status, cranial 
nerves, and coordination/cerebellar function.  
Has been changed to:  
Section 10.7. 5.2 Brief neurological examination  
The brief neurological examination will include selected assessments of: general neurological 
status, reflexes, muscle strength, and coordination/cerebellar function.  
Change #63  
Section 11.7.6  Achenbach CBCL  
Has been changed to:  
Section 10.7.6  Achenbach CBCL  
Paragraphs 1 and 2  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 164 of 274 The Achenbach CBCL is a widely used validated questionnaire to evaluate a child’s 
competencies and behavioral/emotional problems. Behavioral problems will be scored by [CONTACT_31588](s)/legal represe ntative(s). For subjects ≥12 years to <18 years of age, the CBCL/6 to 18 
version will be used. The completion of the Achenbach CBCL will require approximately 45 
minutes.  
Has been changed to:  
The Achenbach CBCL is a widely used validated questionnaire to e valuate a child’s 
competencies and behavioral/emotional problems.  
The Achenbach CBCL consists of the CBCL/1½ -5 for children <5 years and 11 months of age, 
and the CBCL/6 18 for children ≥6 years to <18 years of age. These are to be completed by [CONTACT_31588] (s)/legal representative(s). The completion of the Achenbach CBCL will require 
approximately [ADDRESS_318048]’s 
age should be administered with the following exception: for subjects who completed the  
CBCL/1½ -5 at the Baseline assessment of the previous study and turn 6 years of age within 
1 year after the Baseline assessment of the primary study, the CBCL/1½ -5 should be completed 
for 1 year after the Baseline assessment of the primary study, and subse quently the CBCL/[ADDRESS_318049] 1 year of data before transitioning to the nex t age range.  
Change #64  
Section 11.7.7  BRIEF  
The BRIEF is a validated tool that will be used for the evaluation of subjects ≥5 years of age.  
The BRIEF includes Rating forms used by [CONTACT_67607]’ executive functioning and 
include validity scal es to measure negativity and inconsistency of responses. For each 
developmentally appropriate version of the BRIEF subjects must have at least 1 year of data 
before transitioning to the next age range.  
The BRIEF Rating form contains items in nonoverlappi[INVESTIGATOR_261457]. 
These theoretically and statistically derived scales form 2 broader Indexes: Behavioral 
Regulation (3 scales) and Metacognition (5 scales), as well as a Global Executive Composite 
score. Factor analytic studies and str uctural equation modeling provide support for the 2  factor 
model of executive functioning as encompassed by [CONTACT_941] 2 Indexes.  
Has been changed to:  
Section 10.7.7  BRIEF  
The BRIEF -P and the BRIEF are validated tools that will be used for the evaluation of subjects 
≥2 years to <5 years of age and ≥[ADDRESS_318050]’s age should be completed, with the following ex ception: For 
subjects who completed the BRIEF -P at the Baseline assessment of the previous study and turn 5 
years of age within 1 year after the Baseline assessment of the primary study, the BRIEF -P 
should be completed for 1 year after the Baseline assessm ent of the primary study, and 
subsequently the BRIEF should be completed. The BRIEF -P and BRIEF will be administered 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 165 of 274 according to the tabular schedules of study procedures (Section 5.2). The BRIEF -P and BRIEF 
will be used only in countries where a translat ed scale is available. For each developmentally 
appropriate version of the BRIEF subjects must have at least 1 year of data before transitioning 
to the next age range.  
The BRIEF -P and BRIEF include rating forms used by [CONTACT_67607]’ executive  
functioning. Executive functions broadly encompass a set of cognitive skills that are responsible 
for the planning, initiation, sequencing, and monitoring of complex goal directed behavior.  
The BRIEF -P rating form consists of items that measure various a spects of executive 
functioning: Inhibit, Shift, Emotional Control, Working Memory, and Plan/Organize. The 
clinical scales form [ADDRESS_318051] indexes (Inhibitory Self Control, Flexibility, and Emergent 
Metacognition) and 1 composite score (Global Executive Compo site).  
The BRIEF rating form contains items in nonoverlappi[INVESTIGATOR_207235]. These theoretically and 
statistically derived scales form 2 broader Indexes: Behavioral Regulation (3 scales) and 
Metacognition (5 scales), as well as a Global Executive Composi te score.  
Both the BRIEF -P and the BRIEF include validity scales to measure negativity and 
inconsistency of responses.  
Change #65  
Section 11.7.8  Tanner stage  
The Tanner Stage will be performed for subjects who are <18 years of age, according to the 
schedul e of study assessments in Table 5‒1 and Table 5‒2. The investigator or qualified 
designee will evaluate the subject’s sexual development using the 3 -item scale.  
Has been changed to:  
Section 10.7.8  Tanner stage  
The Tanner Stage will be performed only for su bjects who are pubescent at Visit 1 or who enter 
puberty during the course of the study, according to the schedule of study assessments in Table 
5‒1 and Table 5‒2. The investigator or qualified designee will evaluate the subject’s sexual 
development using the 3 -item scale, according to the tabular schedules of study procedures 
(Section 5.2). The investigator should use clinical judgment in deciding which subjects are 
selected for the evaluation of Tanner Stage (ie, those subjects who are pubescent at Visit 1 or 
who will enter puberty during the course of the study).  
Change #66  
Section 12.3.2  Database entry and reconciliation  
Has been changed to:  
Section 11.3.[ADDRESS_318052] sentence  
The study will be performed using rem ote data capture; the data are entered into the eCRFs once 
and are subsequently verified.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 166 of 274 Has been changed to:  
This study will be performed using remote data capture; the data are entered into the eCRFs once 
and are subsequently verified.  
Change #[ADDRESS_318053] 
1 evaluable assessment of plasma concentration data.  
Change #[ADDRESS_318054] been retrieved and entered, all queries issued and answered to the extent 
possible, and prior to locking the clinical database, a Data Review Meeting will be held. 
Important protocol deviations (ie, those considered to have an impact on interpretation of safety, 
efficacy, or study conduct) will be identified and reviewed by a panel consisting of the Clinical 
Program Manager, the study biostatistician, study physician, a representative of the monitoring 
team, and other appropr iate team members.  
Has been changed to:  
Section 12.[ADDRESS_318055] Data Cleaning 
Plan. To the extent feasible, rules for identifying prot ocol deviations will be defined without 
review of the data and without consideration of the frequency of occurrence of such deviations. 
Whenever possible, criteria for identifying important protocol deviations will be implemented 
algorithmically to ensure consistency in the classification of important protocol deviations across 
all subjects.  
Important protocol deviations will be reviewed as part of the ongoing data cleaning process prior 
to database lock to confirm exclusion from analysis sets.  
Change #69  
Section 13.7  Planned interim analysis and data monitoring  
No interim analysis is planned for this study.  
Has been changed to:  
Section 12.7  Planned interim analysis and data monitoring  
No interim analysis or Data Monitoring Committee is planned. However, dat a may be reported 
prior to the completion of this study to support annual reports, regulatory submissions, and 
publications.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 167 of 274 Change #70  
Section 13.8  Determination of sample size  
Has been changed to:  
Section 12.8  Determination of sample size  
Paragraph 1  
The sample size of this open -label extension study will be determined by [CONTACT_261538]0982 
study, where approximately 200 subjects will be randomized.  
Has been changed to:  
The sample size of this open -label extension study will be determined by [CONTACT_261538]0 982 
study, where approximately 200 subjects are planned to be randomized.  
Change #71  
Section 16   References  
Has been changed to:  
Section 15   References  
The following reference was deleted:  
Hauser WA, Annegers JF, Kurland LT. Incidence of epi[INVESTIGATOR_261458], Minnesota: 1935 -1984. Epi[INVESTIGATOR_8330]. 1993;34:453 -68. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 168 of 274 16.5 Appendix 5: Protocol Amendment [ADDRESS_318056] remain on the dose for 
≥7 days before a subsequent dose escalation. Additionally, the purpose of the  amendment was to 
remove superfluous description of a substudy, to clarify the requirement for ECG at subsequent 
visits, requirement for endocrinology and timing of endocrinology assessments, pregnancy 
testing, definition of contraceptive methods, and seiz ure count, and to add a definition of the 
Enrolled Set. Several assessments will not be done in Years 3 -5, including brief physical 
examination (complete physical examination will be done),  complete neurological examination 
(brief neurological examination  will be done), and health outcome measures. The protocol was 
also updated according to the new UCB protocol template, for example, with the addition of text 
regarding potential drug -induced liver injury (PDILI).  
Modifications and changes  
Specific changes  
Change #1  
Title page:  
The title was updated from “Protocol EP0012 Amendment  1” to “Protocol EP0012 
Amendment  2.” 
The information below was revised to include Protocol Amendment 2 and the type of protocol 
amendment:  
Protocol/Amendment Number  Date  Type of a mendment  
Final Protocol  [ADDRESS_318057] 2012  Not applicable  
Protocol Amendment 1  27 Jan 2015  Substantial  
Has been changed to:  
Protocol/Amendment Number  Date  Type of amendment  
Final Protocol  [ADDRESS_318058] 2012  Not applicable  
Protocol Amendment 1  27 Jan 2015  Substantial  
Protocol Amendment 2  09 Jun 2016  Substantial  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 169 of 274 Change #[ADDRESS_318059] INFORMATION  
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Phone:   
Fax:  
Clinical Project Manager  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Phone:   
Fax:  
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  [ADDRESS_318060]  
Raleigh, NC [ZIP_CODE]  
UNITED STATES  
Phone:   
Fax:  
Interactive Voice/Web Response System  
Name:  [CONTACT_261557]:  Lady Bay House, Meadow Grove  
Nottingham, NG23HF  
[LOCATION_006]  
Phone:  +44 [PHONE_5428]  
Fax: +44 [PHONE_5426]  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 170 of 274 SERIOUS ADVERSE EVENT REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World (except Japan):  [PHONE_1064]  
[LOCATION_003]:  +[PHONE_5427]  
 or +[PHONE_299]  
 or +[PHONE_300]  
Canada:  +[PHONE_1063]  
Email  Global (except Japan):  
Has been updated to:  
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Phone:   
Email:   
Clinical Project Manager  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Phone:   
Email:   
Clinical Trial Biostatistician  
Name:   
[CONTACT_2761]:  [ADDRESS_318061]  
Raleigh, NC [ZIP_CODE]  
UNITED STATES  
Phone:   
Email:   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 171 of 274 Interactive Response Technology  
Name:  [CONTACT_261557]:  Lady Bay House, Meadow Grove  
Nottingham, NG23HF  
[LOCATION_006]  
Phone:  +44 [PHONE_5428]  
Fax: +44 [PHONE_5426]  
SERIOUS ADVERSE EVENT REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World:  [PHONE_1064]  
[LOCATION_003]:  +[PHONE_299]  
 or +[PHONE_300]  
 
Email  Global: [EMAIL_311]  
Change #[ADDRESS_318062] OF ABBREVIATIONS  
ALP  alkaline phosphatase  
BMI  body mass index  
EDC  electronic data capture  
EI-AED  enzyme -inducing antiepi[INVESTIGATOR_261459]/IWRS  interactive voice/web response system  
MAO -A monoamine oxidase A  
MAP  managed access program  
PDILI  potential drug -induced liver injury  
PS patient safety  
SFU Safety Follow Up  
TMF  trial master file  
These abbreviations have also been changed wherever they occur throughout the protocol.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 172 of 274 Change #4  
Section 1, SUMMARY  
Paragraph 5  
During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased in 
steps of no more than 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects who have 
dose adjustments must remain on the dose for ≥3 days (in order to reach steady state) before a 
subsequent dose adjustment.  
Has been changed to:  
During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optim ize tolerability and seizure reduction. Lacosamide doses may be increased or decreased in 
steps of no more than 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects must remain 
on the dose for ≥7 days before a subsequent dose escalation.  
Change #[ADDRESS_318063]’s country for the treatment of PGTC 
seizures in subjects with IGE, or until UCB has determined that the clinical development 
program for the in dication will be formally discontinued, or until UCB decides to close the 
study.  
Has been changed to:  
A telephone contact [CONTACT_18378] [ADDRESS_318064]’s country for the treatment of PGTC seizures in subjects 
with IGE, or until UCB has determined that the clinical development program for the indication 
will be formally discontin ued, or until UCB decides to close the study.  
Change #6  
Section 1, SUMMARY  
Paragraph 10  
The primary safety variables are adverse events (AEs) and subject withdrawals due to AEs. 
Secondary safety variables are changes in hematology, chemistry, and urinalysi s parameters; 
changes in 12 -lead electrocardiograms (ECGs); and changes in vital sign measurements (ie, 
blood pressure [BP] and pulse rate), including body weight and physical (including neurological) 
examination findings. In addition, for pediatric subjec ts <18 years of age, safety will be 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 173 of 274 evaluated using behavioral assessments (Achenbach Child Behavior Checklist [CBCL]), and 
cognitive function assessments (Behavior Rating Inventory of Executive Function®/Behavior 
Rating Inventory of Executive Function -Preschool Version® [BRIEF®/BRIEF -P®]). Efficacy 
variables are evaluations of seizure frequency, based on information included in subject diaries, 
and health outcome variables, including the Patient Weighted Quality of Life in Epi[INVESTIGATOR_261460] -Form 31 (QOLIE -31-P), the Pediatric Quality of Life Inventory™ (PedsQL™), the 
3-level EuroQol 5 Dimension Quality of Life Assessment (EQ -5D-3L) Quality of Life 
Assessment, healthcare resource use, the number of working or school days lost by [CONTACT_1766], and 
the number of days with help from a caregiver.  
Has been changed to:  
The primary safety variables are adverse events (AEs), subject withdrawals due to AEs, 
incidence of new seizure types, and increase in absence seizure days per 28 days or myoclonic 
seizure days per 28 d ays during the Treatment Period. Secondary safety variables are changes in 
hematology, chemistry, and urinalysis parameters; changes in 12 -lead electrocardiograms 
(ECGs); and changes in vital sign measurements (ie, blood pressure [BP] and pulse rate), 
including body weight and physical (including neurological) examination findings. In addition, 
for pediatric subjects <18 years of age, safety will be evaluated using behavioral assessments 
(Achenbach Child Behavior Checklist [CBCL]), and cognitive function as sessments (Behavior 
Rating Inventory of Executive Function®/Behavior Rating Inventory of Executive Function -
Preschool Version® [BRIEF®/BRIEF -P®]). The seizure efficacy variables are evaluations of 
seizure frequency, based on information included in subject  diaries. The health outcome 
variables, including the Patient Weighted Quality of Life in Epi[INVESTIGATOR_261379] -Form 31 
(QOLIE -31-P), the Pediatric Quality of Life Inventory™ (PedsQL™), the 3 -level EuroQol 
5 Dimension Quality of Life Assessment (EQ -5D-3L), he althcare resource use, the number of 
working or school days lost by [CONTACT_261478][INVESTIGATOR_002], and the number of days with help from a 
caregiver due to epi[INVESTIGATOR_261382] 2 years of treatment.  
Change #[ADDRESS_318065] prevalent neurological disorder in the world. More than 40 million 
people suffer from epi[INVESTIGATOR_002] –about 1% of the world’s population (Dichek, 1999). Epi[INVESTIGATOR_261461] a wide range of epi[INVESTIGATOR_31630] t hat may be of genetic, 
structural/metabolic, or unknown origin.  
Has been changed to:  
Epi[INVESTIGATOR_207210]. It is estimated to affect 
almost 70 million people worldwide (Ngugi et al, 2011). Epi[INVESTIGATOR_261462] a wide range of epi[INVESTIGATOR_261463], structural/metabolic, or unknown 
origin.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 174 of 274 Change #[ADDRESS_318066] that exposure -response in pediatric and adult subjects 
treated with LCM will be similar. Lacosamide is evaluated in pediatric subjects 1 month to 17 
years of age in 2 completed studies and 1 ongoing study: SP847 (open -label, Phase 2, PK, 
tolerability, and safety study), SP1047 (PK study with a 1  day Evaluation Period), and SP848 
(open -label long -term safety study).  
Has been changed to:  
Preliminary safety and PK data suggest that exposure -response in pediatric and adult subjects 
treated with LCM will be similar. Lacosamide has been evaluated in 2 completed pediatric 
studies, both in subjects aged 1 month to 17 years (SP847 [open -label, adjunctive therapy, 
pharmacokinetic study in partial -onset seizures] and SP1047 [open -label pharmacokinetic study 
in epi[INVESTIGATOR_002]]). Subjects from SP847 were also able t o enroll into an ongoing open -label long -term 
safety study (SP848). In addition, lacosamide is being evaluated in the following ongoing 
pediatric efficacy and safety studies:  
• SP0967 (ages ≥1 month to <4 years) as adjunctive therapy in partial -onset seizur es 
• SP0969 (ages ≥4 to <17 years) as adjunctive therapy in partial -onset seizures  
• EP0034, Open -label extension study to SP0967 and SP0969  
• SP0966 (ages ≥1 month to <18 years) as adjunctive therapy, exploratory study in subjects 
with epi[INVESTIGATOR_261464] #9  
Section 4.1.1, Primary safety variables  
The primary safety variables are:  
• Adverse events as reported spontaneously by [CONTACT_3184]/or caregiver or observed by [CONTACT_1275]  
• Subject withdrawals due to AEs  
Has been changed to:  
The primary safety variables are:  
• Adverse events as reported spontaneously by [CONTACT_3184]/or caregiver or observed by [CONTACT_1275]  
• Subject withdrawals due to AEs  
• Incidence of new seizure types during the Treatment Period  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 175 of 274 • Subjects w ith an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days with 
absence seizures per 28 days during the Treatment Period as compared to the Prospective 
Baseline  
• Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in day s with 
myoclonic seizures per 28 days during the Treatment Period as compared to the Prospective 
Baseline  
Change #10  
Section 4.1.2, Secondary safety variables  
Bullet point 3  
• Changes in vital sign measurements (ie, BP and pulse rate), including body weight and 
physical (including neurological) examination findings  
Has been changed to:  
• Changes in vital sign measurements (ie, BP and pulse rate), including BMI and physical 
(including neurological) examination findings  
Change #11  
Section 4.2.2, Secondary efficacy variable  
The secondary efficacy variable is:  
• Percent change in PGTC seizure frequency per 28 days from Baseline, where Baseline is 
defined as the 12 -week Historical Baseline and 4 -week Prospective Baseline periods 
immediately prior to randomization in the parent study (SP0982)  
Has been changed to:  
The secondary efficacy variable is:  
• Percent change in PGTC seizure frequency per 28 days from Combined Baseline, where 
Combined Baseline is defined as the combined 12 -week Historical Baseline and 4 -week 
Prospective Baseline periods immediately prior to randomization in the parent study 
(SP0982)  
Change #12  
Section 4.2.3, Other efficacy variables  
The other efficacy variables are:  
• Percent change in days with myoclonic seizures per 28 days from Bas eline  
• Percent change in days with absence seizures per 28 days from Baseline  
• Percentage of subjects with at least a 50% reduction in PGTC seizure frequency compared to 
Baseline  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 176 of 274 • Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to 
Baseline  
• Percentage of subjects with at least a 50% reduction in absence seizure days compared to 
Baseline  
• Seizure -free status (yes/no) for PGTC seizures  
• Seizure -free status (yes/no) for myoclonic seizures  
• Seizure -free status (yes/no) for absen ce seizures  
• Seizure -free status (yes/no) for all generalized seizure types  
• Change from Baseline in QOLIE -31-P subscale (Seizure Worry, Daily Activities/Social 
Functioning, Energy/Fatigue, Emotional Well -being, Mental Activity/Cognitive Functioning, 
Overall  Quality of Life, and Medication Effects) and total scores in subjects ≥18 years of age 
or change from Baseline in the PedsQL subscale (Physical Functioning, Emotional 
Functioning, Social Functioning, and School Functioning) and total scores in subjects <1 8 
years of age  
• Change from Baseline in the EQ -5D-3L visual analogue scale (VAS) score and change in 
utility as converted from the 5 dimensions (for subjects ≥12 years of age)  
• Healthcare resource use: medical procedures, hospi[INVESTIGATOR_602], and healthcare pro vider visits  
• Number of working or school days lost by [CONTACT_1130]  
• Number of days with help from a caregiver  
Has been changed to:  
The other efficacy variables are:  
• Change in days with myoclonic seizures per 28 days relative to the Prospective Baseline  
• Percent c hange in days with myoclonic seizures per 28 days relative to the Prospective 
Baseline  
• Change in days with absence seizures per 28 days relative to the Prospective Baseline  
• Percent change in days with absence seizures per 28 days relative to the Prospective Baseline  
• Percentage of subjects with at least a 50% reduction in PGTC seizure frequency compared to 
the Combined Baseline  
• Percentage of subjects with at least a 50% reduction in myoclonic seizure days compared to 
the Prospective Baseline  
• Percen tage of subjects with at least a 50% reduction in absence seizure days compared to the 
Prospective Baseline  
• Seizure -free status (yes/no) for PGTC seizures  
• Seizure -free status (yes/no) for all generalized seizure types  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 177 of 274 • Change from Baseline in QOLIE -31-P sub scale (Seizure Worry, Daily Activities/Social 
Functioning, Energy/Fatigue, Emotional Well -being, Mental Activity/Cognitive Functioning, 
Overall Quality of Life, and Medication Effects) and total scores in subjects ≥18 years of age 
or change from Baseline i n the PedsQL subscale (Physical Functioning, Emotional 
Functioning, Social Functioning, and School Functioning) and total scores in subjects <[ADDRESS_318067] two years of treatment  
• Change from Baseline in the EQ -5D-3L visual analogue scale ( VAS) score and change in 
utility as converted from the 5 dimensions (for subjects ≥12 years of age) for the first two 
years of treatment  
• Healthcare resource use: medical procedures, hospi[INVESTIGATOR_602], and healthcare provider visits 
for the first two years of treatment  
• Number of working or school days lost by [CONTACT_261481][INVESTIGATOR_261399]  
• Number of days with help from a caregiver due to epi[INVESTIGATOR_261465] #13  
Section 5.1, Study description  
Para graph 3  
Subjects who completed SP0982 will start at Visit 1 on a dose of LCM 10mg/kg/day for 
pediatric subjects weighing <30kg, LCM 8mg/kg/day for pediatric subjects weighing ≥30kg to 
<50kg, and LCM 400mg/day (200mg bid) for adult subjects (≥18 years of ag e) or pediatric 
subjects weighing ≥50kg. Subjects who are eligible Baseline failures from SP0982 will start at 
Visit 1 on a dose of LCM 2mg/kg/day for pediatric subjects weighing <50kg, and LCM 
100mg/day (50mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing 
≥50kg.  
Paragraph 6  
During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased in 
steps of no more than 2mg/ kg/day (oral solution) or 100mg/day (tablets). Subjects who have 
dose adjustments must remain on the dose for ≥3 days (in order to reach steady state) before a 
subsequent dose adjustment.  
Have been changed to:  
Paragraph 3  
Randomized subjects meeting SP098 2 exit criteria and subjects who completed SP0982 will start 
at Visit 1 on a dose of LCM 10mg/kg/day for pediatric subjects weighing <30kg, LCM 
8mg/kg/day for pediatric subjects weighing ≥30kg to <50kg, and LCM 400mg/day (200mg bid) 
for adult subjects (≥18  years of age) or pediatric subjects weighing ≥50kg. Subjects who are 
eligible Baseline failures from SP0982 will start at Visit 1 on a dose of LCM 2mg/kg/day for 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 178 of 274 pediatric subjects weighing <50kg, and LCM 100mg/day (50mg bid) for adult subjects (≥18 
years  of age) or pediatric subjects weighing ≥50kg.  
Paragraph 6  
During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased in 
steps of no mo re than 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects must remain 
on the dose for ≥7 days before a subsequent dose escalation.  
Change #[ADDRESS_318068]’s country for the 
treatment of PGTC seizures in subjects with IGE, or until UCB has determined that the clinical 
development program for the indication will be formally discontinued, or until UCB decides to 
close the study.  
Paragraph 11  
Subjects and/or their caregiver will be dispensed a seizure diary to record all types of seizures, 
concomitant AEDs, and other pertinent health status information. Subjects must bring their diary 
to each visit. Seizure frequency and type will be verified by a reliably documente d seizure 
history collected (eg, in a seizure diary).  
Have been changed to:  
Paragraph [ADDRESS_318069]’s country for the treatment 
of PGTC seizures in subjects with IGE, or until UCB has determined that the clinical 
development program for the indication will be formally discontinued, or until UCB decides to 
close the study.  
Paragraph 11  
Subjects and/or their caregiver will be dispensed a seizure diary to record all types of seizures, 
concomitant AEDs, and other pertinent health status information. Subjects must bring their diary 
to each visit. Baseline seizure frequency and ty pe will be verified by a reliably documented 
seizure history collected (eg, in a seizure diary during SP0982).  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 179 of 274 Change #[ADDRESS_318070] paragraph  
Depending on the local regulations, after 2 years, subjects may continue to r eceive LCM in a 
named patient program.  
Has been changed to:  
Depending on the local regulations, after 2 years, subjects may continue to receive LCM in a 
managed access program (MAP).  
Change #16  
Section 5.1.3, Anticipated regions and countries  
This study is  planned to be conducted in the US, Canada, Europe, Asia, and Australia with 
possible extension to other countries and regions.  
Has been changed to:  
This study is planned to be conducted in the US, Europe, Asia, and Australia with possible 
extension to oth er countries and regions.  
Change #17  
Table 5‒1: Schedule of study assessments for Years 1 and 2 for EP0012 (Treatment 
Period, ET Visit, Termination Visit, and Unscheduled Visit)  
Rows  
A row was added to schedule laboratory tests for endocrinology at Visit 1, ET and Termination 
Visits.  
Work/school days lost and Days with help from a caregiver were changed to Work/school days 
lost due to epi[INVESTIGATOR_002], and Days with help from a caregiver due to epi[INVESTIGATOR_002].  
Footnotes  
o Urinalysis will be required for subjects ≥5 year s of age only.  
p Pregnancy tests will be performed for female subjects of childbearing potential only. Serum 
 pregnancy tests will be conducted at the following visits: Visit 1 (W0), ET, and 
 Termination Visit. All other pregnancy tests will be urine dipst ick. 
Have been changed to:  
o Urinalysis will be required for all subjects.  
p If the patient was treated in SP0982, endocrinology should be done if age was <18 years at 
SP0982 Visit 1. If the patient was a Baseline failure in SP0982, endocrinology should be  
done if age is <18 years at EP0012 Visit 1.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 180 of 274 q Pregnancy tests will be performed for female subjects of childbearing potential only. Serum 
pregnancy tests will be conducted at the following visits: Visit 1 (W0), ET, and Termination 
Visit. All other pregnan cy tests will be urine dipstick. Baseline failures from SP0982 may 
have an additional urine pregnancy test at V1 of EP0012, at the investigator’s discretion.  
Change #18  
Table 5‒2: Schedule of study assessments for Years 3 through 5 for EP0012 
(Treatment Pe riod, ET Visit, Termination Visit, and Unscheduled Visit)  
Rows  
A row was added to schedule laboratory tests for endocrinology at ET and Termination Visits.  
The following assessments have been removed from the schedule for Years 3 through 5: Physical 
exam ( brief), Neurological exam (complete), EQ -5D-3L, QOLIE -31-P/PedsQLs, Healthcare 
resource use, Work/school days lost, and Days with help from a caregiver.  
The following assessments will now be done at Visits 13, 15, and 17 only: 12 -lead ECG,  
Achenbach CBCL, and BRIEF.  
Footnotes  
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone 
contacts, at the discretion of the investigator. In addition to the required assessments listed 
above depending on the type of visit (clinic or telephone), further assessments can be 
completed as needed and may include ECG, vital signs, laboratory tests, etc. The C -SSRS 
must be performed if the Unscheduled Visit is due to an AE.  
q Pregnancy tests will be performed for female subjects of childbe aring potential only. Serum 
pregnancy tests will be conducted at the following visits: Visit 1 (W0), ET, and Termination 
Visit. All other pregnancy tests will be urine dipstick.  
Has been changed to:  
b Unscheduled Visits may be performed at any time after V isit 1 as clinic visits or telephone 
contacts, at the discretion of the investigator. In addition to the required assessments listed 
above depending on the type of visit (clinic or telephone), further assessments can be 
completed as needed and may include physical or neurological examination, ECG, vital 
signs, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to 
a psychiatric AE.  
o Laboratory tests are applicable for combined Visit 17/Termination Visit. If Visit 17 is not t he 
Termination Visit, laboratory tests are not required.  
p If the patient was treated in SP0982, endocrinology should be done if age was <18 years at 
SP0982 Visit 1. If the patient was a Baseline failure in SP0982, endocrinology should be 
done if age is <1 8 years at EP0012 Visit 1.  
q Pregnancy tests will be performed for female subjects of childbearing potential only. Serum 
pregnancy tests will be conducted at the following visits: Visit 1 (W0), ET, and Termination 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318071] at V1 of EP0012, at the investigator’s discretion.  
Change #19  
Table 5‒3: Schedule of study assessments (Taper Period and Safety Follow -Up 
Period) for EP0012  
Rows  
Neuro logical exam (complete), Work/school days lost, and Days with help from a caregiver were 
changed to Neurological exam (brief), Work/school days lost due to epi[INVESTIGATOR_002], and Days with help 
from a caregiver due to epi[INVESTIGATOR_002].  
The following footnote has been added : 
i Healthcare resource use, work/schools days lost due to epi[INVESTIGATOR_002], and days with help from a 
caregiver due to epi[INVESTIGATOR_261405] 
≤2 years. These assessments are not applicable for patients tapering down  or performing the 
SFU-visits during Years 3, 4 or 5).  
Change #[ADDRESS_318072] completed or be an eligible Baseline failure from the parent study 
(SP0982), as defined in Section 5.1.  
Has been changed to:  
2. Subject must have completed or be an eligible Baseline failure from the parent study 
(SP0982), as defined in Section 5.1. Note: Other subjects screened for SP0982 may be 
considered for roll -over to EP0012 if the investigator considers that the subject could benefi t 
from treatment with open -label LCM and based on prior discussion with and approval from 
the UCB Study Physician or representative.  
Change #21  
Section 6.2, Exclusion criteria  
A new criterion has been added:  
4. Subject has ≥2x upper limit of normal (ULN) o f any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are  >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).  
For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, 
a Baseline diagnosis and/or the cause of a ny clinically meaningful elevation must be 
understood and recorded in the Case Report form (CRF).  
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no  further ongoing clinically 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318073], or ALP up to 25% above the exclusion limit may be repeated 
once fo r confirmation. This includes re -screening.  
Change #22  
Section 6.3, Withdrawal criteria  
Bullet point 5  
• Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality 
(ie, transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly monitoring 
of LFTs should continue until resolved (ie, <3xULN or stable condition). The investigator 
will decide whether or not to stop the study drug.  
Has been changed to:  
• Discontinuation criteria for potential drug -induced liver injury (PDILI) are described in 
Section 6.3.1.  
Change #23  
A new section has been added:  
Section 6.3.1, Potential drug -induced liver injury IMP discontinuation criteria  
Subjects wit h PDILI must be assessed to determine if IMP must be discontinued. In addition, all 
concomitant medications and herbal supplements that are not medically necessary should also be 
discontinued.  
The PDILI criteria below require immediate and permanent disco ntinuation of IMP:  
• Subjects with either of the following:  
− ALT or AST ≥ 5xULN  
− ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
The PDILI criterion below requires immediate discontinuation of IMP:  
• Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia  (ie, >5%).  
If a nondrug -related cause for the symptoms can be confirmed, these subjects may resume IMP 
administration after discussion with the responsible UCB physician, but only when the 
requirements for rechallenge with IMP as provided in Section 10.3. 1.2.1 are followed.  
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 183 of 274 • Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever , rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).  
Evaluation of PDILI must be initiated as described in Section 10.3.1. If subjects are unable to 
comply with the applicable monitoring schedule, IMP m ust be discontinued immediately. See 
Section 6.3 for when and how to discontinue subjects from the IMP. See Section 8.2 for the 
procedures to be performed at the time of discontinuation.  
Investigators should attempt to obtain information on subjects in the  case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP d iscontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The CRF must document the primary 
reason for IMP discontinuation.  
Change #24  
Section 7.2, Treatment(s) to be administered  
New paragraph 2:  
Tablets must not be broken . In rare cases where uneven dosing (e.g., 350mg/day, 450mg/day, 
550mg/day, etc) is medically needed, although the interactive response technology (IRT) will not 
dispense the exact dose, please contact [CONTACT_261539].  
Change #25  
Section 7.2.1, Treatment Period  
Paragraph 4  
During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased in 
steps of no more t han 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects who have 
dose adjustments must remain on the dose for ≥3 days (in order to reach steady state) before a 
subsequent dose adjustment.  
Table 7‒2:  Lacosamide dosing for subjects requiring taper  
Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  Week 4  
11 or 12mg/kg/day  9mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
9 or 10mg/kg/day  8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
7 or 8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  NA 
5 or 6mg/kg/day  4mg/kg/day  2mg/kg/day  NA NA 
3 or 4mg/kg/day  2mg/kg/day  NA NA NA 
750 to 800mg/day  600mg/day  400mg/day  200mg/day  100mg/day  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 184 of 274 Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  Week 4  
650 to 700mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
550 to 600mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
450 to 500mg/day  400mg/day  300mg/day  200mg/day  100mg/day  
350 or 400mg/day  300mg/day  200mg/day  100mg/day  NA 
250 or 300mg/day  200mg/day  100mg/day  NA NA 
150 or 200mg/day  100mg/day  NA NA NA 
Has been changed to:  
Paragraph 4  
During EP0012, investigators will be allowed to increase or decrease the dose of LCM to 
optimize tolerability and seizure reduction. Lacosamide doses may be increased or decreased in 
steps of no more than 2mg/kg/day (oral solution) or 100mg/day (tablets). Subjects must remain 
on the dose for ≥7 days before a subsequent dose escalation.  
Table 7‒2:  Lacosamide dosing for subjects requiring taper  
Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  Week 4  
11 or 12mg/kg/day  9mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
9 or 10mg/kg/day  8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
7 or 8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  NA 
5 or 6mg/kg/day  4mg/kg/day  2mg/kg/day  NA NA 
3 or 4mg/kg/day  2mg/kg/day  NA NA NA 
800mg/day  600mg/day  400mg/day  200mg/day  100mg/day  
700mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
600mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
500mg/day  400mg/day  300mg/day  200mg/day  100mg/day  
400mg/day  300mg/day  200mg/day  100mg/day  NA 
300mg/day  200mg/day  100mg/day  NA NA 
200mg/day  100mg/day  NA NA NA 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 185 of 274 Change #26  
Section 7.5, Handling and storage requirements  
Paragraphs 1 through 3  
The investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by [CONTACT_207278] a secured area with 
limited access.  
Appropriate storage conditions must be ensured by [CONTACT_261532] a temperature log (showing minimum and maximum temperatures  reached over 
the time interval) in accordance with local requirements on a regular basis.  
In case an out -of-range temperature is noted, it must be immediately communicated to the 
Clinical Project Manager (CPM) (or designee) before further use of the IMP a nd communicated 
to the sponsor’s designee in accordance with the pharmacy manual.  
Have been changed to:  
The investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by [CONTACT_261540] a secured area with 
limited access according to the storage conditions mentioned on the label.  
Appropriate storage conditions must be ensured by [CONTACT_261497] (eg, room, 
refrigeration unit) or by [CONTACT_37142] a temper ature log (showing actual and 
minimum/maximum temperatures reached over the time interval) in accordance with local 
requirements on a regular basis.  
In case an out -of-range temperature is noted, it must be immediately reported as per the 
instructions conta ined in the IMP Handing Manual  
Change #[ADDRESS_318074] (due to breakage or wastage), not used, disposed of at the study site, or returned to 
the sponsor’s designee must also be recorded on the appropriate forms. All supplies and 
pharmacy documentation must be made available  throughout the study for UCB (or designee) to 
review.  
Paragraph 5  
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers) and unused IMP containers must be reconciled and returned to UCB’s designee, 
preferably in their original package. Investigational medicinal product intended for the study 
cannot be used for any other purpose than that described in this protocol.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318075] been changed to:  
Paragraph [ADDRESS_318076], damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or ret urned to the sponsor’s designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.  
Paragraph 5  
Periodically, and/or after completion of the c linical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expi[INVESTIGATOR_261466], regulations, and UCB SOPs or returned to UCB (or 
designee). I nvestigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.  
Change #[ADDRESS_318077]. Sites are encouraged to call subjects to inquire about their diary completion. 
Investigators shoul d advise subjects and/or caregivers about the importance of reporting 
non-PGTC seizures. Subjects should be reminded that diaries must include daily entries even if 
no seizures have occurred.  
Has been changed to:  
Timely completion of the subject diary is e ssential for evaluation of safety and efficacy. Subject 
diary completion, including AED usage, will be evaluated at each clinic visit and telephone 
contact. Sites are encouraged to call subjects to inquire about their diary completion. 
Investigators should  advise subjects and/or caregivers about the importance of reporting 
non-PGTC seizures.  
Change #29  
Section 7.8, Concomitant medication(s)/treatment(s)  
All concomitant medication and treatment must be recorded in the appropriate study documents 
(eg, eCRF a nd source document).  
Contraceptive treatment is allowed for female subjects of childbearing potential.  
The use of neuroleptics, monoamine oxidase inhibitors, barbiturates (except for treatment of 
epi[INVESTIGATOR_002]), and narcotic analgesics is prohibited throughout the study. However, in the case of 
narcotics or marijuana, certain limited usage may become necessary (eg, acute medical situation, 
perioperative period for subjects requiring surgery). Upon learning of such situations, the 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318078]’s further participation in the study.  
The use of vigabatrin and felbamate is also prohibited throughout the study.  
Only stable use of amphetami nes and sedative antihistamines is allowed during the study. Also, 
only stable, low doses of anxiolytics or hypnotics are allowed for nonepi[INVESTIGATOR_261447].  
Stable use of benzodiazepi[INVESTIGATOR_261409], but intermittent use is only 
allowe d as rescue medication for epi[INVESTIGATOR_261447] (maximum 1 dose per week).  
During the Treatment Period, new concomitant AEDs may be introduced, if the concomitant 
medication has been approved by [CONTACT_261541] n in 
the subject’s country. For example, a new AED may be added when the subject has not optimally 
or adequately responded (lack of efficacy or tolerance) to LCM. Concomitant AEDs may be 
carefully tapered and discontinued to achieve LCM monotherapy, if cli nically appropriate. The 
Medical Monitor must be consulted prior to initiation of concomitant AED withdrawal.  
Section 7.8.1, Rescue medication  
The intermittent use of benzodiazepi[INVESTIGATOR_261467] (see 
Section  7.8). 
Have been cha nged to:  
Section 7.8, Concomitant medication(s)/treatment(s)  
All concomitant medication and treatment must be recorded in the appropriate study documents 
(eg, eCRF and source document).  
7.8.1  Permitted concomitant treatments (medications and therapi[INVESTIGATOR_014])  
Female subjects not surgically sterile or 2 years postmenopausal should practice 1 highly 
effective method of contraception (according to ICH guidance, defined as those that result in a 
failure rate of <1% per year when used consistently and correctly), un less sexually abstinent, for 
the duration of the study. Recommended contraception methods for subjects on enzyme -inducing 
antiepi[INVESTIGATOR_006] (EI -AEDs) or not on EI -AEDs are detailed in Section 16.6. Subjects on 
EI-AEDs who do not use one of the highly eff ective contraception methods recommended for 
this group may practice 2 combined methods of contraception (ie, combined hormonal 
contraception plus barrier method with spermicidal agent).  
The initiation of felbamate treatment while participating in EP0012 i s prohibited.  
The use of neuroleptics except for clozapi[INVESTIGATOR_140730]. The use of barbiturates and narcotic 
analgesics is also allowed. Stable use of benzodiazepi[INVESTIGATOR_261409], but 
intermittent use is only allowed as rescue medication for epi[INVESTIGATOR_261447] (maximum 1 dose 
per week).  
During the Treatment Period, new concomitant AEDs may be introduced, if the concomitant 
medication has been approved by [CONTACT_261542]’s coun try. For example, a new AED may be added when the subject has not optimally 
or adequately responded (lack of efficacy or tolerance) to LCM. Concomitant AEDs may be 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318079] be consulted prior to initiation of concomitant AED withdrawal.  
7.8.2  Prohibited concomitant treatments (medications and therapi[INVESTIGATOR_014])  
The following medications/therapi[INVESTIGATOR_207178]:  
• Clozapi[INVESTIGATOR_050]  
• MAO -A inhibitors  
• Vigabatrin  
Therapy that becomes necessary (in the investigator’s opi[INVESTIGATOR_1649]) during the course of the study 
must not be refused to a subject, even if described above as a therapy that is expressly not 
permitted. In cases where this occurs but withdrawal criteria have not been met, the advisability 
of the subject’s continuation in the study must be discussed between the Medical Monitor and 
the investigator.  
Change #30  
Section 8.1.1, Visit 1 (Week 0)  
Bullet points 13, 24, and 25  
• Blood and urine s amples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a serum pregnancy test [for women of childbearing potential])*.  
• Work/school days lost*  
• Days with help from a caregiver * 
Have been changed to:  
• Blood and urine sampl es for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology for subjects <[ADDRESS_318080] [for women of childbearing potential])*. Baseline failures from SP0982 may 
have an additi onal urine pregnancy test at V1 of EP0012, at the investigator’s discretion.  
• Work/school days lost due to epi[INVESTIGATOR_002]*  
• Days with help from a caregiver  due to epi[INVESTIGATOR_002]*  
Change #31  
Section 8.1.2, Visits 2 to 8 (Weeks 2 to 46, Year 1)  
Bullet points 22 and 23  
• Work/school days lost  
• Days with help from a caregiver  
Have been changed to:  
• Work/school days lost due to epi[INVESTIGATOR_261412].
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 189 of 274 • Days with help from a caregiver  due to epi[INVESTIGATOR_261468] #32  
Section 8.1.3, Visits 9 to 11 (Weeks 62 to 94, Year 2)  
Bullet points 22 and 23  
• Work /school days lost  
• Days with help from a caregiver  
Have been changed to:  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_261468] #33  
Section 8.1.4, Visits 12, 13, 14, 15, 16, and 17 (Weeks 118, 142, 166, 190, 214, and 
238, Years 3 to 5)  
Bullet points 2, 3, 4, 9, and 17 through 23  
• Physical examination (brief, Visit 12, 14, and 16; complete, Visit 13, 15, and 17)  
• Neurological examination (brief, Visit 12, 14, and 16; complete, Visit 13, 15, and 17)  
• ECG (12 -lead) assessmen t 
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and a urine pregnancy test [for women of childbearing potential])  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (fo r subjects <18 years of age)  
• Achenbach CBCL for subjects ≥6 years to <18 years of age  
• BRIEF for subjects ≥5 to <18 years of age  
• Healthcare resource use  
• Work/school days lost  
• Days with help from a caregiver  
Have been changed to:  
Bullet points 2, 3, 4, 9, 10, 18, and 19  
• Physical examination (complete, Visit 13, 15, and 17)  
• Neurological examination (brief, Visit 12, 14, and 16)  
• ECG (12 -lead) assessment (Visit 13, 15, and 17)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 190 of 274 • Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and urinalysis) (laboratory tests are applicable for combined Visit 17/Termination 
Visit. If Visit 17 is not the Termination Visit, laboratory tests are not required)  
• Urine pregnancy test [for women of childbearing potential])  
• Achenbach CBCL for s ubjects ≥6 years to <18 years of age (Visits 13, 15, and 17)  
• BRIEF for subjects ≥5 to <18 years of age (Visits 13, 15, and 17)  
EQ-5D-3L, QOLIE -31-P, Healthcare resource use, Work/school days lost, and Days with help 
from a caregiver were removed from Table  5-[ADDRESS_318081] 2 years of treatment.  
Change #34  
Section 8.2 Early Termination Visit  
Bullet points 3 and 9, and health outcome bullets  
• Neurological examination (complete)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a serum pregnancy test [for women of childbearing potential])  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 yea rs of age)  
• Healthcare resource use  
• Work/school days lost  
• Days with help from a caregiver  
Have been changed to:  
• Neurological examination (brief)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology for subjects <[ADDRESS_318082] [for women of childbearing potential])  
The following assessments are only applicable at the ET Visit for subjects early terminating the 
study within the first 2 years (see Section 4.2.3):  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver due to epi[INVESTIGATOR_261412].
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 191 of 274 Change #35  
Section 8.3 Termination Visit  
Paragraph 2  
Taper of LCM is not required for subjects who complete the study and continue on commercially 
available LCM. Subjects transitioning to commercially available LCM will do so immediately 
and will continue at a dose determined by [CONTACT_093].  
Bullet points 3 and 9, and health outcome bullets  
• Neurological examination (complete)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a serum pregnancy test [for women of childbearing potential])  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Healthcare resource use  
• Work/school days lost  
• Days with help from a caregiver  
Have been changed to:  
Paragraphs 2 and 3  
Patients transitioning to the MAP will complete the Treatment Period after 2 years but continue 
their treatment with MAP LCM.  
Taper of LCM is not required for subjects who complete the study and continue on MAP LCM 
or co mmercially available LCM. Subjects transitioning to MAP LCM or commercially available 
LCM will do so immediately and will continue at a dose determined by [CONTACT_093].  
Bullet points 3 and 9, and health outcome bullets  
• Neurological examination (complet e) Note: Complete neurological exam to be performed for 
patients terminating the study during Years 1 -2, brief exam for patients terminating during 
Years 3 -5. 
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endo crinology for subjects <[ADDRESS_318083] [for women of childbearing potential])  
The following assessments are only applicable at the Termination Visit for subjects terminating 
the study within the first 2 years (see Section 4.2.3):  
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Healthcare resource use  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 192 of 274 • Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver due to e pi[INVESTIGATOR_261468] #36  
Section 8.4.1, End of Taper Visit  
Bullet points 3, 14, 15, and 16  
• Neurological examination (complete)  
• Healthcare resource use  
• Work/school days lost  
• Days with help from a caregiver  
Have been changed to:  
• Neurological examination (brief)  
The following assessments are only applicable at the End of Taper Visit for subjects 
terminating/early terminating the study during the first 2 years (see Section 4.2.3):  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_261468] #37  
Section 8.4.2, Safety Follow -Up Visit  
Bullet points 3, 10, 11, and 12  
• Neurological examination (complete)  
• Healthcare resource use  
• Work/school days lost  
• Days with help from a caregiver  
Have been changed to:  
• Neurological  examination (brief)  
The following assessments are only applicable at the Safety Follow -Up Visit for subjects 
terminating/early terminating the study during the first 2 years (see Section 4.2.3):  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_30989] y 
• Days with help from a caregiver  due to epi[INVESTIGATOR_261412].
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 193 of 274 Change #38  
Section 8.5, Unscheduled Visit  
Bullet points 2 and 3  
• Physical examination (brief)  
• Neurological examination (brief)  
Paragraph [ADDRESS_318084] been changed to:  
• Physical examination (brief) during the first 2 years  
• Neurological examination (brief) during the first 2 years  
Paragraph 3  
If Unscheduled Visit is due to a psychiatric AE, then the C -SSRS is required.  
Change #[ADDRESS_318085] should be remind ed to bring the diary to each clinic visit.  
The following information will be recorded on a daily basis as applicable:  
• Seizure type  
• Number of seizures  
Investigators should advise subjects and/or caregivers about the importance of reporting 
non-PGTC seizure s. Subjects should be reminded that diaries must include daily entries even if 
no seizures have occurred.  
Has been changed to:  
9.[ADDRESS_318086] should be reminded to bring the di ary to each clinic visit.  
9.1.1  PGTC seizures  
The following information will be recorded as applicable:  
• Seizure type  
• Number of PGTC seizures  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318087] diary, the following information will be recorded:  
• Seizure type  
• Number of seizures to be recorded although for the purpose of data analysis, only th e number 
of days with seizure will be analyzed.  
Investigators should advise subjects and/or caregivers about the importance of reporting absence 
and myoclonic seizures.  
Change #40  
9.2 Health outcome variables  
The following text has been added:  
Health outc ome variables will be evaluated during the first two years of treatment.  
Change #[ADDRESS_318088] been changed  to: 
9.2.[ADDRESS_318089] 2 years of treatment.  
Change #42  
Section 10, ASSESSMENT OF SAFETY  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 195 of 274 A new section 10.1.1 Definitions has been added and 10.2.1 Definition of serious adverse event 
has been moved up to Section 10.1. 1.2 Serious adverse event, following [IP_ADDRESS] Adverse event.  
Section 10.5 Anticipated serious adverse events has been moved up to Section [IP_ADDRESS].1.  
Section 10.[ADDRESS_318090] has been moved up to Section [IP_ADDRESS].  
Section 10.1.5 Rule  for repetition of an adverse event has been moved up to Section [IP_ADDRESS].  
Section 10.2.2 Procedures for reporting serious adverse events has been moved up to Section 
[IP_ADDRESS] Additional procedures for reporting serious adverse events.  
Change #43  
Section [IP_ADDRESS], Adverse events of special interest  
A bullet point has been added:  
• Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the biochemical 
abnormalit y, must ALWAYS be reported to UCB as an AE of special interest (ie, without 
waiting for any additional etiologic investigations to have been concluded). Follow -Up 
information should then be reported if an alternative etiology is identified during 
investiga tion and monitoring of the subject.  
Change #[ADDRESS_318091] to follow -up.  
Has been changed to:  
An AE should be followed until it has resolved, has a stable sequelae, the investigator determines 
that it is no longer clinically significant, or the subject is lost to follow -up. This follow -up 
requireme nt applies to AEs, SAEs, and AEs of special interest; further details regarding follow 
up of PDILI events are provided in Section [IP_ADDRESS].  
New paragraph 3  
Information on SAEs obtained after clinical database lock will be captured through the patient 
Safet y (PS) database without limitation of time.  
Change #[ADDRESS_318092] intake of any IMP, UCB’s Drug Safety 
department should be informed immediately. The subject should be withdrawn from the study as 
soon as pregnancy is known, and the following should be completed:  
• The subject should return for an ET visit.  
• The subject should immediately stop the intake of the IMP or be down -titrated as instructed 
at the ET visit.  
• A Safety Follow -Up Visit should be scheduled [ADDRESS_318093]’s partner for completion.  
The pregnancy will be do cumented on the Pregnancy Report and Outcome form provided to the 
investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed -up using the Pregnancy Report and Outcome form in which the investigator has to 
report on the health of the mother and of the child. The health of the child must be followed for 
[ADDRESS_318094] that follow up is continued for a period longer than 
30 days.  
A pre gnancy becomes an SAE in the following circumstances: miscarriage, abortion, or 
anomaly/birth defect of the child. Those SAEs must be additionally reported using the 
Investigator SAE Report Form.  
Have been changed to:  
Section 10.1.4, Pregnancy  
Paragraph [ADDRESS_318095] immediately notify UCB’s Patient Safety (PS) department by [CONTACT_18388] (for contact [CONTACT_261543]). The subject should be withdrawn from 
the study as soon as pregnancy is known (by [CONTACT_18463]), and the following should 
be completed:  
• The subject should re turn for an ET visit.  
• The subject should immediately stop the intake of the IMP or be down -titrated as instructed 
at the ET visit.  
• A Safety Follow -Up Visit should be scheduled [ADDRESS_318096] has discontinued her 
IMP.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 197 of 274 Paragraphs 3 through 5  
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the investi gator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for [ADDRESS_318097] to follow up and/or refuses to give information, written documentation of 
attempts to contact [CONTACT_261544]. 
UCB’s PS depart ment is the primary contact [CONTACT_261545], eventual birth, and follow up.  
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, UCB 
will ask the investigator or desi gnee to contact [CONTACT_261546]/IEC and 
should be available in the investigator site file. In case of questions about the consent process, 
the investigator may contact [CONTACT_58973]/contract research organization (CRO) contract monitor for 
the study. The investigator will complete the Pregnancy Report and Outcome form and send it to 
UCB’s PS department (for contact [CONTACT_261547]) only after the partner has agreed that additional information can be 
captured and has provided the signed Partner Pregnancy Consent form. UCB’s PS department is 
also the primary contact [CONTACT_261548], 
eventual birth, and follow up.  
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital 
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report Form.  
Change #46  
The following secti on has been added:  
Section 10.1.5, Suspected transmission of an infectious agent via a medicinal 
product  
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases mus t be reported immediately, recorded in 
the AE module of the CRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered  an infectious agent.  
Change #47  
The following section has been added:  
Section 10.2, New seizure types  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318098] diaries (see Section 9.1).  
Change #48  
Section 10.6.1, Liver function tests  
Refer to Section 6.3 for LFT withdrawal criteria.  
Transaminases (AST, ALT, or both) ≥3x but <5xULN, in the pr esence of total bilirubin 
≥2xULN, or transaminases (AST, ALT, or both) ≥5xULN will result in immediate 
discontinuation of study drug and withdrawal of the subject from the study. The LFTs will be 
repeated as soon as possible, and in no case more than 1  week later.  
Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality (ie, 
transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly monitoring of LFTs 
should continue until resolved (ie, <3xULN or stable condition). The investigator is to decide 
whether or not to stop the study drug.  
In all cases of transaminases (AST, ALT, or both) ≥3xULN, testing for hepatitis A, B, and C wil l 
be performed. In all cases of transaminases (AST, ALT, or both) ≥8xULN or a potential case of 
drug-induced liver injury (ie, Hy’s law), testing for hepatitis E immunoglobulin M antibodies 
will be performed.  
Referral to a specialist (ie, hepatologist or g astroenterologist) is at the discretion of the 
investigator. This is recommended especially if the transaminase abnormalities >3xULN persist 
after discontinuation of the study drug.  
Has been changed to:  
Section 10.3.1, Evaluation of PDILI  
The PDILI IMP dis continuation criteria for this study are provided in Section 6.3.1, with the 
accompanying required follow -up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section [IP_ADDRESS]), and, if applicable, also reported as an 
SAE (see Section [IP_ADDRESS]).  
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 10 -3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section [IP_ADDRESS]). The lo cal 
hepatologist is the expert usually consulted by [CONTACT_58979]. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be req uired and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in Section 
[IP_ADDRESS]).  
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318099] be taken if the results from the 2 
laboratory tests are significantly dif ferent. Data from the local and central laboratory are to be 
recorded on the applicable CRF pages.  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, th e investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.  
When IMP is stopped due to PDILI (as de scribed in Section 6.3.1), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings, and the requirements 
provided in Secti on [IP_ADDRESS].[ADDRESS_318100] not occur.  
The table below summarizes the approach to investigate PDILI.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 200 of 274 Table 10 -3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULNb NA Hepatology consult.c 
Medic al Monitor 
must be notified 
within 24  hours 
(eg, by [CONTACT_67600]) and subject 
discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Must have 
repeat liver chemistry 
values and additional 
testing completed ASAP 
(see Section [IP_ADDRESS]); 
recommended to occur at 
the site with HCP.  Monitoring of liver 
chemistry values at 
least twice per 
week until values 
normalize, 
stabilize, or return 
to within Baseline 
values.d 
 ≥8xULN  NA NA 
≥3xULN  NA Yes Immediate, 
temporary or 
permanent, IMP 
discontinuation.  
≥3xULN 
(and ≥2x 
Baseline) 
and 
<5xULN  <2xULN  No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.  Further investigation 
– immediate IMP 
discontinuation not 
required (see Section 
[IP_ADDRESS]).  Not required unless 
otherwise medically 
indicated (at discretion 
of investigator).  
≥5xULN 
(and ≥2x 
Baseline)  <2xULN  No Discussion with 
Medical Monitor 
required.  Immediate, 
permanent IMP 
discontinuation.  Essential: Every attempt 
must be made to have 
repeat liver chemistry 
values and additional 
testing completed within 
48 hours at the site with 
HCP (see Section 
[IP_ADDRESS]).  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soo n as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug -induced liver injury; ULN=upper limit of normal  
a Hepatitis symptoms include fatigue, nausea, vomiti ng, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).  
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should b e discussed with the Medical Monitor.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB  28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 201 of 274 c Details provided in Section [IP_ADDRESS]. The local hepatologist is the expert usually consulted by [CONTACT_261549]. This would usually be a hepatologist,  but may be a gastroenterologist.  
d Unless an alternative monitoring schedule is agreed by [CONTACT_58982]. Determination of stabilization is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 202 of 274 [IP_ADDRESS] Consultation with Medical Monitor and local hepatologist   
Potential drug -induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by [CONTACT_58980]), and the subject must be discussed with the Medical 
Monitor as soon as possible. If required, the subject must also be discus sed with the local 
hepatologist. The local hepatologist is the expert usually consulted by [CONTACT_261512]. This would usually be a 
hepatologist, but may be a gastroenterologist. If determin ed necessary, this discussion should 
be followed by a full hepatology assessment (see Section [IP_ADDRESS]) and SAE report (if 
applicable).  
[IP_ADDRESS] Immediate action: determination of IMP discontinuation  
All PDILI events require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by [CONTACT_58984]) 
to immediate and permanent discontinuation (see Section  6.3.1 an d Table 10 -3 for details).  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also consider dose 
reduction for medically necessary concomitant m edication and consider changing any 
medically required concomitant medication known to be hepatotoxic to a suitable alternative.  
[IP_ADDRESS].1 IMP restart/rechallenge (if applicable)  
Rechallenge with a substance potentially causing drug -induced liver injury i s dangerous, may 
be fatal, and must not occur.  
Subjects who are immediately discontinued from IMP due to having met certain criteria for 
PDILI (as described in Section 6.3.1 and Table 10 -3), but for whom an alternative diagnosis 
is confirmed, can rarely re start IMP. Rechallenge with IMP can occur only if ALL of the 
following requirements are met:  
• The results of additional testing and monitoring described in Section [IP_ADDRESS] and Section 
[IP_ADDRESS] confirm a nondrug -related cause for the abnormal hepatic labora tory parameters 
and any associated symptoms (ie, a subsequent alternative diagnosis fully explains the 
hepatic findings).  
• No alternative treatment options are available to the subject.  
• The subject has shown clear therapeutic benefit from the IMP.  
• Subject’ s ALT or AST elevations do not exceed ≥3xULN.  
• Subject’s total bilirubin is <1.5xULN.  
• Subject has no signs or symptoms of hypersensitivity.  
• The rechallenge is approved by [CONTACT_261513] a hepatologist. The 
hepatologist must be external t o UCB. It is recommended that the hepatologist be a local 
hepatology expert or the hepatologist treating the subject.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 203 of 274 • Subject agrees to the investigator -recommended monitoring plan.  
[IP_ADDRESS] Testing: identification/exclusion of alternative etiology  
The mea surements and additional information required for the assessment of PDILI events 
when there is a reasonable possibility  that they may have been caused by [CONTACT_261514] 10 -4 (laboratory measurements) and Table 10 -5 (additional information). Results of 
the laboratory measurements and information collected are to be submitted to the sponsor on 
the corresponding CRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessmen ts should be completed and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for more rapid 
results, a concurrent sample must also be sent to the central laboratory.  
The following measurements are to be as sessed:  
Table 10 -4 PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Eosinophil count  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation  
Additional  Prothrombin time/INRa 
Serum pregnancy test  
PK sample  
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb -IgM=hepatitis B core antibody -IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 204 of 274 LDH=lactate dehydrogenase; PDILI=potential drug -induced liver in jury; PK=pharmacokinetic; 
RNA=ribonucleic acid; ULN=upper limit of normal  
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
The following additional information is to be collected:  
Table 10 -5: PDILI information to be collected  
New or  updated information  
Concomitant prescription and over -the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
• History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other 
“fatty liver disease”)  
• Adverse reactions to drugs  
• Allergies  
• Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
• Recent travel  
• Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by 
[CONTACT_5071], should not be used as an explanation for significant AST and/or ALT elevations.)  
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatig ue, 
nausea, vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, 
jaundice, fever, or rash)  
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary 
function  
Alcohol and illicit drug use  
Results of liver imaging or liver biopsy, if done  
Results of any specialist or hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury  
[IP_ADDRESS] Follow -Up evaluation  
Potential drug -induced liver injury events require follow -up monitoring as described in 
Table  10-3. 
Monitoring should continue until liver chemistry values normalize, stabilize, or return to 
Baseline. Determination of stabilization is at the discretion of the investigator in consultation 
with the hepatologist (as applicable) and UCB responsible physician, as needed.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 205 of 274 Change #49  
Section 12.1, Definition of analysis sets  
The following subsection has been added:  
12.1.1  Enrolled Set  
The Enr olled Set (ES) will consist of all subjects who have a signed Informed Consent/
Assent form.  
Change #50  
Section 12.3.1, Safety analyses  
A new Paragraph 2 has been added:  
Incidence of new seizure types and increase in absence seizure days per 28 days or myo clonic 
seizure days per 28 days during the Treatment Period will be summarized. Laboratory 
measurements as described in Section 10.3 and other safety measurements as described in 
Section 10.4 will be presented.  
Change #51  
Section 12.4, Planned efficacy ana lyses  
Paragraph 2  
Days with myoclonic or absence seizures are more clinically relevant endpoints; therefore, 
days with myoclonus and absence will be summarized separately using the same method for 
PGTC seizures. Subjects who were seizure -free from all gen eralized seizures will also be 
tabulated (PGTC, myoclonic and absence seizures combined).  
Has been changed to:  
Days with myoclonic or absence seizures are more clinically relevant endpoints; therefore, 
change in and percent change in days with myoclonus and absence will be summarized. The 
percentage of subjects with 50% reduction in days with absence and myoclonic seizures per 
28 days compared to the Prospective Baseline will be presented. Subjects who were seizure 
free from all generalized seizures will also be tabulated.  
Change #52  
Section 15, REFERENCES  
Dichek B. Epi[INVESTIGATOR_002]: an ancient ailment that still eludes a cure. Scrip Magazine. 
1999;Feb:9 -11. 
Has been changed to:  
Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of 
epi[INVESTIGATOR_002]: a systematic review and meta -analysis. Neurology. 2011;77(10):1005 -12. doi: 
10.1212/WNL.0b013e31822cfc90.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 206 of 274 The following reference has been added:  
Food and Drug Administration. Guidance for Industry. Drug -induced liver injury: 
premarketing clinic al evaluation. US Dept of Health and Human Services, Center for Drug 
Evaluation and Research, Center for Biologics Evaluation and Research, 07/2009.  
Change #53  
Appendix 6: Contraception Table was added in Section 16.6.  
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 207 of 274 16.6 Appendix 6: Protocol Amendment [ADDRESS_318101] been made:  
• To allow the Safety Follow -Up for subjects tapered in SP0982 after the 125th event occurs 
in SP0982, this will be performed at Visit [ADDRESS_318102] their 
4-week Safety Follow -Up in EP0012.  
• To restructure the safety variables  
• The planned number of subject is aligned with the pi[INVESTIGATOR_261469]0982  
• To update the introduction section with regulatory information on the marketin g 
authorization of Vimpat and to provide an update on the lacosamide (LCM) clinical 
program.  
• To clarify the potential drug -induced liver injury (PDILI) criteria requiring immediate 
and permanent discontinuation of the investigational medicinal product (IMP ). 
• To update the title page and study physician contact [CONTACT_261550].  
Modifications and changes  
Specific changes  
Change #1  
Title page:  
The title was updated from  “Protocol EP0012 Amendment  2” to “Protocol EP0012 
Amendment  3.” 
The information below was revised to include Protocol Amendment 3 and the type of 
protocol amendment:  
Protocol/Amendment Number  Date  Type of amendment  
Final Protocol  [ADDRESS_318103] 2012  Not applicab le 
Protocol Amendment 1  27 Jan 2015  Substantial  
Protocol Amendment 2  09 Jun 2016  Substantial  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 208 of 274 Has been changed to:  
Protocol/Amendment Number  Date  Type of amendment  
Final Protocol  [ADDRESS_318104] 2012  Not applicable  
Protocol Amendment 1  27 Jan 2015  Substantial  
Protocol Amendment 2  09 Jun 2016  Substantial  
Protocol Amendment 3  29 Nov 2017  Substantial  
Change #[ADDRESS_318105] INFORMATION  
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Phone:   
Email:   
Clinical Project Manager  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Phone:   
Email:   
 
Has been changed to:  
Sponsor Study Physician  
Name:   
[CONTACT_2761]:  Alfred -Nobel -Strasse 10  
[ZIP_CODE] Monheim  
GERMANY  
Phone:   
Email:   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318106] Manager  
 
 
 
 
 
 
Change #3  
Section 1 SUMMARY  
Paragraph 1 (last sentence)  
It is estimated that approximately 200 subjects across approximately 150 sites will be 
enrolled in EP0012.  
Paragraph 2  
Subjects who completed SP0982 will start at Visit 1 on a dose of LCM 10mg/kg/day for 
pediatric subjects weighing <30kg, LCM 8mg/kg/day for pediatric subjects weighing ≥30kg 
to <50kg, and LCM 400mg/day (200mg twice daily [bid]) for adult subjects (≥18 years of 
age) or pediatric subjects weighing ≥50k g. 
Paragraph 10  
The primary safety variables are adverse events (AEs), subject withdrawals due to AEs, 
incidence of new seizure types, and increase in absence seizure days per 28 days or 
myoclonic seizure days per 28 days during the Treatment Period. Secon dary safety variables 
are changes in hematology, chemistry, and urinalysis parameters; changes in 12 -lead 
electrocardiograms (ECGs); and changes in vital sign measurements (ie, blood pressure [BP] 
and pulse rate), including body mass index (BMI) and physic al (including neurological) 
examination findings. In addition, for pediatric subjects <18 years of age, safety will be 
evaluated using behavioral assessments (Achenbach Child Behavior Checklist [CBCL]), and 
cognitive function assessments (Behavior Rating I nventory of Executive Function®/Behavior 
Rating Inventory of Executive Function -Preschool Version® [BRIEF®/BRIEF -P®]). The 
seizure efficacy variables are evaluations of seizure frequency, based on information included 
in subject diaries. The health outcome  variables, including the Patient Weighted Quality of 
Life in Epi[INVESTIGATOR_261379] -Form 31 (QOLIE -31-P), the Pediatric Quality of Life Inventory™ 
(PedsQL™), the 3 -level EuroQol -5 Dimension Quality of Life Assessment (EQ -5D-3L), 
healthcare resource use, the n umber of working or school days lost by [CONTACT_261551][INVESTIGATOR_002], and the number of days with help from a caregiver due to epi[INVESTIGATOR_261470] 2 years of treatment.  Name:   
[CONTACT_2761]:  Allée de la Recherche 60  
1070 Brussels  
BELGIUM  
Phone:   
Email:   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 210 of 274 Has been changed to:  
Paragraph 1 (last sentence)  
It is estimated that u p to [ADDRESS_318107] met its 
protocol -defined stoppi[INVESTIGATOR_261471]0012 or taper off study 
medication. Subjects who completed SP0982 will start at Visit 1 on a dose of LCM 
10mg/kg/day for pediatric subjects weighing <30kg, LCM 8mg/kg/day for pediatric subjects 
weighing ≥30kg to <50kg, and LCM 400mg/day (200mg twice daily [bid]) for adult subjects 
(≥18 years of age) or pediatric subjects weighing ≥50kg. Subjects who are e ligible Baseline 
failures from SP0982 will start at Visit 1 on a dose of LCM 2mg/kg/day for pediatric subjects 
weighing <50kg, and LCM 100mg/day (50mg bid) for adult subjects (≥18 years of age) or 
pediatric subjects weighing ≥50kg.   
Paragraph 10  
The prima ry safety variables are a dverse events (AEs), s ubject withdrawals due to AEs, 
incidence of new seizure types, and increase in absence seizure days per 28 days or 
myoclonic seizure days per 28 days during the Treatment Period. Secondary safety variables 
are percentage of treatment -emergent marked abnormalities in hematology, and chemistry 
parameters; percentage of treatment -emergent marked abnormalities in 12 -lead 
electrocardiograms (ECGs); and percentage of treatment -emergent marked abnormalities in 
vital s ign measurements (ie,  blood pressure [BP] and pulse rate).  Other safety variables 
include changes in hematology, chemistry, and urinalysis parameters, changes in 12 -lead 
ECGs, and changes in in vital sign measurements (ie, BP and pulse rate), including wei ght 
and height and physical (including neurological) examination findings.  In addition, for 
pediatric subjects <18 years of age, safety will be evaluated using behavioral assessments 
(Achenbach Child Behavior Checklist [CBCL]), and cognitive function asse ssments 
(Behavior Rating Inventory of Executive Function®/Behavior Rating Inventory of Executive 
Function -Preschool Version® [BRIEF®/BRIEF -P®]). The seizure efficacy variables are 
evaluations of seizure frequency, based on information included in subject d iaries. The health 
outcome variables, including the Patient Weighted Quality of Life in Epi[INVESTIGATOR_261379] -
Form 31 (QOLIE -31-P), the Pediatric Quality of Life Inventory™ (PedsQL™), the 3 -level 
EuroQol -5 Dimension Quality of Life Assessment (EQ -5D-3L), healthcare resource use, the 
number of working or school days lost by [CONTACT_261478][INVESTIGATOR_002], and the number of days 
with help from a caregiver due to epi[INVESTIGATOR_261382] 2 years of treatment.  
Change #4  
Section 2 INTRODUCTION  
Paragraph 7  
Lacosamide has been approved in the European Union (oral tablets, oral solution [syrup], and 
solution for intravenous [iv] infusion) as adjunctive therapy in the treatment of partial -onset 
seizures with or without secondary generalization in patients 16 ye ars of age and older. 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 211 of 274 Lacosamide has also been approved in the US (oral tablets, oral solution [syrup], and solution 
for iv infusion) as monotherapy and adjunctive therapy in the treatment of partial -onset 
seizures in patients [ADDRESS_318108] years. Further information on LCM nonclinical results, as well as the PK, 
efficacy, and safety profiles, can be obtained from the current version of the LCM 
Investigator’s Brochure.  
Paragr aph [ADDRESS_318109] that exposure -response in pediatric and adult subjects 
treated with LCM will be similar. Lacosamide has been evaluated in 2 completed pediatric 
studies, both in subjects aged 1 month to 17 years (SP847 [open -label, adjunctive therapy, 
pharmacokinetic study in partial -onset seizures] and SP1047 [open -label pharmacokinetic 
study in epi[INVESTIGATOR_002]]). Subjects from SP847 were also able to enroll into an ongoing open -label 
long-term safety study (SP848).  
In addition, lacosa mide is being evaluated in the following ongoing pediatric efficacy and 
safety studies:  
• SP0967 (ages ≥1 month to <4 years) as adjunctive therapy in partial -onset seizures  
• SP0969 (ages ≥4 to <17 years) as adjunctive therapy in partial -onset seizures  
• EP0034, open -label extension study to SP0967 and SP0969  
• SP0966 (ages ≥1 month to <18 years) as adjunctive therapy, exploratory study in subjects 
with epi[INVESTIGATOR_261472]:  
Paragraph 7  
Lacosamide has be en approved in the European Union (oral tablets, oral solution [syrup], and 
solution for intravenous [iv] infusion) as monotherapy or adjunctive therapy in the treatment 
of partial -onset seizures with or without secondary generalization in patients 4 years  of age 
and older. Lacosamide has also been approved in the US (oral tablets, oral solution [syrup], 
and solution for iv infusion) as monotherapy or adjunctive therapy in the treatment of partial -
onset seizures in patients 17 years of age and older. The sa fety and efficacy of LCM has also 
been evaluated in Phase 2/[ADDRESS_318110] that the exposure -response in pediatric and 
adult subjects treated with LCM will be similar. Lacosamide has been evaluated in 3 
completed pediatric studies; 2 studies in subjects aged 1 month to 17 years, and i n subjects 
with epi[INVESTIGATOR_002] ≥4 years to <17 years of age with uncontrolled partial -onset seizures. Subjects 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 212 of 274 who completed the Maintenance Period were offered the opportunity to participate in the 
open -label extension study.  
In addition, LCM is being evaluated  in the following ongoing pediatric efficacy and safety 
studies:  
• SP0967 (ages ≥1 month to <4 years) as adjunctive therapy in partial -onset seizures  
• EP0034, open -label extension study to SP0967 and SP0969  
• SP0966 (ages ≥1 month to <18 years) as adjunctive t herapy, exploratory study in subjects 
with epi[INVESTIGATOR_261394], as well as the PK, efficacy, and safety 
profiles, can be obtained from the current version of the LCM Investi gator’s Brochure.  
Change #5  
Section 4.1.2 Secondary safety variables  
Secondary safety variables are:  
• Changes in hematology, chemistry, and urinalysis parameters  
• Changes in 12 -lead ECGs  
• Changes in vital sign measurements (ie, BP and pulse rate), including B MI and physical 
(including neurological) examination findings  
Has been changed to:  
Secondary safety variables are:  
• Percentage of treatment -emergent marked abnormalities in hematology and chemistry 
parameters  
• Percentage of treatment -emergent marked abnormal ities in 12 -lead ECGs  
• Percentage of treatment -emergent marked abnormalities in vital sign measurements (ie, 
BP and pulse rate)  
Change #6  
Section 4.1.3 Other safety variables  
• Achenbach CBCL1½ -5 or CBCL/6 -18 
• Cognitive function assessment BRIEF/BRIEF -P 
Has been changed to:  
• Changes in hematology, chemistry, and urinalysis parameters  
• Changes in 12 -lead ECGs  
• Changes in vital sign measurements (ie, BP and pulse rate), including weight and height 
and physical (including neurological) examination findings  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 213 of 274 • Achenbach CBCL1½ 5 or CBCL/6 18 (for pediatric subjects only)  
• Cognitive function assessment BRIEF/BRIEF -P (for pediatric subjects only)  
Change #[ADDRESS_318111] completed the LCM SP0982 study as well as eligible Baseline failures 
from SP0982. Approximately 200  subjects from approximately 150 study sites are planned to 
be enrolled in EP0012.  
For the purposes of this study, Base line failures, randomized subjects who meet SP0982 exit 
criteria, and study completers from SP0982 who are eligible for inclusion in EP0012 are 
defined as:  
SP0982 Baseline failures  
• Subjects who complete the Prospective Baseline Period of SP0982 and meet al l entry 
criteria except the minimum PGTC seizure criteria required for randomization (Baseline 
failures)  
Randomized subjects meeting SP0982 exit criteria  
• Subjects who completed the first 6 weeks of the Treatment Period (after randomization) 
of SP0982 and experienced ≥2 PGTC seizures during that time or  
• Subjects who experience a second PGTC seizure after the first 6 weeks of the Treatment 
Period of SP0982  
SP0982 completers  
• Subjects who experience <2 PGTC seizures within the 24 -week Treatment Period of 
SP0982  
Randomized subjects meeting SP0982 exit criteria and subjects who completed SP0982 will 
start at Visit 1 on a dose of LCM 10mg/kg/day for pediatric subjects weighing <30kg, LCM 
8mg/kg/day for pediatric subjects weighing ≥30kg to <50kg, and LCM 400mg/d ay (200mg 
bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50kg. Subjects who 
are eligible Baseline failures from SP0982 will start at Visit 1 on a dose of LCM 2mg/kg/day 
for pediatric subjects weighing <50kg, and LCM 100mg/day (5 0mg bid) for adult subjects 
(≥18 years of age) or pediatric subjects weighing ≥50kg.  
Has been changed to:  
Paragraph [ADDRESS_318112] completed the LCM SP0982 (or have left the primary study at the time of 
the 125th event, whichever came first)  as well as eligible Baseline fa ilures from SP0982. 
Then, some subjects who tapered in SP0982 after the 125th event may enter EP0012 for the 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 214 of 274 Safety Follow -Up only (ICF to be signed beforehand). Up to 250  subjects from 150 to 180 
study sites are planned to be enrolled in EP0012.  
For the p urposes of this study, Baseline failures, randomized subjects who meet SP0982 exit 
criteria, and study completers from SP0982 who are eligible for inclusion in EP0012 are 
defined as:  
SP0982 Baseline failures  
• Subjects who complete the Prospective Baseline P eriod of SP0982 and meet all entry 
criteria except the minimum PGTC seizure criteria required for randomization (Baseline 
failures)  
Randomized subjects meeting SP0982 exit criteria  
• Subjects who completed the first 6 weeks of the Treatment Period (after randomization) 
of SP0982 and experienced ≥2 PGTC seizures during that time or  
• Subjects who experience a second PGTC seizure after the first 6 weeks of the Treatment 
Period of SP0982  
SP0982 completers  
• Subjects who experience <2 PGTC seizures within the 24 -week Treatment Period of 
SP0982  
• Subjects who were ongoing in SP0982 when the 125th event occurred  
SP0982 Safety Follow -Up subjects  
• Subjects tapered in SP0982 after the 125th event oc curs will enter EP0012 for the Safety 
Follow -Up Visit only.  
Randomized subjects meeting SP0982 exit criteria and subjects who completed SP0982 will 
start at Visit 1 on a dose of  LCM  10mg/kg/day for pediatric subjects weighing <30kg, LCM 
8mg/kg/day for ped iatric subjects weighing ≥30kg to <50kg, and LCM 400mg/day (200mg 
bid) for adult subjects (≥18 years of age) or pediatric subjects weighing ≥50kg. Subjects who 
are eligible Baseline failures from SP0982 will start at Visit 1 on a dose of  LCM 2mg/kg/day 
for pediatric subjects weighing <50kg, and LCM  100mg/day (50mg bid) for adult subjects 
(≥18 years of age) or pediatric subjects weighing ≥50kg. In addition, once [ADDRESS_318113] 
had a second PGTC seizure in SP0982 (ie, the 125th event has occurred),  that s tudy will have 
met its protocol -defined end. All subjects ongoing in SP0982 will transition into EP0012 for 
further long term treatment for a Safety Follow -Up. 
Change #[ADDRESS_318114]  
Bullet 5 has been updated.  
− An End of Taper Vi sit will occur after the final LCM dose for subjects who taper off 
LCM. Following the End of Taper Visit, there will be a [ADDRESS_318115] 
dose of study drug.  
Has been changed to:  
− An End of Taper Visit will occur after the final LCM dose for subjects who taper off 
LCM. Following the End of Taper Visit, there will be a [ADDRESS_318116] 
dose of study drug. The same design will apply to some of the subjects ta pered in 
SP0982 at the time of the 125th event and who entered EP0012 for the Safety 
Follow -Up Visit only and to subjects who entered EP0012 for a Safety Follow -up 
Visit after discontinuing SP0982 due to the study stoppi[INVESTIGATOR_007].  
Change #9  
Section 5.1.2 Planned number of subjects and site(s)  
Up to 200 subjects across approximately 150 international sites are planned to be enrolled in 
this study.  
Has been changed to:  
Up to 250 subjects across 150 to 180 international sites are planes to be enrolled in this study.  
Change #10  
Section 5.2 Schedule of study assessments  
The schedule of study assessments for treatment Years 1 to 2 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit) is provided in Table 5‒1. An additional schedule 
of study assessments f or treatment Years 3 to 5 (Treatment Period, ET Visit, Termination 
Visit, and Unscheduled Visit) is provided in Table 5‒2. The schedule of study assessments 
for the Taper and Safety Follow -Up is provided in Table 5‒3.  
Has been changed to:  
The schedule of s tudy assessments for treatment Years 1 to 2 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit) is provided in Table 5 -1. An additional schedule 
of study assessments for treatment Years 3 to 5 (Treatment Period, ET Visit, Termination 
Visit, and Unscheduled Visit) is provided in Table 5 -2 for subjects <18 years and Table 5 -3 
for subjects ≥18 years. The schedule of study assessments for the Taper Period and Safety 
Follow -Up Visit (including subjects who tapered in SP0982 after the 125th event consented to 
enter EP0012 for the Safety Follow -up only) is provided in Table 5 -4. 
 
Table 5 -1 
A has been added to explain that Visit 6, Visit 7 and Visit 10 will not be performed according 
to Protocol Amendment 3.  Footnote ‘b’ has ‘vital signs’ removed and for footnote ‘d’ Week 
30 Week 38 and Week 78 has been added to footnote for consistency.  
Note: Visit 6, Visit 7 and Visit 10 (**) assessments will not be performed according to 
Protocol Amendment 3.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 216 of 274 b Unscheduled Visits may be performed at any time aft er Visit 1 as clinic visits or telephone contacts, at the 
discretion of the investigator. In addition to the required assessments listed above, depending on the type of visit 
(clinic or telephone), further assessments can be completed as needed and may inc lude ECG, vital signs, 
laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to an AE.  
d Telephone contacts are required every 8 weeks including Week 30 and Week 38 during the study, except 
during weeks in which a clinic visit  is planned (eg, Week 62). Therefore, telephone contacts in Year 2 are 
scheduled for Week 54, Week 70, Week 78, and Week 86.  
Has been changed to:  
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the  
discretion of the investigator. In addition to the required assessments listed above, depending on the type of visit 
(clinic or telephone), further assessments can be completed as needed and may include ECG, laboratory tests, 
etc. The C -SSRS must be perfo rmed if the Unscheduled Visit is due to an AE.  
d Telephone contacts are required every 8 weeks  including Week 30 and Week 38 during the study, except 
during weeks in which a clinic visit is planned (eg, Week 62). Therefore, telephone contacts in Year 2 are  
scheduled for Week 54, Week 70, Week 78, and Week 86.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
 
Confidential  Page 217 of 274 Table 5 -2 
Table title has been updated for pediatrics only, a note has been a dded and footnote ‘b’ and ‘h’ have been updated.   
Table 5 -2: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5     
Visitc TCd V12 V13 V14 V15 V16 V17/ Terme ET Visitf Term  Visitg LCM Solution Dispensation 
Visith Unscheduled Visit  
Week   118 142 166 190 214 238    NA 
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of th e investigator. In addition to the 
required assessments listed above, depending on the type of visit (clinic or telephone), furthe r assessments can be completed as needed and may include ECG, 
vital signs, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to an AE.  
h Dispensation Visit will occur 12 weeks after each 24 -weekly visit Year 3 onwards and will be for the purpose of dispensing LCM solution for pediatric subjects 
<50kg.  
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
 
Confidential  Page 218 of 274 Has been changed to  
Table 5 -2: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit for subjects <18 years)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5     
Visitc TCd V12 V13 V14 V15 V16 V17/ 
Terme ET Visitf Term  Visitg LCM Solution Dispensation 
Visith Unscheduled Visit  
Week   118 142 166 190 214 238    NA 
Note: Subjects who turn 18 years during the course of this study will be considered as pediatric, however these subjects will not need to complete the Achenbach 
CBCL and BRIEF assessments.  
h Dispensation Visit will occur 12 weeks after each 24 -weekly visit from Year 2 (Visit 11) to Year 3 onwards and will be for the purpose of dispensing LCM 
solution f or pediatric subjects <50kg.  
Change #11  
The following table has been added for adult subjects for Years 3 to 5.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
 
Confidential  Page 219 of 274 Table 5 -3: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit  for subjects ≥18 years)  
 
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5     
Visitc TCd V12 V13 V14 V15 V16 V17/ 
Terme ET Visitf Term  Visitg LCM Solution 
Dispensation Visith Unscheduled Visit  
Week   118 142 166 190 214 238    NA 
Concomitant medications 
and AED(s)  X X X X X X X X X  X 
Laboratory testsh  X  X  X X X X   
Pregnancy testi  X X X X X X X X   
Dispense subject diary   X X X X X X X X   
Subject diary return/review   X X X X X X X X  X 
Call IRT  X X X X X X X X  X 
Dispense LCM   X X X X X X X X X  
LCM review/return   X X X X X X X X X  
Withdrawal criteria  X X X X X X X X X  X 
AE reporting  X X X X X X X X X  X 
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ET=early termination; IRT=interactive 
response technology; LCM=lacosamide; NA=not applicable; Term=Termination; V=Visit  
a The Treatment Period will continue for at least 2 years.  
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of th e investigator. In addition to the 
required assessments listed above, depending on the type of visit (clinic or tele phone), further assessments can be completed as needed and may include 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318117] be performed if the Unscheduled Visit is due to a psychiatric 
AE. 
c A window of ±[ADDRESS_318118] every 8 weeks if no clinic 
visit is scheduled.  
d Telephone contacts are required every 8 weeks during the study. Telephone contacts are not required d uring weeks in which a clinic visit is planned (eg, 
Week 118). Therefore, telephone contacts are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 158, Week 
174, Week 182; Year [ADDRESS_318119] and/or legal representative t o best manage the subject's 
epi[INVESTIGATOR_002].  
f An ET Visit must be completed for all subjects who prematurely discontinue from the study.  This will be followed by [CONTACT_261486], an End of Taper Visit, and 
a Safety Follow -Up Period; see Table [ADDRESS_318120] be completed for all subjects who complete the study. This can be combined with Visit 17 if appropri ate. For subjects who wil l not 
continue on LCM, this visit will be followed by [CONTACT_261486], an End of Taper Visit, and a Safety Follow -Up Period; see Table [ADDRESS_318121] visit in the study.  
h Laboratory tests include chemistr y, hematology and urinalysis.  
i Pregnancy tests will be performed for female subjects of childbearing potential only. Serum pregnancy tests will be conducted  at the following visits: Visit 1 
(W0), ET, and Termination Visit. All other pregnancy tests will be urine dipstick. Baseline failures from SP0982 may have an additional urine pregnancy 
test at V1 of EP0012, at the investigator’s discretion  
 
Change #12  
Table 5 -4 
A note and footnote ‘b’ have been amended.  
b There will be a 30 -day ( -1/+3 days) Safety Follow -Up Period for subjects who complete the End of Taper Visit for SP0982 and EP0012. The Safety Follow -Up 
Period consists of a Clinic Visit 2 weeks after the End of Taper Visit followed 2 weeks later by a TC Visit.  
Has been changed to  
Note: The schedule of study assessments for the Taper Period and Safety Follow -Up Visit includes some of the subjects who tapered in SP0982 after the 125th 
event who consented to enter EP0012 for the Safety Follow -Up only.  
b Ther e will be a 30 -day ( -1/+3 days) Safety Follow -Up Period for subjects who complete the End of Taper Visit. The Safety Follow -Up Period consists of a 
Clinic Visit 2 weeks after the End of Taper Visit followed 2 weeks later by a TC Visit.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 221 of 274 Change #13  
Section 6.3 Withdrawal criteria  
The following new criterion has been added  
1. Tapered subjects from SP0982 who enter EP0012 after the 125th event will be withdrawn at 
the enrollment visit  and enter directly into the Safety Follow -Up Period without and ET Visit 
being performed in EP0012.  
Change #[ADDRESS_318122] (IMP) 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued.  
The PDILI criteria below r equire immediate and permanent discontinuation of IMP:  
Subjects with either of the following:  
− ALT or AST ≥5xULN  
− ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
The PDILI criterion below requires immediate discontinuation of IMP:  
Subjects with ALT  or AST ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative ca use), 
rash, or eosinophilia (ie, >5%).  
Has been changed to:  
Subjects with PDILI must be assessed to determine if IMP must be immediately and permanently 
discontinued. In addition, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued.  
The PDILI criteria bel ow require immediate and permanent discontinuation of IMP:  
− ALT or AST ≥5xULN  
− ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity. Hepatitis sy mptoms include fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), 
rash, or eosinophilia (ie, >5%).  
Change #15  
Section 7.2 Treatment(s) to be administered  
Paragraph [ADDRESS_318123] not be broken . In rare cases where uneven dosing (e.g., 350mg/day, 450mg/day, 
550mg/day, etc) is medically needed, although the interactive response technology (IRT) will not 
dispense the exact dose, please contact [CONTACT_261552] l monitor for additional instructions.  
Has been changed to:  
Tablets must not be broken . In rare cases where uneven dosing (e.g., 350mg/day, 450mg/day, 
550mg/day, etc) is medically needed, although the interactive response technology (IRT) will not 
dispense  the exact dose, please contact [CONTACT_261553]. If 
subjects are taking an odd number of tablets per day, (eg, 7 tablets totaling 350mg), they should 
take the lower dose in the morning (eg, 150mg [3 tablets]) and the higher dose in the evening 
(eg, 200mg [4 tablets]).  
Change #16  
Section 7.2.1 Treatment Period  
Paragraph 1 and 3  
At Visit 1, subjects who completed SP0982 will start on a dose of LCM 10mg/kg/day for 
pediatric subjects weighing <30kg, LCM 8mg/kg/day for pediatric s ubjects weighing ≥30kg to 
<50kg, and LCM 400mg/day (200mg bid) for adult subjects (≥18 years of age) or pediatric 
subjects weighing ≥50kg. Subjects who are eligible Baseline failures from SP0982 will start at 
Visit 1 on a dose of LCM 2mg/kg/day for pediatr ic subjects weighing <50kg, and LCM 
100mg/day (50mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing 
≥50kg.  
At any time during the course of the study if it becomes apparent that a subject is unable to attain 
at least this minimum dose of 4mg/kg/day (oral solution) or 200mg/day (tablets), then the subject 
must enter the Taper Period and be withdrawn from the study.  
Has been changed to:  
At Visit 1, subjects who completed SP0982 will start on a dose of LCM 10mg/kg/day for 
pediatric su bjects weighing <30kg, LCM 8mg/kg/day for pediatric subjects weighing ≥30kg to 
<50kg, and LCM 400mg/day (200mg bid) for adult subjects (≥18 years of age) or pediatric 
subjects weighing ≥50kg. Subjects who are eligible Baseline failures from SP0982 will sta rt at 
Visit 1 on a dose of LCM 2mg/kg/day for pediatric subjects weighing <50kg, and LCM 
100mg/day (50mg bid) for adult subjects (≥18 years of age) or pediatric subjects weighing 
≥50kg.  
Subjects who tapered in SP0982 after the 125th event will enroll at Vi sit [ADDRESS_318124] this minimum dose of 4mg/kg/day 
(oral solution) or 200mg/day (tab lets), then the subject must enter the Taper Period and be 
withdrawn from the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 223 of 274 Change #17  
Section 8.1.1 Visit 1 (Week 0)  
The following tasks and procedures are to be performed at this visit (for subjects who have 
completed SP0982, assessments marked [*] should have already been completed during the last 
visit of the previous protocol and do not need to be repeated at Visit 1; for eligible Baseline 
failures from SP0982, a full Visit 1 is required including all scheduled tasks and procedures).  
Has been changed to:  
The following tasks and procedures are to be performed at this visit (for subjects who have 
completed SP0982, assessments marked [*] should have already been completed during the last 
visit of the previous protocol and do not need to be repeated at Visit 1 ; for eligible Baseline 
failures from SP0982, a full Visit 1 is required including all scheduled tasks and procedures). 
Tapered subjects from SP0982 will enter EP0012 for the Safety Follow -Up only and will be 
withdrawn at Visit [ADDRESS_318125] been performed. Details of the Safety 
Follow -Up are provided in Section  8.4.2 and Section 8.4.3.  
Change #18  
Section 8.1.2 Visits 2 to 8 (Weeks 2 to 46, Year 1)  
Section 8.1.2 Visits 2 to 8 (Weeks 2 to 46, Year 1)  
The following tasks and procedures are t o be performed at these visits:  
• Concomitant medications and AEDs  
• Physical examination (brief, Visit 2, 3, 4, 5, 6, and 7; complete, Visit 8)  
• Neurological examination (brief, Visit 2, 3, 4, 5, 6, and 7; complete, Visit 8)  
• ECG (12 -lead) assessment (Visit 2, 4, 6, and 8 only)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight (Visit 4, 6, and 8 only)  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Vis it 8 only)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and urinalysis) [Visit 2, 5, and 8 only] , and a urine pregnancy test [for women of 
childbearing potenti al])  
Has been changed to:  
8.1.2 Visits 2 to 8 (Weeks 2 to 46, Year 1, excluding Visit 6 and Visit 7)  
The following tasks and procedures are to be performed at these visits:  
• Concomitant medications and AEDs  
• Physical examination (brief, Visit 2, 3, 4, and 5; complete, Visit 8)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 224 of 274 • Neurological examination (brief, Visit 2, 3, 4, and 5; complete, Visit 8)  
• ECG (12 -lead) assessment (Visit 2, 4, and 8 only)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight (Visit 4,and 8 only)  
• Tanner staging  (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 8 only)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and urinalysis) [Visit 2, 5, and 8 only] , and a urine pregnancy test [for women of 
childbearing potential])  
Change #19  
Section 8.1.3 Visits 9 to 11 (Weeks 62 and 94, Year 2 ) 
The following tasks and procedures are to be performed at these visits:  
• Concomitant medications and AEDs   
• Physical examination (brief, Visit 9 and 10; complete, Visit 11)  
• Neurological examination (brief, Visit 9 and 10; complete, Visit 11)  
• ECG (12-lead) assessment (Visit 9, 10, and 11)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight and height (height at Visit 9 only)  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 11 only)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, urinalysis, and a urine pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (Visit 9 and 11) (for subjects ≥12 years of age)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 225 of 274 • QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (f or subjects <18 years of age) (Visit 9  
and 11  only)  
• Achenbach CBCL for subjects <18 years of age  (Visit 9 and 11 only)  
• BRIEF for subjects <18 years of age  (Visit 9 and 11 only)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help fr om a caregiver  due to epi[INVESTIGATOR_261473]:  
8.1.3  Visits 9 and 11 (Weeks 62 and 94, Year 2, excluding Visit 10 ) 
The following tasks and procedures are to be performed at these visits:  
• Concomitant medications and AEDs   
• Physical examination (brief, Visit 9; complete, Visit 11)  
• Neurological examination (brief, Visit 9; complete, Visit 11)  
• ECG (12 -lead) assessment (Visit 9, and 11)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight and height (height at Visit 9 only)  
• Tanner stag ing (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 11 only)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (include s hematology, 
chemistry, urinalysis, and a urine pregnancy test [for women of childbearing potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• EQ-5D-3L (Visit 9 a nd 11) (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age) (Visit 9  
and 11  only)  
• Achenbach CBCL for subjects <18 years of age  (Visit 9 and 11 only)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 226 of 274 • BRIEF for subjects <18 years of age  (Visit 9 a nd 11 only)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_261468] #20  
Section 8.1.4  Visits 12, 13, 14, 15, 16, and 17 (Weeks 118, 142, 166, 190, 
214, and 238, Years 3 to 5)  
This section has been split into two - [IP_ADDRESS] and [IP_ADDRESS]  
[IP_ADDRESS] Subjects <18 years  
The following tasks and procedures are to be performed at these visits:  
• Concomitant medications and AEDs  
• Physical examination (complete, Visit 13, 15, and 17)  
• Neurological examination (br ief, Visit 12, 14, and 16)  
• ECG (12 -lead) assessment (Visit 13, 15, and 17)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight and height (height at Visit 12, 14, and 16)  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 13, 15, and 17)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and urinalysis) ( laboratory tests are applicable for combined Visit 17/Termination 
Visit. If Visit 17 is not the Termination Visit, laboratory tests are not required). Laboratory 
tests are not performed at Visit 13 and Visit 15 according to Protocol Amendment 3.  
• Urine preg nancy test (for women of childbearing potential)  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• Achenbach CBCL for subjects ≥6 years to <18 years of age (Visit 13, 15, a nd 17)  
• BRIEF for subjects ≥5 to <18 years of age (Visit 13, 15, and 17)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 227 of 274 [IP_ADDRESS] Subjects ≥18 years  
• The following tasks and procedures are to be performed at these visits:  
• Concomitant medications and AEDs  
• Blood and urine samples for clinical laboratory asse ssments (includes hematology, 
chemistry, and urinalysis) (laboratory tests are applicable for combined Visit 17/Termination 
Visit. If Visit 17 is not the Termination Visit, laboratory tests are not required. Laboratory 
tests are not performed at Visit 13 a nd Visit 15 according to Protocol Amendment 3.  
• Urine pregnancy test (for women of childbearing potential)  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
Change #[ADDRESS_318126]  
Telephone contacts are required every 8 weeks during Year 2 to Year 5, except during weeks in 
which a clinic visit is planned (eg, Week 62). Therefore, telephone contacts in Year 2 are 
scheduled for Week 54, Week 70, and Wee k 86. Telephone contacts in Years 3 to 5 are 
scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 
158, Week 174, Week 182; Year 5 - Week 198, Week 206, Week 222, and Week 230.  
Has been changed to:  
Telephone contacts are r equired at Week 30 and Week 38 and every 8 weeks during Year 2 to 
Year 5, except during weeks in which a clinic visit is planned (eg, Week 62). Therefore, 
telephone contacts in Year 2 are scheduled for Week 54, Week 70, and Week 86. Telephone 
contacts in Y ears 3 to 5 are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; 
Year 4 - Week 150, Week 158, Week 174, Week 182; Year 5 - Week 198, Week 206, Week 222, 
and Week 230.  
Change #22  
Section 8.2 Early Termination Visit  
This section has been updat ed to indicate the tasks and procedures which exclude subjects ≥18 
years.  
The following tasks and procedures are to be performed at this visit:  
• Concomitant medications and AEDs  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 228 of 274 • Physical examination (complete)  
• Neurological examination (brief)  
• ECG (12 -lead) assessment  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight and height  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study)  
• C-SSRS a ssessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology for subjects <[ADDRESS_318127] [for women of childbearing  potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• Achenbach CBCL for subjects <18 years of age  
• BRIEF for subjects <[ADDRESS_318128] 2 years (see Section 4.2.3 ): 
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_261473]: 
The following tasks and procedures are to be performed at this visit:  
• Concomitant medications and AEDs  
• Physical examination (complete) excluding subjects ≥[ADDRESS_318129] 2 years  
• Neurological examination (brief) excluding subjects ≥[ADDRESS_318130] 2 years  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 229 of 274 • ECG (12 -lead) assessment excluding subjects ≥[ADDRESS_318131] 2 years  
• Vital signs ( pulse rate, BP) including orthostatic assessments excluding subjects ≥[ADDRESS_318132] 2 years  
• Body weight and height excluding subjects ≥[ADDRESS_318133] 2 years  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) excluding subjects ≥[ADDRESS_318134] 2 
years  
• C-SSRS assessment (for sub jects ≥6  years of age) excluding subjects ≥[ADDRESS_318135] 
2 years  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology for subjects <[ADDRESS_318136] [for women of childbearing potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• Achenbach CBCL for subjects <18 years of age  
• BRIEF for subjects <[ADDRESS_318137] 2 years (see Section 4.2.3 ): 
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_261468] #23  
Section 8.3 Termination Visit  
This section has been updated to indicate the tasks and procedures which exclude subjects 
≥18 years.  
The following tasks and procedures are to be performed at this visit:  
• Concomitant medications and AEDs  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 230 of 274 • Physical examination ( complete)  
• Neurological examination (complete) Note: Complete neurological exam to be performed for 
patients terminating the study during Years 1 -2, brief exam for patients terminating during 
Years 3 -5. 
• ECG (12 -lead) assessment  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight and height  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study)  (excluding subjects ≥18 years)  
• C-SSRS assessment (for subjects ≥6 years of age) (excluding subjects ≥18 years)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology for subjects <[ADDRESS_318138] [for women of childb earing potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary for subjects undergoing taper  
• Subject diary return/review  
• Dispense LCM for subjects undergoing taper  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• Achenbach CBCL for subjects <18 years of ag e 
• BRIEF for subjects <[ADDRESS_318139] 2 years (see Section 4.2.3 ): 
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_261474] a caregiver  due to epi[INVESTIGATOR_261473]:  
The following tasks and procedures are to be performed at this visit:  
• Concomitant medications and AEDs  
• Physical examination (complete)  excluding subjects ≥[ADDRESS_318140] 2 years  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 231 of 274 • Neurological examination (complete) Note: Complete neurological exam to be performed for 
patients terminating the study during Years 1 -2 for all subjects and brief exam for subjects 
<18 years terminating during Years 3 -5 (excluding subjects ≥18 years). Ne urological exam is 
excluded for subjects ≥[ADDRESS_318141] 2 years.  
• ECG (12 -lead) assessment excluding subjects ≥[ADDRESS_318142] 2 years  
• Vital signs ( pulse rate, BP) including orthostatic assessments excluding subjects ≥[ADDRESS_318143] 2 years  
• Body weight and height excluding subjects ≥[ADDRESS_318144] 2 years  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study)  excluding subjects ≥[ADDRESS_318145] 2 
years  
• C-SSRS assessment (for subjects ≥6  years of age) excluding subjects ≥[ADDRESS_318146] 
2 years  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, endocrinology for subjects <[ADDRESS_318147] [for women of childbearing potential])  
• Contact [CONTACT_12067]  
• Dispense subject diary for subjects undergoing taper  
• Subject diary return/review  
• Dispense LCM for subjects undergoing taper  
• LCM review/return  
• Asses s withdrawal criteria  
• AE reporting  
• Achenbach CBCL for subjects <18 years of age  
• BRIEF for subjects <[ADDRESS_318148] 2 years (see Sect ion 4.2.3 ): 
• EQ-5D-3L (for subjects ≥12 years of age)  
• QOLIE -31-P (for subjects ≥18 years of age)/PedsQL (for subjects <18 years of age)  
• Healthcare resource use  
• Work/school days lost due to epi[INVESTIGATOR_002]  
• Days with help from a caregiver  due to epi[INVESTIGATOR_261468] #24  
Section 8.4.1  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 232 of 274 The following sentence has been added at the end of the section:  
Subjects who were already tapered in SP0982 after the 125th event occurred do not need to 
undergo the End of Taper Visit assessments in EP0012 as the assessments were performed in 
SP0982.  
Change #[ADDRESS_318149] dose of study drug 
for a Safety Follow -Up Visit.  During the Safety Follow -Up Visit, the following assessments will 
be performed:  
Has been changed to:  
Following the End of Taper Visit, the subject will return [ADDRESS_318150] dose of study drug  
for a Safety Follow -Up Visit (including s ubjects tapered in SP0982 after the 125th event occurs 
who enter EP0012 only for a Safety Follow -Up Visit) . During the Safety Follow -Up Visit, the 
following assessments will be performed:  
Change #26  
Section 8.5 Uns cheduled Visit  
This section has been updated to indicate the tasks and procedures which exclude subjects ≥18 
years.  
During an Unscheduled Visit the following assessments are required:  
• Concomitant medications and AEDs   
• Physical examination (brief) during th e first 2 years  
• Neurological examination (brief) during the first 2 years  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Contact [CONTACT_12067]  
• Subject diary return/review  
• Assess withdrawal criteria  
• AE reporting  
Has been changed to:  
During an Unsche duled Visit the following assessments are required:  
• Concomitant medications and AEDs   
• Physical examination (brief) during the first 2 years ≥[ADDRESS_318151] 2 years  
• Neurological examination (brief) during the first 2 years ≥[ADDRESS_318152] 2 years  
• Vital signs ( pulse rate, BP) including orthostatic assessments ≥[ADDRESS_318153] 2 years  
• Contact [CONTACT_261554].
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 233 of 274 • Subject diary return/review  
• Assess withdrawal criteria  
• AE reporting  
Change #[ADDRESS_318154] ≥3xULN WITH Symptoms of hepatitis or hypersensitivity row  
Immediate, temporary or permanent, IMP discontinuation.  
Has been changed to:  
Immediate, permanent IMP discontinu ation.  
16.7 Appendix 7: Protocol Amendment [ADDRESS_318155] instance in US, EU, and Japan.  
Modifications and changes  
Global changes  
The following changes were made throughout the protocol:  
• Globally changed PGTC seizures to PGTCS.  
Specific changes  
Change #1  
Title page:  
The title was updated from “Protocol EP0012 Amendment  3” to “Protocol EP0012 
Amendment  4.” 
The information below was revised to include Protocol Amendment 4 and the type of protocol 
amendment:  
Protocol/Amendment Number  Date  Type of amendment  
Final Protoco l [ADDRESS_318156] 2012  Not applicable  
Protocol Amendment 1  27 Jan 2015  Substantial  
Protocol Amendment 2  09 Jun 2016  Substantial  
Protocol Amendment 3  29 Nov 2017  Substantial  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 234 of 274 Has been changed to:  
Protocol/Amendment Number  Date  Type of amendment  
Final Protocol  [ADDRESS_318157] 2012  Not applicable  
Protocol Amendment 1  27 Jan 2015  Substantial  
Protocol Amendment 2  09 Jun 2016  Substantial  
Protocol Amendment 3  29 Nov 2017  Substantial  
Protocol Amendment 4  13 Dec 2019  Substantial  
 
Change #[ADDRESS_318158] 2 years and consists  of a Treatment Period, an up to 4 -week Taper 
Period, and a 30 -day Safety Follow -Up Period. During the Treatment Period, Visit 2 will occur 
2 weeks after Visit 1, and Visit 3 will occur 4  weeks later (Week 6). Clinical visits will then 
occur every [ADDRESS_318159] year, and every 16 weeks in the second year. For subjects who 
continue in the study after Year 2, visits will occur every 24 weeks thereafter until the end of the 
study. From Year 3 onwards, pedia tric subjects weighing <50kg will return to the clinic for an 
additional Dispensation Visit 12 weeks after each 24 -weekly visit, for the dispensation of LCM 
solution; LCM usage will be reviewed and empty LCM bottles will be returned.  
Has been changed to:  
EP0012 will consist of a Treatment Period, an up to 4 -week Taper Period, and a 30 -day Safety 
Follow -Up Period. During the Treatment Period, Visit 2 will occur 2  weeks after Visit 1, and 
Visit 3 will occur 4  weeks later (Week 6). Clinical visits will then o ccur every [ADDRESS_318160] year, and every 16 weeks in the second year. For subjects who continue in the study after 
Year 2, visits will occur every 24 weeks thereafter until the end of the study. From Year 2 (Visit 
11) to 3 onwards, pediatric subjec ts weighing <50kg will return to the clinic for an additional 
Dispensation Visit 12 weeks after each 24 -weekly visit, for the dispensation of LCM solution; 
LCM usage will be reviewed, and empty LCM bottles will be returned.  
Change #3  
Section 4.1.1  Primary safety variables  
The primary safety variables are:  
• Adverse events as reported spontaneously by [CONTACT_3184]/or caregiver or observed by [CONTACT_1275]  
• Subject withdrawals due to AEs  
• Incidence of new seizure types during the Treatment Period  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 235 of 274 • Subjects w ith an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days with 
absence seizures per 28 days during the Treatment Period as compared to the Prospective 
Baseline  
• Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in day s with 
myoclonic seizures per 28 days during the Treatment Period as compared to the Prospective 
Baseline  
Has been changed to:  
The primary safety variables are:  
• Adverse events as reported spontaneously by [CONTACT_3184]/or caregiver or observed by [CONTACT_1275]  
• Subject withdrawals due to AEs  
• Incidence of new appearance of absence and/or myoclonic seizures during the Treatment 
Period  
• Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days with 
absence seizures per 28 days compa red to the Prospective Baseline  
• Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days with 
myoclonic seizures per 28 days compared to the Prospective Baseline  
• Percentage of subjects with at least 50% worsening in days with abse nce seizures  
• Percentage of subjects with at least 50% worsening in days with myoclonic seizures  
Change #[ADDRESS_318161] udy completers from SP0982 who are eligible for inclusion in EP0012 are defined 
as: 
 
SP0982 Baseline failures  
• Subjects who complete the Prospective Baseline Period of SP0982 and meet all entry criteria 
except the minimum PGTC seizure criteria required for randomization (Baseline failures)  
Randomized subjects meeting SP0982 exit criteria  
• Subjects who completed the first 6 weeks of the Treatment Period (after randomization) of 
SP0982 and experienced ≥[ADDRESS_318162] 6 weeks of the Treatment Period 
of SP0982  
SP0982 completers  
• Subjects who experience <2 PGTC seizures within the 24 -week Treatment Period of SP0982  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 236 of 274 • Subjects who were ongoing in SP0982 when the 125th event occurred  
SP0982 Safety Follow -Up subjects  
• Subjects tapered in SP0982 after the 125th event occ urs will enter EP0012 for the Safety 
Follow -Up Visit only.  
Has been changed to:  
For the purposes of this study, Baseline failures, randomized subjects who meet SP0982 exit 
criteria, study completers from SP0982 who are eligible for inclusion in EP0012, SP 0982 Safety 
Follow -Up subjects, and Other are defined as:  
SP0982 Baseline failures  
• Subjects who complete the Prospective Baseline Period of SP0982 and meet all entry criteria 
except the minimum PGTCS criteria required for randomization (Baseline failures)  
Randomized subjects meeting SP0982 exit criteria  
• Subjects who completed the first 6 weeks of the Treatment Period (after randomization) of 
SP0982 and experienced ≥[ADDRESS_318163] 6 weeks of the Treatment Period of 
SP0982  
SP0982 completers  
• Subjects who experience <2 PGTCS within the 24 -week Treatment Period of SP0982  
• Subjects who were ongoing in SP0982 when the 125th event occurred  
SP0982 Safety Follow -Up subjects  
• Subjects tapered in SP098 2 after the 125th event occurs will enter EP0012 for the Safety 
Follow -Up Visit only  
Other  
• Subjects that enrolled in EP0012 that did not fall into the above categories  
Change #[ADDRESS_318164] 2 years and consists  of a Treatment Period, an up to 4 -week Taper 
Period, and a 30 -day Safety Follow -Up Period. Visit 1 of EP0012 is the same as the Final Clinic 
Visit of SP0982 for completers and subjects who meet the SP0982 exit criteria. Eligible Baseline  
failures from SP0982 who choose to enter this study will undergo a complete Visit 1. Visit 2 will 
occur 2 weeks after Visit 1, and Visit  3 will occur 4  weeks later (Week 6). Clinic visits will then 
occur every [ADDRESS_318165] year, and every 16 week s in the second year. For subjects who 
continue in the study after Year 2, visits will occur every 24 weeks thereafter until the end of the 
study. From Year 3 onwards, pediatric subjects weighing <50kg will return to the clinic for an 
additional Dispensati on Visit 12 weeks after each 24 -weekly visit, for the dispensation of LCM 
solution; LCM usage will be reviewed and empty LCM bottles will be returned.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318166]’s country for the treatment 
of PGTC seizures in subjects w ith IGE, or until UCB has determined that the clinical 
development program for the indication will be formally discontinued, or until UCB decides to 
close the study.  
Have been changed to:  
EP0012 will last at least [ADDRESS_318167] of a Treatment Period,  an up to 4 -week Taper 
Period, and a 30 -day Safety Follow -Up Period. Visit 1 of EP0012 is the same as the Final Clinic 
Visit of SP0982 for completers and subjects who meet the SP0982 exit criteria. Eligible Baseline 
failures from SP0982 who choose to enter  this study will undergo a complete Visit 1. Visit 2 will 
occur 2 weeks after Visit 1 and Visit  3 will occur 4  weeks later (Week 6). Clinic visits will then 
occur every [ADDRESS_318168] year, and every 16 weeks in the second year. For subjects who 
continue in the study after Year 2, visits will occur every 24 weeks thereafter until the end of the 
study. From Year 2 (Visit 11) to 3 onwards, pediatric subjects weighing <50kg will return to the 
clinic for an additional Dispensation Visit 12 weeks after ea ch 24 -weekly visit, for the 
dispensation of LCM solution; LCM usage will be reviewed, and empty LCM bottles will be 
returned.  
A telephone contact [CONTACT_18378] 8  weeks if no clinic visit is scheduled. Telephone contacts 
will be used to obtain informati on regarding concomitant medication use, and assess withdrawal 
criteria and AEs, as well as to ensure subjects are compliant with LCM administration and diary 
completion.  
Change #[ADDRESS_318169] 
and/or their parent(s)/legal representative(s) to best manage the subject’s epi[INVESTIGATOR_002]. Taper of 
LCM may not be required for some subjects who complete the study depending on the treatment 
option selected by [CONTACT_207259]/or their parent(s)/legal 
representative(s).  
Has been changed to:  
At the completion of the study, investigators should discuss treatment options with the subject 
and/or their parent(s)/le gal representative(s) to best manage the subject’s epi[INVESTIGATOR_002]. Taper of 
LCM (Taper Visit and SFU) may not be required for some subjects who leave the study 
depending on the treatment option selected by [CONTACT_261555]/or  their parent(s)/legal representative(s).  
Change #[ADDRESS_318170]’s country for the treatment of PGTC seizures in subjects with IGE, or until UCB has 
determined that the clinical development program for the indication will be formally 
discontinued, or until the sponsor decides to close the study . It is anticipated that at least [ADDRESS_318171]’s country at the time the sponsor closes the study, access to LCM 
will be provided according to local laws . 
The following study periods are defined:  
• A Treatment Period lasting at least 2 years . 
• An up to 4 -week Taper Period and a 30 -day Safety Follow -Up Period.  
− Subjects continuing LCM treatment with commercially available LCM will transition to a 
dose determined by [CONTACT_093] . 
− Subjects tapering o ff LCM will do so over a period of up to 4 weeks (see taper schedule, 
Table 7‒2). 
− An End of Taper Visit will occur after the final LCM dose for subject s who taper off 
LCM. Following the End of Taper Visit, there will be a [ADDRESS_318172] visit/telephone contact [CONTACT_261556].  
Depending on the local regulations, after 2 years, subjects may continue to receive LCM in  a 
managed access program (MAP).  
Has been changed to:  
For adult subjects, treatment will continue for at least 2 years.  Once 2 years of participation are 
reached, adult subjects will continue to participate until 1 of the 2 following conditions are met.  
• LCM is approved for use for the treatment of PGTCS in subjects with IGE in the subject’s 
country for or until the latest approval is granted either by [CONTACT_16096], FDA, or PMDA.  
• For pediatric subjects, treatment will continue until the latest of 1 of the followin g 
2 conditions  are met:  
− up to 5 years of participation or  
− until the latest approval is granted either by [CONTACT_16096], FDA, or PMDA  
Adult and pediatric subjects are completers if they continue in the study for the maximum 
duration in their respective region.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 239 of 274 The following study periods are defined:  
• A Treatment Period lasting for at least 5 years (238 weeks) for the population less than 
18 years old at enrollment and will be shorter for adults leaving the study when the PGTCS 
indication approvals are being obtained during the course of the study.  
• An up to 4 -week Taper Period and a 30 -day Safety Follow -Up Period.  
− Subjects continuing LCM treatment with commercially available LCM will transition to a 
dose determined by [CONTACT_261484] (Taper Visit 
and SFU).  
− Subje cts tapering off LCM will do so over a period of up to 4 weeks (see taper schedule, 
Table 7‒2). 
− An End of Taper Visit (latest 3 days after the final do se) will occur after the final LCM 
dose for subjects who taper off LCM. Following the End of Taper Visit, there will be a 
30-day Safety Follow -Up Period. The Safety Follow -Up Period consists of a clinic visit [ADDRESS_318173] visit/telephone contact [CONTACT_261556].  
Subjects who entered EP0012 as <18 year s and become adults (≥18 years) during the study, will 
remain in the study for at least 5 years (238 weeks).  
Change #8  
Section 5.2  Schedule of study assessments  
Table 5 -1 Schedule of study assessments for Years 1 and 2 for EP0012 (Treatment Period, ET 
Visit, Termination Visit, and Unscheduled Visit)  
Footnote ‘a’  
The Treatment Period will continue for at least 2 years.  
Footnote ‘e’  
An ET Visit must be completed for all subjects who prematurely discontinue from the study. 
This will be followed by [CONTACT_261486], an End of Taper Visit, and a Safety Follow -Up Period; see 
Table  5-4. 
Has been changed to:  
Footnote ‘a’  
The duration of the Treatment Period will continue for at least [ADDRESS_318174] age 
group and is defined in Section 5.1.1 . 
Footnote ‘e’  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318175] be completed for all subjects who prematurely discontinue from the study. 
This will be followed by [CONTACT_261486], an End of Taper Visit, and a Safety Follow -Up Period; s ee 
Table  5-4. For subjects who continue on commercial LCM, the early Termination Visit is the last 
visit in the study.   
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 241 of 274 Change #9  
Section 5.2  Schedule of study assessments  
Table  5‒2: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, Termination 
Visit, and Unscheduled Visit for subjects <18  years)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5     
Visitc TCd V12 V13 V14 V15 V16 V17/ 
Terme ET Visitf Term  Visitg LCM Solution 
Dispensation Visith Unscheduled 
Visit  
Week   118 142 166 190 214 238    NA 
Concomitant medications and 
AED(s)  X X X X X X X X X  X 
Physical exam (complete)i   X  X  X X X   
Neurological exam (brief)j  X  X  X   X   
12-lead ECGk   X  X  X X X   
Vital signs (BP and pulse)  including 
orthostatic assessmentsl  X X X X X X X X  X 
Body weight and heightm  X X X X X X X X   
Tanner Stagen   X  X  X X X   
Laboratory tests   X  X  X Xo X X   
Endocrinologyp        X X   
Pregnancy testq  X X X X X X X X   
Call IRT  X X X X X X X X  X 
C-SSRSr  X X X X X X X X  X 
Dispense subject diary   X X X X X X X X   
Subject diary return/review   X X X X X X X X  X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 242 of 274 Table  5‒2: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, Termination 
Visit, and Unscheduled Visit for subjects <18  years)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5     
Visitc TCd V12 V13 V14 V15 V16 V17/ 
Terme ET Visitf Term  Visitg LCM Solution 
Dispensation Visith Unscheduled 
Visit  
Week   118 142 166 190 214 238    NA 
Dispense LCM   X X X X X X X X X  
LCM review/return   X X X X X X X X X  
Withdrawal criteria  X X X X X X X X X  X 
AE reporting  X X X X X X X X X  X 
Achenbach CBCLs   X  X  X X X   
BRIEFt   X  X  X X X   
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; BP=blood pressure; BRIEF=Behavior Rating Inventory of Executive Function; BRIEF -P=Behavior Rating 
Inventory of Executive Function -Preschool Version; CBCL=Child Behavior Checklist; C -SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; ET=early termination; exam=examination; IRT=interactive response technology; LCM =lacosamide; NA=not applicable; 
Term=Termination; V=Visit  
Note: Subjects who turn [ADDRESS_318176] 2 years.  
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of th e investigator. In addition to the 
required assessments listed above, depending o n the type of visit (clinic or telephone), further assessments can be completed as needed and may include 
physical or neurological examination, ECG, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to a psychiatric AE.  
c A window of ±[ADDRESS_318177] every 8 weeks if no clinic 
visit is scheduled.  
d Telephone contacts are required every 8 weeks during the study. Telephone conta cts are not required during weeks in which a clinic visit is planned 
(eg, Week 118). Therefore, telephone contacts are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 158, 
Week 174, Week 182; Year [ADDRESS_318178] and/or legal representative t o best manage the subject's 
epi[INVESTIGATOR_002].  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318179] be completed for all subjects who prematurely disco ntinue from the study. This will be followed by [CONTACT_261486], an End of Taper Visit, and 
a Safety Follow -Up Period; see Table  5-4. 
g A Termination Visit must be completed for all subjects who complete the study. This can be combined with Visit 17 if appropriate. For subjects who wil l not 
continue on LCM, this visit will be followed by [CONTACT_261486], an End of Taper Visit, and a Safety Follow -Up Period; see Table  5-4. For subjects who continue 
on LCM, the Termination Visit is the last visit in the study.  
h Dispensation Visit will occur 12 weeks after each 24 -weekly vi sit from Year 2 (Visit 11) to Year 3 onwards and will be for the purpose of dispensing LCM 
solution for pediatric subjects <50kg.  
i The complete physical examination will include cardiac and respi[INVESTIGATOR_261401]. 
j The brief neurological examination will include selected assessment of general neurological status, reflexes, muscle strength , and coordination/cerebellar 
function.  
k The ECG recordings should be performed at the same time of day (when possible) and prior  to blood sample collection and vital sign assessments. Care 
should be taken to assure proper lead placement and quality ECG recordings. If possible, subjects should rest in a supi[INVESTIGATOR_261402] 5 minutes prior to 
each recording and should be motionl ess during the recording. In pediatric subjects (<18 years of age) a 12 -lead ECG (2  interpretable recordings) 
approximately [ADDRESS_318180] be performed.  
l Blood pressure measurements should be taken with the proper placement and proper sized cuf f to obtain accurate measurements.  
m Height will be recorded at Visits 12, 14, and 16, and at the ET and Termination Visit.  
n The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who enter puberty during the course of t he study.  
o Laboratory tests are applicable for combined Visit 17/Termination Visit. If Visit 17 is not the Termination Visit, laboratory  tests are not required.  
p If the patient was treated in SP0982, endocrinology should be done if age was <18 years at SP0982 Visit 1 . If the patient was a Baseline failure in SP0982, 
endocrinology should be done if age is <18 years at EP0012 Visit 1.  
q Pregnancy tests will be performed for female subjects of childbearing potential only. Serum pregnancy tests will be conducted  at the foll owing visits: Visit 1 
(W0), ET, and Termination Visit. All other pregnancy tests will be urine dipstick. Baseline failures from SP0982 may have an additional urine pregnancy 
test at V1 of EP0012, at the investigator’s discretion.  
r The C -SSRS will be complet ed for all subjects ≥6 years of age (see Section 10.4.3 ).  
s The Achenbach CBCL: CBCL/6 -18 for children ≥6 years to <18 years of age; to be completed b y the parent(s)/legal representative(s) (estimated completion 
time 45 minutes). For each version of the CBCL, subjects must have at least 1 year of data before transitioning to the next a ge range. The Achenbach CBCL 
should be completed by [CONTACT_261487]/l egal representative, if possible (see Section 10.4.6 ).  
t The BRIEF should be used for subjects who are ≥[ADDRESS_318181] 
1 year of data before transitioning to  the next age range (see Section  10.4.7 ). 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 244 of 274 Has been changed to:  
Table  5‒2: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit for subjects <18  years at enrollment)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5 + Extended 
Period     
Visitc TCd V12 V13 V14 V15 V16 V17 Vxf ET Visitg Term  Visith LCM Solution 
Dispensation Visiti Unscheduled 
Visit  
Week   118 142 166 190 214 238 X    NA 
Concomitant medications and 
AED(s)  X X X X X X X X X X  X 
Physical exam (complete)j   X  X  X X (odd 
visits only)  X X   
Neurological exam (brief)k  X  X  X X X (even 
visit only)   X   
12-lead ECGl   X  X  X X (odd 
visits only)  X X   
Vital signs (BP and pulse)  
including orthostatic 
assessmentsm  X X X X X X X X X  X 
Body weight and heightn  X X X X X X X (even 
visits only)  X X   
Tanner Stageo   X  X  X X (odd 
visits only)  X X   
Laboratory tests   X  X  X Xp Xp X X   
Endocrinologyq         X X   
Pregnancy testr  X X X X X X X X X   
Call IRT  X X X X X X X X X  X 
C-SSRSs  X X X X X X X X X  X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318182] diary return/review   X X X X X X X X X  X 
Dispense LCM   X X X X X X X X X X  
LCM review/return   X X X X X X X X X X  
Withdrawal criteria  X X X X X X X X X X  X 
AE reporting  X X X X X X X X X X  X 
Achenbach CBCLt   X  X  X X (odd 
visits only)  X X   
BRIEFu   X  X  X X (odd 
visits only)  X X   
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; BP=blood pressure; BRIEF=Behavior Rating Inventory of Executive Function; BRIEF -P=Behavior Rating 
Inventory of Executive Function -Preschool Version; CBCL=Child Behavior Checklist; C -SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; ET=early termination; exam=examination; IRT=interactive response technology; LCM=lacosamide; NA=not ap plicable; 
Term=Termination; V=Visit; Vx=Visit X  
Note: Subjects who turn [ADDRESS_318183] age group and is defined in Section 5.1.1 . 
b Unscheduled Visits may be performed at any time a fter Visit 1 as clinic visits or telephone contacts, at the discretion of the investigator. In addition to the 
required assessments listed above, depending on the type of visit (clinic or telephone), further assessments can be completed  as needed and may i nclude 
physical or neurological examination, ECG, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to a psychiatric AE.  
c A window of ±[ADDRESS_318184] every 8 weeks if no 
clinic visit is scheduled.  
d Telephone contacts are required every 8 weeks during the study. Telephone contacts are not required during weeks in which a c linic visit is planned 
(eg, Week 118). Therefore, tel ephone contacts are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 158, 
Week 174, Week 182; Year [ADDRESS_318185] and/or legal representative t o best manage the subject's 
epi[INVESTIGATOR_002].  
f Subjects may require additional routine visits (Visit X) if the study is still ongoing at Week [ADDRESS_318186]. Vx visits are to be performed 
every 24 weeks. Additional routine visits should be scheduled and performed in accordance with footnote ‘b’ to avoid visit wi ndow deviations. 
Assessments must be performed in accordance with Table  5‒3. 
g An ET Visit must be completed for all subjects who prematurely discontinue from the study. This will be followed by [CONTACT_261486] , an End of Taper Visit, 
and a Safety Follow -Up Period; see Table  5-4. For subjects who continue on commercial LCM, the early Termination Visit is the last visit in the study.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318187] scheduled visit 
if appropriate. For subjects who will not continue on LCM, this visit will be followed by [CONTACT_261486], an End of Taper Visit, a nd a Safety Follow -Up 
Period; see Table  5-4. For subjects who continue on LCM, the Termination Visit is the last visit in the study.  
i Dispensation Visit will occur 12 weeks after each 24 -weekly visit from Year 2 (Visit 11) to Year 3 onwar ds and will be for the purpose of dispensing 
LCM solution for pediatric subjects <50kg.  
j The complete physical examination will include cardiac and respi[INVESTIGATOR_261401]. 
k The brief neurological examination will  include selected assessment of general neurological status, reflexes, muscle strength, and coordination/cerebellar 
function.  
l The ECG recordings should be performed at the same time of day (when possible) and prior to blood sample collection and vital  sign assessments. Care 
should be taken to assure proper lead placement and quality ECG recordings. If possible, subjects should rest in a supi[INVESTIGATOR_261402] 5 minutes prior 
to each recording and should be motionless during the recording. In pediatric sub jects (<18 years of age) a 12 -lead ECG (2  interpretable recordings) 
approximately [ADDRESS_318188] be performed.  
m Blood pressure measurements should be taken with the proper placement and proper sized cuff to obtain accurate measurements.  
n Height will be recorded at Visits 12, 14, 16, Visit X (even visits), and at the ET and Termination Visit.  
o The Tanner Stage will be performed only for subjects who are pubescent at Visit [ADDRESS_318189] scheduled visit/Termination Visit. If the last scheduled visit is not the Termination Visit, laboratory 
tests are not required.  
q If the patient was treated in SP0982, endocrinology should be done if age was <18 years at SP098 2 Visit 1. If the patient was a Baseline failure in SP0982, 
endocrinology should be done if age is <18 years at EP0012 Visit 1.  
r Pregnancy tests will be performed for female subjects of childbearing potential only. Serum pregnancy tests will be conducted  at the following visits: 
Visit 1 (W0), ET, and Termination Visit. All other pregnancy tests will be urine dipstick. Baseline failures from SP0982 may have an additional urine 
pregnancy test at V1 of EP0012, at the investigator’s discretion.  
s The C -SSRS will b e completed for all subjects ≥6 years of age (see Section 10.4.3 ).  
t The Achenbach CBCL: CBCL/6 -18 for children ≥6 years to <18 years of age; to be c ompleted by [CONTACT_7071](s)/legal representative(s) (estimated 
completion time 45 minutes). For each version of the CBCL, subjects must have at least 1 year of data before transitioning to  the next age range. The 
Achenbach CBCL should be completed by [CONTACT_105332] e parent/legal representative, if possible (see Section 10.4.6 ).  
u The BRIEF should be used for subjects who are ≥[ADDRESS_318190] 
1 year of data before transitioning to the next age range (see Section  10.4.7 ). 
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 247 of 274  
Table 5 -3: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, Termination Visit, 
and Unscheduled Visit for subjects ≥18  years)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of study  Year 3  Year 4  Year 5     
Visitc TCd V12 V13 V14 V15 V16 V17/ 
Terme ET Visitf Term  Visitg LCM Solution Dispensation 
Visit  Unscheduled 
Visit  
Week   118 142 166 190 214 238    NA 
Concomitant medications and 
AED(s)  X X X X X X X X X  X 
Laboratory testsh  X  X  X X X X   
Pregnancy testi  X X X X X X X X   
Dispense subject diary   X X X X X X X X   
Subject diary return/review   X X X X X X X X  X 
Call IRT  X X X X X X X X  X 
Dispense LCM   X X X X X X X X X  
LCM review/return   X X X X X X X X X  
Withdrawal criteria  X X X X X X X X X  X 
AE reporting  X X X X X X X X X  X 
AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ET=early termination; IRT=interactive 
response technology; LCM=lacosamide; NA=not applicable; Term=Termination; V=Visit  
a The Treatment Period will continue for at least 2 years.  
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of th e investigator. In addition to the 
required assessments listed above, depending on the type of visit (clinic or telephone), further assessments can be completed as needed and may include 
physical or neurological examination, ECG, vital signs, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due to a psychiatric 
AE. 
c A window of ±[ADDRESS_318191] every 8 we eks if no clinic 
visit is scheduled.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 248 of 274 d Telephone contacts are required every 8 weeks during the study. Telephone contacts are not req uired during weeks in which a clinic visit is planned (eg, 
Week 118). Therefore, telephone contacts are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 158, Week 
174, Week 182; Year [ADDRESS_318192] and/or legal representative t o best manage the subject's 
epi[INVESTIGATOR_002].  
f An ET Visit must be completed for all subjects who prematurely discontinue from the  study. This will be followed by [CONTACT_261486], an End of Taper Visit, and 
a Safety Follow -Up Period; see Table  5-4. 
g A Termination Visit must be completed for all subjects who complete the study. This can be combined with Visit 17 if appropri ate. For subjects who will not 
continue on LCM, this visit will be  followed by [CONTACT_261486], an End of Taper Visit, and a Safety Follow -Up Period; see Table  5-4. For subjects who continue 
on LCM, the Termination Visit is th e last visit in the study.  
h Laboratory tests include chemistry, hematology and, urinalysis.  
i Pregnancy tests will be performed for female subjects of childbearing potential only. Serum pregnancy tests will be conducted  at the following visits: Visit 1 
(W0),  ET, and Termination Visit. All other pregnancy tests will be urine dipstick. Baseline failures from SP0982 may have an additi onal urine pregnancy 
test at V1 of EP0012, at the investigator’s discretion.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 249 of 274  Has been changed to:  
Table 5 -3: Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment Period, ET Visit, 
Termination Visit, and Unscheduled Visit for subjects ≥18  years)  
 Treatment perioda End of Study period   Unscheduledb 
Duration  Open -label: up to approximately 5 years  Up to 5 weeks    
Year of 
study  Year 3  Year 4  Year 5 +Extended Period     
Visitc TCd V12 V13 V14 V15 V16 V17e Vxe ET Visitf Term  Visitg LCM 
Solution 
Dispensati
on Visit  Unscheduled 
Visit  
Week   118 142 166 190 214 238 X    NA 
Concomitant 
medications 
and AED(s)  X X X X X X X X X X  X 
Laboratory 
testsh  X  X  X X X X X   
Pregnancy 
testi  X X X X X X X X X   
Dispense 
subject diary   X X X X X X X X X   
Subject diary 
return/review   X X X X X X X X X  X 
Call IRT  X X X X X X Xe X X  X 
Dispense 
LCM   X X X X X X X X X X  
LCM 
review/return   X X X X X X X X X X  
Withdrawal 
criteria  X X X X X X X X X X  X 
AE reporting  X X X X X X X X X X  X 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 250 of 274 AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ET=early termination; 
IRT=interactive response technology; LCM=lacosamide; NA=not applicable; Term=Termination; V=Visit; Vx=Visit X  
a The duration of the Treatment Period will vary by [CONTACT_261488] 5.1.1 . 
b Unscheduled Visits may be performed at any time after Visit 1 as clinic visits or telephone contacts, at the discretion of th e investigator. In addition to 
the required assessments listed above, depending on the type of visit (clinic or telephone), further assessments can be completed as needed and may 
include physical or neurological examination, ECG, vital signs, laboratory tests, etc. The C -SSRS must be performed if the Unscheduled Visit is due  to 
a psychiatric AE.  
c A window of ±[ADDRESS_318193] every 8 weeks if no 
clinic visit is scheduled.  
d Telephone contacts are required every 8 weeks during th e study. Telephone contacts are not required during weeks in which a clinic visit is planned 
(eg, Week 118). Therefore, telephone contacts are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 134; Year 4 - Week 150, Week 158, 
Week 174, Week 182; Year [ADDRESS_318194] and/or 
legal representative to best manage the subject's epi[INVESTIGATOR_002].  
f An ET Visit must be completed for all subjects who prematurely discontinue from the study. For subjects who will not continue  on LCM, this visit w ill 
be followed by [CONTACT_261486], an End of Taper Visit, and a Safety Follow -Up Period; see Table  5-4. For subjects who continue on commercial LCM, the 
early Termination Visit is the last visit in the study. Investigators should discuss treatment options with the subject and/or lega l representative to best 
manage the subject's epi[INVESTIGATOR_002].  
g A Termination Visit must be completed for all subjects who complete the Tr eatment Period (Week 238 or extended treatment period). This can be 
performed in alignment of the date of the last scheduled visit if applicable. For subjects who will not continue on commercia l LCM, this visit will be 
followed by [CONTACT_261486], an End of Tape r Visit, and a Safety Follow -Up Period; see Table  5-4. For subjects who continue on LCM, the Termination 
Visit is the last visit in the study. A Terminati on Visit is to be done if the subject is leaving the study prior to Week 238 following the approval of the 
PGTCS indication in their respective region/country as follows: for US subjects, when the US approval is obtained; for EU sub jects, if the EU approva l 
is obtained; and for all other adults at the approval of the PGTCS indication in Japan (last targeted approval). When subject s leave the study, 
investigators should discuss treatment options with the subject and/or legal representative to best manage the  subject's epi[INVESTIGATOR_002].  
h Laboratory tests include chemistry, hematology and, urinalysis.  
i Pregnancy tests will be performed for female subjects of childbearing potential only. Serum pregnancy tests will be conducted  at the following visits: 
Visit 1 (W0), ET, and Termination Visit. All other pregnancy tests will be urine dipstick. Baseline failures from SP0982 may have an additional  urine 
pregnancy test at V1 of EP0012, at the investigator’s discretion.  
 
 
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 251 of 274 Table 5 -4: Schedule of study assessments (Taper Perio d and Safety Follow -Up Period)  
Assessment  
 Taper Perioda 
(up to 4 weeks)  Safety Follow -Up Periodb 
End of Taper Visitc 
 Safety Follow -Up Visit  Safety Follow -Up TC  
2 weeks (±2 days) after 
last dose of study drug  30 days ( -1/+3 days) after 
last dose of study drug  
Concomitant medications and AED(s)  X X X 
Physical exam (complete)  X X  
Neurological exam (brief)  X X  
12-lead ECGd X X e  
Vital signs (BP and pulse) including orthostatic 
assessments  X X  
Body weight  X X  
Laboratory tests:     
 Chemistry/hematology  X Xe  
 Endocrinology   Xe  
 Urine pregnancy testf X X  
Contact [CONTACT_12067]  X   
Subject diary return/reviewg X   
LCM review/return  X   
Withdrawal criteria  X   
AE reporting  X X X 
C-SSRSh X X  
Healthcare resource usei X X  
Work/school days lost  due to epi[INVESTIGATOR_261403] X X  
Days with help from a caregiver  due to epi[INVESTIGATOR_261403] X X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 252 of 274 AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; BP=blood pressure; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; IRT=interactive 
response technology; LCM=lacosamide; TC=telephone contact  
[CONTACT_41936]: The schedule of study assessments for the Taper Period and Safety Follow -Up Visit includes some of the subjects who tapered in SP0982 after the 125th 
event who consented to enter EP0012 for the Safety Follow -Up on ly. 
a All subjects who discontinue LCM must complete the End of Taper Visit.  
b There will be a 30 -day ( -1/+3 days) Safety Follow -Up Period for subjects who complete the End of Taper Visit. The Safety Follow -Up Period consists of a 
Clinic Visit 2 weeks after t he End of Taper Visit followed 2 weeks later by a TC Visit.  
c An End of Taper Visit will be scheduled at the end of the Taper Period (up to 4 weeks) depending on dose level achieved; see Table 7‒2. Of note, for 
subjects who enter the Taper Period at ≤2mg/kg/day (oral solution) or 100mg/day (tablets), the End of Taper Visit will take p lace at the ET or Termination 
Visit.  
d The ECG recordings should be performe d at the same time of day (when possible) and prior to blood sample collection and vital sign assessments. Care 
should be taken to assure proper lead placement and quality ECG recordings. If possible, subjects should rest in a supi[INVESTIGATOR_261402] 5 mi nutes prior to 
each recording and should be motionless during the recording. In pediatric subjects (<18 years of age) a 12 -lead ECG (2 interpretable recordings) 
approximately [ADDRESS_318195] be performed.  
e The assessment will only be required fo r subjects with an abnormal value (clinical chemistry, hematology, or endocrinology) or reading (ECG) at the 
previous clinic visit.  
f Pregnancy tests will be performed for female subjects of childbearing potential only. A urine pregnancy test will be perform ed. 
g The last subject diary will be returned at the End of Taper Visit.  
h The C -SSRS will be completed for all subjects ≥6 years of age (see Section  10.4.3 ). 
i Healthcare resource use, work/schools days lost due to epi[INVESTIGATOR_002], and days with help from a caregiver due to epi[INVESTIGATOR_261475] ≤2 years. These assessments are not applicable for patients tapering d own or performing the SFU -visits during Years 3, 4 or 5).  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 253 of 274 Has been changed to:  
Assessment  
 Taper Perioda 
(up to 4 weeks)  Safety Follow -Up Periodb 
End of Taper Visit (maximum 
3 days after visit)c 
 Safety Follow -Up Visit  Safety Follow -Up TC  
2 weeks (±2  days) after 
last dose of study drug  30 days ( -1/+3 days) after 
last dose of study drug  
Concomitant medications and AED(s)  X X X 
Physical exam (complete)  X X  
Neurological exam (brief)  X X  
12-lead ECGd X X e  
Vital signs (BP and pulse) including orthostatic 
assessments  X X  
Body weight  X X  
Laboratory tests:     
 Chemistry/hematology  X Xe  
 Endocrinology   Xe  
 Urine pregnancy testf X X  
Contact [CONTACT_12067]  X   
Subject diary return/reviewg X   
LCM review/return  X   
Withdrawal criteria  X   
AE reporting  X X X 
C-SSRSh X X  
Healthcare resource usei X X  
Work/school days lost  due to epi[INVESTIGATOR_261403] X X  
Days with help from a caregiver  due to epi[INVESTIGATOR_261403] X X  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 254 of 274 AE=adverse event; AED=antiepi[INVESTIGATOR_32551]; BP=blood pressure; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; IRT=interactive 
response technology; LCM=lacosamide; TC=telephone contact  
[CONTACT_41936]: The schedule of study assessments for the Taper Period and Safety Follow -Up Visit includes some of the subjects who tapered in SP0982 after  the 125th 
event who consented to enter EP0012 for the Safety Follow -Up only.  
j Subjects who will not continue on LCM must complete an End of Taper Visit and a Safety Follow -Up Period; see Table  5-4. For subjects who continue on 
commercial LCM, the (Early) Termination Visit is the last visit in the study.  
k There will be a 30 -day ( -1/+3 days) Safety Follow -Up Period for subjects who complete the End of Taper Visit. The Safety Follow -Up Period consists of a 
Clinic Visit 2 weeks after the End of Taper Visit followed 2 weeks later by a TC Visit.  
l An End of Taper Visit will be scheduled at the end of the Taper Period (up to 4 weeks) depending on dose level achieved ; see Table 7‒2. Of note, for 
subjects who enter the Taper Period at ≤2mg/kg/day (oral solution) or 100mg/day (tablets), the End of Taper Visit will ta ke place at the ET or Termination 
Visit.  
m The ECG recordings should be performed at the same time of day (when possible) and prior to blood sample collection and vital  sign assessments. Care 
should be taken to assure proper lead placement and quality ECG re cordings. If possible, subjects should rest in a supi[INVESTIGATOR_207187] 5 minutes prior to 
each recording and should be motionless during the recording. In pediatric subjects (<18 years of age) a 12 -lead ECG (2 interpretable recordings) 
approximately [ADDRESS_318196] be performed.  
n The assessment will only be required for subjects with an abnormal value (clinical chemistry, hematology, or endocrinology) o r reading (ECG) at the 
previous clinic visit.  
o Pregnancy tests will be performed for female subjects of childbearing potential only. A urine pregnancy test will be performed.  
p The last subject diary will be returned at the End of Taper Visit.  
q The C -SSRS will be completed for all subjects ≥6 years of age (see Section  10.4.3 ). 
r Healthcare resource use, work/schools days lost due to epi[INVESTIGATOR_002], and days with help from a caregiver due to epi[INVESTIGATOR_261476] y after ≤2 years. These assessments are not applicable for patients tapering down or performing the SFU -visits during Years 3, 4 or 5).  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 255 of 274 Change #10  
Section 6.2  Exclusion criterion #[ADDRESS_318197] has ≥2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).  
For randomized subj ects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, 
a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the eCRF.  
If subject has >ULN ALT, AST, or ALP that does not meet the ex clusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor.  
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes re -screening.  
Has been changed to:  
Subject has ≥2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase ( ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
ident ify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).  
For all subjects who entered EP0012 directly with a Baseline result >ULN for ALT, AST, 
ALP, or total bilirubin, a Baseline diagnosis and/or the cause of any clinically meaningful 
elevation must be understood and recorded in the eCRF.  
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation.  
Change #[ADDRESS_318198] complete the ET Visit and an up to 4 -week taper 
followed by [CONTACT_261531] (see taper schedule, Table 7‒2). Following the End of 
Taper Visit, there will be a [ADDRESS_318199] and/or their parent(s)/legal representative(s) to best manage the subject’s epi[INVESTIGATOR_002]. 
Taper of LCM may not be required for some subjects who complete the study depending on 
the treatment option selected by [CONTACT_207259]/or 
parent(s)/legal representative(s).  
Have been changed to:  
Subjects withdrawing from the study must compl ete the ET Visit and (if they do not proceed 
with commercially available LCM)  an up to 4 -week taper followed by [CONTACT_261531] 
(see taper schedule, Table 7‒2). Following the End of Taper Visit, there will be a [ADDRESS_318200] and/or their parent(s)/legal representative(s) to best manage the subject’s 
epi[INVESTIGATOR_002]. T aper of LCM may not be required for some subjects who complete the study 
depending on the treatment option selected by [CONTACT_261483]/or parent(s)/legal representative(s).  
Change #12  
Section 7.2.1  Treatment period  
Table 7-2 Lacosamide dosing for subjects requiring taper  
Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  Week 4  
11 or 12mg/kg/day  9mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
9 or 10mg/kg/day  8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
7 or 8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  NA 
5 or 6mg/kg/day  4mg/kg/day  2mg/kg/day  NA NA 
3 or 4mg/kg/day  2mg/kg/day  NA NA NA 
800mg/day  600mg/day  400mg/day  200mg/day  100mg/day  
700mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
600mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
500mg/day  400mg/day  300mg/day  200mg/day  100mg/day  
400mg/day  300mg/day  200mg/day  100mg/day  NA 
300mg/day  200mg/day  100mg/day  NA NA 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 257 of 274 Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  Week 4  
200mg/day  100mg/day  NA NA NA 
ET=early termination; LCM=lacosamide  
Note: The oral solution is dosed as mg/kg/day and tablets are dosed as mg/day.  
aSubjects will begin taper on ET/Termination Visit.  
Has been changed to:  
Dose of LCM at 
ET/Termination Visita LCM taper schedule  
Week 1  Week 2  Week 3  Week 4  
11 or 12mg/kg/day  9mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
9 or 10mg/kg/day  8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  
7 or 8mg/kg/day  6mg/kg/day  4mg/kg/day  2mg/kg/day  NA 
5 or 6mg/kg/day  4mg/kg/day  2mg/kg/day  NA NA 
4mg/kg/day  2mg/kg/day  NA NA NA 
800mg/day  600mg/day  400mg/day  200mg/day  100mg/day  
700mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
600mg/day  500mg/day  300mg/day  200mg/day  100mg/day  
500mg/day  400mg/day  300mg/day  200mg/day  100mg/day  
400mg/day  300mg/day  200mg/day  100mg/day  NA 
300mg/day  200mg/day  100mg/day  NA NA 
200mg/day  100mg/day  NA NA NA 
ET=early termination; LCM=lacosamide  
Note: The oral solution is dosed as mg/kg/day and tablets are dosed as mg/day.  
aSubjects will begin taper on ET/Termination Visit.  
Change #13  
Section 8.1.4  Visits 12, 13, 14, 15, 16, and 17 (Weeks 118, 142, 166, 
190, 214, and 238, Years 3 to 5)  
[IP_ADDRESS] Subjects <18years  
The following tasks and procedures are to be performed at these visits :  
• Concomitant medications and AEDs  
• Physical examination (complete, Visit 13, 15, and 17) 
• Neurological examination (brief, Visit 12, 14, and 16)  
• ECG (12 -lead) assessment (Visit 13, 15, and 17)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 258 of 274 • Body weight and height (height at Visit 12, 14, and 16)  
• Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 13, 15, and 17)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hema tology, 
chemistry, and urinalysis) (laboratory tests are applicable for combined Visit 
17/Termination Visit. If Visit 17 is not the Termination Visit, laboratory tests are not 
required. Laboratory tests are not performed at Visit 13 and 15 according to Pro tocol 
Amendment 3.  
• Urine pregnancy test (for women of childbearing potential)  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• Achenbach CBCL for subjects ≥6 years to <18 years of age (Visit 13, 15, and 17)  
• BRIEF for subjects ≥5 to <18 years of age (Visit 13, 15, and 17)  
 
Has been changed to:  
8.1.4 Visits 12, 13, 14, 15, 16, 17 and 17X (Weeks 118, 142, 166, 190, 214, and 
238, and X, Years 3 to 5 + Extended Period)  
[IP_ADDRESS] S ubjects <18years  
The following tasks and procedures are to be performed at these visits (Visit X [Vx] visits are 
to be performed every 24 weeks):  
• Concomitant medications and AEDs  
• Physical examination (complete, Visit 13, 15, 17, and odd numbered visits the reafter)  
• Neurological examination (brief, Visit 12, 14, 16, and even numbered visits thereafter)  
• ECG (12 -lead) assessment (Visit 13, 15, 17, and odd numbered visits thereafter)  
• Vital signs ( pulse rate, BP) including orthostatic assessments  
• Body weight and height (height at Visit 12, 14, 16, and even numbered visits thereafter)  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 259 of 274 • Tanner staging (will be performed only for subjects who are pubescent at Visit 1 or who 
enter puberty during the course of the study) (Visit 13, 15, 17, and odd numbered visits 
thereafter)  
• C-SSRS assessment (for subjects ≥6  years of age)  
• Blood and urine samples for clinical laboratory assessments (includes hematology, 
chemistry, and urinalysis) (laboratory tests are applicable for combined Visit 
17/Termination Visit. If Visit 17 is not the Termination Visit, laboratory tests are not 
required. Laboratory tests are not performed at Visit 13 and 15 according to Protocol 
Amendment 3.  
• Urine pregnancy test (for women of childbearing potential)  
• Contact [CONTACT_12067]  
• Dispense subject diary  
• Subject diary return/review  
• Dispense LCM  
• LCM review/return  
• Assess withdrawal criteria  
• AE reporting  
• Achenbach CBCL for subjects ≥6 years to <18 years of age (Visit 13, 15, 17, and odd 
numbered visits thereafter)  
• BRIEF for subjects ≥5 to <18 years of age (Visit 13, 15, 17, and odd numbered visits 
thereafter)  
Change #14  
Section [IP_ADDRESS]  Subjects ≥[ADDRESS_318201] paragraph  
The following tasks and procedures are to be performed at these visits.  
Has been changed to:  
The following tasks and procedures are to be performed at  these visits, additional routine 
visits (Visit X) can be done after Visit 17 (Vx visits are to be performed every 24 weeks) with 
assessments described in Table  5‒3. 
Change #[ADDRESS_318202] paragraph  
Telephone contacts are required at Week 30 and Week 38 and every 8 weeks during Year 2 
to Year 5, except during weeks in which a clinic visit is planned (eg, Week 62). Therefore, 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 260 of 274 telephone contacts in Year 2 are scheduled for Week 54, Week 70 and Week 86. Telephone 
contacts in Years 3 to 5  are scheduled for: Year 3 - Week 102, Week 110, Week 126, Week 
134; Year 4 - Week  150, Week 158, Week 174, Week 182; Year 5 - Week 198, Week 206 , 
Week 222, and Week  230. 
Has been changed to:  
Telephone contacts are required at Week 30 and Week 38 and every 8 weeks during Year 2 
to Year 5, except during weeks in which a clinic visit is planned (eg, Week 62). Therefore, 
telephone contacts in Year 2 a re scheduled for Week 54, Week 70, Week 78 and Week 86. 
Telephone contacts in Years 3 to 5  are scheduled for: Year 3 - Week 102, Week 110, Week 
126, Week 134; Year 4 - Week  150, Week 158, Week 174, Week 182; Year 5 - Week 198, 
Week 206, Week 214, Week 222,  Week 230, Week  238, and every 8 weeks during the 
Extended Period.  
Change #[ADDRESS_318203] paragraph  
Subjects withdrawing from the study will complete the ET Visit, and LCM will be tapered 
over a period of up to 4 weeks (see taper schedule, Table 7‒2). 
Has been changed to:  
Subjects withdrawing from the study will complete the ET Visit, and LCM will be tapered 
over a period of up to 4 weeks if not continuing with commercially available LCM (see taper 
schedule, Table 7‒2). 
Change #17  
Section 8.3  Termination visit  
Paragraphs 1, 2, and 3  
Subjects completing the Treatment Period and not continuing with commercially available 
LCM will complete the Ter mination Visit, and LCM will be tapered over a period of up to 
4 weeks (see taper schedule, Table 7‒2). Once LCM becomes commercially available and the  
subject elects to continue treatment, they must also complete the Termination Visit and 
transition to commercially available LCM.  
Patients transitioning to the MAP will complete the Treatment Period after 2 years but 
continue their treatment with MAP LCM.  
Taper of LCM is not required for subjects who complete the study and continue on MAP 
LCM or commercially available LCM. Subjects transitioning to MAP LCM or commercially 
available LCM will do so immediately and will continue at a dose determined by [CONTACT_1275]. Note: this visit can be combined with Visit [ADDRESS_318204] been changed to:  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 261 of 274 A Termination Visit will be completed by [CONTACT_261499] 1 of the following conditions:   
8. The subject chooses to transition  to commercial LCM.  
9. The subject chooses not to continue treatment with LCM.   
Subjects not continuing treatment with LCM will complete the Termination Visit, and LCM 
will be tapered over a period of up to 4  weeks (see taper schedule, Table 7‒2). Subjects who 
continue treatment with commercial LCM must also complete the Termination Visit.  
Taper of LCM is not required for subjects who leave the Termination  Visit and transition to 
commercial LCM. Subjects transitioning to commercial LCM will do so immediately and 
will continue at a dose determined by [CONTACT_093].  In this instance, the Termination Visit 
will serve as the subject's last visit in the stud y.   
Change #[ADDRESS_318205] should be reminded to bring the diary to each clinic visit.  
Has been changed to:  
Subjects will keep a diary to record all seizure activity from Visit [ADDRESS_318206] be consistent with the 
seizure information (including specific type  of seizure) reported in the seizure diary.  
Change #19  
Section [IP_ADDRESS]  Adverse events  
Added fourth paragraph:  
Should an AE involving a seizure be reported, it must be consistent with the seizure 
information (including specific type of seizure) reported in  the seizure diary.  
Change #20  
Section [IP_ADDRESS]  Serious adverse events  
Added second paragraph:  
If commercial LCM is given during hospi[INVESTIGATOR_059], this needs to be recorded on the CRF.  
Change #[ADDRESS_318207] diaries (see Section 9.1). 
Has been changed to:  
Section 10.2  New seizure types, increase in days with and worsening of days with 
absence or myoclonic seizures  
Incidence of new seizur e types, increase in absence seizure days or myoclonic seizure days 
per 28 days during the Treatment Period, and 50% worsening in days with absence seizures 
or myoclonic seizures per [ADDRESS_318208] diaries (see Section 9.1). 
 
Change #22  
Section [IP_ADDRESS]  Testing: identification/exclusion of alternative 
etiology  
Table 10 -4 (laboratory measurements):  
Table 10 -4: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunolog
y Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and 
quantitative)  
Hematology  Eosinophil count  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 263 of 274 Table 10 -4: PDILI laboratory measurements  
Serum CPK and LDH to evaluate possible muscle injury causing 
transaminase elevation  
Additional  Prothrombin time/INRa 
Serum pregnancy test  
PK sample  
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb -IgM=hepatitis B core antibody -IgM;  
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; 
RNA=ribonucleic acid; ULN=upper limit of normal  
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderne ss; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
Has been changed to:  
Table 10 -4: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunolog
y Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Differential count, hematocrit, hemoglobin, platelet count, RBC and WBC  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Albumin, AST, ALT, ALP, GGT, serum CPK, and LDH to evaluate possible 
muscle injury causing transaminase elevation  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 264 of 274 Table 10 -4: PDILI laboratory measurements  
Additional  Prothrombin time/INRa 
Serum pregnancy test  
PK sample  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine 
phosphokinase; GGT=gamma glutamyl transferase; HBcAb -IgM=hepatitis B core antibody -IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RBC=red blood 
cell count; RNA=ribonucleic acid; ULN=upper l imit of normal; WBC=white blood cell count  
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 265 of 274 Change #23  
Section 12.3.1  Safety analysis  
Second paragraph  
Incidence of new s eizure types and increase in absence seizure days per 28 days or myoclonic 
seizure days per 28 days during the Treatment Period will be summarized. Laboratory 
measurements as described in Section 10.3 and other safety measurements as described in 
Section 10.4 will be presented.  
Has been changed t o: 
Incidence of new seizure types, increase in days with absence seizure or myoclonic seizures 
per 28 days during the Treatment Period, and 50% worsening in days with absence seizures 
or myoclonic seizures per 28 days during the Treatment Period will be su mmarized. 
Laboratory measurements as described in Section 10.3 and other safety measurements as 
described in Section 10.4 will be presented.  
Change #24  
Section 12.4  Planned efficacy analysis  
Second paragraph  
Days with myoclonic or absence seizures are more clinically relevant endpoints; therefore, 
change in and percent change in days with myoclonus and absence will be summarized. The 
percentage of subjects with 50% reduction in days with absence and myoclonic seizures per 
28 days compared to the Prospective Baseline will be presented. Sub jects who were seizure -
free from all generalized seizures will also be tabulated.  
Has been changed to:  
Days with myoclonic or absence seizures are more clinically relevant endpoints; therefore, 
change in and percent change in days with myoclonic and/or abs ence seizures will be 
summarized. The percentage of subjects with 50% reduction in days with absence and/or 
myoclonic seizures per 28 days compared to the Prospective Baseline will be presented. 
Subjects who were seizure -free from all generalized seizures will also be tabulated.  
Change #[ADDRESS_318209] Data 
Cleaning Plan. To the extent feasible, rules for identifying protocol deviat ions will be defined 
without review of the data and without consideration of the frequency of occurrence of such 
deviations. Whenever possible, criteria for identifying important protocol deviations will be 
implemented algorithmically to ensure consistency  in the classification of important protocol 
deviations across all subjects.  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 266 of 274 Important protocol deviations will be reviewed as part of the ongoing data cleaning process 
prior to database lock to confirm exclusion from analysis sets.  
Has been changed to:  
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on key safety outcomes for an individual subject. The criteria for 
identifying important protocol deviations and the classification of important p rotocol 
deviations will be defined within the project Data Cleaning Plan. To the extent feasible, rules 
for identifying protocol deviations will be defined without review of the data and without 
consideration of the frequency of occurrence of such deviatio ns. Whenever possible, criteria 
for identifying important protocol deviations will be implemented algorithmically to ensure 
consistency in the classification of important protocol deviations across all subjects.  
Important protocol deviations will be review ed as part of the ongoing data cleaning process 
prior to database lock.  
Change #[ADDRESS_318210] personal health data in this study is allowed for the purpose of 
scientific research to evaluate the efficacy and the safety of the tested drug, in accordance 
with legal requirements from:  
• the laws governing the conduct of clinical studies (ie, the provisions of the French Public 
Health Code and the EU clinical trial regulation 536/[ADDRESS_318211] and analyze such data before they are submitted to health authorities)  
• the EU regulation 1235/[ADDRESS_318212] 25 years to ensure the validity of the research.  
The subjects will be informed that the Sponsor is legally entitled and ob liged to keep, retain, 
and use your medical data to ensure the quality of scientific results and to comply with legal 
or judicial retention periods.  
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 267 of 274 16.8 Appendix 8: Protocol Amendment 5  
Rationale for the amendment  
The primary purpose of this amendment was to update the protocol based on comments 
received on the pediatric investigational plan as well as to clarify/solve inconsistencies 
between different sections of the protocol and to correct some minor errors . 
Modif ications and changes  
Specific changes  
Change #1  
Title page:  
The title was updated from “Protocol EP0012 Amendment  4” to “Protocol EP0012 
Amendment  5.” 
The information below was revised to include Protocol Amendment 5 and the type of 
protocol amendment:  
Protocol/Amendment Number  Date  Type of amendment  
Final Protocol  [ADDRESS_318213] 2012  Not applicable  
Protocol Amendment 1  27 Jan 2015  Substantial  
Protocol Amendment 2  09 Jun 2016  Substantial  
Protocol Amendment 3  29 Nov 2017  Substantial  
Protocol Amendment 4  13 Dec 2019  Substantial  
 
Has been changed to:  
Protocol/Amendment Number  Date  Type of amendment  
Final Protocol  [ADDRESS_318214] 2012  Not applicable  
Protocol Amendment 1  27 Jan 2015  Substantial  
Protocol Amendment 2  09 Jun 2016  Substantial  
Protocol Amendment 3  29 Nov  2017  Substantial  
Protocol Amendment 4  13 Dec 2019  Substantial  
Protocol Amendment 5  27 Aug 2020  Non-substantial  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 268 of 274 Change #2  
4.1.1  Primary safety variables  
The primary safety variables are:  
• Adverse events as reported spontaneously by [CONTACT_3184]/or car egiver or observed by 
[CONTACT_093]  
• Subject withdrawals due to AEs  
• Incidence of new appearance of absence and/or myoclonic seizures during the Treatment 
Period  
• Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days 
with absence seizures per 28 days compared to the Prospective Baseline  
• Subjects with an increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days 
with myoclonic seizures per 28 days compared to the Prospective Baseline  
• Percentage of subjects with at lea st 50% worsening in days with absence seizures  
• Percentage of subjects with at least 50% worsening in days with myoclonic seizures  
 
Has been changed to:  
The primary safety variables are:  
• The incidence of TEAEs over the duration of the Treatment Period.  
• Subject withdrawals due to TEAEs  
• Incidence of new appearance of absence and/or myoclonic seizures during the Treatment 
Period  
• An increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days with absence 
seizures per 28 days compared to the Prospective  Baseline  
• An increase of up to 25%, >25% to 50%, >50% to 75%, and >75% in days with 
myoclonic seizures per 28 days compared to the Prospective Baseline  
• At least 50% worsening in days with absence seizures  
• At least 50% worsening in days with myoclonic seizu res 
 
Change #3  
4.2.3  Other efficacy variables  
Bullets 5, 6 and 7  
• Percentage of subjects with at least a 50% reduction in PGTCS frequency compared to 
the Combined Baseline  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 269 of 274 • Percentage of subjects with at least a 50% reduction in myoclonic seizure days compar ed 
to the Prospective Baseline  
• Percentage of subjects with at least a 50% reduction in absence seizure days compared to 
the Prospective Baseline  
 
Has been changed to:  
• At least a 50% reduction in PGTCS frequency compared to the Combined Baseline  
• At least a 50% reduction in myoclonic seizure days compared to the Prospective Baseline  
• At least a 50% reduction in absence seizure days compared to the Prospective Baseline  
 
Change # [ADDRESS_318215]  
Paragraph 1, bullet #2  
• For pediatric subj ects, treatment will continue until the latest of 1 of the following 
2 conditions  are met:  
− up to 5 years of participation or  
− until the latest approval is granted either by [CONTACT_16096], FDA, or PMDA  
Has been changed to:  
• For pediatric subjects, treatment will continue until 1 of the following 2 conditions  are 
met: 
− up to 5 years of participation or  
− until the approval of the extension of indication to cover the target age group is 
granted  
Change # 5 
5.2 Schedule of study ass essments  
Table 5‒2:  Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment 
Period, ET Visit, Termination Visit, and Unscheduled Visit for subjects <18 years at 
enrollment)  
Neurological exam (brief): added ‘X’ to study ET Visit  
Footnote ‘ p’ 
Laboratory tests are applicable for combined the last scheduled visit/Termination Visit. If the 
last scheduled visit is not the Termination Visit, laboratory tests are not required.  
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 270 of 274 Table 5 -3 Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment 
Period, ET Visit, Termination Visit, and Unscheduled Visit for subjects ≥18 years at 
enrollment)  
Deleted footnote ‘e’ from V17.  
Added footnote ‘i’:  
i Laboratory tests are applicable for the combined  last scheduled visit/Termination Visit.  If 
the last scheduled visit is not the Termination Visit, laboratory tests are not required.  
 
Table  16-6:Schedule of study assessments (Taper Period and Safety Follow -Up Pe riod)  
Table header column 2  
End of Taper Visit (maximum 3 days after visit)  
Has been changed to:  
Table 5‒2:  Schedule of study assessments for Years 3 through 5 for EP0012 (Treatment 
Period, ET Visit, Termination Visit, and Unscheduled Visit for subjects <1 8 years at 
enrollment)  
Footnote ‘p’  
Laboratory tests are applicable for combined the last scheduled visit/Termination Visit. If the 
last scheduled visit is not the Termination Visit, laboratory tests are not required.  
 
Table  16-7:Schedule of study assessments (Taper Period and Safety Follow -Up Period)  
Table header column 2  
End of Taper Visit (maximum [ADDRESS_318216] dose)  
 
Change # 6 
Section [IP_ADDRESS]  Subjects <18 years  
Bullet #3  
• Neurological examination (brief, Visit 12, 14, 16, and even numbered visits thereafter)  
Has been changed to:  
• Neurological examination (brief, Visit 12, 14, 16, 17, and even numbered visits 
thereafter)  
 
Change # [ADDRESS_318217] withdrawal due to AE will  be presented giving 
absolute and relative frequencies for the course of the study. Additionally, per year 
frequencies will be provided, where the denominator will be adjusted for the number of 
subjects still at risk, ie, the number of subjects entering th e respective year of the study. 
Relative years will be used for this type of analysis, not calendar years.  
Has been changed to:  
The incidence of all TEAEs, treatment emergent SAEs and TEA Es leading to premature 
discontinuation from study drug will also be summarized descriptively. Additional 
summaries will be provided by [CONTACT_174802]. All tables 
of TEAEs will include Medical Dictionary for Regulatory Activ ities primary System Organ 
Class and Preferred Term. Further details on the analysis of each variable will be given in the 
SAP.  
  
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   28 Aug 2020  
Clinical Study Protocol  Lacosamide  EP0012  
   
Confidential  Page 272 of 274 16.9 Appendix 9: Contraception Table  
Method  Abbreviatio
n no EI -AEDs  EI-
AEDs    
combined injectable contraceptives  CIC ok ok   
combined patch  P ok needs barrier   
combined vaginal ring  R ok needs second method  
low-dose combined oral contraceptives  COC  ok needs barrier   
      
etonogestrel implant  ETG ok ok   
levonorgestrel implant  LNG  ok ok   
depot medroxyprogesterone acetate  DMPA  ok ok   
      
norethisterone enantate  NET-EN ok ok   
      
progestogen -only pi[INVESTIGATOR_261477] -bearing intrauterine devices  Cu-IUDs  ok ok   
levonorgestrel -releasing IUDs  LNG -IUDs  ok ok   
      
barrier methods  BARR  not eligible  not eligible   
fertility awareness -based methods  FAB not eligible  not eligible   
lactational amenorrhoea method  LAM  not eligible  not eligible   
coitus interruptus  CI not eligible  not eligible   
female and male sterilization  STER  ok ok   
      
 
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
UCB   [ADDRESS_318218].  
Investigator:  
 
 
__________________________________  
Printed name   
 
 
__________________________________  
Date/Signature  
[CONTACT_261558].
UCB   [ADDRESS_318219] this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
 
 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.
Approval Signatures
Name: [CONTACT_261559]0012-protocol-amend-5
Version: 1 . 0
Document Number: CLIN-000158392
Title:EP0012 Protocol Amendment 5 - Open multicenter extension, evaluate long-term
safety,efficacy of adjunctive LCM for uncontrolled PGTC seizures (IGE)
Approved Date: [ADDRESS_318220]: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 28-Aug-2020 15:55:58 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Medical
Date of Signature: 31-Aug-2020 08:01:31 GMT[PHONE_006]
Approval
Verdict: ApprovedName: 
[CONTACT_18469]: Clinical
Date of Signature: 31-Aug-2020 13:51:25 GMT[PHONE_006]
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.